

ALIXPARTNERS, LLP

Exhibit A

Detailed Description of Fees, Hours and Descriptions by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/01/20	JD	Prepare a case progress and business plan update summary for L. Donahue (AlixPartners).	0.40
02/01/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) re: AlixPartners recommendations for Rhodes turnaround implementation plan	0.20
02/01/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re: AlixPartners recommendations for Rhodes turnaround implementation plan	0.20
02/02/20	JD	Participate in call with J. O'Connell, T. Coleman (PJT), M. Heubner, C. Robertson (Davis Polk), C. Landau, M. Kesselman and J. Lowne (Purdue) re: prep for Monday meeting.	1.10
02/03/20	JD	Working session with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) re: key items from Ad Hoc meeting	2.70
02/03/20	DS	Distribute recap from Ad Hoc Committee meeting among Debtors' advisors	1.70
02/03/20	DS	Working session with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) re: key items from Ad Hoc meeting	2.70
02/03/20	DS	Development of individual analyses re: legal and settlement framework to be used in key issues materials	2.10
02/03/20	LMB	Review court docket for pertinent dates and deadlines	0.20
02/03/20	IA	Working session with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) re: key items from Ad Hoc meeting	2.70
02/04/20	LJD	Conversation with L. Donahue and J. DelConte (both AlixPartners) re: case status and go forward plan.	0.50
02/04/20	DS	Update key issues presentation and send to J. DelConte (AlixPartners) for review	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/04/20	DS	Draft response to TXP manager re: motions/order that address specific aspect of ongoing operations	0.90
02/04/20	JD	Conversation with L. Donahue and J. DelConte (both AlixPartners) re: case status and go forward plan.	0.50
02/04/20	JD	Draft responses to various case status open questions.	2.40
02/05/20	JD	Call with J. Lowne (Purdue), J. Turner and R. Schnitzler (both PJT) re: go forward business	0.60
02/05/20	ESK	Review interco transfer report for compliance and review	1.20
02/05/20	ESK	Call with R. Collura and E. Kardos (both AlixPartners) re: report review	0.20
02/05/20	RC	Call with R. Collura and E. Kardos (both AlixPartners) re: report review	0.20
02/05/20	KM	Analysis of Rhodes Technologies site closure and slide edits	1.40
02/05/20	KM	Dashboard discussion with K. McCafferty and R. Sublett (both AlixPartners)	0.30
02/05/20	KM	Edits to dashboard slide for Board meeting deck	0.20
02/05/20	RDS	Dashboard discussion with K. McCafferty and R. Sublett (both AlixPartners)	0.30
02/06/20	NAS	Consolidate notes and follow-up items from weekly debtor advisor call with Purdue, PJT, and Davis Polk,	0.20
02/06/20	NAS	Partial attendance in call with J. Lowne, M. Kesselmen, R. Aleali (all Purdue), J. Turner, J. O'Connell (both PJT), M. Huebner (Davis Polk), L. Donahue, B. Folse, J. DelConte, M. Hartley, G. Koch, I. Arana, and N. Simon (all AlixPartners) re: weekly status update.	0.40
02/06/20	DS	Review of latest production by Davis Polk e-discovery team for purposes of posting to Intralinks	0.80
02/06/20	JD	Call with J. Lowne, M. Kesselmen, R. Aleali (all Purdue), J. Turner, J. O'Connell (both PJT), M. Huebner (Davis Polk),	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		L. Donahue, B. Folse, J. DelConte, M. Hartley, G. Koch, I. Arana, and N. Simon (all AlixPartners) re: weekly status update.	
02/06/20	BF	Planning regarding LAM diligence and travel to Asia	0.30
02/06/20	BF	Call with J. Lowne, M. Kesselmen, R. Aleali (all Purdue), J. Turner, J. O'Connell (both PJT), M. Huebner (Davis Polk), L. Donahue, B. Folse, J. DelConte, M. Hartley, G. Koch, I. Arana, and N. Simon (all AlixPartners) re: weekly status update.	0.70
02/06/20	LJD	Call with J. Lowne, M. Kesselmen, R. Aleali (all Purdue), J. Turner, J. O'Connell (both PJT), M. Huebner (Davis Polk), L. Donahue, B. Folse, J. DelConte, M. Hartley, G. Koch, I. Arana, and N. Simon (all AlixPartners) re: weekly status update.	0.70
02/06/20	GJK	Call with J. Lowne, M. Kesselmen, R. Aleali (all Purdue), J. Turner, J. O'Connell (both PJT), M. Huebner (Davis Polk), L. Donahue, B. Folse, J. DelConte, M. Hartley, G. Koch, I. Arana, and N. Simon (all AlixPartners) re: weekly status update.	0.70
02/06/20	MH	Call with J. Lowne, M. Kesselmen, R. Aleali (all Purdue), J. Turner, J. O'Connell (both PJT), M. Huebner (Davis Polk), L. Donahue, B. Folse, J. DelConte, M. Hartley, G. Koch, I. Arana, and N. Simon (all AlixPartners) re: weekly status update.	0.70
02/06/20	IA	Prepare for and attend call with J. Lowne, M. Kesselmen, R. Aleali (all Purdue), J. Turner, J. O'Connell (both PJT), M. Huebner (Davis Polk), L. Donahue, B. Folse, J. DelConte, M. Hartley, G. Koch, I. Arana, and N. Simon (all AlixPartners) re: weekly status update.	1.30
02/07/20	IA	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	
02/07/20	SJC	Prepare for and attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.60
02/07/20	HK	Prepare for and attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	1.00
02/07/20	SKL	Prepare for and attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
02/07/20	MH	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/07/20	MH	Determine motion eligibility for a customs invoice.	0.40
02/07/20	GJK	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/07/20	FOS	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners team update call.	
02/07/20	LJD	Prepare for and attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
02/07/20	LJD	Call with J. O'Connell, T. Coleman (both PJT), M. Huebner (Davis Polk), L. Donahue, and J. DelConte (both AlixPartners) re: strategic business plan process.	0.70
02/07/20	MFR	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/07/20	JD	Prepare for and attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
02/07/20	JD	Call with J. O'Connell, T. Coleman (both PJT), M. Huebner (Davis Polk), L. Donahue, and J. DelConte (both AlixPartners) re: strategic business plan process.	0.70
02/07/20	JD	Review ongoing work streams and prepare update for group.	0.50
02/07/20	DS	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/07/20	DS	Re-activate my Davis Polk account to receive secure files from production to upload	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/07/20	DS	Watermark insurance documents to allow them to be transmitted to interested parties	0.50
02/07/20	DS	Correspondence with A. DePalma (AlixPartners) re: diligence / protective order process	0.20
02/07/20	NAS	Partial attendance in call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.20
02/07/20	RC	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/07/20	KM	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/07/20	RDS	Attend call with L. Donahue, R. Collura, J. DelConte, G. Koch, I. Arana, N. Simon, F. Silva, K. McCafferty, M. Rule, M. Hartley, R. Sublett, D. Samikkannu, S. Caniff, S. Lemack, and K. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/09/20	DS	Correspondence with A. DePalma (AlixPartners) re: procedures on view only platform and new productions	0.40
02/09/20	JD	Call with L. Donahue (AlixPartners), M. Kesselmen, C. Landau, J. Lowne (all Purdue), T. Coleman (PJT) and M. Huebner (Davis Polk) re: upcoming meetings.	0.70
02/09/20	JD	Correspondence with C. McMillian (Davis Polk) and R. Aleali (Purdue) re: diligence materials and information	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		sharing under the protective order.	
02/09/20	JD	Correspondence with T. Melvin (PJT), C. Robertson (Davis Polk), R. Aleali and E. Ruiz (Purdue) re: UCC diligence questions.	1.20
02/10/20	DS	Correspondence with J. DelConte (AlixPartners) re: posting procedures for insurance docs	0.30
02/10/20	DS	Correspondence with H. Ku (AlixPartners) re: process on diligence and uploading documents	0.30
02/11/20	DS	Correspondence with C. McMillian (Davis Polk) re: specific diligence question on OxyContin	0.50
02/11/20	JD	Deal with logistics of setting up biweekly status update meetings and correspondence with PJT and Davis Polk re: same.	0.70
02/11/20	JD	Correspondence with Davis Polk re: diligence productions and review draft materials to be provided.	0.80
02/11/20	JD	Catch up call re: business planning with L. Donahue and J. DelConte (both AlixPartners)	0.50
02/11/20	LJD	Prepare for and attend catch up call re: business planning with L. Donahue and J. DelConte (both AlixPartners)	0.80
02/12/20	JD	Call with C. McMillian (Davis Polk) and J. DelConte (AlixPartners) re: diligence and redaction process.	0.40
02/12/20	DS	Discussion with C. McMillian (Davis Polk) re: the need to scrub metadata from Excel files	0.40
02/12/20	DS	Correspondence with C. McMillian (Davis Polk) and T. Melvin (PJT) re: specific items requested to be expedited by PJT	0.30
02/12/20	DS	Discussion re: view only platform access with K. Knechtel (FTI) and D. Samikkannu (AlixPartners)	1.70
02/12/20	DS	Investigate source of PEO stamp on specific document	1.00
02/13/20	DS	Review redaction comments provided by C. McMillian	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		(Davis Polk)	
02/13/20	DS	Review of specific document as requested by Davis Polk to determine confidentiality parameters	0.80
02/13/20	DS	Final review of draft cash report	0.40
02/13/20	DS	Draft response to Davis Polk's questions re: locations to upload files	0.60
02/13/20	DS	Correspondence with K. Chau (Davis Polk) re: secured files attached to upload	0.30
02/13/20	DS	Upload new production documents to Intralinks	1.80
02/13/20	JD	Correspondence with C. Robertson and C. McMillian (both Davis Polk) re: designation protocol and upcoming production batches.	0.80
02/14/20	JD	Review initial document production for the UCC.	0.70
02/14/20	JD	Review work completed to date and prepare updated work stream agenda.	0.60
02/14/20	JD	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
02/14/20	JD	Conversations with C. McMillian, J. McClammy (Davis Polk), and J. DelConte (AlixPartners) re: document production process.	0.60
02/14/20	JD	Review and upload documents to the data room for UCC and AHC advisors and members.	3.10
02/14/20	JD	Call with J. DelConte and D. Smikkannu (both AlixPartners) re: status and next steps of uploading produced documents to Intralinks	0.30
02/14/20	DS	Correspondence with C. McMillian (Davis Polk) re: notifications in Intralinks	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/14/20	DS	Draft detailed update on workstreams to J. DelConte and I. Arana (both AlixPartners) for status meeting	0.80
02/14/20	DS	Call with J. DelConte and D. Smikkannu (both AlixPartners) re: status and next steps of uploading produced documents to Intralinks	0.30
02/14/20	DS	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/14/20	DS	Upload UCC production documents to Intralinks, updating Excel files with appropriate labels	1.40
02/14/20	DS	Upload non-consenting states document production to Intralinks	2.80
02/14/20	RC	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
02/14/20	LJD	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
02/14/20	MFR	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/14/20	BF	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack,	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	
02/14/20	MH	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/14/20	GJK	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/14/20	HK	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
02/14/20	FOS	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.60
02/14/20	SKL	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/14/20	IA	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/14/20	IA	Follow up on approvals and comments on weekly cash report.	0.60
02/14/20	SJC	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
02/14/20	RDS	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.60
02/14/20	ADD	Call with L. Donahue, B. Folse, R. Collura, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/15/20	DS	Upload remaining assigned documents to Intralinks from non-consenting states production	1.50
02/17/20	JD	Catch up call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: case progress.	0.20
02/18/20	JD	Call with J. O'Connell, J. Turner (both PJT), and J. DelConte (AlixPartners) re: planning for Thursday meeting.	0.30
02/18/20	JD	Review investigation billable hours to provide to Davis Polk.	0.40
02/18/20	JD	Catch up call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: ongoing work streams and weekly deliverables.	0.70
02/18/20	JD	Correspondence with internal AlixPartners team re: consumer products expertise.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/18/20	JD	Review materials posted to the data room over the weekend.	1.10
02/18/20	DS	Confirmation of status to enter cash report into production process	0.40
02/18/20	DS	Draft production request for Davis Polk to produce reports from prior week	0.50
02/19/20	DS	Send request to Purdue analyst re: process of obtaining invoices re: noticing process	0.70
02/19/20	JD	Meeting with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: AlixPartners work streams update.	0.30
02/19/20	JD	Review and provide comments for Thursday update meeting.	0.30
02/20/20	MH	Review ongoing workstream progress.	0.20
02/20/20	MH	Create accounts payable release file.	0.70
02/21/20	MH	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.60
02/21/20	FOS	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/21/20	BF	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/21/20	MFR	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/21/20	LJD	Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/21/20	GJK	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/21/20	SJC	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/21/20	IA	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/21/20	HK	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/21/20	JD	Review ongoing work streams and prepare update for group.	0.70
02/21/20	JD	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/21/20	JD	Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call. Review correspondence from management, Davis Polk and PJT.	0.80
02/21/20	DS	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/21/20	RC	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/21/20	NAS	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.60
02/21/20	ADD	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/21/20	KM	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/21/20	JDH	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	
02/21/20	RDS	Call with L. Donahue, B. Folse, R. Collura, K. McCafferty, J. DelConte, M. Rule, G. Koch, M. Hartley, R. Sublett, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, and A. DePalma, F. Silva, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/22/20	JD	Correspondence with L. Donahue (AlixPartners) re: 2020 rates.	0.30
02/25/20	JD	Catch up call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: ongoing work streams.	0.30
02/25/20	DS	Communication with A. DePalma (AlixPartners) re: diligence process	0.80
02/25/20	KM	Edit dashboard slide for Board meeting deck	0.30
02/25/20	KM	Rhodes Technologies site closure analysis and slide edits	1.40
02/26/20	KM	Board meeting deck review for Rhodes	0.30
02/26/20	KM	Call with D. Selby and K. McCafferty (both AlixPartners) to discuss PMO resources and availability	0.50
02/26/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss ten year business plan adjustments and work plan for next week	0.50
02/26/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss ten year business plan adjustments and work plan for next week	0.50
02/26/20	DS	Meeting with financial analyst (Purdue) re: outstanding items needed for report deliverables	0.80
02/26/20	DS	Review input data for December and January monthly flash reports	0.90
02/26/20	DS	Review draft weekly sales report and provide feedback to	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		S. Lemack (AlixPartners)	
02/27/20	JD	Call with C. McMillian, K. Benedict (both Davis Polk), T. Melvin (PJT), I. Arana, J. DelConte (both AlixPartners), R. Silbert and R. Aleali (both Purdue) to discuss diligence process as it relates to State AGs	0.60
02/27/20	JD	Partial participation in a call with R. Silbert (Purdue), T. Baker (Dentons), T. Melvin (PJT) and K. Benedict (Davis Polk) re: AG diligence response process.	0.30
02/27/20	JD	Conversation with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan process.	0.50
02/27/20	JD	Review outstanding UCC diligence questions and proposed responses. Correspondence with M. Atkinson (Province) re: same.	0.70
02/27/20	IA	Call with C. McMillian, K. Benedict (both Davis Polk), T. Melvin (PJT), I. Arana, J. DelConte (both AlixPartners), and R. Aleali (Purdue) to discuss diligence process as it relates to State AGs	0.60
02/27/20	NAS	Draft weekly summary points for 2/28 AlixPartners Purdue engagement team coordination call.	0.40
02/27/20	NAS	Review list of remaining diligence items provided to counsel (Davis Polk).	0.50
02/27/20	KM	Purdue Board meeting participation	1.20
02/27/20	KM	Purdue Board meeting preparation and deck review	1.60
02/28/20	JDH	Prepare for and attend conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	1.00
02/28/20	ADD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack,	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/28/20	IA	J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	IA	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.60
02/28/20	NAS	Call with I. Arana (AlixPartners), C. McMillian (Davis Polk), T. Melvin (PJT), R. Silbert and R. Aleali (both Purdue) to discuss diligence process and communications with state AGs.	0.50
02/28/20	RC	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	DS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.40
02/28/20	JD	Correspondence with F. Silva (AlixPartners) re: outstanding diligence items	0.50
02/28/20	JD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
02/28/20	HK	AlixPartners team update call. Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	FOS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	SKL	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	SJC	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	GJK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	LJD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
02/28/20	MFR	Conference call with L. Donahue, B. Folse, R. Collura, A.	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	
02/28/20	BF	Prepare for and attend conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
02/28/20	MH	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, D. Samikkannu, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
03/01/20	NAS	Correspondence re: current Mundipharma diligence status with counsel (Davis Polk).	0.20
03/02/20	JD	Conversation with A. DePalma and J. DelConte (both AlixPartners) re: outstanding diligence process.	0.20
03/02/20	DS	Provide S. Lemack (AlixPartners) with detailed workplan on the following items: outstanding requests, weekly sales, cash report, and customer programs report	1.40
03/02/20	DS	Provide data to S. Lemack (AlixPartners) re: monthly flash report	0.70
03/02/20	DS	Correspondence with S. Lemack (AlixPartners) re: Rhodes review of weekly sales report	0.20
03/02/20	MH	Update noticing information for vendors whose notices were sent to the Debtors address.	0.40
03/02/20	MH	Advise client on response to equipment lessor seeking to repossess leased equipment.	0.30
03/02/20	MH	Update the critical vendor tracking report and reconcile to all activity sources.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/02/20	ADD	Conversation with A. DePalma and J. DelConte (both AlixPartners) re: outstanding diligence process.	0.20
03/03/20	JD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: business planning progress and work plan going forward.	0.70
03/03/20	JD	Review historical diligence requests from the unsecured creditors committee and the ad hoc committee since the bankruptcy filing.	1.70
03/03/20	JD	Review the status of the latest diligence requests and responses, progress on document redactions, and timing to upload remaining documents.	0.70
03/04/20	JD	Draft an agenda for the meeting with PJT, AlixPartners, Davis Polk and management on Thursday re: case update.	0.70
03/04/20	JD	Correspondence with C. McMillian (Davis Polk) and A. DePalma (AlixPartners) re: board material diligence requests.	0.60
03/04/20	JD	Correspondence with Associate General Counsel re: communications with various business development partners.	0.40
03/04/20	JD	Correspondence with J. Lowne (Purdue) re: autoinjector reporting requirements. Review order re: same.	0.30
03/04/20	DS	Correspondence with S. Lemack (AlixPartners) re: review process for weekly sales report	0.40
03/05/20	JD	Review correspondence from C. McMillian (Davis Polk) and A. DePalma (AlixPartners) re: due diligence requests and proposed diligence materials.	0.40
03/05/20	JD	Review updated MA AG and UCC diligence questions and proposed responses.	0.50
03/05/20	JD	Coordinate schedules and plan meetings for business plan	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/05/20	JD	presentation reviews with management and advisors. Call with A. DePalma and J. DelConte (both AlixPartners) re: open diligence questions.	0.20
03/05/20	NAS	Review motion for extension of preliminary injunction and supporting declaration.	0.80
03/05/20	NAS	Call with R. Collura, M. Hartley, and N. Simon (all AlixPartners) to discuss TXP Services data request process.	0.50
03/05/20	RC	Call with R. Collura, M. Hartley, and N. Simon (all AlixPartners) to discuss TXP Services data request process.	0.50
03/05/20	MH	Call with R. Collura, M. Hartley, and N. Simon (all AlixPartners) to discuss TXP Services data request process.	0.50
03/05/20	MH	Prepare for call with supply chain management on treatment of vendors with caps in trade agreements.	0.90
03/05/20	MH	Research legal invoices to Rhodes to prepare response to collection notices.	0.60
03/06/20	MH	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, H. Ku, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call (partial attendance).	0.70
03/06/20	FOS	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	MFR	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/06/20	LJD	Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	GJK	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, H. Ku, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	IA	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	HK	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, H. Ku, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call (partial attendance).	0.30
03/06/20	RC	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	DS	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, H. Ku, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/06/20	JD	Review correspondence from R. Aleali (Purdue) re: HR diligence files.	0.30
03/06/20	JD	Update agenda for internal AlixPartners call.	0.60
03/06/20	JD	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	JD	Correspondence with A. DePalma (AlixPartners) re: data room structure	0.20
03/06/20	ADD	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	JDH	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, H. Ku, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	KM	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, H. Ku, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call (partial attendance).	0.70
03/06/20	RDS	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/09/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners)	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		re: case progress check and ongoing work streams.	
03/09/20	JD	Review data room files for files that can be initially produced for new committees.	0.50
03/09/20	JD	Review and comment on draft responses to various questions received from the Ad Hoc Committee.	0.70
03/09/20	NAS	Review and revise request tracker to be sent to TXP Services.	0.40
03/10/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: case progress.	1.10
03/10/20	JD	Review open diligence list and status of proposed responses.	0.40
03/10/20	JD	Correspondence with C. MacDonald (Purdue) re: open professional fee invoices.	0.30
03/10/20	JD	Review materials provided to Purdue legal to be responsive to UCC diligence questions.	0.70
03/10/20	JD	Correspondence with Davis Polk re: open UCC diligence questions.	0.80
03/11/20	JD	Develop Purdue travel plan and contingency work plans.	2.00
03/11/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: case update.	0.30
03/11/20	JD	Meeting with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: open diligence questions and approval process.	0.50
03/11/20	JD	Catch up call with B. Folse and J. DelConte (both AlixPartners) re: go forward planning.	0.20
03/11/20	BF	Catch up call with B. Folse and J. DelConte (both AlixPartners) re: go forward planning.	0.20
03/12/20	BF	Catch up call with B. Folse and J. DelConte (both AlixPartners) re: go forward planning.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/12/20	LJD	Participate in a call with J. O'Connell, J. Turner (both PJT), M. Huebner, T. Graulich (both Davis Polk), J. Lowne, R. Aleali (both Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	0.50
03/12/20	JD	Catch up call with B. Folse and J. DelConte (both AlixPartners) re: go forward planning.	0.20
03/12/20	JD	Participate in a call with J. O'Connell, J. Turner (both PJT), M. Huebner, T. Graulich (both Davis Polk), J. Lowne, R. Aleali (both Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	0.50
03/12/20	JD	Review and provide ordinary course professional tracker. Provide comments re: same.	0.80
03/12/20	JD	Update Purdue travel planning and go forward team planning.	0.50
03/12/20	JD	Review executive team bios and job description details re: DOJ diligence questions.	0.80
03/12/20	JD	Analyze historical sales and promotion spending, historical Avrio operating profitability, historical Avrio cost allocations and new brokerage agreements.	2.10
03/12/20	JD	Review detailed Avrio innovation forecasts.	0.60
03/13/20	JD	Review ongoing workstreams and prepare agenda for weekly update call.	0.40
03/13/20	JD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	JD	Call with J. DelConte (AlixPartners) and Associate General Counsel re: case progress and ongoing work streams.	0.40
03/13/20	JD	Review materials previously provided to the UCC and AHC	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		via email against materials posted to the dataroom.	
03/13/20	JD	Review draft Ad Hoc Committee diligence responses and associated diligence materials.	0.80
03/13/20	DS	Prepare for and attend conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	NAS	Prepare for weekly AlixPartners engagement team coordination call.	0.50
03/13/20	NAS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	RC	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	LJD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	BF	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	FOS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N.	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/13/20	MH	Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	GJK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	HK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call (partial attendance).	0.80
03/13/20	IA	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	RDS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	KM	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re:	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		weekly AlixPartners team update call.	
03/13/20	ADD	Prepare for AlixPartners Purdue engagement team update call.	0.30
03/13/20	ADD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/16/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) re: DOJ due diligence requests.	0.20
03/16/20	DS	Correspondence with S. Lemack (AlixPartners) re: diligence approval process	0.20
03/16/20	JD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: case work stream coordination and business plan progress.	0.40
03/16/20	JD	Call with J. Lowne (Purdue), R. Schnitzler (PJT), and J. DelConte (AlixPartners) re: business plan progress.	0.40
03/16/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) re: DOJ due diligence requests.	0.20
03/16/20	JD	Call with J. Turner (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.30
03/17/20	NAS	Review motions related to extension of preliminary injunction.	0.40
03/18/20	NAS	Attend (telephonically) 3/18 Purdue Pharma hearing and review docket filings related to extension of preliminary injunction.	3.10
03/18/20	JD	Prepare agenda for biweekly update call and talking points for discussion with management and advisors.	0.60
03/18/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: court update and outstanding diligence requests.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/18/20	DS	Draft detailed workplan to I. Arana and S. Lemack (both AlixPartners) re: reporting items	1.20
03/19/20	DS	Follow up with Purdue analyst re: outstanding request items	0.30
03/19/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: case progress and open items.	0.60
03/19/20	JD	Call with J. Turner (PJT), M. Atkinson (Province), and J. DelConte (AlixPartners) re: business status.	0.20
03/20/20	RC	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	NAS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	DS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	JD	Review ongoing workstreams and prepare agenda and talking points for weekly AlixPartners coordination and update call.	0.40
03/20/20	JD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/20/20	IA	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	SJC	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	HK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	GJK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	MH	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	FOS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	BF	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/20/20	MFR	Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	LJD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	ADD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	ADD	Prepare for weekly AlixPartners team update call.	0.50
03/20/20	KM	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	RDS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/23/20	JD	Prepare team coordination plan for business planning workstream.	0.40
03/23/20	JD	Correspondence with Davis Polk and Wiggins & Dana re:	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		diligence process.	
03/23/20	JD	Call with R. Collura and J. DelConte (both AlixPartners) to discuss license agreements and related responses to the UCC's requests.	0.50
03/24/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Aleali (Purdue) to discuss third party information and MDL production	0.60
03/24/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Hoff (Wiggin and Dana) to discuss materials produced during the MDL.	0.30
03/24/20	JD	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes updates.	0.30
03/24/20	RDS	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes updates.	0.30
03/24/20	KM	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes updates.	0.30
03/24/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Aleali (Purdue) to discuss third party information and MDL production	0.60
03/24/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Hoff (Wiggin and Dana) to discuss materials produced during the MDL.	0.30
03/25/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: diligence process.	0.20
03/25/20	JD	Call with C. Robertson (Davis Polk) and J. DelConte (AlixPartners) re: open items and information sharing.	0.20
03/26/20	JD	Call with J. O'Connell, R. Schnitzler, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman (both Purdue), L. Donahue, G. Koch, and J. DelConte (all AlixPartners) re: case progress update and planning call.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/26/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: diligence materials review.	0.30
03/26/20	JD	Call with C. Oluwole (Davis Polk), M. Florence (Skadden), R. Aleali (Purdue), T. Melvin (PJT), J. DelConte, and A. DePalma (both AlixPartners) re: DOJ requests.	0.40
03/26/20	ADD	Call with C. Oluwole (Davis Polk), M. Florence (Skadden), R. Aleali (Purdue), T. Melvin (PJT), J. DelConte, and A. DePalma (both AlixPartners) re: DOJ requests.	0.40
03/27/20	ADD	Prepare for weekly AlixPartners team update call.	0.50
03/27/20	JD	Correspondence with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) re: diligence productions.	0.50
03/27/20	JD	Review HRT funding motions and declarations and provide comments re: same.	0.80
03/27/20	JD	Review and provide comments on agenda for weekly call.	0.30
03/27/20	JD	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	JD	Finalize DOJ responses for Duff & Phelps and prepare for production.	0.70
03/30/20	ADD	Update Purdue Interested Party list at request of Davis Polk.	3.30
04/01/20	JD	Review ongoing work streams and plan go forward staffing.	0.50
04/01/20	JD	Review ongoing work stream progress and create agenda for update call with management, Davis Polk and PJT.	0.60
04/01/20	SJC	Review and compilation of distributions for selected transactions.	3.00
04/01/20	SJC	Review and compilation of distributions for selected	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		transactions (continued).	
04/02/20	SJC	Review and compilation of distributions for selected transactions.	3.20
04/02/20	SJC	Review and compilation of distributions for selected transactions (continued).	3.00
04/02/20	JD	Review documents being produced in response to various diligence questions from the UCC and AHC.	0.80
04/02/20	JD	Review materials provided in response to certain business development agreements.	0.50
04/02/20	JD	Review open questions from the department of labor and associated responses.	0.30
04/02/20	JD	Review diligence question list from Duff & Phelps and review data room for potential responses.	0.60
04/03/20	DS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	JDH	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	JD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	SJC	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	IA	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley,	0.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	
04/03/20	SKL	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	LJD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	MFR	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	GJK	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	FOS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	MH	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	ADD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/06/20	SJC	Compile distribution support for ex-us distributions.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/08/20	DS	Review draft Customer Programs report.	0.30
04/09/20	JD	Meeting with G. Koch, M. Hartley, L. Donahue (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	0.40
04/09/20	MH	Meeting with G. Koch, J. DelConte, L. Donahue (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	0.40
04/10/20	MH	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	FOS	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	MFR	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	LJD	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	LJD	Call with J. DelConte, L. Donahue (both AlixPartners) re: follow up questions from the Board on the business plan presentation.	0.20
04/10/20	SJC	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue,	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/10/20	SKL	M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners) re: follow up questions from the Board on the business plan presentation.	0.20
04/10/20	JD	Call with J. Turner (PJT) re: Rhodes planning.	0.30
04/10/20	JD	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	NAS	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	IA	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	RC	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	ADD	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	ADD	Prepare for AlixPartners Purdue engagement team update	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		call.	
04/10/20	KM	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	RDS	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/12/20	JD	Call with C. Robertson (Davis Polk) re: HRT motion. Research federal and state spending on Naloxone.	0.50
04/13/20	MH	Scheduled transitions of case management responsibilities to new consultants.	0.50
04/13/20	KM	Coordination of Rhodes business plan implementation effort.	0.20
04/14/20	JD	Review materials provided for RxPricing data examples.	0.70
04/14/20	JD	Review correspondence and materials proposed to be produced for various UCC diligence requests.	1.00
04/14/20	JD	Correspondence with C. Robertson (Davis Polk) and E. Kardos (AlixPartners) re: fee examiner and interim fee applications.	0.50
04/15/20	JD	Review updated contract signing authority listing.	0.30
04/15/20	JD	Review latest third party consent forms and latest presentations given those permissions.	0.40
04/15/20	JD	Review 363 primer materials from Davis Polk to share with Purdue.	0.50
04/16/20	JD	Call with R. Aleali (Purdue) re: updated case progress and outstanding work streams.	0.50
04/16/20	JD	Call with E. Vonnegut, T. Graulich (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte (both AlixPartners) re: case update and team coordination.	
04/16/20	JD	Review UCC diligence request and progress to date on providing certain items. Look through Intralinks to see what has been uploaded.	1.00
04/16/20	ADD	Research specific entity included in conflict list at request of Davis Polk.	0.60
04/17/20	KM	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	ADD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	JDH	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	RDS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	JD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	JD	Correspondence with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) re: diligence materials and VDR costs. Review Intralinks quotes and contract.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/17/20	DS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	IA	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	NAS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	FOS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	LJD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	MFR	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	SKL	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	SJC	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/19/20	LJD	Review correspondence re: creditor presentation	0.30
04/19/20	LJD	Review and comment on monthly reporting package.	1.50
04/19/20	LJD	Review the creditor presentation.	1.60
04/19/20	LJD	Work on staffing issues.	0.30
04/19/20	JD	Correspondence with A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: next steps in providing certain materials to the creditor groups.	0.40
04/20/20	JD	Review correspondence re: permission to disclose Nielsen data.	0.40
04/20/20	JD	Correspondence with E. Diggs (Davis Polk) and H. Ku (AlixPartners) re: contract database comparison. Review Intralinks for uploaded contracts.	1.00
04/20/20	JD	Correspondence with E. Kardos (AlixPartners) and C. Robertson (Davis Polk) re: hearing on Wednesday.	0.20
04/20/20	JD	Correspondence with E. Kardos (AlixPartners) re: fee examiner.	0.30
04/20/20	LJD	Review and comment on revised creditor presentation.	1.10
04/20/20	LJD	Update call with PJT.	0.40
04/20/20	LJD	Call with K. Buckfire (Board member)	0.70
04/20/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.40
04/21/20	LJD	Review correspondence.	0.30
04/21/20	JD	Review correspondence from A. DePalma (AlixPartners) re: redaction search terms.	0.30
04/21/20	JD	Call with J. DelConte, R. Collura (both AlixPartners) re: hearing preparation questions.	0.20
04/21/20	JD	Review creditor diligence emails to provide to Davis Polk in preparation for court hearing.	1.00
04/21/20	JD	Review historical billings and create summary of forensic	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		billings.	
04/21/20	RC	Call with J. DelConte, R. Collura (both AlixPartners) re: hearing preparation questions.	0.20
04/22/20	JD	Call with J. Turner (PJT) re: post D&P catch up call.	0.20
04/22/20	JD	Correspondence with J. Turner (PJT) re: buyers log.	0.30
04/22/20	JD	Review and edited latest creditor presentation.	0.70
04/22/20	JD	Review updated Project Catalyst slide.	0.40
04/22/20	JD	Review summary of contract listings from Intralinks and from DPW site.	0.70
04/22/20	JD	Review draft board minutes to posted for creditor advisors.	1.00
04/23/20	JD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case progress and go forward planning.	0.70
04/23/20	JD	Review interim fee application order and check AlixPartners figures against fee applications.	0.30
04/23/20	JD	Correspondence with K. Laurel (Purdue) re: employee stats.	0.40
04/23/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence.	0.30
04/23/20	JD	Meeting with M. Huebner (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Kesselman (Purdue), S. Birnbaum (Dechert) and the mediators re: question and answer session.	2.40
04/23/20	LJD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) re: case progress and go forward planning.	
04/23/20	LJD	Review and comment on creditor deck.	1.50
04/23/20	RDS	Preparation for discussion on Project Catalyst.	0.40
04/23/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty (AlixPartners) re: Project Catalyst analysis.	1.10
04/23/20	RDS	Create scenario analysis slide reviewing a fill-the-plant scenario.	1.30
04/23/20	RDS	Call with R. Schnitzler, J. Turner (both PJT), P. Strassburger, D. Lundie, J. Lowne, (all Purdue), K. McCafferty (AlixPartners) re: Project Catalyst	0.50
04/23/20	RDS	Comment on external lender informational document.	1.00
04/23/20	KM	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case progress and go forward planning.	0.70
04/24/20	KM	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	ADD	Review current status of diligence work stream in preparation for AlixPartners engagement team update call.	0.50
04/24/20	ADD	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	RDS	Analysis of Customer and Product Profitability -DAG.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/24/20	RDS	Analysis of IQVIA data to draw insight for API partnership revenue growth assumptions.	1.20
04/24/20	RDS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	LJD	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	LJD	Weekly update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.20
04/24/20	LJD	Update call with K. Buckfire (Board member).	0.20
04/24/20	MFR	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	GJK	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	FOS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	SJC	Review support for 2015 distributions (continued).	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/24/20	SJC	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	SKL	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	JD	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	JD	Correspondence with D. Consola (Davis Polk) re: fee examiner.	0.20
04/24/20	DS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	JDH	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	RC	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/24/20	NAS	Prepare for AlixPartners Purdue engagement team weekly update call.	0.50
04/24/20	NAS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	IA	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/27/20	LJD	Review board deck for meeting on 4/30.	1.50
04/29/20	LJD	Call with J. Dubel (Purdue) re: expectations for April 30 board meeting.	0.60
04/29/20	LJD	Review and respond to email correspondence.	0.40
04/29/20	LJD	Review updated info for board meeting.	1.50
04/29/20	JD	Call with R. Aleali (Purdue) re: proposed diligence responses.	0.30
04/29/20	JD	Follow up call with R. Aleali (Purdue) re: open diligence items.	0.20
04/29/20	JD	Review Rhodes transformation proposal and correspondence with J. Lowne (Purdue) re: same.	0.50
04/29/20	JD	Correspondence with J. Lowne (Purdue), T. Melvin (PJT) and A. DePalma (AlixPartners) re: diligence responses.	0.60
04/30/20	IA	Review March ordinary course professionals' payments report to be filed.	0.80
04/30/20	LJD	Prepare for and attend Purdue board meeting.	4.20
05/01/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	
05/01/20	MFR	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	RC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	
05/01/20	JD	Call with R. Aleali (Purdue) re: post hearing catch up.	0.40
05/01/20	ADD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	JDH	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/04/20	JD	Call with R. Aleali (Purdue) re: update on business plan call, due diligence update and go forward planning.	1.20
05/04/20	JD	Review previous fee statements and respond to questions from J. Lowne (Purdue).	0.80
05/04/20	LJD	Update call with PJT.	0.40
05/04/20	LJD	Debrief call with J. Dub el (Purdue board member).	0.60
05/05/20	LJD	Review communication.	0.50
05/05/20	JD	Review of AlixPartners invoice with J. Lowne (Purdue).	0.30
05/05/20	JD	Review AlixPartners February invoice prior to review call with J. Lowne (Purdue).	0.40
05/06/20	JD	Call with J. DelConte and L. Donahue (both AlixPartners) re: case progress and go forward planning.	0.50
05/06/20	LJD	Call with J. DelConte and L. Donahue (both AlixPartners) re: case progress and go forward planning.	0.50
05/06/20	LJD	Review and comment on updated UCC deck.	1.10
05/07/20	LJD	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT) and L. Donahue, J. DelConte (both AlixPartners).	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/07/20	LJD	Call with M. Huebner (Davis Polk) re: case update.	0.30
05/07/20	LJD	Review correspondence.	0.50
05/07/20	JD	Prepare for weekly update call with PJT, AlixPartners, DPW and management.	0.30
05/07/20	JD	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT) and L. Donahue, J. DelConte (both AlixPartners).	0.90
05/07/20	JD	Call with R. Aleali (Purdue) re: catch up post weekly call.	0.30
05/08/20	RC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	JD	Review status of open items in preparation for weekly update call.	0.30
05/08/20	JD	Call with R. Aleali (Purdue) re: open items and go forward planning.	1.00
05/08/20	JD	Call with R. Collura, J. DelConte (both AlixPartners) re: status of the intercompany and non-cash transfers report and special committee related work.	0.30
05/08/20	LJD	Call with M. Huebner (Davis Polk) re: Purdue update.	0.30
05/08/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A.	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/08/20	MFR	DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	FOS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	JDH	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	KM	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A.	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	
05/08/20	ADD	Compile Rhodes' counterparties to use for search terms to redact for third-party information.	1.20
05/08/20	ADD	Prepare for Purdue AP Team update call.	0.40
05/08/20	ADD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	RDS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/11/20	IA	Call with I. Arana and J. DelConte (both AlixPartners) re: current work plan.	0.30
05/11/20	JD	Call with I. Arana and J. DelConte (both AlixPartners) re: current work plan.	0.30
05/12/20	HK	Provide contract copies and supporting data per PrimeClerk request on behalf of contract counterparty.	0.20
05/13/20	JD	Prepare draft agenda for 5/14 call with Davis Polk, PJT, AlixPartners and Purdue.	0.70
05/13/20	JD	Review correspondence from C. Oluwole (Davis Polk) re: 2004 discovery requests.	0.30
05/15/20	RC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) re: Weekly team update call.	
05/15/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	JD	Review family response to NY AG press release.	0.30
05/15/20	JD	Review and provide comments on the agenda for the weekly call.	0.20
05/15/20	JDH	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	FOS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) re: Weekly team update call.	
05/15/20	MFR	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	RDS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	ADD	Prepare for AlixPartners Purdue engagement team updated call.	0.50
05/15/20	ADD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	KM	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/19/20	LJD	Call with PJT.	0.30
05/19/20	JD	Call with E. Vonnegut (Davis Polk) re: confirmation process.	0.50
05/19/20	JD	Review and provide comments monthly Nalmafene spending report in order to get it posted for creditor advisors.	0.50
05/20/20	JD	Call with C. Oluwole (Davis Polk), R. Aleali (Purdue), T. Melvin (PJT), A. DePalma and J. DelConte (both	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/20/20	ADD	AlixPartners) re: buyer log. Call with C. Oluwole (Davis Polk), R. Aleali (Purdue), T. Melvin (PJT), A. DePalma and J. DelConte (both AlixPartners) re: buyer log.	0.40
05/21/20	JD	Participate in weekly update call with T. Coleman, J. Turner, J. O'Connell (all PJT), M. Huebner, T. Graulich, C. Robertson (all Davis Polk), M. Kesselman, J. Lowne, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: status update and go forward planning.	0.70
05/21/20	LJD	Participate in weekly update call with T. Coleman, J. Turner, J. O'Connell (all PJT), M. Huebner, T. Graulich, C. Robertson (all Davis Polk), M. Kesselman, J. Lowne, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: status update and go forward planning.	0.70
05/21/20	GJK	Participate in weekly update call with T. Coleman, J. Turner, J. O'Connell (all PJT), M. Huebner, T. Graulich, C. Robertson (all Davis Polk), M. Kesselman, J. Lowne, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: status update and go forward planning.	0.70
05/22/20	MFR	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	LJD	Update call with L. Donahue, J. DelConte (both AlixPartners) re: staffing considerations.	0.30
05/22/20	FOS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		team update call.	
05/22/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	JD	Update call with L. Donahue, J. DelConte (both AlixPartners) re: staffing considerations.	0.30
05/22/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	JD	Review and provide comments on agenda for AlixPartners call.	0.30
05/22/20	RC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	
05/22/20	KM	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	RDS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/23/20	JD	Review and provide comments on Prime Clerk invoice summary. Correspondence with Davis Polk re: same.	0.50
05/26/20	LJD	Review April financial results presentations and other pre-reads.	2.10
05/26/20	LJD	Review Rhodes organizational realignment deck and provide comments.	0.80
05/27/20	JD	Call with J. Doyle (Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Rhodes Tech agreements.	0.30
05/27/20	ADD	Call with J. Doyle (Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Rhodes Tech agreements.	0.30
05/29/20	ADD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	ADD	Prepare for AlixPartners Purdue engagement team update meeting.	0.40
05/29/20	ADD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	KM	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma,	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/29/20	RDS	A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	JD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.40
05/29/20	JD	Review ongoing work streams and prepare agenda for weekly AlixPartners call.	0.80
05/29/20	JD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.50
05/29/20	NAS	Call with J. DelConte and L. Donahue (both AlixPartners) re: case planning and staffing updates.	0.80
05/29/20	RC	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	LJD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.50
05/29/20	LJD	Call with J. DelConte and L. Donahue (both AlixPartners) re: case planning and staffing updates.	0.80
05/29/20	MFR	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/29/20	GJK	McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	SJC	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	SKL	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
Total			392.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Lisa Marie Bonito	0.20	450.00	90.00
Andrew D DePalma	21.30	515.00	10,969.50
Sam K Lemack	8.40	515.00	4,326.00
Nate A Simon	16.50	515.00	8,497.50
Hart Ku	4.60	515.00	2,369.00
Fernando O Silva	9.10	645.00	5,869.50
Sam J Canniff	26.70	645.00	17,221.50
David Samikkannu	43.30	690.00	29,877.00
Isabel Arana de Uriarte	16.70	690.00	11,523.00
Jon D Hecht	6.30	690.00	4,347.00
Elizabeth S Kardos	1.40	710.00	994.00
Ryan D Sublett	17.20	735.00	12,642.00
Michael Hartley	12.40	840.00	10,416.00
Gabe J Koch	10.50	840.00	8,820.00
Mark F Rule	9.80	910.00	8,918.00
Jesse DelConte	113.60	950.00	107,920.00
Kevin M McCafferty	17.00	950.00	16,150.00
Richard Collura	10.30	1,090.00	11,227.00
Barry Folse	4.60	1,090.00	5,014.00
Lisa Donahue	42.30	1,195.00	50,548.50
Total Hours & Fees	392.20		327,739.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
02/03/20	SKL	Review the latest EastWest cash activity and categorize accordingly for the weekly cash report	2.10
02/03/20	SKL	Review the latest IAC cash activity and prepare list of open items and questions for J. Liceaga (TXP), R. Haberman, and E. Nowakowski (both Purdue).	1.40
02/03/20	SKL	Prepare updated Purdue and Rhodes cash summaries for the weekly cash report.	1.40
02/04/20	SKL	Review historical AIP and LTRP payments and prepare an updated summary per HR request.	1.60
02/04/20	SKL	Prepare for and participate in meeting with E. Nowakowski (Purdue) to discuss outstanding IAC questions re: weekly cash reporting.	0.40
02/04/20	SKL	Review and reconcile the latest Paysource transaction information and update the weekly cash report accordingly.	1.50
02/04/20	SKL	Prepare updates to the Purdue forecast and update the forecast-to-variance slides re: weekly cash reporting.	1.50
02/04/20	SKL	Prepare updates to the Rhodes forecast and update the forecast-to-variance slides re: weekly cash reporting.	1.30
02/04/20	SKL	Review the docket for the latest fee applications filed and update the retained and restructuring professional trackers accordingly.	1.30
02/04/20	SKL	Finalize updates to the weekly cash report and prepared for distribution for final review.	2.10
02/04/20	IA	Review paysource payments for the week ended 01/31	1.20
02/05/20	IA	Review of Purdue actuals tracking for week ended 01/31	2.10
02/05/20	SKL	Begin review and reconciliation of the December rebate payments and began updating the Customer Programs report accordingly.	2.30
02/05/20	SKL	Prepare and update the Medicare Part D and Coverage	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
02/05/20	SKL	Gap Payments sections re: Customer Programs report.	1.20
02/05/20	SKL	Prepare and update the GPO and Co-payments sections re: Customer Programs report.	2.30
02/05/20	SKL	Prepare the updated deck re: Customer Programs report and circulate for review and sign-off.	1.40
02/05/20	SKL	Update the forecast-to-variance analysis re: weekly cash reporting, based on the latest feedback provided.	0.90
02/05/20	SKL	Finalize reconciliation of the latest GPO payments and put together updated list of action items/outstanding items for the company to review and provide feedback on re: Customer Programs report.	2.10
02/06/20	SKL	Review the latest operational and financial information provided re: Monthly Flash report and begin preparing the updated report accordingly.	2.10
02/06/20	SKL	Finalize updates to the Customer Programs report and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.00
02/06/20	SKL	Finalize updates to the Weekly Cash report and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.00
02/06/20	DS	Correspondence with R. Sublett (AlixPartners) re: draft workplan for Avrio business plan workstream	2.30
02/07/20	SKL	Continue to review the latest operational / financial summary provided by R. Aleali (Purdue) and prepare updates to the December Flash report accordingly.	1.50
02/07/20	SKL	Prepare the redacted version of the Custom Programs report and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.30
02/07/20	SKL	Make final updates to the Cash Report and Customer Programs Report and provide to the DPW team to upload for advisors.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
02/07/20	SKL	Review the December MOR and prepare updated slides re: Consolidated Balance Sheet information re: Monthly Flash Report.	1.30
02/07/20	SKL	Continue to make final updates to the Monthly Flash Report and prepare and provide an update to the team re: outstanding items.	1.00
02/10/20	SKL	Review the latest EastWest cash activity provided by J. Liceaga (TXP) and categorize the transactions.	2.30
02/10/20	SKL	Review and reconcile the latest Paysource cash activity and categorize for the weekly cash report.	1.70
02/10/20	SKL	Review and reconcile the latest investment activity report provided by J. Liceaga (TXP) and update the cash actuals summary accordingly.	1.40
02/10/20	SKL	Review and reconcile the latest IAC cash activity and prepare list of questions for J. Liceaga (TXP) and E. Nowakowski (Purdue).	2.00
02/10/20	SKL	Prepare the updated weekly cash report and circulate the deck internally for feedback and comments.	2.00
02/10/20	IA	Review updated company weekly collections forecast for Purdue.	0.40
02/10/20	IA	Review cash actuals and Paysource payments for week ended 02/07	2.20
02/11/20	IA	Review Purdue cash actuals report and provided comments to team prior to review by management.	1.40
02/11/20	IA	Follow up on payments to third party rebate manager for cash actuals reporting variance explanations.	0.60
02/11/20	SKL	Finalize the weekly cash report based on the latest feedback provided by the team and circulate for final sign-off.	2.30
02/11/20	SKL	Prepare updated forecast-to-actuals slides for the weekly	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		cash report for both Purdue and Rhodes.	
02/11/20	SKL	Finalize updates to the monthly Flash Report and circulate internally for final sign-off.	2.50
02/11/20	SKL	Review the docket for the latest fee applications filed and update the Restructuring Professional and Retained Professional trackers.	1.30
02/11/20	DS	Draft detailed follow up request list for Rhodes budget files for purpose of updating cash forecast	0.80
02/11/20	DS	Review draft weekly cash report and send feedback comments to S. Lemack (AlixPartners)	1.80
02/12/20	IA	Review updated cash actuals report for Purdue including rebate detail.	1.30
02/13/20	SKL	Finalize updates to the weekly cash report and circulate the deck for final sign-off.	1.30
02/13/20	DS	Draft response to FTI based on initial questions on cash report	0.40
02/13/20	DS	Retrieve and send old cash forecast to FTI	0.40
02/14/20	DS	Call with I. Arana, D. Samikkannu (both AlixPartners), K. Knechtel, and K. Tirabassi (FTI) re: questions on cash forecast	0.40
02/14/20	JD	Review and provide comments on draft cash report.	0.50
02/14/20	IA	Call with I. Arana, D. Samikkannu (both AlixPartners), K. Knechtel, and K. Tirabassi (FTI) re: questions on cash forecast	0.40
02/18/20	SKL	Review and reconcile the latest EastWest cash report and began categorizing cash transactions for the weekly cash report.	2.30
02/18/20	SKL	Prepare the updated reports for the January Monthly Operating Report re: cash and investment activity and circulate to the team for final sign-off.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
02/18/20	DS	Respond to R. Collura (AlixPartners) re: process of tracking down historical bank activity reports	0.70
02/19/20	DS	Correspondence with R. Collura (AlixPartners) re: follow up process re: historical cash activity	0.50
02/19/20	DS	Draft outline of questions to TXP manager re: historical cash activity tracking	0.40
02/19/20	DS	Call with D. Samikkannu (AlixPartners) and J. Liceaga (TXP) re: process of tracing specific historical cash transactions to old bank systems	0.50
02/19/20	DS	Discussion with R. Collura and D. Samikkannu (both AlixPartners) re: information obtained from call with TXP manager	0.40
02/19/20	RC	Discussion with R. Collura and D. Samikkannu (both AlixPartners) re: information obtained from call with TXP manager	0.40
02/19/20	SKL	Review the latest information re: Customer Rebates and prepare and update the 13-week Rhodes cash forecast accordingly.	2.10
02/19/20	SKL	Prepare updated forecast-to-actuals variance report for the weekly cash report and prepare the updates slides for the weekly cash reporting deck.	1.00
02/19/20	SKL	Finalize review of the IAC and Investment cash activity and prepare list of open items for J. Liceaga (TXP) and E. Nowakowski (Purdue) to provide additional information on.	2.10
02/19/20	SKL	Finalize updates to the Purdue and Rhodes summaries re: weekly cash report.	2.00
02/19/20	SKL	Prepare updates to the 13-week Rhodes cash forecast re: operating expenses.	2.10
02/20/20	SKL	Finalize updates to the weekly cash report and circulate	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		to the AlixPartners team for final review.	
02/21/20	SKL	Finalize updates to the weekly cash report and circulate to J. Lowne (Purdue) for final sign-off.	1.70
02/21/20	SKL	Continue to finalize updates to the latest 13-week cash forecast for Rhodes.	2.60
02/21/20	SKL	Finalize updates to the Retained Professional and Restructuring Professional tracker re: cash forecasts.	2.00
02/21/20	SKL	Finalize updates to the 13-week Cash Forecast summary page for Rhodes and provide update to the AlixPartners team for further review and sign-off.	1.20
02/21/20	IA	Review cash actuals report for the week ended 02/14.	1.40
02/21/20	DS	Review and provide comments to S. Lemack (AlixPartners) re: cash report	1.20
02/22/20	JD	Review and provide comments on the cash report prior to sending it out to management.	0.50
02/24/20	DS	Provide detailed feedback to S. Lemack (AlixPartners) re: Rhodes forecast	1.70
02/24/20	SKL	Continue to update the OpEx and AP section of the Purdue 13-week cash forecast.	2.10
02/24/20	SKL	Update the Purdue 13-week cash forecast with the latest upcoming miscellaneous expenses that J. Lowne (Purdue) provided.	1.30
02/24/20	SKL	Continue to finalize the customer rebate section of the Purdue 13-week cash forecast.	1.50
02/25/20	SKL	Review and reconcile the latest EastWest cash transactions provided by J. Liceaga re: weekly cash reporting.	2.30
02/25/20	SKL	Finalize review of the latest IAC transactions and Investment related transactions for the latest weekly cash report.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
02/25/20	SKL	Review the latest updates provided on the Rhodes 13-week cash forecast, and update the Cash Receipts and OpEx sections accordingly.	2.10
02/25/20	SKL	Finalize updates to the Rhodes 13-week cash forecast deck and circulate to the AlixPartners team for final sign-off and approval.	2.30
02/25/20	SKL	Finalize IAC disbursement/receipt updates for the Purdue and Rhodes 13-week cash forecast.	2.30
02/26/20	SKL	Prepare and finalize the weekly cash reporting deck and circulated to the AlixPartners team for final sign-off.	2.10
02/26/20	SKL	Finalize the remaining updates for the Purdue 13-week cash forecast based on the feedback provided, and circulate final deck to the AlixPartners team for sign-off.	2.20
02/26/20	SKL	Review and reconcile the latest Paysource transactions report and begin categorizing for the weekly cash report.	2.00
02/26/20	DS	Correspondence with S. Lemack (AlixPartners) re: professional fees for cash forecast	0.40
02/27/20	DS	Review and provide detailed comments on cash forecast to S. Lemack (AlixPartners)	1.40
02/28/20	DS	Review final draft of cash forecast and provide approval	0.90
02/28/20	DS	Review and provide comments to draft monthly flash report	1.40
02/28/20	SKL	Make final updates to both the Rhodes and Purdue 13-Week Cash forecast and circulate to J. Lowne (Purdue) for final sign-off.	1.90
03/02/20	SKL	Review, reconcile, and categorize all of the Paysource cash transactions for this week's cash report.	2.10
03/02/20	SKL	Provide cash report, flash report, and cash forecast to the DPW team for final sign-off and upload	0.50
03/02/20	SKL	Review and reconcile the latest EastWest cash	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		transactions and categorize for this week's cash report.	
03/02/20	SKL	Review and reconcile the latest Purdue investment activity for the weekly cash report.	2.40
03/02/20	SKL	Review the latest Purdue and Rhodes IAC activity and prepare list of updates for E. Nowakowski (Purdue) to comment on.	2.00
03/02/20	IA	Meeting with J. Tran (Purdue), D. Sammikkanu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio diligence questions	1.40
03/02/20	DS	Correspondence with J. DelConte (AlixPartners) re: professional fees budget	0.30
03/02/20	DS	Develop and send budget request list to Rhodes team	0.90
03/03/20	SKL	Review and reconcile the latest forecast-to-actuals variances for Purdue and update in the weekly cash report.	1.40
03/03/20	SKL	Review and reconcile the latest forecast-to-actuals variances for Rhodes and update in the weekly cash report.	1.30
03/03/20	SKL	Review the January cash actuals reports to pull the latest Purdue rebate payments and begin categorizing accordingly in the January Customer Programs report.	2.30
03/03/20	SKL	Review the January cash actuals reports to pull the latest Rhodes rebate payments and begin categorizing accordingly in the January Customer Programs report.	2.10
03/03/20	SKL	Begin reconciling the latest Purdue rebates from the cash actuals report against the Purdue rebates report provided by E. Nowakowski (Purdue).	1.90
03/04/20	SKL	Begin reconciling the latest Rhodes rebates from the cash actuals report against the Purdue rebates report provided by R. Haberlin (Purdue).	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/04/20	SKL	Prepare for and participate in Managed Care marketing meeting with B. Shank, M. Ronning (both Purdue), J. DelConte, and S. Lemack (both AlixPartners)	1.20
03/05/20	SKL	Begin reconciling the January Prompt Pay Discounts and update the January Customer Programs Report accordingly.	1.40
03/05/20	SKL	Prepare the updated weekly cash reporting deck and circulate internally for final sign-off.	2.30
03/05/20	SKL	Review and reconcile the latest IAC feedback provided from J. Lineage (TXP) and E. Nowakowski (Purdue) and update the weekly cash report accordingly.	1.30
03/05/20	SKL	Review the latest fee applications filed on the court docket and update the Retained Professional and Restructuring Professional trackers accordingly.	1.70
03/05/20	SKL	Review and reconcile the latest Private Insurance rebates and update the January Customer Programs Report accordingly.	1.00
03/05/20	IA	Review updated cash report for week ended 02.28	1.10
03/05/20	IA	Review updated funding request information received from Purdue rebates manager.	0.60
03/05/20	DS	Review and provide S. Lemack (AlixPartners) with detailed comments on cash report	1.60
03/06/20	JD	Review and provide comments on the weekly cash forecast to actual reporting.	0.50
03/06/20	IA	Review and provide comments to weekly cash report for week ended 02/28	1.70
03/06/20	SKL	Finalize remaining updates to the weekly cash report and circulate to J. Lowne (Purdue) for final sign-off.	2.20
03/06/20	SKL	Review the feedback and action items from the 03/04 Managed Care meeting and prepare updated Purdue	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		timeline.	
03/06/20	SKL	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	SKL	Finalize reconciliation of the Purdue and Rhodes rebate schedules.	1.70
03/09/20	SKL	Finalize updates to the Chapter 11 timeline for the Managed Care follow-up discussion.	1.30
03/09/20	SKL	Review the latest EastWest Cash transactions provided by J. Liceaga (TXP) and categorize accordingly.	2.10
03/09/20	SKL	Review the latest Paysource cash activity re: Weekly Cash Report and categorize accordingly.	1.20
03/09/20	IA	Review cash transactions source files for the week ended 03/06.	1.20
03/10/20	SKL	Review and reconcile the latest Investment activity and update the prior week's cash summaries accordingly	1.70
03/10/20	SKL	Reconcile the Jan GPO fees and update the January Customer Programs report accordingly.	1.30
03/10/20	SKL	Reconcile the January vendor chargebacks and fee for services and update the January Customer Programs report accordingly.	2.00
03/10/20	SKL	Prepare for and participate in meeting with J. Liceaga, O. Ingber (both TXP), and S. Lemack (AlixPartners) to discuss the latest IAC activity re: weekly cash report.	1.10
03/10/20	SKL	Finalize updates to the IAC summaries re: weekly cash reporting and update the deck accordingly.	1.80
03/10/20	SKL	Continue to make updates to the January Flash report re: headcount.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/11/20	SKL	Update the Rhodes Cash Forecast with the latest cash actuals and prepare forecast-to-variance slides.	2.10
03/11/20	SKL	Update the Purdue Cash Forecast with the latest cash actuals and prepare forecast-to-variance slides.	2.40
03/11/20	SKL	Finalize updates to the weekly cash report and circulate the deck for final sign-off and feedback.	2.40
03/11/20	SKL	Review the latest Pipeline report and begin updating the timeline slides accordingly.	1.10
03/11/20	SKL	Review of draft pipeline presentation for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners),	0.60
03/11/20	IA	Review Paysource cash payments for the week ended 03/06 and updated actuals tracking report.	1.10
03/12/20	SKL	Continue to make updates to the latest Purdue timeline and circulate internally for final sign-off and feedback.	1.80
03/12/20	SKL	Update the latest Pipeline report to ensure consistent formatting throughout.	1.40
03/12/20	DS	Review and provide comments to S. Lemack (AlixPartners) on weekly cash report	1.70
03/13/20	SKL	Finalize updates to the weekly cash report and circulate to the team for final sign-off.	1.80
03/13/20	SKL	Update the Customer Programs report with the latest feedback received from Christine Ostrowski discussion re: Private Insurance and Medicare Part D rebates.	2.70
03/13/20	SKL	Prepare for and participate in Customer Programs discussion with C. Ostrowski (Purdue) and S. Lemack (AlixPartners).	0.60
03/13/20	SKL	Prepare the latest Customer Programs deck and circulate internally for final sign-off.	2.30
03/13/20	SKL	Review and reconcile the latest Cumberland funding's re:	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/16/20	SKL	Medicare Part D and Private Insurance Program rebates and update the Customer Programs report accordingly.	0.30
03/16/20	SKL	Call with D. Samikkannu and S. Lemack (both AlixPartners) re: Customer Programs report review.	0.80
03/16/20	SKL	Working session with D. Samikkannu and S. Lemack (both AlixPartners) re: allocation of 3rd party rebate funding's and payments.	1.10
03/16/20	SKL	Finalize updates to the January Flash report and circulate to the AlixPartners team for final review.	2.30
03/16/20	SKL	Continue to finalize updates to the Purdue and Rhodes Private Insurance Program section of the Customer Programs Report.	1.10
03/16/20	SKL	Additional updates to the GPO section of the January Customer Programs Report.	2.80
03/16/20	SKL	Prepare additional sections to the Private Insurance and Medicare Part D section of the January Customer Programs Report and circulate to C. Ostrowski (Purdue) for final sign-off.	0.60
03/17/20	IA	Review Paysource payments for week ended 03/13	2.40
03/17/20	SKL	Finalize updates to the latest Pipeline deck and circulate to the AlixPartners team for final sign-off.	2.40
03/17/20	SKL	Finalize remaining updates to the January Customer Programs Report and circulate to the AlixPartners team for final sign-off.	1.20
03/17/20	SKL	Begin review of the latest weekly cash transactions and begin categorization of the EastWest bank transactions accordingly.	2.40
03/18/20	SKL	Review the February cash reports and to update and format for the February Monthly Operating Report.	2.70
03/18/20	SKL	Reconcile and put together the updated report re:	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/18/20	SKL	February investment activity for the Monthly Operating Report and circulate to the TXP team for final sign-off.	1.70
03/19/20	SKL	Finalize reconciliation of the cash and investment activity for the month of February and circulate the updated information for the February Monthly Operating Report.	1.90
03/19/20	SKL	Review and reconcile the latest Paysource transactions and begin categorizing accordingly re: weekly cash reporting.	1.40
03/19/20	SKL	Finalize review of the latest investment activity and update the Purdue and Rhodes cash summaries accordingly.	2.00
03/19/20	DS	Review and reconcile the latest IAC cash activity re: weekly cash reporting, and circulate list of outstanding cash inquiries to E. Nowakowski (Purdue) and J. Liceaga (TXP).	1.80
03/19/20	DS	Review Rhodes Controller's commercial files underlying FY 2020 budget	2.00
03/20/20	SKL	Update Rhodes cash flow model for sales forecasts by individual product	0.60
03/20/20	SKL	Prepare for and participate in Purdue workstream update call with the AlixPartners team.	2.70
03/20/20	SKL	Reconcile the latest cash transaction information from J. Liceaga (TXP) and update the weekly cash report accordingly.	2.10
03/20/20	SKL	Finalize the weekly cash report and prepare updated list of outstanding items for E. Nowakowski (Purdue) re: weekly cash report.	1.10
03/20/20	SKL	Finalize the remaining updates for the January Flash report and circulate to J. Lowne and R. Aleali (both Purdue) for final review and sign-off.	1.80
03/20/20	SKL	Continue to review and finalize updates to the latest	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		version of the Purdue Business Plan deck.	
03/23/20	SKL	Review and reconcile the latest Accounts Receivable pulldown from SAP and begin categorizing and formatting the file to implement in the upcoming Rhodes 13-week cash forecast.	2.40
03/23/20	SKL	Finalize reconciliation of the latest fee applications filed by Retained Professionals and update the Retained Professional tracker accordingly.	2.30
03/23/20	SKL	Finalize reconciliation of the latest fee applications filed by Retained Professionals and update the Restructuring Professional tracker accordingly.	2.70
03/23/20	SKL	Prepare updated DSO and DPO analyses to be used in the upcoming Rhodes 13-week cash forecast.	1.90
03/23/20	IA	Review and provide comments to Purdue cash actuals report for week ended 03.13.2020	1.40
03/23/20	IA	Review recent Medicaid and commercial rebate payments through third party vendor.	1.10
03/24/20	IA	Review paysource payments for the week ended 03.20.2020	1.30
03/24/20	SKL	Finalize updates to the Cash Actuals report (week ended 03/13) and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.80
03/24/20	SKL	Review and reconcile the latest East West cash report provided by J. Liceaga (TXP) and categorize the transactions accordingly.	2.10
03/24/20	SKL	Review and reconcile the latest Paysource transaction report and categorize the transactions accordingly.	1.80
03/24/20	SKL	Finalize review of the latest cash transaction reports and prepare list of open questions to J. Liceaga (TXP) and E. Nowakowski (Purdue).	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/24/20	SKL	Update the latest cash forecasts with the latest cash actuals and begin reviewing discrepancies between the forecast and actuals.	1.80
03/24/20	SKL	Continue to update the latest Rhodes 13-week cash forecast and begin making updates to the rebate section of the forecast.	1.80
03/24/20	JD	Review and provide comments on latest cash forecast to actual analysis.	0.50
03/25/20	DS	Update product detail of sales budget in Rhodes cash forecast model, tying out to P&L	2.60
03/25/20	SKL	Prepare and finalize updates to the customer and other receipt section of the latest Rhodes 13-week cash forecast.	2.40
03/25/20	SKL	Finalize updates to the IAC disbursement section of the latest Rhodes 13-week cash forecast.	1.20
03/25/20	SKL	Finalize updates to the IAC receipt section of the latest Rhodes 13-week cash forecast.	1.20
03/25/20	SKL	Begin rolling forward the previous Rhodes 13-week cash forecast and update the summary section of the latest Rhodes 13-week cash forecast.	2.30
03/25/20	SKL	Review and reconcile the latest Accounts Payable pulldown from SAP and begin categorizing and formatting the file to implement in the upcoming Rhodes 13-week cash forecast.	2.50
03/26/20	SKL	Continue to reconcile and prepare updated IAC disbursement/receipt summaries re: weekly cash reporting.	2.40
03/26/20	SKL	Finalize updates to the operating expense section of the latest Rhodes 13-week cash forecast.	2.60
03/26/20	DS	Update cost by product in Rhodes cash flow model (revise	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		for FY 2020 budget)	
03/27/20	DS	Review of weekly cash report	0.40
03/27/20	JD	Review and provide comments on weekly cash forecast to actual analysis.	0.60
03/27/20	SKL	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	SKL	Update the Purdue and Rhodes cash summaries re: weekly cash actuals, based on the latest information provided by E. Nowakowski (Purdue) and J. Liceaga (TXP).	2.60
03/27/20	SKL	Finalize the latest forecast-to-actuals analysis for the Purdue slides of the weekly cash report.	1.50
03/27/20	SKL	Finalize the latest forecast-to-actuals analysis for the Rhodes slides of the weekly cash report.	1.20
03/27/20	SKL	Prepare and finalize the weekly cash report deck and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.70
03/27/20	IA	Analysis of historical Purdue net sales trends to inform updated collections forecast.	1.10
03/27/20	IA	Review cash actuals report for week ended 03/20/2020	0.70
03/27/20	IA	Update Purdue cash forecast customer collections based on company short term forecast and actual run rates.	1.20
03/30/20	IA	Modify Purdue cash forecast model for 13 week period starting with week ended 03/27, included actuals, and modified operating expense assumptions.	2.30
03/30/20	IA	Recalculate outgoing benefit payments (LTRP, AIP and Retention) in the week of 04/03 to update payroll and	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		benefit payment estimates for Purdue and Rhodes	
03/30/20	SKL	Finalize updates to the weekly cash reporting summaries based on the feedback received from E. Nowakowski (Purdue) and J. Liceaga (TXP).	1.30
03/30/20	SKL	Review the latest East West cash transactions provided by J. Liceaga (TXP) and begin categorizing accordingly for the weekly cash report.	2.10
03/30/20	SKL	Review the latest Paysource cash transactions and begin categorizing accordingly for the weekly cash report.	1.60
03/30/20	SKL	Prepare an updated IAC transaction summary for Rhodes and Purdue and provide E. Nowakowski (Purdue) and J. Liceaga (TXP) with list of open questions.	1.80
03/30/20	SKL	Reconcile the latest investment activity and update the Purdue and Rhodes cash summaries accordingly re: weekly cash reporting.	0.70
03/30/20	SKL	Review and reconcile the latest Rhodes weekly sales report and prepare update for the company to review.	1.10
03/30/20	SKL	Review and reconcile the latest Purdue weekly sales report and prepare update for the company to review.	0.70
03/31/20	SKL	Review and reconcile the latest fee applications filed on the docket for Restructuring Professionals and update the Restructuring forecast accordingly.	1.60
03/31/20	SKL	Review and reconcile the latest fee applications filed on the docket for Retained Professionals and update the Retained forecast accordingly.	1.40
03/31/20	SKL	Prepare and implement the latest Accounts Payable reconciliation into the Rhodes 13-week cash forecast.	1.40
03/31/20	SKL	Prepare and implement the latest Accounts Receivable reconciliation into the Rhodes 13-week cash forecast.	1.20
03/31/20	SKL	Begin refreshing the latest 13-week Rhodes cash forecast	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		by pulling forward the cash actuals and 13-week summaries in the forecast.	
03/31/20	SKL	Continue to update the latest 13-week Rhodes cash forecast by updating the operating expenses and payroll sections of the forecast.	2.20
03/31/20	DS	Update Rhodes cash flow model for FY 2020 budget details including detailed CoGS data as well as sales adjustments	1.30
04/01/20	IA	Update operating expenses and AP actuals in Purdue 13 week cash flow model.	1.80
04/01/20	SKL	Continue to update the Customer Rebate section of the latest 13-week Rhodes cash forecast.	1.60
04/01/20	SKL	Finalize updates to the latest 13-week Rhodes cash forecast and circulate internally for review and sign-off.	2.30
04/01/20	SKL	Review the February financial deck and began preparing the February Flash report accordingly.	2.10
04/01/20	SKL	Finalize updates to and formatting of the February Flash report and circulated internally for review and sign-off.	2.40
04/02/20	SKL	Continue to review the Purdue rebates from the February cash actuals and implemented into the February Customer Programs report.	2.10
04/02/20	SKL	Continue to review the Rhodes rebates from the February cash actuals and implemented into the February Customer Programs report.	1.90
04/02/20	SKL	Reconcile the latest Purdue rebate information provided by E. Nowakowski (Purdue) and finalized updates to the Prompt Pay Discounts and Sales Returns pieces of the February Customer Program's report.	1.70
04/02/20	SKL	Reconcile the latest Rhodes rebate information provided by P. Phouthasone (Rhodes Pharma) and finalized updates to the Prompt Pay Discounts and Sales Returns	1.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		pieces of the February Customer Program's report.	
04/02/20	SKL	Reconcile the latest Purdue rebate information provided by E. Nowakowski (Purdue) and finalized updates to the Wholesaler Chargeback section of the February Customer Program's report.	1.30
04/02/20	IA	Review updated company April rebate forecast and adjusted Purdue 13 week cash flow model to reflect latest assumptions and known near term payments.	1.70
04/02/20	IA	Update variance reporting for Purdue forecast to actuals comparison for the week ended 03.27.	0.60
04/02/20	IA	Review retained professionals and restructuring firm professional fee trackers included in latest Purdue 13 week forecast.	1.70
04/02/20	DS	Update Rhodes cash flow model for FY 2020 budget details including cost allocations per product.	1.10
04/03/20	DS	Review particular wording of a section of weekly cash report.	0.10
04/03/20	JD	Review and provide comments on weekly cash forecast to actual analysis.	0.50
04/03/20	SKL	Preparation of updated weekly cash reporting deck and circulated to the AlixPartners team for final sign-off.	2.10
04/03/20	SKL	Review the January Flash report and prepared and circulated updated deck per DPW and R. Aleali (Purdue) request.	1.20
04/03/20	SKL	Preparation of and finalize updates to the February Flash report and circulate to the AlixPartners team for final sign-off.	1.80
04/03/20	SKL	Finalize updates to the weekly cash reporting deck based off the latest feedback provided by E. Nowakowski (Purdue) and J. Liceaga (TXP).	2.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/03/20	SKL	Reconcile the latest Rhodes rebate information provided by P. Phouthasone (Rhodes Pharma) and finalized updates to the Wholesaler Chargeback section of the February Customer Program's report.	1.10
04/03/20	IA	Review cash actuals report for week ended 03/27.	1.30
04/06/20	IA	Review updated professional fees schedule now showing 20% holdback fee payments.	1.40
04/06/20	IA	Review updated short term weekly collections forecast prepared by TXP.	0.40
04/06/20	SKL	Continue updating the Retained Professional tracker and forecast with the latest Interim Fee application information and updated the Purdue and Rhodes cash forecast accordingly.	1.90
04/06/20	SKL	Update the Restructuring Professional tracker and forecast with the latest Interim Fee application information and updated the Purdue and Rhodes cash forecast accordingly.	2.10
04/06/20	SKL	Update the Medicaid section of the February Customer Programs report with the state-by-state Medicaid breakout for Rhodes.	1.10
04/06/20	SKL	Update the Medicaid section of the February Customer Programs report with the state-by-state Medicaid breakout for Purdue.	1.00
04/06/20	SKL	Preparation of and finalized the GPO fee section of the February Customer Programs report.	1.30
04/06/20	SKL	Finalize updates to the Private Insurance Program rebates section of the February Customer Programs report and circulated to C. Ostrowski (Purdue) for final sign-off.	1.20
04/06/20	JD	Review and provide comments on the latest cash flow forecast. Compare against previous forecast and latest actual results.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/06/20	DS	Review updates to the cash forecast made by S. Lemack (AlixPartners).	0.20
04/07/20	SKL	Continue finalizing reconciliation of the Rhodes' rebates and updated the Rhodes rebate summary of the February Customer Programs report accordingly.	2.30
04/07/20	SKL	Finalize reconciliation of the Purdue rebates and updated the Purdue rebate summary of the February Customer Programs report accordingly.	2.10
04/07/20	SKL	Preparation and finalization of the Medicare Part D rebate section of the February Customer Programs report based on the latest feedback provided by C. Ostrowski (Purdue) and re-circulated for final sign-off.	2.90
04/08/20	SKL	Review and reconcile the latest Rhodes weekly sales report and circulated the updated version for final sign-off.	1.30
04/08/20	SKL	Review and reconcile the latest Purdue weekly sales report and circulated the updated version for final sign-off.	1.40
04/08/20	SKL	Review the latest East West cash transactions provided by J. Liceaga (TXP) and began categorizing accordingly for the weekly cash report.	2.30
04/08/20	SKL	Review the latest Paysource cash transactions and began categorizing accordingly for the weekly cash report.	1.80
04/08/20	SKL	Review and reconcile the latest IAC activity re: weekly cash report and updated the week ending 04/03 report accordingly.	1.60
04/09/20	SKL	Review the latest feedback provided by J. Liceaga (TXP) and E. Nowakowski (Purdue) and updated the weekly cash report accordingly.	2.10
04/09/20	SKL	Preparation and finalization of redacted version of the February Customer Programs report and circulated to the	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		Davis Polk team accordingly.	
04/09/20	SKL	Update the latest cash forecast based on the feedback provided by the company and re-circulated for final sign-off.	0.80
04/09/20	SKL	Finalize updates to the latest cash forecast and circulated to the company accordingly for final sign-off.	1.30
04/09/20	SKL	Finalize updates to the Purdue summary re: weekly cash report.	1.20
04/09/20	SKL	Finalize updates to the Rhodes summary re: weekly cash report.	1.00
04/10/20	SKL	Preparation of the latest Purdue forecast-to-actuals variance report re: weekly cash report.	1.40
04/10/20	SKL	Preparation of the latest Rhodes forecast-to-actuals variance report re: weekly cash report.	1.10
04/10/20	SKL	Review the latest Tech Ops scorecard and updated the February flash report accordingly.	1.00
04/10/20	SKL	Continue to finalize the February flash report and circulated internally for final sign-off.	2.30
04/10/20	SKL	Finalize updates to the IAC section of the latest weekly cash report and re-circulated internally for final sign-off.	1.20
04/10/20	SKL	Finalize updates to the latest weekly cash reporting deck and circulated internally for review and sign-off.	1.20
04/13/20	SKL	Finalize updates to the weekly cash report and circulate to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.10
04/13/20	SKL	Reviewed and reconciled the Purdue and Rhodes March bank statements and began preparing the account balance section of the March Monthly Operating Report.	2.30
04/13/20	SKL	Finalize updates to the account balance section of the March Monthly Operating report and provided to the TXP	2.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		team for final sign-off.	
04/13/20	SKL	Finalize updates to the February Flash report and circulated to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.20
04/13/20	SKL	Review the latest financial reporting inquiry from the Province team and provided updates accordingly.	0.70
04/13/20	SKL	Made final updates to the forecast-to-variance slides of the weekly cash report and updated the deck accordingly.	0.90
04/13/20	IA	Review cash actuals report for week ended 04/01.	1.40
04/13/20	IA	Follow up with payroll (TXP) on payments for employee benefit programs and reconciled to cash actuals report.	0.70
04/13/20	IA	Draft outline of LTRP payment bridges for discussion with HR.	0.90
04/13/20	IA	Update creditor draft slides to incorporate redactions and comments received from legal.	1.80
04/13/20	JD	Review and provide comments on weekly cash forecast to actual report.	0.50
04/14/20	DS	Meeting with S. Lemack (AlixPartners) re: the Rhodes cash forecast and implementation plan for the Rhodes 2020 budget.	0.80
04/14/20	SKL	Finalized updates to the latest cash report and flash report and circulated to the Davis Polk team to begin the production process.	0.60
04/14/20	SKL	Review and reconcile the March cash activity and prepare the latest cash activity report for the March Monthly Operating Report.	2.10
04/14/20	SKL	Finalized updates to the March cash activity reconciliation and circulated the latest cash activity report internally to include in the March Monthly Operating Report.	2.40
04/14/20	SKL	Review and reconciliation of the latest East West	2.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		transaction report and began categorizing accordingly re: weekly cash reporting.	
04/14/20	SKL	Review and reconciled the latest cash investment activity and updated the Purdue and Rhodes summaries accordingly re: weekly cash reporting.	1.30
04/14/20	SKL	Meeting with D. Samikkannu (AlixPartners) re: the Rhodes cash forecast and implementation plan for the Rhodes 2020 budget.	0.80
04/15/20	SKL	Review and reconciled the latest Paysource transaction report and began categorizing accordingly re: weekly cash reporting.	2.50
04/15/20	SKL	Review and reconciled the latest IAC cash activity, prepared list of open items for J. Liceaga (TXP) and E. Nowakowski (Purdue), and updated the IAC sections accordingly re: weekly cash reporting.	1.60
04/15/20	SKL	Update the weekly cash reporting summaries based on the latest feedback provided by J. Liceaga (TXP) and E. Nowakowski (Purdue).	1.70
04/15/20	SKL	Preparation of the latest Rhodes weekly sales report based on the information provided by P. Phouthasone (Purdue).	0.80
04/16/20	SKL	Review the 2020 Rhodes budget prior to implementing into the Rhodes cash forecast.	1.10
04/16/20	SKL	Finalize updates to the Purdue/Rhodes bank balances and updated the March Monthly Operating Report accordingly,	1.30
04/16/20	SKL	Preparation of updates to the Purdue forecast and updated the Purdue forecast-to-actuals accordingly.	1.60
04/16/20	SKL	Preparation of updates to the Rhodes forecast and updated the Rhodes forecast-to-actuals accordingly.	1.40
04/16/20	SKL	Finalize updates to the Purdue and Rhodes IAC summaries based on the latest feedback provided by E.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		Nowakowski (Purdue).	
04/16/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: accounts payable and critical vendor process.	0.60
04/17/20	SKL	Continue to update the latest weekly cash report and prepare and circulate the reporting deck for review and sign-off.	2.00
04/17/20	SKL	Preparation of the latest Purdue weekly sales report and circulated to the AlixPartners team accordingly.	0.70
04/17/20	SKL	Finalize updates to the latest cash report and re-circulated for final approval.	2.30
04/17/20	SKL	Implement the 2020 Rhodes budget into the latest forecast.	2.30
04/17/20	IA	Provide comments to cash report for week ended 04/10.	0.20
04/17/20	DS	Review cash report and provide comments to S. Lemack (AlixPartners).	0.10
04/17/20	IA	Review cash report for week ended 04/10.	1.40
04/20/20	JD	Review and provide comments on latest cash flow forecast to actual report. Correspondence with S. Lemack (AlixPartners) re: same.	0.80
04/20/20	SKL	Finalize updates to the weekly cash report and circulated to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.20
04/20/20	SKL	Preparation of vendor payment analysis per M. Hartley request.	0.60
04/20/20	SKL	Preparation of updated forecast-to-actual variance analysis and circulated updated deck for final sign-off.	1.60
04/20/20	SKL	Review and reconcile the latest EastWest cash transaction report and began categorizing accordingly.	2.30
04/20/20	SKL	Review and reconcile the Paysource transactions report and began categorizing accordingly.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/21/20	SKL	Review and reconciled the latest IAC cash activity, prepared list of open items for J. Liceaga (TXP) and E. Nowakowski (Purdue), and updated the IAC sections accordingly re: weekly cash reporting.	2.60
04/21/20	SKL	Finalize updates to the Rhodes and Purdue weekly sales report and circulated to the Davis Polk team to begin the production process.	1.00
04/21/20	SKL	Continue to update the Rhodes cash forecast with the latest COGS info from the 2020 budget.	1.30
04/21/20	SKL	Call with D. Samikkannu (AlixPartners) re: Rhodes budget update.	0.70
04/21/20	DS	Call with S. Lemack (AlixPartners) re: Rhodes budget update.	0.70
04/22/20	DS	Review of cash report.	0.40
04/22/20	SKL	Update the weekly cash reporting summaries based on the latest feedback provided by J. Liceaga (TXP).	2.10
04/22/20	SKL	Update the Rhodes cash forecast with the latest Rhodes Pharma product sales info.	2.60
04/22/20	SKL	Update the Rhodes cash forecast with the latest royalty estimates from the 2020 budget.	2.10
04/22/20	SKL	Update the operating expense section of the Rhodes forecast with the latest operating expense breakout from the 2020 Rhodes budget.	1.40
04/23/20	SKL	Review of the Purdue 2020 budget and support files to begin updating the forecast accordingly before today's budget call with E. Nowakowski (Purdue).	2.30
04/23/20	SKL	Update the Purdue forecast with the latest cash actuals and prepared the latest forecast-to-variance report.	1.80
04/23/20	SKL	Update the Rhodes forecast with the latest cash actuals and prepared the latest forecast-to-variance report.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/23/20	SKL	Continue to review the operating expense breakout of the Rhodes 2020 budget and updated the Rhodes forecast accordingly.	1.10
04/23/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) re: the 2020 Purdue P&L and 13-week Cash Forecast.	0.80
04/23/20	SKL	Meeting with E. Nowakowski (Purdue) and I. Arana, S. Lemack (both AlixPartners) to review the 2020 Purdue P&L and Balance Sheet.	1.00
04/23/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) re: the 2020 Purdue P&L and 13-week Cash Forecast.	0.80
04/23/20	IA	Review 2019 Purdue budget backup files and put together request list for discussion with Purdue finance prior to updating cash forecast to match latest 2020 budget.	1.70
04/23/20	IA	Review latest fee applications filed on docket to update cash forecast.	0.80
04/24/20	IA	Review and provide comments to cash actuals report for week ended 04/17.	1.40
04/24/20	IA	Review weekly rebate payments for March and April for actuals report and upcoming updated Purdue forecast.	1.20
04/24/20	DS	Review of cash report.	0.10
04/24/20	JD	Review and provide comments on weekly cash forecast to actuals.	0.50
04/24/20	SKL	Finalize updates to the weekly cash report based on the feedback provided by E. Nowakowski (Purdue).	2.40
04/24/20	SKL	Finalize updates to the weekly cash report and prepared the weekly cash report deck and circulated internally for final sign-off.	2.20
04/24/20	SKL	Review the latest cash inquiries provided by Province and prepared list of updates accordingly.	0.60
04/24/20	SKL	Began updating the Rhodes cash forecast with the latest	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		Rhodes Tech information provided in the 2020 Rhodes budget.	
04/27/20	SKL	Meeting with I. Arana and S. Lemack (both AlixPartners) re: the 2020 Purdue budget and 13-week Cash Forecast.	0.30
04/27/20	SKL	Meeting with D. Samikkannu (AlixPartners) and S. Lemack (AlixPartners) re: the 2020 Rhodes budget and 13-week Cash Forecast.	0.90
04/27/20	SKL	Review latest deliverables provided by E. Nowakowski (Purdue) and prepared updated breakdown of outstanding requests.	1.40
04/27/20	SKL	Prepare and circulate latest cash reporting package for the Davis Polk team to move into production.	0.50
04/27/20	SKL	Review the February flash report and updated the deck for non-PEO designation.	2.10
04/27/20	SKL	Continue to review and finalize updates to the Rhodes cash forecast re: 2020 budget implementation.	2.20
04/27/20	SKL	Continue updates to the Rhodes cash forecast based on feedback provided	1.20
04/27/20	DS	Call with S. Lemack (AlixPartners) re: cost buildup of Rhodes budget.	0.90
04/27/20	IA	Draft response to UCC request for additional information on restricted cash in business plan projections.	1.50
04/27/20	IA	Review retention trackers and 2020 estimated payments to inform PHI cash flow analysis.	1.40
04/27/20	IA	Follow up with company on request from UCC for additional details on projected restricted cash.	0.90
04/27/20	IA	Meeting with I. Arana and S. Lemack (both AlixPartners) re: the 2020 Purdue budget and 13-week Cash Forecast.	0.30
04/28/20	SKL	Continue to finalize the Rhodes Tech sales assumptions piece of the Rhodes cash forecast.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/28/20	SKL	Continue to review and make updates to the Rhodes Tech COGS and Operating Expense section of the Rhodes cash forecast.	2.50
04/28/20	SKL	Review and reconciled the latest EastWest cash transaction report and began categorizing accordingly.	2.40
04/28/20	SKL	Review the latest IAC cash activity from this past week's cash transactions and began creating the IAC summaries accordingly.	1.30
04/29/20	SKL	Review and reconciled the Paysource transactions report and began categorizing accordingly.	2.00
04/29/20	SKL	Review the latest investment activity provided in last week's cash transaction report and updated the Purdue and Rhodes summaries accordingly.	0.70
04/29/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) to continue discussing the Purdue cash forecast and implementation plan for the Purdue 2020 budget.	0.50
04/29/20	SKL	Continue to finalize implementation of the 2020 Rhodes Pharmaceutical and Rhodes Tech budgets into the Rhodes cash forecast.	2.00
04/29/20	SKL	Update the cash transaction categorizations based on the latest feedback provided by J. Liceaga (TXP).	1.60
04/29/20	SKL	Continue to finalize the weekly cash report and prepared and circulated list of open cash inquiries to E. Nowakowski (Purdue).	1.60
04/29/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) to continue discussing the Purdue cash forecast and implementation plan for the Purdue 2020 budget.	0.50
04/30/20	SKL	Create accounts payable release file.	0.80
04/30/20	SKL	Review the February flash report and March financials report and prepared list of items re: FTI inquiries.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/30/20	SKL	Begin updating the Purdue sales forecast of the Purdue cash forecast based on the latest feedback provided from E. Nowakowski (Purdue).	2.20
04/30/20	SKL	Continue updating the Purdue cash forecast with the latest 2020 budget information.	1.40
04/30/20	SKL	Call with D. Samikkannu (AlixPartners) to review overall Rhodes budget update.	0.40
04/30/20	SKL	Walkthrough accounts payable release process with M. Hartley (AlixPartners) and S. Lemack (AlixPartners).	0.70
04/30/20	SKL	Review and reconcile the latest Rhodes weekly sales by product information.	0.60
04/30/20	DS	Call with S. Lemack (AlixPartners) to review overall Rhodes budget update.	0.40
05/01/20	IA	Review weekly Paysource payments and latest fee applications filed to inform updated Purdue cash budget.	1.60
05/01/20	SKL	Finalize updates to the Rhodes Tech expense section of the latest Rhodes forecast.	1.60
05/01/20	SKL	Created accounts payable release file.	0.90
05/01/20	SKL	Update the Rhodes forecast with the latest cash actuals and prepared the latest forecast-to-variance report.	1.60
05/01/20	SKL	Update the Purdue forecast with the latest cash actuals and prepared the latest forecast-to-variance report.	1.80
05/01/20	SKL	Finalize updates to the weekly cash report and circulated internally for final sign-off.	2.10
05/03/20	IA	Review cash actuals report for week ended 04/24.	1.20
05/04/20	JD	Review and provide comments on latest weekly cash forecast to actual report.	0.60
05/04/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) re: latest updates to the Purdue forecast.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/04/20	SKL	Meeting with M. Hartley, I. Arana and S. Lemack (all AlixPartners) re: latest OCP updates and OCP tracking process.	0.50
05/04/20	SKL	Created accounts payable release file.	0.70
05/04/20	SKL	Finalize updates to the weekly cash report and circulated for final sign-off.	1.30
05/04/20	SKL	Review the latest Purdue 2020 P&L provided by E. Nowakowski (Purdue) and continue to implement into the latest Purdue forecast.	2.60
05/04/20	SKL	Continue review of the latest Purdue 2020 P&L provided by E. Nowakowski (Purdue) and implementation into the Purdue forecast.	2.50
05/04/20	SKL	Review the operating expenses from the 2020 Purdue budget and begin implementing in the Purdue forecast.	1.20
05/04/20	IA	Meeting with M. Hartley, I. Arana and S. Lemack (all AlixPartners) re: latest OCP updates and OCP tracking process.	0.50
05/04/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) re: latest updates to the Purdue forecast.	0.40
05/04/20	IA	Review comments to Purdue cash actuals report and provided answers to rebates variance questions.	0.50
05/04/20	IA	Review May commercial rebates forecast prepared by client, to be incorporated into Purdue 13 week cash flow forecast.	1.70
05/04/20	IA	Review short term collections report and forecast prepared by Purdue for week ended 05/08.	0.40
05/04/20	MH	Meeting with M. Hartley, I. Arana and S. Lemack (all AlixPartners) re: latest OCP updates and OCP tracking process.	0.50
05/05/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) re:	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		the Op. Ex. breakdown within the 2020 budget re: Purdue forecast.	
05/05/20	IA	Review Purdue G&A by department budget breakdown to understand IAC charges, employee costs, and other credits to be adjusted in Purdue cash flow forecast.	2.40
05/05/20	IA	Summarize adjustments to Purdue G&A in cash flow forecast in schedule for discussion with cash team.	1.10
05/05/20	SKL	Continue reviewing the operating expenses from the 2020 Purdue budget and implementation to the Purdue forecast.	2.40
05/05/20	SKL	Review the COGS section of the 2020 Purdue budget and begin implementing in the Purdue forecast.	2.40
05/05/20	SKL	Continue review of the COGS section of the 2020 Purdue budget and begin implementing in the Purdue forecast.	2.70
05/05/20	SKL	Created accounts payable release file.	0.90
05/05/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) re: the Op. Ex. breakdown within the 2020 budget re: Purdue forecast.	0.80
05/06/20	SKL	Call with S. Lemack, I. Arana (both AlixPartners) re: Purdue cash flow forecast updates.	0.40
05/06/20	SKL	Created accounts payable release file.	0.90
05/06/20	SKL	Review the docket for the latest fee applications filed by restructuring professionals and updated the restructuring professional tracker accordingly.	2.60
05/06/20	SKL	Review the docket for the latest fee applications filed by retained professionals and updated the retained professional tracker accordingly.	2.30
05/06/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/06/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.00
05/06/20	IA	Review Purdue budget files and updated headcount plan to estimate benefits included in PL to be shown as payroll and benefits cash payments in 13 week forecast.	1.80
05/06/20	IA	Review filed fee applications against professional fees forecast to update estimates in latest version of Purdue cash flow forecast.	1.70
05/06/20	IA	Call with S. Lemack, I. Arana (both AlixPartners) re: Purdue cash flow forecast updates.	0.40
05/07/20	IA	Update Avrio dashboard to show April consumption and market share data by brand and product.	2.30
05/07/20	IA	Update Purdue cash forecast for Rhodes budgeted sales, API purchases, North Carolina charges, and other shared services payments.	1.80
05/07/20	IA	Perform analysis of quarterly sales, collections, and rebate payments to adjust Purdue budget amounts in cash flow forecast.	2.40
05/07/20	IA	Update G&A expenses in Purdue cash flow forecast to exclude credits for amounts charged or paid to IACs .	1.70
05/07/20	IA	Update payroll and benefit estimates in Purdue forecast, pulling out salaries and benefit charges from PL expense categories and reconciling to latest employee roster and headcount plan.	2.60
05/07/20	SKL	Finalize review and reconciliation of the latest Paysource transaction report and updated the cash report accordingly.	1.00
05/07/20	SKL	Prepare the updated IAC transaction summaries and prepared list of open-items for J. Liceaga (TXP) and E. Nowakowski (Purdue).	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/07/20	SKL	Continue to finalize updates to the Purdue forecast and begin reviewing the forecast-to-actual variances.	2.70
05/07/20	SKL	Update the weekly cash report with the latest feedback provided by J. Liceaga (TXP).	1.10
05/07/20	SKL	Consolidated Monthly Operating Reports filed to date and circulated to R. Aleali (Purdue).	0.40
05/07/20	SKL	Prepare updated critical vendor analysis and breakdown per J. Lowne (Purdue) request.	0.50
05/07/20	SKL	Prepare the weekly cash reporting deck.	1.80
05/07/20	SKL	Created accounts payable release file.	0.80
05/07/20	JD	Correspondence with J. Lowne, H. Benson (both Purdue), J. DelConte, S. Lemack (both AlixPartners) re: critical vendor payments.	0.30
05/08/20	SKL	Created accounts payable release file.	0.90
05/08/20	SKL	Finalize updates to the Rhodes forecast and put together the Rhodes forecast-to-actuals variance report.	2.10
05/08/20	SKL	Finalized updates to the weekly cash report and finished preparing the deck.	1.80
05/08/20	SKL	Prepare and update the latest cash forecast deck.	2.30
05/08/20	SKL	Finalize updates to the Purdue and Rhodes forecast and begin implementing relevant information into the forecast deck.	2.20
05/08/20	IA	Review Q1 rebate payments and update rebates forecast in updated Purdue 13 week cash flow model.	1.90
05/08/20	IA	Update bankruptcy professional fees forecast in Purdue 13 week cash flow model.	0.60
05/08/20	IA	Update OCP legal fees and retained firms forecast in Purdue 13 week cash flow model.	1.70
05/08/20	IA	Update IAC transactions forecast in Purdue 13 week cash	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		flow model.	
05/08/20	IA	Update summary schedules (IAC, rebates, professional fees) in Purdue 13 week cash flow model, to be included in updated forecast overview presentation.	2.20
05/09/20	IA	Review updated cash forecast overview presentation and provided comments.	1.30
05/09/20	SKL	Finalize updates to the latest cash forecast and circulated internally for final review.	1.40
05/11/20	SKL	Created accounts payable release file.	0.70
05/11/20	SKL	Update the Rhodes cash forecast based on the latest feedback provided.	2.20
05/11/20	SKL	Finalize updates to the latest Rhodes and Purdue forecast and circulated internally for sign-off.	2.50
05/11/20	SKL	Consolidated monthly flash reports and distributed to R. Aleali (Purdue) per her request.	0.40
05/11/20	SKL	Finalize updates to the 05/01 cash report and circulated internally for sign-off.	1.10
05/11/20	SKL	Prepare 13-week comparison of cash actuals and the latest cash forecast and circulated internally for review and sign-off.	1.40
05/11/20	IA	Follow up on payments of professional fees for filed fee applications.	0.60
05/11/20	JD	Review and provide comments on latest updated cash flow forecast and last week's forecast to actual report.	1.80
05/12/20	JD	Review and comment on final draft of the cash forecast and cash forecast to actual report.	0.60
05/12/20	IA	Review comments to cash report, update forecast model and provide answers before resubmitting for internal approvals.	1.90
05/12/20	IA	Update Rhodes intercompany transactions in Purdue cash	1.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		forecast model.	
05/12/20	SKL	Prepare additional updates to the rebates section of the Rhodes forecast and re-circulated for final sign-off.	1.20
05/12/20	SKL	Prepare breakdown of outstanding prepetition invoices and ensured an invoice related to a particular contract assumption was included in the daily invoice release file.	0.60
05/12/20	SKL	Review and reconcile the March Board deck and begin preparing the March Flash Report accordingly.	2.60
05/12/20	SKL	Finalize updates to the March Flash report, put together a breakdown of slides included/excluded from the March Board deck, and circulated internally for sign-off.	2.80
05/12/20	SKL	Created accounts payable release file.	0.90
05/12/20	SKL	Discussion with C. MacDonald (Purdue), and M. Hartley, S. Lemack (both AlixPartners) re: OCP tracking and invoices submitted to docket.	0.70
05/12/20	MH	Discussion with C. MacDonald (Purdue), and M. Hartley, S. Lemack (both AlixPartners) re: OCP tracking and invoices submitted to docket.	0.70
05/13/20	SKL	Created accounts payable release file.	0.90
05/13/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.10
05/13/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.80
05/13/20	SKL	Review and reconcile the latest investment activity and circulated list of open items to J. Liceaga (TXP) to provide additional insight/detail.	1.20
05/13/20	SKL	Process final updates to the other receipts section of the Purdue forecast per J. Lowne (Purdue) feedback and re-circulated for final sign-off.	1.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/13/20	SKL	Review and reconcile the latest Purdue and Rhodes weekly sales reports and circulated to the company for final sign-off.	1.20
05/13/20	JD	Review comments from J. Lowne (Purdue) re: latest cash flow forecast.	0.30
05/14/20	JD	Review current cash balances and cash balances listed in the latest MOR.	0.30
05/14/20	IA	Review docket for latest fee applications filed.	0.80
05/14/20	SKL	Review and reconcile the latest feedback provided by J. Liceaga (TXP) re: Investment activity and updated the weekly cash report accordingly.	1.30
05/14/20	SKL	Created accounts payable release file.	0.80
05/14/20	SKL	Finalize updates to the Rhodes summary re: weekly cash report.	1.20
05/14/20	SKL	Finalize updates to the Purdue summary re: weekly cash report.	1.30
05/14/20	SKL	Discussion with M. Hartley, S. Lemack (both AlixPartners) re: indemnification cost approval process.	0.60
05/14/20	SKL	Review and reconcile the April OCP payment activity and begin preparing the April Monthly Operating Report accordingly.	1.80
05/14/20	SKL	Finalize review of IAC cash activity from week ended 05/08 and prepared list of open items for E. Nowakowski (Purdue) and J. Liceaga (TXP).	1.30
05/15/20	SKL	Review and reconcile the April cash activity and prepared the updated cash activity slides for the April Monthly Operating Report.	2.40
05/15/20	SKL	Review and reconcile the April investment activity and prepared the updated investment activity slide for the April Monthly Operating Report.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/15/20	SKL	Updated the Purdue forecast with the latest cash activity and prepared the Purdue forecast-to-actuals slides accordingly re: weekly cash report.	1.30
05/15/20	SKL	Created accounts payable release file.	0.80
05/18/20	SKL	Created accounts payable release file.	0.80
05/18/20	IA	Review professional fee payment timing based on recently filed fee applications.	1.10
05/18/20	SKL	Review and reconcile the latest rebate information provided by J. Liceaga (TXP) and updated the cash report deck accordingly.	1.30
05/18/20	SKL	Prepare the latest professional payment piece of the April Monthly Operating Report and circulated to the Purdue team for final sign-off.	2.70
05/18/20	SKL	Refreshed the professional payment piece of the April Monthly Operating Report based on the feedback provided internally and circulated for final sign-off.	1.80
05/18/20	SKL	Finalize updates to the March flash report and circulated to J. Lowne, R. Aleali (both Purdue) for final sign-off.	2.10
05/18/20	JD	Review professional fee payment status.	0.40
05/19/20	SKL	Prepare updated reconciliation of the latest critical vendor inquiries and prepared analysis on the latest executed critical vendor agreement.	2.30
05/19/20	SKL	Finalize updates to the latest cash report and circulated to J. Lowne, R. Aleali (both Purdue) for final sign-off.	2.50
05/19/20	SKL	Refreshed the March flash report with the latest feedback provided and distributed to the Davis Polk team to begin the production process.	0.70
05/19/20	SKL	Review latest OCP vendor ID inquiry and updated the retained professional tracker accordingly.	1.10
05/19/20	IA	Review and provide comments to cash report for week	1.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		ended 05/08/2020.	
05/19/20	SKL	Created accounts payable release file.	0.80
05/20/20	SKL	Created accounts payable release file.	1.70
05/20/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.30
05/20/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.70
05/20/20	SKL	Review and reconcile the latest investment and IAC activity and circulated list of open items to J. Liceaga (TXP) to provide additional insight and detail.	2.60
05/21/20	SKL	Update the Purdue forecast with the latest cash actuals and prepared the latest forecast-to-actuals.	2.10
05/21/20	SKL	Update the Rhodes forecast with the latest cash actuals and prepared the latest forecast-to-actuals.	1.30
05/21/20	SKL	Prepare the 05.08 weekly cash report and circulated internally for final sign-off.	2.40
05/21/20	SKL	Created accounts payable release file.	1.80
05/21/20	SKL	Meeting with D. Sanil (Purdue), F. Bell (LPW), M. Hartley, S. Lemack (both AlixPartners) re: open LPW Training Partner payment inquiries.	0.40
05/21/20	MH	Meeting with D. Sanil (Purdue), F. Bell (LPW), M. Hartley, S. Lemack (both AlixPartners) re: open LPW Training Partner payment inquiries.	0.40
05/21/20	JD	Review and provide comments on cash report for week ended 5/8.	0.60
05/22/20	SKL	Created accounts payable release file.	0.80
05/22/20	SKL	Review and reconcile the latest Prime Clerk invoices and updated the restructuring professional's tracker accordingly.	1.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/22/20	SKL	Prepare updated Prime Clerk invoice/payment breakdown and rollforward and circulated internally for final sign-off.	2.70
05/22/20	SKL	Update the Rhodes fee for service and private insurance section of the March Customer Programs report.	2.50
05/26/20	SKL	Created accounts payable release file.	0.80
05/26/20	SKL	Review and reconcile latest critical vendor breakdown and provided vendor update.	1.30
05/26/20	SKL	Continue to update the 05/15 weekly cash report and provided updated list of outstanding inquiries to E. Nowakowski (Purdue).	2.40
05/26/20	SKL	Review the docket for the latest restructuring fee applications and updated the restructuring tracker accordingly.	1.40
05/26/20	SKL	Review the docket for the latest retained professional fee applications and updated the retained professional tracker accordingly.	1.20
05/26/20	SKL	Update the Rhodes summary of the March Customer Programs report.	1.00
05/27/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.90
05/27/20	SKL	Review and reconcile the latest investment and IAC activity and circulated list of open items to J. Liceaga (TXP) to provide additional background and support.	1.60
05/27/20	SKL	Created accounts payable release file.	1.20
05/27/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.50
05/28/20	SKL	Update the Rhodes forecast with the latest cash actuals and prepared the latest forecast-to-actuals.	1.50
05/28/20	SKL	Update the Purdue forecast with the latest cash actuals	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		and prepared the latest forecast-to-actuals.	
05/28/20	SKL	Prepare the updated 5/22 weekly cash report and prepared list of open items for E. Nowakowski (Purdue) to provide additional detail on.	2.30
05/28/20	SKL	Created accounts payable release file.	1.50
05/29/20	SKL	Created accounts payable release file.	0.70
05/29/20	SKL	Prepare the monthly OCP report with April activity.	1.30
05/29/20	SKL	Continue to update the latest weekly cash report with the latest feedback provided by E. Nowakowski (Purdue).	2.30
05/29/20	SKL	Review and reconcile the latest Purdue weekly sales report and circulated for final sign-off.	1.10
05/29/20	SKL	Review and reconcile the latest Rhodes weekly sales report and circulated for final sign-off (cont.).	1.00
Total			754.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	610.80	515.00	314,562.00
David Samikkannu	33.00	690.00	22,770.00
Isabel Arana de Uriarte	97.20	690.00	67,068.00
Michael Hartley	1.60	840.00	1,344.00
Jesse DelConte	11.00	950.00	10,450.00
Richard Collura	0.40	1,090.00	436.00
Total Hours & Fees	754.00		416,630.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
02/01/20	JD	Prepare and email around responses to management, Davis Polk and PJT on open UCC diligence requests on potential auto injector deal.	1.40
02/02/20	ADD	Download files in data room to create archive/backup	1.10
02/03/20	ADD	Meeting to discuss Relativity review and redaction process per Protective Order with I. Arana, A. DePalma, and S. Lemack (all AlixPartners).	0.60
02/03/20	ADD	Compile supporting documentation and files to respond to UCC request.	2.10
02/03/20	ADD	Call with Davis Polk eDiscovery team (J. Chen, A. Guo and others) to discuss progress and answer questions re: specific files.	0.50
02/03/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.80
02/03/20	JD	Debtor advisors pre-meeting with J. DelConte and D. Samikkannu (both AlixPartners) before meeting with Ad Hoc Committee advisors and clients	1.00
02/03/20	JD	Financial presentation meeting with J. DelConte and D. Samikkannu (both AlixPartners) to Ad Hoc Committee advisors and clients	1.60
02/03/20	JD	Key issues discussion between with J. DelConte, D. Samikkannu (both AlixPartners), Debtors' advisors, Ad Hoc Committee advisors, and clients	0.70
02/03/20	JD	Legal and settlement discussions between with J. DelConte, D. Samikkannu (both AlixPartners), Debtors' advisors, Ad Hoc Committee advisors, and clients	2.10
02/03/20	DS	Debtor advisors pre-meeting with J. DelConte and D. Samikkannu (both AlixPartners) before meeting with Ad Hoc Committee advisors and clients	1.00
02/03/20	DS	Financial presentation meeting with J. DelConte and D. Samikkannu (both AlixPartners) to Ad Hoc Committee	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		advisors and clients	
02/03/20	DS	Legal and settlement discussions between with J. DelConte, D. Samikkannu (both AlixPartners), Debtors' advisors, Ad Hoc Committee advisors, and clients	2.10
02/03/20	DS	Key issues discussion between with J. DelConte, D. Samikkannu (both AlixPartners), Debtors' advisors, Ad Hoc Committee advisors, and clients	0.70
02/03/20	SKL	Meeting to discuss Relativity review and redaction process per Protective Order with I. Arana, A. DePalma, and S. Lemack (all AlixPartners).	0.60
02/03/20	IA	Meeting to discuss Relativity review and redaction process per Protective Order with I. Arana, A. DePalma, and S. Lemack (all AlixPartners).	0.60
02/04/20	IA	Follow up on status of requests and responses related to nalmeferine injector and setting up of call to discuss with committees.	1.40
02/04/20	IA	Follow up on status of weekly sales report for Purdue and monthly flash report operational slides.	0.70
02/04/20	ADD	Manage data room access and add individuals and groups at the request of counsel.	1.20
02/04/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	1.80
02/04/20	ADD	Compile search terms for relativity redaction review process.	0.80
02/04/20	ADD	Research and respond to Davis Polk eDiscovery team inquiry re: post-protective order diligence designation processing.	1.10
02/04/20	ADD	Request additional information from Purdue's grant administration office in response to a diligence request.	0.40
02/04/20	ADD	Review protective order for details on diligence file	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		designation.	
02/04/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	0.50
02/05/20	ADD	Review and redact files for competitively sensitive and third-party confidential information.	2.60
02/05/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	3.10
02/05/20	ADD	Manage data room access and add individuals and groups at the request of counsel.	1.30
02/05/20	ADD	Research information available to fulfill UCC diligence request.	0.70
02/05/20	IA	Draft diligence response communication to committees re: nalmefene injector.	0.90
02/05/20	IA	Review , edit and follow up on approvals of nalmefene auto injector diligence materials in preparation for call with committee advisors.	2.30
02/05/20	IA	Follow up on R&D spend cash flows for nalmefene auto injector and drafting of summary of assumptions and amounts.	1.10
02/06/20	SKL	Meeting with D. Samikkannu, S. Lemack, and A. DePalma (all AlixPartners) re: document management process with protective order and party designations	1.40
02/06/20	DS	Meeting with D. Samikkannu, S. Lemack, and A. DePalma (all AlixPartners) re: document management process with protective order and party designations	1.40
02/06/20	JD	Call re: auto injector with A. Preiss (Akin Gump), R. Ringer (Kramer Levin), M. Atkinson (Province), M. Diaz (FTI), S. Pohl (Brown Rudnick), H. Schenk (Houlihan), L. Szlezinger (Jefferies) and J. Lowne (Purdue).	0.90
02/06/20	JD	Review materials prior to call re: auto injector agreement.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
02/06/20	ADD	Meeting with D. Samikkannu, S. Lemack, and A. DePalma (all AlixPartners) re: document management process with protective order and party designations	1.40
02/06/20	ADD	Call with Purdue grants administrator to discuss the creation of a list of grant payments to fulfill diligence request.	0.40
02/06/20	ADD	Research information available to fulfill UCC diligence request.	0.50
02/06/20	ADD	Compile documentation submitted directly to UCC/AHC advisors for DOJ production.	0.70
02/06/20	ADD	Identify documentation in the data room obtained directly from MDL production.	1.10
02/06/20	ADD	Review data room access and update post-protective order permissions groups.	1.60
02/06/20	ADD	Review of January accounts payable not covered by motion file.	0.60
02/06/20	ADD	Process production files from Davis Polk and upload files to data room.	1.80
02/06/20	ADD	Manage data room access and add individuals and groups at the request of counsel.	0.90
02/07/20	ADD	Process production files from Davis Polk and upload files to data room.	2.10
02/07/20	ADD	Manage data room access and add individuals and groups at the request of counsel.	1.00
02/07/20	ADD	Review of file permissions for documents being processed by Davis Polk's eDiscovery team.	1.20
02/07/20	JD	Conversations with M. Atkinson (Province) and K. Knechtel (FTI) re: insurance update.	0.60
02/07/20	SKL	Prepare and provide update re: bank account information per UST request.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
02/10/20	SKL	Prepare updated insurance documentation for the Intralinks site and provide to Davis Polk team to upload.	0.60
02/10/20	IA	Follow up on data room access for Jefferies team.	0.30
02/10/20	LJD	Pre-meeting prior to the UCC meeting with M. Huebner and others (Davis Polk), T. Coleman and others (PJT), C. Landau and others (Purdue), L. Donahue, and Jesse DelConte (both AlixPartners).	1.10
02/10/20	LJD	Prepare for and attend meeting with Davis Polk, PJT, management, L. Donahue, J. DelConte (both AlixPartners), Akin Gump, Bayard, Province, Jefferies and the UCC members and counsel.	3.20
02/10/20	JD	Pre-meeting prior to the UCC meeting with M. Huebner and others (Davis Polk), T. Coleman and others (PJT), C. Landau and others (Purdue), L. Donahue, and Jesse DelConte (both AlixPartners).	1.10
02/10/20	JD	Prepare for and attend meeting with Davis Polk, PJT, management, L. Donahue, J. DelConte (both AlixPartners), Akin Gump, Bayard, Province, Jefferies and the UCC members and counsel.	3.60
02/11/20	ADD	Add individuals to data room at the request of Davis Polk and organize newly added members into groups.	2.30
02/11/20	ADD	Respond to questions re: diligence upload process from Davis Polk.	0.30
02/12/20	ADD	Research and respond to questions from Davis Polk re: diligence and data room access.	0.40
02/12/20	ADD	Research and respond to questions from PJT regarding diligence process.	0.30
02/12/20	ADD	Update data room permissions at the request of Davis Polk.	0.80
02/12/20	JD	Pre-meeting with T. Coleman, J. O'Connell (PJT), M. Huebner (Davis Polk), C. Landau, M. Kesselman, J.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Lowne (Purdue) and J. DelConte (AlixPartners) re: non-consenting states meeting.	
02/12/20	JD	Meeting with the non-consenting state AGs, A. Troop (Pillsbury), S. Birnbaum (Dechert), C. Landau, M. Kesselmen, J. Lowne (Purdue), M. Huebner (Davis Polk), T. Coleman, J. O'Connell (both PJT), and J. DelConte (AlixPartners) re: business plan update and case discussion.	4.00
02/12/20	IA	Review received UCC questions on business plan.	0.80
02/12/20	IA	Review of UCC first and second requests diligence lists received from PJT, for follow up with company.	1.40
02/13/20	IA	Summarize follow up UCC questions to be shared with management and distribute questions to relevant parties within company.	2.10
02/13/20	IA	Review and update of actuals cash reporting and variance explanations for Purdue for the week ended 02/07	2.30
02/13/20	JD	Review status of UCC diligence requests, draft responses to date and correspondence with Province re: same.	0.70
02/14/20	IA	Review of first batch of documents produced by Davis Polk for the consenting and non-consenting states groups and mapping to Intralinks folders.	2.30
02/14/20	SKL	Review latest documentation provided by Davis Polk and categorize and upload to the Intralinks site accordingly.	2.00
02/14/20	SKL	Continue to review additional documentation provided by Davis Polk and categorize and upload to the Intralinks site accordingly.	2.30
02/14/20	SKL	Finalize review and categorization of documentation provided by the Davis Polk team and update to the Intralinks site per Davis Polk request.	1.90
02/14/20	ADD	Upload tax documents from UCC diligence production provided by DPW to the data room.	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
02/14/20	ADD	Respond to questions re: diligence upload process from Davis Polk.	0.40
02/14/20	ADD	Respond to questions re: diligence upload process from AlixPartners team.	0.50
02/14/20	ADD	Upload employee and financial data from UCC diligence production provided by DPW to the data room.	2.80
02/14/20	ADD	Review access of new parties add to the data room.	1.00
02/16/20	IA	Review submitted documents and consolidate responses to UCC question in one document for review by management.	2.30
02/17/20	IA	Review submitted documents and consolidate responses to UCC question in one document for review by management.	1.60
02/17/20	JD	Conference call with M. Diaz (FTI), J. Bessonette (Kramer Levin), J. Turner (PJT), C. Robertson (Davis Polk), (G. Coutts (Houlihan), and J. DelConte (AlixPartners) re: auto injector.	0.80
02/17/20	JD	Correspondence with E. Ruiz (Purdue) and J. DelConte (AlixPartners) re: new auto injector diligence questions.	0.30
02/18/20	JD	Catch up call with T. Melvin, J. Turner (both PJT), J. DelConte, and I. Arana (both AlixPartners) re: diligence process.	0.50
02/18/20	IA	Catch up call with T. Melvin, J. Turner (both PJT), J. DelConte, and I. Arana (both AlixPartners) re: diligence process.	0.50
02/18/20	ADD	Develop data room permissions spreadsheet to review permissions applied to filed uploaded to the data room.	2.30
02/18/20	ADD	Manage Intralinks data room access requests and add individuals at request of Davis Polk.	0.30
02/18/20	ADD	Upload designated and bates stamped documents to data	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		room and permission documents for the UCC.	
02/18/20	ADD	Review and update Intralinks data room permissions at request of Davis Polk.	0.60
02/18/20	ADD	Add designations and confidentiality language to Excel file provided by Davis Polk and uploaded to data room.	0.20
02/18/20	ADD	Call with A. DePalma (AlixPartners), DPW diligence and DPW eDiscovery teams (C. Oluwole and J. Chen) to discuss Purdue diligence: Production Work flow	0.50
02/18/20	ADD	Research possible methods for extracting a intercompany matrix from Purdue's accounting system.	0.40
02/19/20	ADD	Add designation language and bates stamp to the top of each tab in Excel files currently produced	2.40
02/19/20	ADD	Research new UCC diligence requests identifying potential ways to obtain the necessary information.	1.20
02/19/20	ADD	Review Intralinks data room permissions to check that documents from February 14 production were correctly applied.	1.80
02/19/20	ADD	Develop data room permissions spreadsheet to review permissions applied to filed uploaded to the data room.	2.70
02/19/20	JD	Review outstanding diligence requests from the UCC and status of providing answers.	0.70
02/19/20	JD	Correspondence with E. Ruiz (Purdue) re: outstanding Nalmafene auto injector questions.	0.40
02/19/20	JD	Review consolidated management responses to outstanding UCC and state AG diligence questions.	0.70
02/19/20	NAS	Expand insider payments analysis (covering two years prior to filing) as requested by UCC.	0.40
02/20/20	JD	Call with M. Atkinson (Province), J. Turner (PJT), and J. DelConte (AlixPartners) re: open diligence items.	0.40
02/20/20	JD	Call with K. Knechtel (FTI), H. Schenk (Houlihan), T.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
02/20/20	IA	Melvin (PJT), J. DelConte, and I. Arana (both AlixPartners) re: diligence questions.	0.40
02/20/20	SJC	Call with K. Knechtel (FTI), H. Schenk (Houlihan), T. Melvin (PJT), J. DelConte, and I. Arana (both AlixPartners) re: diligence questions.	4.00
02/20/20	ADD	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order	0.40
02/20/20	ADD	Meeting with R. Hoff (Wiggin and Dana) and A. DePlama (AlixPartners) to review new UCC Diligence Requests	3.40
02/20/20	ADD	Upload designated and bates stamped Insurance documents to data room and permission Insurance documents for the UCC.	3.20
02/21/20	ADD	Upload designated and bates stamped tax documents to data room and permission tax documents for the UCC and consenting / non-consenting states.	2.20
02/21/20	ADD	Upload designated and bates stamped Insurance documents to data room and permission Insurance documents for the UCC.	3.40
02/21/20	ADD	Upload designated and bates stamped charitable contribution support documents (batch 1) to data room and permission charitable contribution support documents (batch 1) for the UCC and consenting / non-consenting states.	2.80
02/21/20	NAS	Review data requirements and begin requesting data for 2 year insider payments lookback request.	2.00
02/21/20	JD	Correspondence with Province re: outstanding diligence requests.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
02/22/20	NAS	Coordination with D. Consla (Davis Polk) re: request for 2 year lookback on payments to insiders.	0.20
02/22/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.00
02/24/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.30
02/24/20	IA	Review latest version of diligence tracker for business plan questions and responses and provide comments to PJT on open items.	0.90
02/24/20	IA	Gather responses and relevant support files to UCC questions on business plan to be sent out for internal review by the client.	2.90
02/24/20	IA	Review Canada Supply agreement materials to be shared with committees.	0.80
02/24/20	MH	Create accounts payable release file.	0.30
02/24/20	NAS	Request 2 year insider payment data from various sources at Purdue and TXP.	0.90
02/24/20	NAS	Call with C. McMillian, A. Guo, D. Consla (all DPW), and N. Simon (AlixPartners) re: request for 2 year lookback at payments to insiders and internal follow-ups.	0.40
02/24/20	NAS	Compile, analyze, and track payments to insiders over prior 2 years that have been provided to date.	2.80
02/24/20	ADD	Research Individual Victims Group diligence requests.	0.80
02/24/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.20
02/24/20	ADD	Review interested parties' data room permissions	0.50
02/24/20	ADD	Review outstanding diligence request and follow up with relevant parties.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
02/24/20	ADD	Compile hours the AlixPartners engagement team spend on diligence related activities at the request of Davis Polk.	0.90
02/24/20	ADD	Review and redact third-part confidential information from previously posted cash value transfer diligence items for production under the protective order.	2.10
02/25/20	ADD	Compile hours the AlixPartners engagement team spend on diligence related activities at the request of Davis Polk.	1.40
02/25/20	ADD	Review outstanding diligence request and follow up with relevant parties.	1.70
02/25/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	0.80
02/25/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.20
02/25/20	NAS	Provide overview of IAC tax documents uploaded to Mundipharma data room.	0.80
02/25/20	NAS	Meeting with F. Silva and N. Simon (both AlixPartners) to discuss current status of Intercompany/Non-cash Transfers of Value report.	0.50
02/25/20	NAS	Analysis of existing information related to payments to IACs for purposes of 2 year insider payments lookback.	1.00
02/25/20	NAS	Correspondence with Purdue/TXP employees regarding 2 year insider payment data and preliminary analysis of data provided.	2.60
02/25/20	IA	Prepare estimate of hours spent on diligence based on Davis Polk request.	0.40
02/25/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.10
02/25/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		protective order (continued).	
02/25/20	FOS	Meeting with N. Simon and F. Silva (both AlixPartners) to discuss current status of Intercompany/Non-cash Transfers of Value report.	0.50
02/26/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.40
02/26/20	SJC	Review of redacted information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.10
02/26/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order (continued).	2.20
02/26/20	IA	Call with C. Robertson, C. McMillian (both Davis Polk), and I. Arana (AlixPartners) to discuss business plan diligence process and approvals.	0.30
02/26/20	NAS	Analysis of T&E data provided for 2 year lookback at payments to insiders.	0.40
02/26/20	NAS	Consolidate data provided to-date regarding payments to insiders over 2 years prior to filing.	1.30
02/26/20	ADD	Review and redact third-part confidential information from previously posted cash value transfer diligence items for production under the protective order.	2.80
02/26/20	ADD	Review outstanding diligence request and follow up with relevant parties.	0.90
02/26/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	0.40
02/26/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	0.70
02/26/20	ADD	Review AlixPartners' engagement team member	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		redactions prior to providing to David Polk for production.	
02/27/20	ADD	Submit new diligence requests and follow up with outstanding items.	0.70
02/27/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	0.80
02/27/20	ADD	Review outstanding diligence request and provide status update.	0.70
02/27/20	ADD	Meeting with Rhodes CFO and A. DePalma (AlixPartners) to discuss diligence request.	0.30
02/27/20	ADD	Review and redact third-part confidential information from previously posted cash value transfer diligence items for production under the protective order.	3.10
02/27/20	ADD	Review documents redacted by team member prior to providing to David Polk for production.	2.80
02/27/20	NAS	Analyze data provided and submit final data requests for 2YR lookback at payments to insiders requested by UCC.	1.70
02/27/20	IA	Review business plan diligence questions and proposed answers for Massachusetts and California AGs and follow up on internal approvals.	2.80
02/27/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.00
02/27/20	SJC	Review redactions of information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	1.00
02/28/20	SJC	Reviewing redactions of information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.10
02/28/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		protective order.	
02/28/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order (continued).	1.40
02/28/20	NAS	Analyze data provided for 2YR lookback on payments to insiders requested by UCC.	0.90
02/28/20	ADD	Upload production from Davis Polk eDiscovery team to the data room for the UCC, consenting states, and non-consenting states.	2.80
03/02/20	ADD	Review outstanding diligence request and follow up with relevant parties.	1.20
03/02/20	ADD	Compile diligence requests as of filing file date to support motion at request of Davis Polk	1.70
03/02/20	ADD	Compile and format documentation submitted in response to diligence request for processing and designation.	1.40
03/02/20	NAS	Consolidate data provided for 2YR lookback on payments to insiders and follow-up questions for TXP Payroll team.	1.10
03/02/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.10
03/02/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order (continued).	3.20
03/02/20	SJC	Review and redact 2015 financial update materials in preparation for processing an upload to data room.	1.70
03/02/20	IA	Follow up on approvals and final review of UCC diligence responses to business plan questions.	1.60
03/03/20	SJC	Review and redact 2015 board meeting materials in preparation for processing an upload to data room.	3.20
03/03/20	SJC	Review and redact 2012 board meeting materials in	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/03/20	SJC	preparation for processing an upload to data room.	1.80
03/03/20	NAS	Review and redact 2018 board meeting materials in preparation for processing an upload to data room.	1.80
03/03/20	NAS	Reconcile T&E data provided for purposes of 2YR lookback on payments to insiders requested by UCC.	2.70
03/03/20	ADD	Incorporate data received for Payroll, T&E, and Other Benefits into 2YR lookback to payments to insiders as requested by UCC.	0.60
03/03/20	ADD	Request approval to provide documents submitted in response to diligence requests to the data room.	2.40
03/03/20	ADD	Review and format files submitted in response to diligence requests in preparation for upload to data room.	3.10
03/03/20	ADD	Review and redact third-part confidential information from previously posted cash value transfer diligence items for production under the protective order.	1.50
03/03/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.10
03/04/20	ADD	Compile and format files submitted in response to diligence requests in preparation for processing and designation.	0.70
03/04/20	ADD	Extract and review data room index in response to request from Davis Polk.	1.90
03/04/20	ADD	Review outstanding diligence request and follow up with relevant parties.	0.80
03/04/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	2.80
03/04/20	ADD	Review and redact third-part confidential information from previously posted cash value transfer diligence items for production under the protective order.	0.70
03/04/20	NAS	Review data provided by Purdue/TXP for purposes of 2YR	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		lookback on payments to insiders.	
03/04/20	SJC	Review and redact 2017 board meeting materials in preparation for processing an upload to data room.	3.00
03/04/20	SJC	Review and redact 2016 board meeting materials in preparation for processing an upload to data room.	3.40
03/04/20	SJC	Review information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	1.60
03/05/20	SJC	Review and redact 2015 board meeting materials in preparation for processing an upload to data room.	3.00
03/05/20	NAS	Analysis of fleet vehicle invoices for purposes of 2YR lookback on payments to insiders.	1.70
03/05/20	NAS	Summarize payments to insiders over 2 years prior to filing as requested by UCC.	0.80
03/05/20	ADD	Update data room permissions to give access to documents to new groups.	1.40
03/05/20	ADD	Compile and format files submitted in response to diligence requests in preparation for processing and designation.	2.40
03/05/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) re: open diligence questions.	0.20
03/06/20	ADD	Upload weekly production provided by Davis Polk eDiscovery team and permission files accordingly.	2.30
03/06/20	ADD	Reorganize data room to separate UCC and consenting / non-consenting states folders.	2.20
03/06/20	ADD	Research former employee job titles in response to diligence request.	1.50
03/06/20	ADD	Review outstanding diligence requests, follow up with outstanding items, and update tracker accordingly.	1.80
03/06/20	NAS	Summarize payments to insiders over 2 years prior to	0.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		filing as requested by UCC.	
03/06/20	IA	Call with R. Silbert, R. Aleali (both Purdue), G. Sim (PJT), C. McMillian (Davis Polk), and I. Arana (AlixPartners) to discuss AG diligence.	0.50
03/09/20	IA	Follow up on UCC diligence responses to business plan questions.	1.30
03/09/20	NAS	Analysis of payments to insiders over 2 years prior to filing as requested by UCC.	1.80
03/09/20	NAS	Analyze monthly fleet vehicle invoices to determine amounts related to insiders over 2 years prior to filing.	3.20
03/09/20	ADD	Work with Intralinks support to determine method of filtering certain file types.	0.60
03/09/20	ADD	Compile and submit files to Davis Polk eDiscovery team for designation and processing.	0.50
03/10/20	ADD	Redact third-party confidential information from Board Minutes (2007-2008) in preparation for processing and production.	1.80
03/10/20	ADD	Compile and submit files to Davis Polk eDiscovery team for designation and processing.	0.80
03/10/20	ADD	Compile and format documents submitted in response to diligence request in preparation for approval and submission to Davis Polk.	2.40
03/10/20	ADD	Follow up on outstanding diligence requests with client contracts.	0.60
03/10/20	ADD	Call with Ad-Hoc committee advisors and A. DePalma (AlixPartners) to discuss business plan diligence requests	0.40
03/10/20	ADD	Submit request to client for new diligence items and follow up on outstanding items.	0.80
03/10/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss updates to the TXP information request tracker.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/10/20	NAS	Analysis of T&E and fleet vehicle payments made to insiders over 2 years prior to filing as requested by UCC.	1.80
03/10/20	NAS	Discussions with N. Simon (AlixPartners), E. Nowakowski, and E. Liesman (both Purdue) re: payment procedures for T&E and fleet vehicle invoices.	0.40
03/10/20	NAS	Consolidate list of payments to insiders over 2 years prior to filing and conform to SOFA reporting terminology.	1.50
03/10/20	NAS	Correspondence with K. Laurel (Purdue) and D. Cabral (TXP) and analysis of data provided re: insider payroll over 2 years prior to filing.	2.10
03/10/20	IA	Review files for submission in response to UCC diligence questions on business plan.	0.80
03/10/20	IA	Follow up on UCC business plan diligence requests.	1.10
03/11/20	NAS	Consolidate and summarize all payments to insiders over 2 years prior to filing.	0.80
03/11/20	NAS	Analysis of personal income tax preparation invoices over 2 years prior to filing to determine services provided to insiders.	1.20
03/11/20	NAS	Draft preliminary report of payments to insiders over 2 years prior to filing (as requested by UCC) for internal review.	1.60
03/11/20	ADD	Review documents redacted by teammate for confidential third party information in preparation for processing.	1.70
03/11/20	ADD	Call with Davis Polk and A. DePalma (AlixPartners) to discuss outstanding diligence requests.	0.80
03/11/20	ADD	Follow up on outstanding diligence requests with client contracts.	1.70
03/11/20	ADD	Add new uses to Purdue data room at request of Davis Polk.	1.10
03/11/20	ADD	Redact third-party confidential information from board	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		materials in preparation for designation and upload to VDR.	
03/12/20	ADD	Research and provide update on outstanding UCC diligence items.	0.70
03/12/20	ADD	Remove users (Bayard attorneys) from project data room that no longer represent the UCC.	0.50
03/12/20	ADD	Compile outstanding diligence request into tracker at request of Davis Polk.	1.70
03/12/20	ADD	Submit request to client for new diligence items and follow up on outstanding items.	1.40
03/13/20	ADD	Prepare files submitted in response to diligence requests for upload to data room.	1.60
03/13/20	ADD	Follow up with client re: outstanding diligence requests.	0.90
03/13/20	ADD	Add new users to Purdue dataroom at the request of UCC counsel.	0.40
03/13/20	ADD	Prepare and submit files to Davis Polk for processing (review or redaction and designation).	0.90
03/13/20	ADD	Call with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) to discuss outstanding UCC diligence requests.	0.20
03/13/20	ADD	Attend AG Request Core team meeting call.	0.50
03/13/20	ADD	Redact third-party confidential information from Board Minutes (2007-2008) in preparation for processing and production.	2.80
03/13/20	NAS	Analysis of indemnification payment data for purposes of 2YR lookback on payments to insiders.	0.90
03/13/20	IA	Follow up on OCP monthly spend reporting.	0.60
03/13/20	MH	Call with M. Hartley (AlixPartners) and counsel to discuss OCP reporting variance and update to report.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/14/20	ADD	Review diligence requests received by PJT	1.90
03/15/20	NAS	Analysis of indemnification payments made on behalf of Sackler family members for purposes of 2YR lookback on payments to insiders.	0.80
03/16/20	NAS	Revise report of payments to insiders over 2 years prior to filing as requested by UCC.	1.10
03/16/20	NAS	Quantify T&E reimbursements that were repaid by PRALP in order to exclude from 2YR lookback on payments to insiders.	1.30
03/16/20	SJC	Review and redact 2015 board meeting materials in preparation for processing an upload to data room.	3.00
03/16/20	SJC	Review and redact 2013 board meeting materials in preparation for processing an upload to data room.	3.00
03/16/20	SJC	Review and redact 2014 board meeting materials in preparation for processing an upload to data room.	2.00
03/16/20	ADD	Review and follow up with outstanding diligence request.	1.30
03/16/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	2.90
03/16/20	ADD	Review and redact mid-year and year-end financial presentations included as part of the board materials for 2018 in preparation for processing and upload to data room.	2.60
03/16/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	1.10
03/17/20	ADD	Review and follow up with outstanding diligence request.	2.30
03/17/20	ADD	Review and summarize special committee requests posted in data room for Davis Polk.	1.20
03/17/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery	2.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		team,	
03/17/20	ADD	Review and redact mid-year and year-end financial presentations included as part of the board materials for 2016 in preparation for processing and upload to data room.	2.00
03/17/20	SJC	Review and redact 2010 board meeting materials in preparation for processing an upload to data room.	3.00
03/17/20	SJC	Review and redact 2011 board meeting materials in preparation for processing an upload to data room.	3.30
03/17/20	NAS	Adjust analysis of payments to insiders over 2 years prior to filing for repayments from PRALP.	1.90
03/17/20	NAS	Update summary of payments to insiders over 2 years prior to filing for review by Purdue and DPW.	0.80
03/17/20	JD	Review updated insider payment analysis going back 2 years. Provide comments re: same.	1.40
03/18/20	SJC	Review and redact 2009 board meeting materials in preparation for processing an upload to data room.	3.00
03/18/20	SJC	Review and redact 2009 board meeting materials in preparation for processing an upload to data room (continued).	3.00
03/18/20	ADD	Upload documents provided by DPW eDiscovery team to the data room.	1.10
03/18/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	1.70
03/18/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	0.90
03/18/20	ADD	Review and redact mid-year and year-end financial presentations included part of the board materials for 2017 in preparation for processing and upload to data	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		room.	
03/18/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.10
03/19/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
03/19/20	ADD	Review DOJ access to files in data room at request of Davis Polk.	0.80
03/19/20	ADD	Review file submitted previously shared materials prior to PO to determine need for processing and production.	1.00
03/19/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	1.20
03/19/20	ADD	Review and redact board materials from 2014 to 2015 in preparation for processing and upload to data room.	2.40
03/19/20	JD	Review proposed diligence request responses for potential valuation and solvency materials.	2.00
03/20/20	JD	Call with R. Aleali (Purdue) re: redaction process and diligence update.	0.30
03/20/20	ADD	Review and update date room permissions in response from a Committee requests.	2.10
03/20/20	ADD	Review and redact board materials for year 2015 in preparation for processing and production.	2.90
03/20/20	ADD	Review and follow up with outstanding diligence request.	1.70
03/23/20	ADD	Review and follow up with outstanding diligence request.	2.80
03/23/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	2.20
03/23/20	ADD	Review and redact minutes and decisions from 1999 to 2003 in preparation for processing and upload to data room.	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/23/20	JD	Review third party information redaction process.	0.20
03/23/20	JD	Review latest insider payment analysis going back 2 years.	0.60
03/23/20	NAS	Provide summary and circulate draft of 2YR lookback on payments to insiders to Purdue and DPW for review.	0.90
03/23/20	MH	Review proposed two year look back on insider payments.	1.30
03/23/20	MH	Call with legal operations analyst to reconcile spend reporting with Canadian counsel.	0.70
03/24/20	NAS	Revise 2YR payments to insider's report requested by UCC and respond to questions asked by J. Lowne (Purdue).	0.80
03/24/20	ADD	Review and follow up with outstanding diligence request.	1.70
03/24/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	2.40
03/24/20	ADD	Review and redact minutes and decisions from 2004 to 2006 in preparation for processing and upload to data room.	2.00
03/24/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	1.30
03/25/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.90
03/25/20	ADD	Review and redact minutes and decisions from 2007 to 2011 in preparation for processing and upload to data room.	2.80
03/25/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room.	1.80
03/25/20	NAS	Investigate Rhodes Board director fees listed in 2YR lookback on insider payments following review by J. Lowne (Purdue).	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/25/20	NAS	Research inquiry from UCC re: additional family members with Purdue email addresses.	0.40
03/25/20	NAS	Revise report of payments to insiders over 2 years prior to filing following comments from J. Lowne (Purdue).	1.10
03/25/20	MH	Respond to questions from interested parties on additional family members and possible compensation payments.	0.80
03/26/20	NAS	Revisions to report of payments to insiders over 2 years prior to filing to include non-debtor to debtor cross-charges related to insider salaries.	1.20
03/26/20	IA	Review updated diligence tracker and DOJ requests.	1.10
03/26/20	IA	Review Avrio P&L allocations by innovation and updated growth assumptions.	1.40
03/26/20	JD	Review updated diligence trackers and latest diligence materials.	0.80
03/26/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	3.10
03/26/20	ADD	Review and redact minutes and decisions from 2011 to 2015 in preparation for processing and upload to data room.	2.40
03/26/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
03/27/20	ADD	Call with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) to discuss outstanding diligence requests.	0.30
03/27/20	ADD	Call with A. DePalma (AlixPartners), Davis Polk, PJT and Purdue to discuss state attorney general requests.	0.50
03/27/20	ADD	Review and redact minutes and decisions from 2016 to 2018 in preparation for processing and upload to data room.	2.60
03/27/20	ADD	Review and update date room permissions in response	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		from a Committee requests.	
03/27/20	ADD	Review and follow up with outstanding diligence request.	2.20
03/27/20	NAS	Review transactions related to cross-charge of insider salaries from non-debtor to debtor entities to ensure accuracy of 2YR lookback on insider payments.	0.90
03/27/20	NAS	Discussion with M. Hartley and N. Simon (both AlixPartners) re: insider salary cross-charges from non-debtor to debtor entities.	0.30
03/27/20	MH	Discussion with N. Simon and M. Hartley (both AlixPartners) re: insider salary cross-charges from non-debtor to debtor entities.	0.30
03/27/20	MH	Review possible exceptions to the two year look back on insider payments.	2.10
03/30/20	MH	Create revised report on Ordinary Course Professionals to include additional requested information.	3.10
03/30/20	NAS	Evaluate cross-charge between Purdue and IAC related to payment to insiders for inclusion in 2YR lookback on insider payments.	1.20
03/30/20	ADD	Review and compile documentation in response to outstanding diligence requests to provide to Davis Polk eDiscovery team.	2.80
03/30/20	ADD	Request approval from client to release files to the Committees.	0.90
03/30/20	ADD	Review and update data room access for documents upload from previous production.	0.70
03/30/20	ADD	Download board materials and provide to AlixPartners eDiscovery team for upload to relativity platform.	0.50
03/31/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
03/31/20	ADD	Review outstanding diligence requests and follow up with	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		to obtain responsive files.	
03/31/20	NAS	Respond to follow-up questions from C. Robertson (DPW) and R. Aleali (Purdue) re: 2YR lookback on insider payments and submit final analysis to counsel.	0.30
04/01/20	NAS	Follow-up with Counsel (DPW) re: 2YR lookback on insider payments as requested by UCC.	0.20
04/01/20	JD	Correspondence with M. Huebner and E. Vonnegut (both Davis Polk) re: HRT.	0.40
04/01/20	ADD	Review and redact confidential information from 2018 board materials.	3.20
04/01/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	3.00
04/01/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	2.60
04/02/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	3.10
04/02/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	2.00
04/02/20	ADD	Review and redact confidential information from 2018 board materials.	3.20
04/02/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: third party confidentiality.	0.30
04/02/20	ADD	Call with J. DelConte, A. DePalma (both AlixPartners) re: open diligence items.	0.20
04/02/20	JD	Call with J. DelConte, A. DePalma (both AlixPartners) re: open diligence items.	0.20
04/02/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: third party confidentiality.	0.30
04/02/20	JD	Call with R. Aleali, J. Lowne, J. Doyle (Purdue) and J. Turner (PJT) re: Rhodes business plan.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/02/20	JD	Call with R. Aleali (Purdue) re: open business plan points.	0.30
04/03/20	ADD	Call with Davis Polk diligence team re: outstanding diligence requests.	0.30
04/03/20	ADD	Review and redact confidential information from 2018 board materials.	2.80
04/03/20	ADD	Call with Davis Polk M&A and Diligence teams re: Rhodes Board Materials.	0.60
04/06/20	ADD	Review and redact confidential information from board minutes.	3.20
04/06/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	1.70
04/06/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.50
04/06/20	ADD	Update diligence tracker.	2.10
04/06/20	JD	Review recent statements of work for Pinney and Associates.	0.50
04/06/20	JD	Review and comment on draft talking points for HRT call.	0.40
04/06/20	FOS	Review Avrio Health LP board minutes and resolutions and redact confidential information for production to Committees.	3.50
04/07/20	FOS	Review board minutes and resolutions and redact confidential information for production to Committees.	1.60
04/07/20	ADD	Review and redact confidential information from board minutes.	3.10
04/07/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	1.90
04/07/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.40
04/08/20	ADD	Analysis of intercompany agreements compiled in	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		preparations for diligence request response.	
04/08/20	ADD	Upload production provided by Davis Polk to that data room.	1.30
04/08/20	ADD	Review and redact confidential information from board minutes.	2.90
04/09/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
04/09/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	2.50
04/09/20	ADD	Review and redact confidential information from board minutes.	2.80
04/09/20	JD	Review diligence responses re: S. Baker's historical job titles.	0.50
04/09/20	JD	Review historical board minutes prior to having them provided to creditor advisors.	2.10
04/09/20	IA	Review February flash report before distribution to management for approval.	0.70
04/10/20	JD	Call with J. Lowne, P. Strassburger (both Purdue), E. Vonnegut, C. Robertson (both Davis Polk), J. Turner (PJT) and all UCC and AHC creditor advisors re: HRT motion.	1.00
04/10/20	JD	Call with K. Knechtel and B. Bromberg (both FTI) re: business planning progress.	0.40
04/10/20	ADD	Upload production provided by Davis Polk to the data room.	2.60
04/13/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.20
04/13/20	ADD	Review and redact third party information from board minutes and resolutions.	3.10
04/13/20	ADD	Research and review license agreements and royalty payments.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/13/20	ADD	Review and follow up with outstanding diligence requests.	0.90
04/13/20	JD	Call with J. Turner and T. Melvin (PJT) creditor diligence follow ups.	0.30
04/13/20	JD	Review Duff & Phelps diligence questions in advance of call this afternoon. Review materials identified as responsive to various diligence questions.	1.50
04/13/20	IA	Review requests received from UCC and draft responses on status of open items.	1.30
04/14/20	JD	Review diligence request list from Province. Review against list sent across last week. Review status of materials provided to date.	1.50
04/14/20	ADD	Call with Davis Polk diligence team to review status of outstanding diligence request in preparation for call with UCC advisors.	2.80
04/14/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.60
04/14/20	ADD	Review and redact third party information from board minutes and resolutions.	2.40
04/14/20	ADD	Review status of outstanding diligence request in preparation for call with Davis Polk.	1.70
04/15/20	ADD	Call with Davis Polk Diligence team and Purdue re: outstanding diligence request.	0.50
04/15/20	ADD	Call with Davis Polk Diligence team and Purdue outside Counsel re: redaction process.	0.30
04/15/20	ADD	Review of IP and transfer pricing material for responsiveness to diligence requests.	1.40
04/15/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.30
04/15/20	ADD	Review and redact third party information from board minutes and resolutions.	3.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/16/20	ADD	Review and follow up with outstanding diligence request.	1.70
04/16/20	ADD	Review diligence request and update tracker.	1.80
04/16/20	ADD	Review documentation submitted in response to diligence request at request of Davis Polk.	0.80
04/16/20	ADD	Review board materials submitted and prepared in response to diligence requests.	2.40
04/16/20	IA	Review market overview and product forecast documents to identify third party data that requires third party consent prior to disclosure.	0.60
04/16/20	IA	Follow up on diligence requests related to insider titles and job history.	0.70
04/16/20	IA	Follow up with D. Warren (Purdue) to reconcile differences between latest LTRP tracker and amounts submitted to finance team for accruals.	0.50
04/17/20	IA	Draft initial responses to diligence questions received from UCC (Province) to be reviewed with PJT.	1.00
04/17/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.80
04/17/20	ADD	Review and redact third party information from board minutes and resolutions.	2.70
04/17/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	1.80
04/19/20	ADD	Upload documents processed by Davis Polk in response to diligence requests to the data room for the Committees.	2.30
04/20/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.30
04/20/20	ADD	Review outstanding diligence and update diligence tracker.	1.70
04/20/20	ADD	Review and redact third party information from board minutes and resolutions.	3.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/20/20	ADD	Review files uploaded with the current weeks production and check user access.	1.20
04/20/20	JD	Review and provide comments re: draft responses to various UCC diligence requests.	0.60
04/20/20	IA	Update proposed answers to UCC diligence questions received from Province.	1.20
04/21/20	JD	Review latest Rhodes and Purdue IMS data prior to it being uploaded for the creditor advisors.	0.70
04/21/20	JD	Review latest diligence tracker from PJT and provide comments re: same.	0.70
04/21/20	ADD	Compile diligence request statistics at request of Davis Polk.	3.20
04/21/20	ADD	Follow up with outstanding diligence items.	1.40
04/21/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.70
04/21/20	ADD	Review and redact third party information from board minutes and resolutions.	1.80
04/21/20	ADD	Call with Davis Polk diligence team and Davis Polk eDiscovery team to review updated direct diligence production process.	0.70
04/22/20	ADD	Upload files processed and designated by Davis Polk to the data room.	2.10
04/22/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.50
04/22/20	ADD	Review and redact third party information from board minutes and resolutions.	2.90
04/22/20	ADD	Draft correspondence request approval to upload files to the data room.	1.00
04/22/20	JD	Call with J. Feltman, B. Bartell (both Duff & Phelps) and T. Coleman and J. Turner (both PJT) re: case update.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/23/20	ADD	Review new diligence request and draft correspondence to request responsive materials.	1.50
04/23/20	ADD	Review and redact third party information from board minutes and resolutions.	2.90
04/23/20	ADD	Draft correspondence to request approval to upload files to the data room.	1.20
04/23/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.50
04/24/20	ADD	Upload files processed and designated by Davis Polk to the data room.	3.10
04/24/20	ADD	Preparation of excel file for upload to data room.	1.70
04/24/20	ADD	Draft correspondence to request approval to upload files to the data room.	1.00
04/24/20	ADD	Review and redact third party information from board minutes and resolutions.	2.20
04/24/20	ADD	Call with Davis Polk diligence team re: diligence production for the upcoming weekend.	0.30
04/24/20	IA	Review diligence and status requests received from Province and provided answers.	1.60
04/25/20	ADD	Upload documents submitted in response to diligence requests and processed by Davis Polk to the data room.	1.80
04/27/20	ADD	Call with Davis Polk diligence team re: outstanding diligence items.	0.40
04/27/20	ADD	Compile and review business development agreements submitted in response to diligence requests for processing.	1.60
04/27/20	ADD	Review and follow up with outstanding diligence requests.	2.10
04/27/20	ADD	Review board minutes from 2008 to 2017 to document family member election and resignation dates.	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/27/20	ADD	Review board minutes from 2000 to 2007 to document family member election and resignation dates.	2.50
04/27/20	JD	Call with M. Diaz and B. Bromberg (both FTI) re: open diligence questions.	0.20
04/27/20	JD	Call with M. Diaz (FTI) re: COVID donations.	0.20
04/27/20	JD	Call with M. Atkinson (Province) re: COVID donations.	0.20
04/27/20	JD	Correspondence with M. Atkinson (Province) and M. Diaz (FTI) re: COVID donations.	0.70
04/27/20	JD	Review comprehensive diligence question list received from FTI and check on answers and materials collected to date.	1.00
04/28/20	JD	Review correspondence between M. Atkinson (Province) and R. Collura (AlixPartners) re: open diligence items.	0.30
04/28/20	JD	Review existing responses to open UCC diligence items. Create comprehensive response document for purposes of posting to the data room.	3.30
04/28/20	JD	Review materials relating to OSU addiction center donations and ongoing work.	0.90
04/28/20	JD	Call with M. Huebner (Davis Polk), M. Kesselman, R. Silbert (both Purdue), S. Birnbaum, H. Coleman (both Dechert), J. Turner (PJT), J. DelConte, I. Arana (both AlixPartners) and the Hospital Group re: hospital claims analysis and sizing.	1.50
04/28/20	JD	Review hospital group claims sizing analysis prior to call.	0.60
04/28/20	JD	Review materials provided in response to outstanding diligence questions on the CSR budget and COVID donations.	0.70
04/28/20	IA	Call with M. Huebner (Davis Polk), M. Kesselman, R. Silbert (both Purdue), S. Birnbaum, H. Coleman (both Dechert), J. Turner (PJT), J. DelConte, I. Arana (both	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		AlixPartners) and the Hospital Group re: hospital claims analysis and sizing.	
04/28/20	ADD	Compile data obtained from board materials into spreadsheet with corresponding support.	2.40
04/28/20	ADD	Review data from client's SAP system to identify additional data of interest for diligence request.	2.00
04/28/20	ADD	Call with PJT re: FTI diligence request list.	0.50
04/28/20	ADD	Review board minutes from 1990 to 1999 to document family member election and resignation dates.	2.70
04/29/20	ADD	Call with Davis Polk diligence team re: documents previously produced.	0.20
04/29/20	ADD	Uploaded diligence production from Davis Polk to data room.	1.10
04/29/20	ADD	Review new diligence request list from ad-hoc committee and determine potential sources for requested data.	1.40
04/29/20	ADD	Review debtor board minutes from 1999 - 2017 for third-party confidential information, redacting as appropriate.	3.10
04/29/20	ADD	Draft correspondence to request approval to upload files requested by the UCC to the data room.	0.70
04/29/20	ADD	Review and format materials submitted in response to UCC diligence requests for processing.	1.90
04/30/20	ADD	Call with Davis Polk to review outstanding diligence requests in preparation for hearing.	1.00
04/30/20	ADD	Call with PJT re: new diligence requests.	0.50
04/30/20	ADD	Update diligence request statistics including compiling number of emails received and number of unique questions for DPW.	1.60
04/30/20	ADD	Review and compile data on the number of virtual data room users at request of DPW.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/30/20	ADD	Review and compile materials submitted in response to UCC's diligence requests for processing.	2.70
04/30/20	ADD	Draft correspondence requesting approval to upload documents to the data room.	0.80
04/30/20	SJC	Review Sackler titles history.	1.70
04/30/20	JD	Review Sackler family title history to be provided to creditor advisors.	0.30
05/01/20	ADD	Call with Davis Polk diligence team re: production for upload to data room.	0.60
05/01/20	ADD	Update categories of files produced in response to diligence requests at request of Davis Polk.	0.50
05/01/20	ADD	Update family job title history chart using feedback received from Purdue Client contact, prepared in response to diligence request.	2.10
05/01/20	ADD	Update diligence request tracker in preparation for update call.	0.90
05/01/20	ADD	Upload files provided in response to diligence requests and processed by Davis Polk to the Intralinks virtual dataroom.	1.70
05/01/20	ADD	Review and follow up with outstanding UCC and ad-hoc committee diligence requests.	1.70
05/01/20	ADD	Draft correspondence to request approval to upload files requested by the UCC to the data room.	0.50
05/02/20	ADD	Upload files processed and designated by Davis Polk to the data room.	3.20
05/04/20	ADD	Update data room folder naming convention at request of Davis Polk and move files to appropriate location.	1.40
05/04/20	ADD	Review Rhodes board presentation and identify third-party information for redactions.	1.30
05/04/20	ADD	Discussion with Intralinks support for a view only platform	0.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		options for data room to accommodate committee diligence requests.	
05/04/20	ADD	Draft correspondence to request approval to upload documentation to the data room.	0.60
05/04/20	ADD	Upload documentation provided by Davis Polk eDiscovery team to the dataroom.	0.80
05/04/20	ADD	Review Intralinks to confirm all files from previous week's production were upload.	2.10
05/04/20	ADD	Compile and format documentation submitted in response to diligence requests for processing.	1.70
05/04/20	KM	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R.Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/04/20	JD	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R.Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/04/20	IA	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R.Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/05/20	JD	Review and revise proposed responses to UCC diligence questions.	0.50
05/05/20	JD	Review and draft responses to updated diligence questions from M. Atkinson (Province).	0.70
05/05/20	JD	Review and provide comments on proposed responses from the Company to Ad Hoc Committee business plan	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		diligence questions.	
05/05/20	JD	Review summary of Sackler family company position titles.	0.30
05/05/20	JD	Review diligence files prior to them being finalized and posted.	0.40
05/05/20	ADD	Review outstanding diligence requests and develop strategy for obtaining responsive materials.	2.30
05/05/20	ADD	Call with Davis Polk diligence team re: outstanding diligence requests.	0.50
05/05/20	ADD	Incorporate feedback and update Sackler family positions chart.	1.50
05/05/20	ADD	Review and redaction of Purdue Pharma Inc board minutes from 2007 - 2008.	2.60
05/06/20	ADD	Compile and incorporate responses to UCC diligence questions.	1.90
05/06/20	ADD	Review Rhodes board materials for third-party confidential information and provide redaction to Davis Polk.	2.70
05/06/20	ADD	Call with C. Oluwole, E. Diggs (both Davis Polk), R. Aleali (Purdue) and J. DelConte and A. DePalma (both AlixPartners) re: Sackler family designations.	0.40
05/06/20	ADD	Compile diligence responses and draft correspondence seeking approval to upload document to the data room.	2.50
05/06/20	ADD	Review and redaction of Purdue Pharma Inc board minutes from 2009 - 2011.	2.80
05/06/20	JD	Call with C. Oluwole, E. Diggs (both Davis Polk), R. Aleali (Purdue) and J. DelConte and A. DePalma (both AlixPartners) re: Sackler family designations.	0.40
05/06/20	JD	Correspondence with J. Lowne (Purdue) and J. DelConte, A. DePalma (both AlixPartners) re: open UCC diligence	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		responses.	
05/06/20	JD	Review quarterly financial information provided to date and monthly flash reports posted to date in order to draft a response to outstanding UCC diligence requests.	0.70
05/06/20	JD	Review draft responses from T. Au and D. Rosen (both Purdue) re: AHC diligence requests.	0.50
05/06/20	JD	Review and provide comments on latest UCC diligence tracker from PJT.	0.80
05/07/20	JD	Review various diligence items posted to date per AHC request to disclose certain information on a non-PEO basis to their committee members.	1.60
05/07/20	ADD	Review and redaction of Purdue Pharma Inc board minutes from 2012 - 2013.	2.70
05/07/20	ADD	Research and identify prior production of legal fee detail.	0.60
05/07/20	ADD	Research request for contract using Purdue's contract management system and other contract repositories.	1.40
05/07/20	ADD	Review board materials to verify job titles for insiders and verify start/end dates.	3.10
05/07/20	ADD	Compile business development agreements for processing and upload to the data room.	0.30
05/08/20	ADD	Upload files provided by Davis Polk eDiscovery team to the dataroom for the UCC.	2.80
05/08/20	ADD	Compile and incorporate responses to UCC diligence questions.	1.80
05/08/20	ADD	Research and test view only access feature to grant access to various parties.	0.80
05/08/20	ADD	Draft correspondence to request approval and feedback for documents submitted in response to diligence requests.	0.40
05/08/20	ADD	Call with PJT re: outstanding diligence request.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/11/20	ADD	Compile April liabilities subject to compromise analysis for Purdue Finance team.	2.80
05/11/20	ADD	Upload files to the data room for the committee to access.	0.50
05/11/20	ADD	Compile and format material submitted in response to diligence request in preparation for upload to the data room	2.70
05/11/20	JD	Review current IP complaints with Intellipharmaeueutics prior to providing to the UCC.	0.80
05/11/20	JD	Initial review of existing creditor presentation for potential redaction.	0.70
05/11/20	JD	Call with J. Kochian, D. Vondle (both Akin), M. Atkinson, S. Morrison (both Province), K. Sheridan (Jefferies), J. Normile (Jones Day), J. Lowne, P. Strassburger (both Purdue), T. Melvin, J. Turner (both PJT) re: OxyContin LOE.	0.70
05/11/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: board materials diligence requests.	0.30
05/11/20	JD	Review final version of UCC diligence question responses.	0.30
05/12/20	ADD	Upload files submitted in response to diligence request to the data and permission stakeholders.	1.40
05/12/20	ADD	Identify and review material contracts in response to diligence requests.	2.80
05/12/20	ADD	Draft correspondence to identify potential avenues to acquire materials in response to diligence requests.	0.60
05/12/20	ADD	Compile responses to diligence request in preparation for upload to the data room.	2.90
05/12/20	ADD	Request approval to upload materials submitted in response to diligence requests to the data room.	0.40
05/13/20	ADD	Compile responses for diligence requests reviewing for consistency and formatting.	2.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/13/20	ADD	Research and document D&O title history in response to diligence request.	2.10
05/13/20	ADD	Review and compile responses to diligence requests from the ad-hoc committee.	1.60
05/13/20	JD	Review latest draft Sackler title history draft.	0.20
05/13/20	JD	Review and provide comments on the latest non-PEO creditor business plan presentation.	0.80
05/14/20	JD	Call with J. DelConte, A. DePalma (both AlixPartners) re: diligence process.	0.40
05/14/20	ADD	Compile and format materials submitted in response to diligence requests for processing for upload to data room.	1.90
05/14/20	ADD	Call with J. DelConte, A. DePalma (both AlixPartners) re: diligence process.	0.40
05/14/20	ADD	Compile responses to AHC diligence tracker and circulate updated document for review.	1.70
05/14/20	ADD	Review and redact materials submitted in response to diligence request for third-party confidential information.	1.20
05/14/20	ADD	Update job title history compiled in response to committee diligence request.	0.70
05/14/20	ADD	Review outstanding diligence requests, responses received and update request tracker.	1.20
05/15/20	ADD	Locate and review contracts database to identify material contracts.	1.40
05/15/20	ADD	Upload files from weekly production to data room for the Committees to access.	1.20
05/15/20	JD	Review final diligence materials to be posted in response to UCC diligence questions.	0.50
05/17/20	JD	Review follow up questions from AHC re: non-PEO presentation information.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/18/20	JD	Review latest diligence list from FTI and look into open tax questions.	0.80
05/18/20	JD	Review comments from management on the latest AHC/FTI diligence request responses.	0.50
05/18/20	IA	Review and redact 2019 cash reports to be shared under protective order process.	2.60
05/19/20	ADD	Compile and format responses to diligence request list in preparation for upload to the data room.	2.40
05/19/20	ADD	Review materials submitted in response to diligence requests for potential third-party confidentiality issues.	2.80
05/21/20	JD	Review draft responses from management re: Duff & Phelps questions.	0.70
05/22/20	ADD	Compile and format files provided in response to diligence requests for upload to data room.	2.50
05/22/20	ADD	Review contracts matrix in response to request for information on active Rhodes Tech contracts.	0.80
05/22/20	ADD	Review outstanding diligence requests and update diligence tracker.	0.90
05/26/20	ADD	Research entities submitted by Davis Polk for business relationships to identify third party confidentiality issues.	2.30
05/26/20	ADD	Review responses to outstanding diligence requests and update diligence tracker.	1.30
05/26/20	ADD	Meeting with Davis Polk diligence team and Purdue Associate General Counsel re: third party confidentiality issues.	0.40
05/26/20	ADD	Compile documentation and written responses submitted in response to diligence requests in preparation for upload to the data room.	2.70
05/26/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss updates to the UCC's tax request tracker.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/26/20	JD	Review side by side analysis and retention and severance assumptions to respond to UCC diligence questions.	0.80
05/26/20	JD	Correspondence with B. Schrag (Prime Clerk) re: Prime Clerk invoice analysis. Update analysis per comments.	0.50
05/27/20	JD	Call with J. Turner, T. Melvin (both PJT), J. Lowne, M. Kesselman, R. Aleali, D. Rosen (all Purdue), M. Florence (Skadden), J. Buchu (King & Spading) re: upcoming Duff & Phelps prep call.	1.20
05/27/20	SJC	Review and redact 2008 board meeting minutes in preparation for processing an upload to data room (Continue).	2.00
05/27/20	SJC	Review and redact 2008 board meeting minutes in preparation for processing an upload to data room.	3.00
05/27/20	SJC	Review and redact 2009 board meeting minutes in preparation for processing an upload to data room.	3.00
05/27/20	ADD	Review options to set up data room to provide access to different parties.	0.50
05/28/20	ADD	Review diligence questions and compare to previous request to leverage other previously submitted responses.	1.80
05/28/20	ADD	Compile and format materials submitted in response to diligence request in preparation for upload to the data room.	2.10
05/28/20	ADD	Call with Davis Polk re: UCC tax request meeting.	0.60
05/28/20	ADD	Call with Davis Polk re: response to tax requests and outstanding tax request.	0.50
05/28/20	SJC	Review and redact 2010 board meeting minutes in preparation for processing an upload to data room.	3.00
05/28/20	SJC	Review and redact 2010 board meeting minutes in preparation for processing an upload to data room (Continue).	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/28/20	SJC	Review and redact 2011 board meeting minutes in preparation for processing an upload to data room.	2.00
05/28/20	JD	Meeting with J. Turner, T. Melvin (both PJT), J. Lowne, E. Ruiz, D. Rosen, R. Fanelli (all Purdue), R. Levy, J. Feltman, R. Schwartz, A. Chrysostomou (all Duff & Phelps) re: PHI forecasts.	1.00
05/29/20	JD	Review updated business plan diligence questions from FTI.	0.30
05/29/20	JD	Review final Duff & Phelps diligence question responses in advance of the call next Tuesday.	0.80
05/29/20	SJC	Review and redact 2011 board meeting minutes in preparation for processing an upload to data room (Continue).	3.00
05/29/20	SJC	Review and redact 2011 board meeting minutes in preparation for processing an upload to data room.	2.00
05/29/20	SJC	Review and redact 2012 board meeting minutes in preparation for processing an upload to data room.	2.50
05/29/20	ADD	Upload to the data room production provided by DPW eDiscovery team and provide access to designated parties.	2.10
05/29/20	ADD	Review and analyze Rhodes invoices to identify material contracts.	1.80
05/29/20	ADD	Update diligence tracker in preparation for AG Core team meeting.	0.40
05/29/20	ADD	Review debtor tax returns to confirm that tax returns received were uploaded.	1.40
05/29/20	ADD	Set up share folder for client to upload documents and other diligence materials.	0.40
05/29/20	ADD	Set up Intralinks dataroom for Project Catalyst.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
Total			<u>868.10</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	544.20	515.00	280,263.00
Sam K Lemack	9.40	515.00	4,841.00
Nate A Simon	54.80	515.00	28,222.00
Fernando O Silva	5.60	645.00	3,612.00
Sam J Canniff	109.10	645.00	70,369.50
David Samikkannu	6.80	690.00	4,692.00
Isabel Arana de Uriarte	50.80	690.00	35,052.00
Michael Hartley	9.10	840.00	7,644.00
Kevin M McCafferty	1.60	950.00	1,520.00
Jesse DelConte	72.40	950.00	68,780.00
Lisa Donahue	4.30	1,195.00	5,138.50
Total Hours & Fees	868.10		510,134.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
02/03/20	HK	Review certain post-petition vendor invoices per Davis Polk request.	1.50
02/03/20	HK	Update status tracking documents for vendor trade agreements	0.70
02/03/20	HK	Review customer contracts for contract rejection analysis.	2.80
02/03/20	MH	Finalize and file the Monthly Operating Report.	1.10
02/03/20	NAS	Final review of insider payments section of December 2019 Monthly Operating Report.	0.50
02/04/20	NAS	Provide summary of insider payments to be reported in Monthly Operating Report in order to transition responsibilities to M. Hartley (AlixPartners).	0.30
02/04/20	HK	Update status tracking documents for vendor trade agreements	1.20
02/05/20	HK	Review customer contracts for contract rejection analysis.	2.30
02/05/20	HK	Research vendor contracts for potential proof of claim analysis per Davis Polk request.	2.50
02/05/20	HK	Gather vendor contracts from client contract database for review.	1.30
02/05/20	MH	Call with N. Simon and M. Hartley (both AlixPartners) to discuss insider payments section of Monthly Operating Report.	0.60
02/05/20	NAS	Call with M. Hartley and N. Simon (both AlixPartners) to discuss insider payments section of Monthly Operating Report.	0.60
02/05/20	NAS	Prepare for MOR insider payments session discussion with M. Hartley (AlixPartners).	0.50
02/06/20	HK	Review copies of equipment lease agreements to calculate outstanding obligations.	1.80
02/06/20	HK	Review additional customer contracts for contract	1.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		rejection analysis.	
02/06/20	HK	Draft requested information for draft Motion to Reject Equipment Leases.	0.70
02/06/20	HK	Update status tracking documents for vendor trade agreements	0.80
02/07/20	HK	Review additional customer contracts for contract rejection analysis.	0.40
02/11/20	HK	Review vendor invoices for pre-petition/post-petition confirmation.	0.20
02/12/20	HK	Review trade agreements to align with updated information sharing processes.	0.60
02/13/20	HK	Review vendor invoices for pre-petition/post-petition confirmation.	1.60
02/14/20	HK	Review vendor invoices for pre-petition/post-petition confirmation.	0.60
02/14/20	HK	Discussions with E. Ruiz and S. Daniel (Purdue) on contracts assumption analysis.	0.40
02/17/20	MH	Plan for creation of the January Monthly Operating Report.	0.60
02/17/20	NAS	Prepare initial model and data request tracking for insider payments section of January 2020 Monthly Operating Report.	0.40
02/18/20	NAS	Request all items related to insider payments section of Jan 2020 Monthly Operating Report from Purdue and TXP.	1.20
02/18/20	NAS	Incorporate data received into model for insider payments section of Jan 2020 Monthly Operating Report.	2.40
02/18/20	DS	Review of MOR data prior to report submission	1.20
02/18/20	MH	Update templates for the Monthly Operating Report.	1.10
02/18/20	HK	Update status tracking documents for vendor trade	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		agreements	
02/19/20	HK	Review vendor invoices for pre-petition/post-petition confirmation.	1.20
02/19/20	MH	Update the professional payment schedules for the Monthly Operating Report.	1.60
02/19/20	NAS	Finalize insider payments section of Jan 2020 MOR and review for accuracy.	1.30
02/20/20	NAS	Final review of insider payments section of Jan 2020 Monthly Operating Report.	0.80
02/20/20	MH	Complete the January Monthly Operating Report.	3.40
02/20/20	HK	Review vendor invoices for pre-petition/post-petition confirmation.	0.60
02/20/20	HK	Update status tracking documents for vendor trade agreements	0.40
02/24/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.90
02/24/20	HK	Review trade agreements to align with updated information sharing processes.	0.80
02/26/20	HK	Review vendor payables for potential contract rejection opportunities.	2.80
02/26/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.60
03/02/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.30
03/03/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	2.10
03/03/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.50
03/04/20	HK	Review vendor payables for potential contract rejection	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		opportunities.	
03/04/20	HK	Update status tracking documents for vendor trade agreements	1.20
03/04/20	MH	Call with J. Lowne, E. Ruiz (both Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss additional pre-petition vendor payments under the Critical Vendor Motion.	0.30
03/05/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.60
03/05/20	HK	Call with J. Lowne, E. Ruiz (both Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss additional pre-petition vendor payments under the Critical Vendor Motion.	0.30
03/06/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	2.10
03/06/20	MH	Update tracking report of payments to ordinary course professionals.	2.60
03/06/20	MH	Change the time source for payments to ordinary course professionals to even out payment patterns.	0.80
03/06/20	MH	Update the Monthly Operating Report for February payments to professionals.	1.10
03/06/20	MH	Reconcile tracking of payments to retained professionals, ordinary course professionals, and accounts payable control files.	2.20
03/06/20	MH	Send kick off notice to all contributors to the Monthly Operating Report.	0.20
03/09/20	ADD	Research vendor relationship for conflict checks at request of Davis Polk.	1.20
03/10/20	MH	Meeting with M. Hartley and N. Simon (both AlixPartners) to discuss transition of responsibility for insider payments	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		section of MOR.	
03/10/20	MH	Update accounts payable sources of insider payments for the monthly operating report.	1.20
03/10/20	HK	Update status tracking documents for vendor trade agreements	1.60
03/10/20	NAS	Meeting with M. Hartley and N. Simon (both AlixPartners) to discuss transition of responsibility for insider payments section of MOR.	0.40
03/11/20	HK	Call with E. Ruiz (Purdue), M. Hartley, H. Ku (both AlixPartners), and other company representatives to discuss potential pre-petition royalties' obligations.	0.60
03/11/20	MH	Send updated data requests to all contributing parties for the insider portion of the February Monthly Operating Report.	1.30
03/11/20	MH	Update payroll information for insiders for February Monthly Operating Report.	0.50
03/12/20	NAS	Review requests sent and data provided for insider payments section of Feb 2020 MOR.	0.60
03/15/20	SKL	Call with S. Lemack and D. Samikkannu (both AlixPartners) re: client requests needed for deliverables	0.20
03/16/20	MH	Update accounts payable component of insider tracking report.	2.10
03/16/20	DS	Call with D. Samikkannu and S. Lemack (both AlixPartners) re: Customer Programs report review	0.30
03/16/20	DS	Prepare detailed analysis on Med Part D and 3rd party vendors as part of Customer Programs report	2.20
03/16/20	DS	Review certain calculations in Customer Programs report	0.90
03/16/20	DS	Call with S. Lemack and D. Samikkannu (both AlixPartners) re: client requests needed for deliverables	0.20
03/17/20	DS	Review draft Customer Programs report and provide	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		comments to S. Lemack (AlixPartners)	
03/17/20	DS	Follow up with Head of Customer Programs (Purdue) re: updates and edits made to Customer Programs report	0.30
03/17/20	NAS	Walk-through of MOR insider payments model with M. Hartley and N. Simon (both AlixPartners).	0.70
03/17/20	NAS	Review latest draft of insider payments section of MOR for accuracy.	0.20
03/17/20	MH	Call with legal operations to review new, raw detail and discuss changes to Ordinary Course Professional tracking.	0.70
03/17/20	MH	Review proposed insider calculations for February Monthly Operating Report.	0.60
03/17/20	MH	Walk-through of MOR insider payments model with M. Hartley and N. Simon (both AlixPartners).	0.70
03/17/20	HK	Update status tracking documents for vendor trade agreements	1.10
03/18/20	HK	Review available historical IAC licensing agreements.	2.30
03/18/20	MH	Incorporate cash reporting data into the insider report of the Monthly Operating Report.	1.20
03/18/20	MH	Create proposed final insider report for the Monthly Operating Report.	0.90
03/18/20	NAS	Review latest draft of insider payments section of MOR for accuracy.	1.60
03/18/20	DS	Draft email with summary seeking approval from management for Customer Programs report	0.50
03/18/20	DS	Redact draft Customer Programs report prior to submission for production	1.40
03/18/20	DS	Correspondence with J. DelConte (AlixPartners) about key items to review in draft Customer Programs report	0.40
03/19/20	NAS	Final review of insider payment section of Monthly	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Operating Report.	
03/20/20	MH	Finalize and submit the Monthly Operating Report.	1.30
03/25/20	HK	Review company contracts data for sharing with Davis Polk.	1.30
03/25/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	2.50
03/26/20	HK	Review company contracts data for sharing with Davis Polk.	2.60
03/26/20	HK	Provide additional detail to contracts repository to facilitate ability to search.	2.80
03/31/20	MH	Set up monthly template for Monthly Operating Report.	0.90
04/08/20	MH	Reconcile the professional payments in the Monthly Operating Report with legal operations.	0.60
04/09/20	MH	Review new orders on professional fees for professional fee tracking.	0.40
04/13/20	MH	Kick off Monthly Operating Report data requests.	0.50
04/13/20	MH	Preparation of accounts payable portion of the insider report for the Monthly Operating Report.	0.90
04/13/20	NAS	Review correspondence and data sources provided by Purdue/TXP for purposes of March 2020 MOR Insider Payments section.	0.30
04/16/20	JD	Review cash balance and spending details to be sent to the UST.	0.20
04/16/20	MH	Preparation of summary of cash activity for the Monthly Operating Report including first quarter fee estimates.	0.60
04/16/20	MH	Update the tracking of professional fee payments for new retained professionals.	0.40
04/19/20	NAS	Correspondence with M. Hartley (AlixPartners) re: insider payments section of March 2020 MOR.	0.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
04/20/20	NAS	Review preliminary draft of insider payments section of March 2020 MOR.	0.60
04/20/20	NAS	Call with M. Hartley, N. Simon (both AlixPartners) to review insider payments section of March 2020 MOR.	0.50
04/20/20	JD	Review draft MOR prior to filing.	0.60
04/20/20	JD	Review updated Avrio business plan numbers.	0.80
04/20/20	MH	Preparation of insider portion of Monthly Operating Report.	3.90
04/20/20	MH	Call with M. Hartley, N. Simon (both AlixPartners) to review insider payments section of March 2020 MOR.	0.50
04/20/20	MH	Finalize the Monthly Operating Report for March.	1.80
04/21/20	NAS	Review final draft of insider payments section of March 2020 MOR.	0.80
04/30/20	JD	Review final MOR prior to filing.	0.40
04/30/20	JD	Review ordinary course professional payment summary prior to filing.	0.50
04/30/20	MH	Create March report for Ordinary Course Professionals.	3.20
04/30/20	MH	Create final Monthly Operating Report.	1.80
05/11/20	MH	Call with A. DePalma, M. Hartley (both AlixPartners) re: transition of Monthly Operating Report.	0.50
05/11/20	NAS	Request information from Purdue/TXP related to insider payments section of Monthly Operating Report.	0.80
05/11/20	ADD	Call with A. DePalma, M. Hartley (both AlixPartners) re: transition of Monthly Operating Report.	0.50
05/12/20	NAS	Correspondence with Purdue/TXP re: insider payments section of April 2020 MOR.	0.50
05/15/20	NAS	Analyze data for insider payments section of April 2020 MOR.	0.70
05/15/20	MH	Participate in OCP/Retained Professional catch-up call re:	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
05/15/20	SKL	April Monthly Operating Report with M. Hartley, S. Lemack (both AlixPartners). Participate in OCP/Retained Professional catch-up call re: April Monthly Operating Report with M. Hartley, S. Lemack (both AlixPartners).	0.90
05/18/20	NAS	Prepare insider payments section of April 2020 MOR.	0.80
05/18/20	JD	Review information to be provided to the UST prior to asking for an extension on MOR filing.	0.70
05/19/20	JD	Correspondence with Davis Polk and the US Trustee's office re: MOR timing.	0.60
05/20/20	NAS	Review Insider Payments section of Monthly Operating Report for accuracy.	0.50
05/21/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open prepetition vendor payment inquiries and prepared for upcoming meeting with LPW Training Partners.	0.70
05/21/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open prepetition vendor payment inquiries and prepared for upcoming meeting with LPW Training Partners.	0.70
05/26/20	KAS	Email B. Filler and L. Verry (both AlixPartners) request to update retention pleadings.	0.20
05/26/20	KAS	Review and edit draft retention pleadings.	0.70
05/26/20	LCV	Assist with revisions to draft retention documents.	0.30
05/27/20	KAS	Review updated draft retention pleadings from B. Filler (AlixPartners).	0.70
05/27/20	ADD	Review outstanding diligence request and update diligence request tracker to document outstanding requests.	2.70
05/27/20	ADD	Review and research requests for additional information	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		re: interested party list entity clarifications.	
05/28/20	ADD	Compile and prepare April MOR for signature from Purdue.	1.30
05/28/20	ADD	Research options for new Intralinks data room.	0.90
05/28/20	JD	Review draft monthly operating report prior to filing it on the docket.	0.70
05/29/20	MH	Review MOR.	0.40
Total			145.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Laurie C Verry	0.30	510.00	153.00
Kaitlyn A Sundt	1.60	510.00	816.00
Andrew D DePalma	8.80	515.00	4,532.00
Sam K Lemack	1.80	515.00	927.00
Nate A Simon	17.90	515.00	9,218.50
Hart Ku	57.70	515.00	29,715.50
David Samikkannu	8.60	690.00	5,934.00
Michael Hartley	44.50	840.00	37,380.00
Jesse DelConte	4.50	950.00	4,275.00
Total Hours & Fees	145.70		92,951.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/01/20	LJD	Strategy discussion with K. Buckfire - Board member	0.70
02/01/20	DS	Revise OSF lease extension materials for purposes of distributing to constituents	0.50
02/01/20	DS	Further refine OSF lease extension materials based on comments received from J. DelConte (AlixPartners)	0.30
02/01/20	RDS	Review correspondence on KPI dashboard for consolidated Rhodes business	0.20
02/02/20	JD	Review and provide comments on draft presentations to be shared at meeting tomorrow.	0.60
02/02/20	LJD	Review and comment on deck for meeting with ad hoc group	1.20
02/03/20	LJD	Review and comment on Mundipharma diligence and meetings deck	1.50
02/03/20	BF	Call with G. Koch and B. Folse (both AlixPartners) to review Diligence Update/feedback	0.50
02/03/20	MH	Update law firms released as Ordinary Course Professionals.	0.40
02/03/20	MH	Reconcile balances with large patch technology vendor.	1.10
02/03/20	MH	Research petition status of an invoice at the request of company counsel.	0.40
02/03/20	MH	Respond to vendor related emails sent to alternate email address, re: nonpayment of pre-petition invoices.	1.20
02/03/20	MH	Create accounts payable release file.	0.60
02/03/20	MH	Research new legal vendor to determine payment status.	0.40
02/03/20	MH	Update legal and MOR tracking programs to include new vendor ID for Committee counsel.	0.50
02/03/20	MH	Create accounts payable release file.	0.90
02/03/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss next steps for Mundipharma business plan	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/03/20	GJK	analysis and plan for LAM region management meetings.	0.50
02/03/20	GJK	Call and follow up with I. McClatchey (Norton Rose) re: LAM diligence	0.50
02/03/20	GJK	Call with G. Koch and B. Folse (both AlixPartners) to review Diligence Update/feedback	1.00
02/03/20	GJK	Revisions to Diligence Update and coordination with PJT and AlixPartners	2.50
02/03/20	GJK	Review LAM P&L for Mundipharma diligence	2.40
02/03/20	GJK	Review LAM (Asia) P&L and review of model updates for Mundipharma diligence	1.00
02/03/20	GJK	Tracking re: Mundipharma diligence health risks/create support for in person meetings	0.30
02/03/20	GJK	Call with G. Koch, N. Simon, and H. Ku (all AlixPartners) re: feedback on Mundipharma diligence update presentation	0.30
02/03/20	HK	Call with G. Koch, N. Simon, and H. Ku (all AlixPartners) re: feedback on Mundipharma diligence update presentation	2.10
02/03/20	HK	Update IAC diligence tracker with new information provided via the data site.	1.80
02/03/20	HK	Review new uploads to Mundipharma due diligence data site.	0.40
02/03/20	IA	Discussion with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) re: key items to discuss in next day Avrio business plan meeting	1.60
02/03/20	IA	Draft slides for AlixPartners update meeting with board members.	1.70
02/03/20	IA	Reconcile and update Rhodes and North Carolina retention information requested by Rhodes management.	0.80
02/03/20	IA	Follow up and correspondence with W. Chang (TXP) on	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		approved motion orders.	
02/03/20	IA	Review of AHC meeting materials for internal update presentation in upcoming meeting with board members.	1.60
02/03/20	IA	Review of Avrio board materials and prior analyses in preparation for meeting with Avrio management.	2.00
02/03/20	JD	Correspondence with E. Ruiz (Purdue) re: open auto injector diligence questions.	1.00
02/03/20	DS	Discussion with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) re: key items to discuss in next day Avrio business plan meeting	0.40
02/03/20	NAS	Review of new Mundipharma diligence files posted to Norton Rose data room.	0.50
02/03/20	NAS	Call with G. Koch, N. Simon, and H. Ku (all AlixPartners) re: feedback on Mundipharma diligence update presentation.	0.30
02/03/20	NAS	Revise Mundipharma business plan model to incorporate product-level cost detail for LAM region.	2.80
02/03/20	NAS	Revise Mundipharma business plan model to incorporate product-level cost detail for Canada.	2.00
02/03/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss next steps for Mundipharma business plan analysis and plan for LAM region management meetings.	0.30
02/03/20	NAS	Finalize latest draft of Mundipharma business plan model (incorporating product-level detail for LAM and Canada regions) and provide summary of findings to G. Koch and H. Ku (both AlixPartners).	0.60
02/03/20	RDS	Review of Avrio business plan update materials	1.30
02/03/20	RDS	Review "Creative Services" allocation from Purdue to Avrio, which was missed in previous budgeting exercise.	0.70
02/03/20	RDS	Call with J. Northington (Purdue) to discuss continuum of	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		care data request	
02/03/20	RDS	Meeting with R. Shamblem, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech operating KPIs tracking and monitoring	1.20
02/03/20	RDS	Meeting with N. Davis, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: dashboard metrics, tracking approach and reporting requirements	1.70
02/03/20	RDS	Meeting with V. Mancinelli, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma KPI for R&D tracking and monitoring	0.60
02/03/20	RDS	Meeting with R. Shamblan (Purdue) to discuss his preliminary dashboard thoughts	1.50
02/03/20	RDS	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: implementation and communications planning	0.20
02/03/20	RDS	Discussion with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) re: key items to discuss in next day Avrio business plan meeting	0.40
02/03/20	KM	Coventry visit planning and document review	0.80
02/03/20	KM	Analysis and preparation re: Rhodes implementation dashboard and KPIs	1.50
02/03/20	KM	Meeting with N. Davis, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: dashboard metrics, tracking approach and reporting requirements	1.70
02/03/20	KM	Creation of sample dashboard and reporting tracker for Rhodes implementation	0.70
02/03/20	KM	Meeting with V. Mancinelli, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma KPI for R&D tracking and monitoring	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/03/20	KM	Meeting with R. Shamblem, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech operating KPIs tracking and monitoring	1.20
02/03/20	KM	Synthesis of Rhodes Pharma and Rhodes Tech reporting requirements	0.50
02/03/20	KM	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: implementation and communications planning	0.20
02/04/20	KM	Analysis of Rhodes implementation dashboard and KPIs	1.40
02/04/20	KM	Implementation activities for 1Q2020	0.80
02/04/20	KM	Analysis re: Rhodes Tech and Rhodes Pharma Levorphanol product and API qualification	1.00
02/04/20	KM	Call with D. Fogel, and M. Sisoda (both Purdue) re: Levorphanol NPV analysis and API outsourcing	0.80
02/04/20	KM	Analysis review and preparation re: Rhodes Pharma 2020 product pipeline, resource allocation and NPV analysis	0.60
02/04/20	KM	Meeting with V. Mancinelli, K. Kolar, D. Ebere, D. Fogel (all Purdue) re: Rhodes Pharma 2020 product pipeline, resource allocation and NPV analysis	2.20
02/04/20	KM	Meeting with R. Shamblen (Purdue) re: Rhodes Tech KPIs and operational metrics	0.30
02/04/20	KM	Analysis and review re: Rhodes Tech dashboard	0.90
02/04/20	KM	Meeting with D. Lundie, D. Fogel, R. Shamblen, D. Shell, V. Mancinelli (all Purdue) re: Rhodes leadership team update and plan for skip meetings	1.30
02/04/20	KM	Slide preparation re: Rhodes Pharma KPI dashboard	0.90
02/04/20	ADD	Call with A. DePalma and M. Hartley (both AlixPartners) to discuss no motion AP at month end reporting.	0.40
02/04/20	RDS	Call with J. Lowne, C. Chomiack, J. Tran, (all Purdue), J. Turner (PJT), I. Arana, D. Sammikkanu, and R. Sublett	3.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(all AlixPartners) re: Avrio business plan review, ROI analysis of S&P spend and next steps to assemble KPI dashboard for board review	
02/04/20	RDS	Review Avrio materials from meeting.	0.20
02/04/20	RDS	Review Rhodes Pharma R&D implementation plan outline and incorporate changes to R&D staffing model	0.60
02/04/20	NAS	Coordinate and plan meetings with Mundipharma LAM region management for week of 2/10.	0.60
02/04/20	NAS	Review updated tracker for Mundipharma diligence items received and requests sent.	0.70
02/04/20	NAS	Revise Mundipharma business plan model to ensure consistency in sources across all P&L items and revise product groupings incorporated.	2.80
02/04/20	NAS	Mundipharma diligence advisor coordination call re: LAM diligence trip for week of 2/10 and follow-up discussion with G. Koch and N. Simon (both AlixPartners).	0.90
02/04/20	NAS	Review of new charts for Mundipharma diligence report and discussion of key take aways with G. Koch, N. Simon, and H. Ku (all AlixPartners).	0.50
02/04/20	NAS	Incorporate accuracy checks into Mundipharma business plan model and resolve source data discrepancy.	1.70
02/04/20	DS	Process Medicaid state data for Rhodes for purposes of December Customer Programs report	1.10
02/04/20	DS	Review and start drafting work plan in response to Purdue CFO's outline	1.00
02/04/20	DS	Preparation re: Avrio long-term business plan for morning meeting with Purdue CFO and Avrio management	1.20
02/04/20	DS	Call with J. Lowne, C. Chomiack, J. Tran, (all Purdue), J. Turner (PJT), I. Arana, D. Sammikkanu, and R. Sublett (all AlixPartners) re: Avrio business plan review, ROI	3.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		analysis of S&P spend and next steps to assemble KPI dashboard for board review	
02/04/20	JD	Prepare presentation outlining summary business plan for each business segment.	3.20
02/04/20	IA	Update retention by employee data base requested by management to be shared with Willis Towers Watson, showing historical and future payments.	3.10
02/04/20	IA	Prepare for and attend call with J. Lowne, C. Chomiack, J. Tran, (all Purdue), J. Turner (PJT), I. Arana, D. Sammikkanu, and R. Sublett (all AlixPartners) re: Avrio business plan review, ROI analysis of S&P spend and next steps to assemble KPI dashboard for board review	3.80
02/04/20	IA	Prepare for call with J. Lowne, C. Chomiack, J. Tran, (all Purdue), J. Turner (PJT), I. Arana, D. Sammikkanu, and R. Sublett (all AlixPartners) re: Avrio business plan review, ROI analysis of S&P spend and next steps to assemble KPI dashboard for board review	0.30
02/04/20	HK	Draft forecasting analysis for Mundipharma Canada product-level sales	0.60
02/04/20	HK	Review draft business plan model to draft summaries on sales trends in Asia.	1.70
02/04/20	HK	Review draft business plan model to draft summaries on sales trends in Canada.	1.50
02/04/20	HK	Draft forecasting analysis for Mundipharma regional sales data.	1.30
02/04/20	HK	Draft forecasting analysis for Mundipharma Europe product-level sales	2.20
02/04/20	HK	Draft forecasting analysis for Mundipharma LAM product-level sales	1.40
02/04/20	HK	Review of new charts for Mundipharma diligence report and discussion of key take away with G. Koch, N. Simon,	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and H. Ku (all AlixPartners).	
02/04/20	GJK	Coordination, calls and follow up with I. McClatchey (Norton Rose) re: Mundipharma LAM diligence trip	2.00
02/04/20	GJK	Mundipharma diligence advisor coordination call re: LAM diligence trip for week of 2/10 and follow-up discussion with G. Koch and N. Simon (both AlixPartners).	0.90
02/04/20	GJK	Review of new charts for Mundipharma diligence report and discussion of key take aways with G. Koch, N. Simon, and H. Ku (all AlixPartners).	0.50
02/04/20	GJK	Coordination of Mundipharma diligence including advisor call, follow up calls and emails with B. Folse (AlixPartners), B. Bromberg (FTI), and J. Turner (PJT)	1.80
02/04/20	GJK	Review of Mundipharma diligence files re: analgesics	2.00
02/04/20	MH	Research proposed Trade Agreement against open payable for "Triangle" vendor.	0.80
02/04/20	MH	Research open balances for group of clinical/compliance vendors proposed for Trade Agreements.	0.90
02/04/20	MH	Call with A. DePalma and M. Hartley (both AlixPartners) to discuss no motion AP at month end reporting.	0.40
02/04/20	MH	Review accounts payable month end analysis of open pre-petition.	0.90
02/04/20	MH	Create summary of vendors with pre-petition contra balances to be resolved.	0.50
02/04/20	MH	Call with C. Robertson (Davis Polk) to review open balances with large patch technology vendor.	0.70
02/04/20	MH	Review all insider payment tracking files to prepare for staffing transition.	1.10
02/04/20	MH	Create accounts payable release file.	0.60
02/04/20	LJD	Prepare for and attend discussion with T. Coleman (PJT) and M. Huebner (Davis Polk) re: strategy initiatives	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/04/20	LJD	Review and comment on board memo re: strategic approach and next steps	0.90
02/05/20	LJD	Review revised strategy deck for meeting with K. Buckfire and S. Miller (both Board members)	1.40
02/05/20	MH	Discussion re: no motion accounts payable at month end reporting with A. DePalma and M. Hartley (both AlixPartners)	0.40
02/05/20	MH	Research and resolve possible payment made in error related to pre-petition services by a related firm.	0.50
02/05/20	MH	Research invoice in the release list at the request of Accounts Payable.	0.60
02/05/20	MH	Create month end accounts payable analysis to support "subject to compromise" entry.	2.90
02/05/20	MH	Create accounts payable release file.	0.90
02/05/20	MH	Manually release legal invoices approved by Special Committee as indemnifications.	0.80
02/05/20	GJK	Various outreach related to coordinating Dubai diligence to keep on track.	1.20
02/05/20	GJK	Materials review from Lam diligence	1.00
02/05/20	GJK	Mundipharma diligence coordination via email	0.50
02/05/20	GJK	Purdue deck/slides discussion with G. Koch and H. Ku (both AlixPartners)	0.30
02/05/20	HK	Purdue deck/slides discussion with G. Koch and H. Ku (both AlixPartners)	0.30
02/05/20	HK	Update forecasting analysis for Mundipharma LAM product-level sales	2.10
02/05/20	HK	Update Mundipharma business plan analysis with product category sales trends.	2.20
02/05/20	IA	Follow up on reimbursement of board fees with TXP.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/05/20	IA	Review of Avrio retail reports and brand scorecards as part of forecast analysis.	2.80
02/05/20	JD	Correspondence with E. Ruiz (Purdue) re: various auto injector diligence requests.	0.60
02/05/20	JD	Update presentation and Q&A re: case status and business plan update.	1.10
02/05/20	DS	Add details to Avrio business plan workplan, linking to project objectives	1.60
02/05/20	DS	Refine state-by-state analysis of December Medicaid activity	1.30
02/05/20	DS	Refine state-by-state analysis of December Medicaid activity	2.10
02/05/20	DS	Work on Medicare and Medicaid analysis for Rhodes for December Customer Programs report	1.40
02/05/20	DS	Review and refine GPO fees and chargebacks section of December Customer Programs report	1.80
02/05/20	DS	Review and refine GPO fees and chargebacks section of December Customer Programs report	1.50
02/05/20	NAS	Create individual product-level P&L in Mundipharma business plan model.	1.40
02/05/20	NAS	Review of revised Mundipharma charts for IAC diligence report.	0.50
02/05/20	NAS	Resolve source data discrepancy for Mundipharma LAM financials.	0.60
02/05/20	NAS	Create consolidated roll-up for Mundipharma business plan model.	1.50
02/05/20	NAS	Create comparison of product contribution from Analgesic and Non-Analgesic products in Mundipharma business plan model.	1.70
02/05/20	RDS	Review Avrio consumption and marketing ROI materials	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/05/20	RDS	Review Avrio 2019 Y/E retail reports by product / SKU	0.80
02/05/20	RDS	Review Rhodes Pharma KPI dashboard draft and assemble comments for management incorporation	0.30
02/05/20	ADD	Discussion re: no motion accounts payable at month end reporting with A. DePalma and M. Hartley (both AlixPartners)	0.40
02/05/20	KM	Presentation edits re: Rhodes management skip level meetings	1.50
02/05/20	KM	Analysis re: Rhodes Pharma resource allocation	1.00
02/05/20	KM	Review dashboard options for integration and ongoing activities	1.30
02/05/20	KM	Edit Consolidated program improvement dashboard	0.80
02/05/20	KM	Create Ms Excel integrated dashboard reporting spreadsheet	1.30
02/05/20	KM	Presentation edits re: Rhodes management skip level meetings	0.80
02/05/20	KM	Discussion with R. Shamblen (Rhodes) re: Rhodes Tech KPIs and tracking approach	1.40
02/05/20	KM	Build Excel integrated dashboard reporting tool	1.80
02/05/20	KM	Discussion with D. Lundie (Purdue) re: implementation progress	0.60
02/06/20	KM	Create Rhodes Tech pipeline dashboard	0.70
02/06/20	KM	Review Rhodes Pharma resource allocation model	1.30
02/06/20	KM	Discussion with R. Shamblen (Purdue) re: Rhodes Tech dashboard improvements	1.20
02/06/20	KM	Create summary dashboard for full program reporting	1.00
02/06/20	KM	Build Rhodes Pharma Commercial dashboard	0.80
02/06/20	KM	Meeting with D. Fogel, R. Shamblen, V. Mancinelli, D. Shell, K. Kolar, D. Ebere, A. Nadeau, A. Soma (all Purdue)	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: program reporting dashboard progress review	
02/06/20	KM	Meeting with D. Fogel (Purdue) re: financial data tracking for dashboard	0.80
02/06/20	KM	Edit and improve consolidated dashboard package	1.10
02/06/20	KM	Circulate individual reporting dashboards to key stakeholders	0.40
02/06/20	KM	Review and plan for key steps with team members	0.70
02/06/20	RDS	Review Avrio pipeline data, complete analysis to link S&P to future revenue generation by distribution channel / partner	1.30
02/06/20	RDS	Review Avrio scope / work plan prior to February board meeting	0.50
02/06/20	RDS	Attend TMA Distressed Investor Conference	8.00
02/06/20	RDS	Review Rhodes dashboard draft	0.40
02/06/20	DS	Finish up initial draft of Avrio workplan and send to team for review	2.20
02/06/20	DS	Review of Purdue financial analyst data re: Customer Programs vendor	0.70
02/06/20	DS	Review draft Customer Programs report and provide comments to S. Lemack (AlixPartners)	1.60
02/06/20	DS	Review draft Customer Programs report and provide comments to S. Lemack (AlixPartners)	0.40
02/06/20	DS	Correspondence with Purdue CFO re: his comments on draft Customer Programs report	0.40
02/06/20	DS	Correspondence with R. Sublett (AlixPartners) re: draft workplan for Avrio business plan workstream	0.40
02/06/20	JD	Review draft responses to board questions prior to sending to PJT and management.	1.10
02/06/20	JD	Correspondence with PJT and J. Lowne (Purdue) re: board	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		questions.	
02/06/20	IA	Update data base for employee LTRP information to show 2020 grants	1.30
02/06/20	IA	Update data base for employee LTRP information to show 2015, 2016 and 2017 outstanding grant amounts.	1.90
02/06/20	IA	Reconcile and update Rhodes retention tracker to incorporate information requested by management on North Carolina resources.	1.30
02/06/20	IA	Follow up on retainer offset inquiry for D&O attorneys.	0.30
02/06/20	IA	Follow up on board fees reimbursement.	0.60
02/06/20	IA	Review of updated nalmefen injector motion and reconciliation of shown amounts.	2.20
02/06/20	HK	Update forecasting analysis for Mundipharma Europe product-level sales	2.40
02/06/20	GJK	Call and correspondence with I. McClatchy (Norton Rose) to coordinate schedule/agenda for Dubai trip and address scheduling issues	1.40
02/06/20	GJK	LAM diligence review, including analysis developed by H. Ku (AlixPartners) on products in key markets	2.00
02/06/20	GJK	Calls with B. Bromberg and M. Diaz (both FTI) to discuss LAM diligence and Dubai trip schedule	1.50
02/06/20	MH	Create accounts payable release file.	0.90
02/06/20	MH	Reconcile all trade agreement activity with new pre-petition invoices to ensure accurate Critical Vendor report.	1.30
02/06/20	LJD	Review revised deck for board discussion	1.50
02/06/20	LJD	Prepare for and attend dinner meeting with S. Miller and K. Buckfire (both Board members).	2.50
02/06/20	LJD	Call with T. Coleman (PJT).	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/06/20	LJD	Internal coordination re: board meeting and strategy session	0.60
02/07/20	LJD	Review existing business plan and discuss strategic issues	0.90
02/07/20	GJK	Finalize agenda/coordination for Dubai meetings	2.00
02/07/20	GJK	Assess projections provided and analysis by H. Ku (AlixPartners)	2.50
02/07/20	HK	Update Mundipharma business plan analysis with product category sales trends.	2.80
02/07/20	IA	Follow up on net sales by product report for Rhodes and incorporate edits from management.	1.40
02/07/20	IA	Incorporate historical base salary for Purdue employees to WTW request file.	1.60
02/07/20	IA	Incorporate AIP payout as % of historical base salary for Purdue employees to WTW request file.	1.20
02/07/20	IA	Reconcile AIP and LTRP payment information from payroll to performance factors and payout percentages included in files received from HR in response to WTW request.	2.20
02/07/20	IA	Include retention dates in WTW request for Purdue and Rhodes non-executive retention plan participants.	1.70
02/07/20	JD	Call with J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: Rhodes Tech shut down costs and transitions	0.50
02/07/20	JD	Review and provide comments to management re: Rhodes scenario analysis.	0.40
02/07/20	JD	Review draft materials re: OSR lease damages calculation	0.70
02/07/20	JD	Correspondence with Davis Polk re: protective order designations and timing for getting certain materials provided to advisors.	0.80
02/07/20	JD	Review and comment on various diligence materials prior to providing them to creditor advisors.	1.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/07/20	JD	Prepare materials to provide to the committee advisors re: EPL and FL insurance renewals, review draft policies, and correspondence with Davis Polk re: process for getting materials over to the advisors given the protective order.	2.50
02/07/20	DS	Correspondence with S. Lemack (AlixPartners) re: cash report and Customer Programs report	0.20
02/07/20	DS	Send draft workplan to Purdue CFO for his edits	0.20
02/07/20	DS	Correspondence with S. Lemack (AlixPartners) re: cash report and Customer Programs report	0.30
02/07/20	DS	Draft plan for following week and send to Avrio CFO	0.80
02/07/20	DS	Draft plan for following week and send to Avrio CFO	0.40
02/07/20	RDS	Call with J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: Rhodes Tech shut down costs and transitions	0.50
02/07/20	RDS	Correspondence with L. Donahue (AlixPartners) re: impact of Avrio business planning workstream on the overall settlement discussions	0.40
02/07/20	RDS	Comments and correspondence re: updated Rhodes Pharma pipeline rationalization analysis	0.80
02/07/20	RDS	Rhodes Pharma r&d pipeline internal asset avocation and ROIC analysis	1.30
02/07/20	KM	Dashboard update and communication to D. Lundie (Purdue) re: Rhodes dashboard update	0.50
02/07/20	KM	Call with J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: Rhodes Tech shut down costs and transitions	0.50
02/07/20	KM	Discussion with J. Carlisle and D. McGuire (both Purdue) re: NC Tech Ops dashboard review	0.40
02/07/20	KM	NC Tech Ops dashboard improvements	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/08/20	RDS	Correspondence and data request for D. Fogel (Purdue) re: Rhodes Pharma pipeline rationalization.	0.30
02/08/20	LJD	Review work plans for Rhodes Tech and Avria and discuss	1.50
02/09/20	LJD	Call with K. Buckfire - board member - to discuss upcoming board meeting	0.60
02/09/20	LJD	Prepare for and attend call with J. DelConte (AlixPartners), M. Kesselmen, C. Landau, J. Lowne (all Purdue), T. Coleman (PJT) and M. Huebner (Davis Polk) re: upcoming meetings.	0.90
02/09/20	IA	Incorporate VP historical base salary and AIP payout percentages to WTW request.	1.30
02/09/20	IA	Review commentary on claw back provisions for Purdue and Rhodes retention program participants for WTW request.	1.80
02/09/20	IA	Incorporate Rhodes base salary information and calculate AIP payout percentage of target for Rhodes employees, in response to WTW request.	1.50
02/09/20	DS	Update Avrio workplan based on comments from J. DelConte (AlixPartners) and Purdue CFO	1.10
02/09/20	DS	Update Avrio workplan based on comments from J. DelConte (AlixPartners) and Purdue CFO	1.90
02/09/20	RDS	Review Avrio materials ahead of management meeting on Monday	0.60
02/10/20	RDS	Avrio Meeting to discuss budgeting methodology and KPIs for board presentation with J. Tran (Purdue), D. Sammikkanu and R. Sublett (both AlixPartners)	3.80
02/10/20	RDS	Call with D. Fogel (Purdue) and Rhodes finance team to discuss headcount tie out	0.50
02/10/20	RDS	Avrio Meeting to discuss budgeting methodology and KPIs for board presentation with J. Tran, C. Chomiak (Purdue),	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		D. Sammikkanu and R. Sublett (both AlixPartners)	
02/10/20	RDS	Review updated dashboard for Rhodes business and provide commentary to Rhodes finance team	1.50
02/10/20	KM	Rhodes improvement program planning and dashboard development	1.80
02/10/20	KM	Meeting with D. Fogel and N. Davis (both Purdue) re: workforce reconciliation	0.30
02/10/20	KM	Analysis re: Rhodes R&D resource allocation	1.80
02/10/20	DS	Build S&P model for Avrio on a product-by-product basis	2.30
02/10/20	DS	Avrio Meeting to discuss budgeting methodology and KPIs for board presentation with J. Tran (Purdue), D. Sammikkanu and R. Sublett (both AlixPartners)	3.80
02/10/20	DS	Review Avrio business plan materials in detail prior to meeting with management	0.80
02/10/20	DS	Discussion with Purdue Treasurer re: assumptions on revised lease damage analysis	0.50
02/10/20	DS	Summarize key diligence documents received from Avrio management and provide AlixPartners team with detailed summary	1.20
02/10/20	DS	Avrio Meeting to discuss budgeting methodology and KPIs for board presentation with J. Tran, C. Chomiak (Purdue), D. Sammikkanu and R. Sublett (both AlixPartners)	2.40
02/10/20	JD	Meeting with C. Landau, J. Lowne, M. Kesselmen (Purdue), T. Coleman (PJT), M. Huebner (Davis Polk) L. Donahue, and J. DelConte (both AlixPartners) re: business planning process.	0.90
02/10/20	JD	Review updated workplans re: Avrio and Rhodes Tech analysis.	0.80
02/10/20	JD	Review various diligence responses to UCC questions.	0.60
02/10/20	JD	Review final presentations prior to UCC meeting.	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/10/20	NAS	Prepare for Mundipharma diligence meetings with management in Dubai.	0.50
02/10/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) to align on goals and key questions in advance of diligence meetings.	1.00
02/10/20	NAS	Prepare for and attend Mundipharma diligence meeting with G. Koch (AlixPartners) and Adeline Lim (Mundipharma Chief Marketing Officer, Ethical Products).	2.30
02/10/20	NAS	Consolidate notes from 2/10 Mundipharma management meetings for distribution to advisors.	0.60
02/10/20	NAS	Prepare for and attend Mundipharma diligence meeting with G. Koch (AlixPartners) and Y. Okur (Mundipharma, Head of Consumer Products).	2.20
02/10/20	NAS	Preparation discussions with G. Koch, N. Simon (both AlixPartners), and J. Turner (PJT) re: key take away and next steps from 2/10 Mundipharma meetings.	2.00
02/10/20	IA	Review of final database to be sent to Willis Towers Watson showing LTRP historical and outstanding grant information.	1.30
02/10/20	IA	Consolidate data requests and summary recap of Avrio workplan, to be sent to management for follow up.	1.80
02/10/20	IA	Review of updated allocated PLs for Avrio products by brand showing base business and innovations.	2.70
02/10/20	IA	Review Avrio product build by SKU for 2020 forecast.	0.60
02/10/20	IA	Review nalmeferine injector diligence responses to committees' questions prepared by management.	0.70
02/10/20	IA	Follow up on organization chart request by PJT.	0.30
02/10/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.80
02/10/20	HK	Update analysis for LAM country/market-level product	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/10/20	LJD	P&Ls in anticipation for LAM management discussions. Meeting with C. Landau, J. Lowne, M. Kesselmen (Purdue), T. Coleman (PJT), M. Huebner (Davis Polk) L. Donahue, and J. DelConte (both AlixPartners) re: business planning process.	0.90
02/10/20	LJD	Review fee application and comment	0.30
02/10/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) to align on goals and key questions in advance of diligence meetings.	1.00
02/10/20	GJK	Mundipharma diligence meeting with A. Lim (Mundipharma Chief Marketing Officer, Ethical Products) and N. Simon (AlixPartners).	2.00
02/10/20	GJK	Mundipharma diligence meeting with Y. Okur (Mundipharma, Head of Consumer Products) and N. Simon (AlixPartners).	2.00
02/10/20	GJK	Preparation discussions with G. Koch, N. Simon (both AlixPartners), and J. Turner (PJT) re: key take away and next steps from 2/10 Mundipharma meetings.	2.00
02/10/20	GJK	Follow up call with I. McClatchy (Norton Rose) re: coordination for diligence meetings	1.00
02/10/20	MH	Respond to vendor contact to explain the current plan to manage a large provider of transdermal, patches.	0.40
02/10/20	MH	Research legal vendors to ensure correct release settings at the request of Legal Operations.	0.40
02/10/20	MH	Create accounts payable release file.	0.70
02/10/20	MH	Reconcile "triangle" vendor invoices against paid history and open accounts payable.	1.30
02/10/20	MH	Create accounts payable release file.	0.70
02/11/20	MH	Reconcile billing against trade agreements across two vendors with common ownership to ensure correct	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		treatment of invoices.	
02/11/20	MH	Create accounts payable release file.	0.70
02/11/20	GJK	Review and edits to notes from meetings with A. Lim and Y. Okur (both Mundipharma) on LAM business for distribution to larger advisor group. Edits from J. Turner (PJT) and N. Simon (AlixPartners)	1.30
02/11/20	GJK	Review and follow up on China and ANZ analysis	0.40
02/11/20	GJK	Communication with L McCracken (Mundipharma)	0.20
02/11/20	GJK	Meeting with A. Breabout (Mundipharma), J. Turner (PJT), and G. Koch (AlixPartners) to discuss diligence process and next steps	1.00
02/11/20	GJK	Diligence meeting with T. Reiner (Mundipharma), G. Koch, N. Simon (both AlixPartners), and overall Mundipharma and Advisors team	2.00
02/11/20	GJK	Diligence meeting with R. Corder (Mundipharma), G. Koch, N. Simon (both AlixPartners), and advisors re: compliance	1.00
02/11/20	GJK	Meeting with A. Allam (Mundipharma), N. Simon and G. Koch (both AlixPartners) re: META region	1.50
02/11/20	GJK	Review notes and participate in debrief meeting with J. Turner (PJT), G. Broadhead (FTI), N. Simon and G. Koch (both AlixPartners)	0.70
02/11/20	LJD	Review existing work plans for Rhodes and Avrio and comment	1.50
02/11/20	LJD	Prepare for and attend call with board member J. Dubel and L. Donahue (AlixPartners)	0.80
02/11/20	LJD	Conversation with J. O'Connell, T. Melvin, R. Schnitzler (all PJT), L. Donahue, and J. DelConte (both AlixPartners) re: open diligence items and meeting schedules.	0.50
02/11/20	HK	Update analysis for LAM country/market-level product	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/11/20	IA	P&Ls in anticipation for LAM management discussions.	
02/11/20	IA	Gather back up source files and put together list of requested details and schedules to be requested from management in order to update Purdue cash forecast based on 2020 budget.	2.10
02/11/20	IA	Review Avrio consumption information and marketing block charts in support of Avrio forecast analysis.	2.70
02/11/20	IA	Meeting with D. Samikkannu, I. Arana (both AlixPartners), Avrio president, and CMO re: marketing data and analytics	1.40
02/11/20	NAS	Consolidate notes from 2/10 Mundipharma management meetings for distribution to advisors.	0.60
02/11/20	NAS	Prepare for and participate in Mundipharma diligence meeting with T. Reiner (Mundipharma LAM Business Development) and G. Koch (AlixPartners).	2.10
02/11/20	NAS	Mundipharma diligence meeting with R. Corder (Mundipharma Interim Head of Compliance) G. Koch and N. Simon (both AlixPartners).	1.00
02/11/20	NAS	Prepare for and attend Mundipharma diligence meeting with A. Allam (Mundipharma Regional GM, Middle East, Turkey, and Africa), G. Koch and N. Simon (both AlixPartners).	1.80
02/11/20	NAS	Debrief meeting with J. Turner (PJT), G. Broadhead (FTI), and G. Koch (AlixPartners).	0.50
02/11/20	JD	Review updated Avrio analyses re: base vs. innovation income statements.	1.20
02/11/20	JD	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) to discuss work planning and BoD instructions for Rhodes	0.40
02/11/20	JD	Conversation with J. O'Connell, T. Melvin, R. Schnitzler (all PJT), L. Donahue, and J. DelConte (both AlixPartners)	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: open diligence items and meeting schedules.	
02/11/20	JD	Prepare for and participate in a meeting with J. Lowne, D. Fogel (both Purdue), R. Schnitzler (PJT), and J. DelConte (AlixPartners) re: business plan.	1.10
02/11/20	JD	Review and provide comments on OSR analysis.	0.50
02/11/20	JD	Correspondence with PJT and Davis Polk re: presentations for tomorrow's meeting with the non-consenting states.	0.70
02/11/20	DS	Meeting with D. Samikkannu, I. Arana (both AlixPartners), Avrio president, and CMO re: marketing data and analytics	1.40
02/11/20	DS	Review of marketing mix materials provided by Avrio CMO	1.80
02/11/20	DS	Review of Senokot/Colace marketing analyses	1.70
02/11/20	DS	Review of Senokot/Colace marketing analyses	1.20
02/11/20	DS	Communication with J. Chen (Davis Polk) re: detailed thoughts on process with uploading files for production	0.60
02/11/20	DS	Draft follow up questions re: Nielsen report provided by Avrio CFO particularly re: consumption data	0.60
02/11/20	KM	NC scorecard improvements	0.70
02/11/20	KM	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) to discuss work planning and BoD instructions for Rhodes	0.40
02/11/20	KM	Meeting with D. Lundie, D. Fogel, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech strategic plan and AG for OxyContin impacts	1.20
02/11/20	KM	Research and analysis re: API market information	1.10
02/11/20	KM	Discussion with J. Carlisle (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: financial models	0.30
02/11/20	KM	Analysis re: Rhodes Pharma R&D ROI	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/11/20	KM	Meeting with D. Fogel, V. Mancinelli, K. Kolar, D. Ebere (all Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma dashboard, R&D resource allocation and needs going forward	3.10
02/11/20	KM	Meeting with D. Fogel, R. Shamblen (both Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech dashboard, R&D allocation and needs going forward	1.60
02/11/20	KM	Review, analysis and documentation of all Rhodes R&D activities	1.20
02/11/20	KM	Meeting with D. Fogel, J. Carlisle (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: standard cost analysis for Rhodes Pharma products in a stepwise function	0.50
02/11/20	RDS	Meetings with D. Lundie and D. Fogel (Purdue) to catch up on KPI tracking progress	1.20
02/11/20	RDS	Meeting with D. Fogel, J. Carlisle (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: standard cost analysis for Rhodes Pharma products in a stepwise function	0.50
02/11/20	RDS	Meeting with D. Lundie, D. Fogel, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech strategic plan and AG for OxyContin impacts	1.20
02/11/20	RDS	Meeting with J. Carlisle, W. DiNicola, D. Fogel, R. Haberlin (all Purdue), and R. Sublett (AlixPartners) re: KPI dashboard project management	2.40
02/11/20	RDS	Discussion with J. Carlisle (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: financial models	0.30
02/11/20	RDS	Meeting with D. Fogel, V. Mancinelli, K. Kolar, D. Ebere (all Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma dashboard, R&D resource allocation and needs going forward	3.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/11/20	RDS	Meeting with D. Fogel, R. Shamblen (both Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech dashboard, R&D allocation and needs going forward	1.60
02/11/20	RDS	Discussion with J. Carlisle, D. Fogel (both Purdue) and R. Sublett (AlixPartners) on adequate profit margin for Rhodes Pharma generic opioid products	0.30
02/11/20	RDS	Review of Avrio marketing materials as they impact the ROIC for new product development and commercial products	0.60
02/11/20	RDS	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) to discuss work planning and BoD instructions for Rhodes	0.40
02/11/20	RDS	Correspondence with Rhodes Pharma R&D management to finalize resource allocation mode	0.30
02/12/20	RDS	Meeting with J. Carlisle (Purdue), and R. Sublett (AlixPartners) to discuss CPP mode at the SKU level for Rhodes Pharma	1.40
02/12/20	RDS	Partial attendance at meeting with J. DelConte, D. Samikkannu and R. Sublett (all AlixPartners) re: Avrio findings to date and go forward work plan.	0.80
02/12/20	RDS	Meeting with R. Shamblan, P. Chen, L. Rider (all Purdue), and R. Sublett (AlixPartners) re: Rhodes Tech	1.10
02/12/20	RDS	Avrio slide creation to support development and commercial process	0.40
02/12/20	RDS	Adjust Customer and Product Profitability analysis to share with TheBeau	0.60
02/12/20	RDS	Discussion with D. Fogel (Purdue) and R. Sublett (AlixPartners) re: cost-based pricing for Rhodes Gx products	1.00
02/12/20	RDS	Meeting to discuss updated Rhodes Tech R&D personnel	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		allocation exercise with D. Fogel (Purdue)	
02/12/20	RDS	Analysis of variable contribution per SKU for Oxy APAP and Oxy IR, including updated Opioid tax allocation	2.00
02/12/20	RDS	Rhodes Tech R&D dashboard implementation	1.10
02/12/20	RDS	Discussion with D. Lundie, J. Carlisle (both Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: dashboard summary for the Board	0.70
02/12/20	KM	Discussion with D. Lundie, J. Carlisle (both Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: dashboard summary for the Board	0.70
02/12/20	KM	Discussion with N. Davis (Purdue) and K. McCafferty (AlixPartners) re: dashboard reporting	0.30
02/12/20	KM	Discussion with R. Shamblen, L. Ryder, P. Chen (all Purdue), and K. McCafferty (AlixPartners) re: Rhodes Tech R&D resource allocation	1.70
02/12/20	KM	Analysis re: revised Rhodes Tech R&D resource planning	3.80
02/12/20	KM	Continuation of discussion with R. Shamblen, L. Ryder, P. Chen (all Purdue), and K. McCafferty (AlixPartners) re: Rhodes Tech R&D resource allocation	1.70
02/12/20	KM	Update and send dashboard	1.20
02/12/20	KM	Review product profitability analysis	0.70
02/12/20	DS	Update S&P model for new data provided by Avrio CFO, updating specific profitability metrics	2.30
02/12/20	DS	Meeting with J. DelConte, D. Samikkannu and R. Sublett (all AlixPartners) re: Avrio findings to date and go forward work plan.	1.80
02/12/20	DS	Call with D. Samikkannu and J. DelConte (both AlixPartners) re: business plan process.	0.20
02/12/20	DS	Review of IFF payment details received from Purdue financial analyst	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/12/20	DS	Draft response to C. McMillian (Davis Polk) re: the production of financials and potentially competitively sensitive items	1.80
02/12/20	JD	Call with D. Samikkannu and J. DelConte (both AlixPartners) re: business plan process.	0.20
02/12/20	JD	Meeting with J. DelConte, D. Samikkannu and R. Sublett (all AlixPartners) re: Avrio findings to date and go forward work plan.	1.80
02/12/20	JD	Correspondence with FTI re: open diligence questions and review materials re: same.	0.50
02/12/20	JD	Correspondence with E. Kardos and L. Donahue (both AlixPartners) re: internal resources.	0.30
02/12/20	JD	Correspondence with C. McMillian (Davis Polk) re: diligence materials and confidentiality.	0.60
02/12/20	NAS	Consolidate notes from 2/11 Mundipharma diligence meetings for distribution to advisors.	0.80
02/12/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: take away from diligence meetings to-date and goals for remaining management meetings.	1.50
02/12/20	NAS	Mundipharma Digital overview with A. Lim (Mundipharma Chief Marketing Officer, Ethical Products) and N. Simon (AlixPartners).	0.50
02/12/20	NAS	Meeting with G. Sellers (Mundipharma), G. Koch, and N. Simon (both AlixPartners) re: ANZ diligence, including advisors and other group	1.50
02/12/20	NAS	Meeting with P. Wang (Mundipharma), G. Koch, and N. Simon (both AlixPartners) re: China diligence, including other advisors	1.80
02/12/20	NAS	Meeting with R. Singh, P. Singh (both Mundipharma), G. Koch and N. Simon (both AlixPartners) re: LAM region for	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma diligence	
02/12/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) and G. Broadhead (FTI) re: impressions from Dubai Mundipharma diligence meetings and next steps.	2.50
02/12/20	IA	Review of final order and confirmation of market access program payments for Purdue.	0.60
02/12/20	IA	Review Individual performance factors for Rhodes employees to be incorporated in LTRP calculations file and reconciliation to estimates.	1.70
02/12/20	IA	Review of received benchmarking and spend analog information received in support of S&P analysis for Avrio.	1.90
02/12/20	IA	Review key milestones information received and timing of S&P spend in newly reallocated P&Ls for Avrio	2.20
02/12/20	IA	Follow up on Purdue 2020 budget timing and source files.	0.40
02/12/20	HK	Update analysis for LAM country/market-level product P&Ls in anticipation for LAM management discussions.	1.30
02/12/20	LJD	Call with board member re: business plan, strategy and next steps	0.80
02/12/20	LJD	Review correspondence	0.50
02/12/20	LJD	Work on staffing and strategy for business plan	0.80
02/12/20	GJK	Meeting with G. Sellers (Mundipharma), G. Koch, and N. Simon (both AlixPartners) re: ANZ diligence, including advisors and other group	1.50
02/12/20	GJK	Presentation of digital marketing initiatives by Mundipharma	0.50
02/12/20	GJK	Meeting with P. Wang (Mundipharma), G. Koch, and N. Simon (both AlixPartners) re: China diligence, including other advisors	1.80
02/12/20	GJK	Meeting with R. Singh, P. Singh (both Mundipharma), G. Koch and N. Simon (both AlixPartners) re: LAM region for	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma diligence	
02/12/20	GJK	Review of P&L documents and analysis by H. Ku (AlixPartners) for Mundipharma	1.50
02/12/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) and G. Broadhead (FTI) re: impressions from Dubai Mundipharma diligence meetings and next steps.	2.50
02/12/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: take away from diligence meetings to-date and goals for remaining management meetings.	1.50
02/12/20	MH	Create accounts payable release file.	0.70
02/12/20	MH	Create new Critical Vendor report for management.	2.00
02/12/20	MH	Create new Critical Vendor report for the UCC.	0.80
02/13/20	MH	Create accounts payable release file.	0.70
02/13/20	GJK	Follow up items and planning for Mundipharma diligence	2.10
02/13/20	HK	Call with N. Simon and H. Ku (both AlixPartners) to discuss IAC business plan model updates.	0.60
02/13/20	HK	Review European country-level P&L data to update IAC business plan model.	2.70
02/13/20	HK	Review Asian country-level P&L data to update IAC business plan model.	2.20
02/13/20	IA	Review of business plan, submitted questions, and available documents in response to UCC questions.	1.70
02/13/20	IA	Review final LTRP slides presented to compensation committee.	0.70
02/13/20	IA	Meeting with D. Samikkannu, I. Arana (AlixPartners), Avrio President, and CFO re: business plan send and metrics dashboard	1.50
02/13/20	IA	Meeting with D. Samikkannu, I. Arana (both AlixPartners), Avrio President, and CFO re: innovation	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		metrics dashboard	
02/13/20	IA	Meeting with J. DelConte, D. Samikkannu, and I. Arana (all AlixPartners) to review progress and key deliverables re: Avrio business plan.	0.40
02/13/20	IA	Call with R. Sublett, I. Arana, and D. Sammikkanu (all AlixPartners) to discuss Avrio business planning workstream and status of dashboard and ROIC analysis for S&P spend	0.30
02/13/20	NAS	Prepare for Mundipharma business plan model overview discussion with H. Ku (AlixPartners).	0.30
02/13/20	NAS	Call with N. Simon and H. Ku (both AlixPartners) to discuss IAC business plan model updates.	0.60
02/13/20	JD	Review information provided to date re: Avrio business plan backup and analyze existing business plan.	1.30
02/13/20	JD	Review Rhodes Tech sensitivity analyses, status of implementation plan and roll out plan for Rhodes management team.	1.80
02/13/20	JD	Correspondence with C. McMillian (Davis Polk) re: diligence responses and designation protocol.	0.50
02/13/20	JD	Conversation with R. Aleali, M. Ronning (both Purdue), C. Robertson (Davis Polk), and J. DelConte (AlixPartners) re: customer discussions.	0.90
02/13/20	JD	Meeting with J. DelConte, D. Samikkannu, and I. Arana (all AlixPartners) to review progress and key deliverables re: Avrio business plan.	0.40
02/13/20	JD	Correspondence with J. Lowne (Purdue), C. MacDonal (Purdue) and B. Schrag (Prime Clerk) re: professional fee payments.	0.30
02/13/20	DS	Correspondence with T. Melvin (PJT) re: valuation metrics (i.e. multiples range) of consumer health products business	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/13/20	DS	Inquire about external data support for marketing assumptions	0.20
02/13/20	DS	Meeting with D. Samikkannu, I. Arana (AlixPartners), Avrio President, and CFO re: business plan send and metrics dashboard	1.50
02/13/20	DS	Meeting with D. Samikkannu, I. Arana (both AlixPartners), Avrio President, and CFO re: innovation metrics dashboard	1.20
02/13/20	DS	Meeting with J. DelConte, D. Samikkannu, and I. Arana (all AlixPartners) to review progress and key deliverables re: Avrio business plan.	0.40
02/13/20	DS	Call with R. Sublett, I. Arana, and D. Samikkannu (all AlixPartners) to discuss Avrio business planning workstream and status of dashboard and ROIC analysis for S&P spend	0.30
02/13/20	KM	Review analysis for customer and product profitability	1.00
02/13/20	KM	Analysis re: API market competitive analysis	0.30
02/13/20	KM	Meeting with B. Thebeau, V. Mancinelli, D. Fogel, R. Haberin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Oxy-APA and Oxy-IR re-bidding analysis and approach	3.00
02/13/20	KM	Dashboard updates	0.50
02/13/20	KM	Meeting with D. Fogel (Purdue) re: Rhodes API manufacturing plant options	1.70
02/13/20	KM	Slide preparation re: Rhodes API manufacturing plant options	1.00
02/13/20	KM	Slide preparation re: Rhodes product re-bidding approach and roll-out	1.10
02/13/20	KM	Discussion with D. Fogel (Purdue) re: CPP and Rhodes Tech plant options review	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/13/20	RDS	Review Rhodes Tech Rationalization	0.50
02/13/20	RDS	Assemble strategic partnership materials for Rhodes Tech discussions	0.70
02/13/20	RDS	Prepare for and attend meeting with B. Thebeau, V. Mancinelli, D. Fogel, R. Haberin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Oxy-APA and Oxy-IR re-bidding analysis and approach	3.70
02/13/20	RDS	Rhodes Tech rationalization and implications for Purdue strategic planning process	1.20
02/13/20	RDS	Slide creation - Rhodes Tech scenario analysis for shut down or other strategic partnership	1.90
02/13/20	RDS	Slide creation - Rhodes Pharma pricing implementation plan	0.50
02/13/20	RDS	Call with R. Sublett, I. Arana, and D. Sammikkanu (all AlixPartners) to discuss Avrio business planning workstream and status of dashboard and ROIC analysis for S&P spend	0.30
02/14/20	RDS	Avrio dashboard construction	0.80
02/14/20	RDS	Continue to iterate changes and live data implementation for the Rhodes dashboard data input	1.80
02/14/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss Rhodes Pharma rebidding slides	0.50
02/14/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: dashboard and implementation plan	0.80
02/14/20	RDS	Review Levorphenol analysis update and correspond with D. Fogel (Purdue) on results	0.40
02/14/20	KM	Meeting with N. Davis, D. Fogel (both Purdue), and K. McCafferty re: January Dashboard reporting and open items	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/14/20	KM	Slide preparation re: CPP and approach for ClarusONE and WBAD	0.50
02/14/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: dashboard and implementation plan	0.80
02/14/20	KM	Slide preparation re: CPP and approach for ClarusONE and WBAD - continued	0.20
02/14/20	KM	Update and refine dashboard reporting with N. Davis (Purdue)	0.20
02/14/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss Rhodes Pharma rebidding slides	0.50
02/14/20	DS	Correspondence with C. Robertson (Davis Polk) re: specific nuances of Kentucky and other settlements	0.50
02/14/20	JD	Review auto injector diligence questions and responses prior to providing materials to UCC and AHC advisors.	0.70
02/14/20	JD	Review materials re: Rhodes business plan, open diligence questions and proposed responses.	1.00
02/14/20	JD	Review updated HRT materials.	0.40
02/14/20	JD	Draft initial updated Purdue strategic review work plan.	2.10
02/14/20	IA	Review company assignments on UCC questions and follow up on progress on responses.	1.60
02/14/20	IA	Review of Avrio files showing gross and net sales by product for budget and actuals by product.	1.30
02/14/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.30
02/14/20	HK	Review Asian country-level P&L data to update IAC business plan model.	2.10
02/14/20	HK	Review European country-level P&L data to update IAC business plan model.	2.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/14/20	GJK	Discussion with I. McClatchey (Norton Rose) and G. Koch (AlixPartners) re: diligence	0.50
02/15/20	RDS	Slide creation - update Rhodes Pharma headcount allocation analysis	0.60
02/15/20	RDS	Review changes to RELT transformation presentation	0.30
02/16/20	KM	Rhodes implementation plan refinement	0.40
02/16/20	KM	Discussion and analysis with D. Fogel, N. Davis (both Purdue), and K. McCafferty (AlixPartners) re: dashboard updates and changes	1.10
02/16/20	RDS	Review Rhodes scorecard and dashboard progress	0.60
02/16/20	RDS	Changes to RELT transition presentation slides	0.60
02/16/20	GJK	Edit notes from Feb 12th Mundipharma diligence meetings and send out to advisor group	1.00
02/17/20	MH	Create accounts payable release file.	0.70
02/17/20	IA	Call with I. Arana and D. Samikkannu (both AlixPartners) re: upcoming meeting on Avrio workplan and status	0.20
02/17/20	JD	Develop agenda for strategic planning meeting tomorrow.	0.50
02/17/20	DS	Call with I. Arana and D. Samikkannu (both AlixPartners) re: upcoming meeting on Avrio workplan and status	0.20
02/17/20	NAS	Consolidate list of key take away from Mundipharma management meetings in Dubai and plan for week ahead.	0.80
02/18/20	NAS	Review list of Mundipharma follow-up items and remaining diligence requests after meetings with management in Dubai.	0.80
02/18/20	NAS	Review new raw data upload files to be included in Mundipharma business plan model.	0.60
02/18/20	DS	Call with L. Donahue, J. DelConte, D. Samikkannu, I. Arana, R. Sublett and K. McCafferty (all AlixPartners) re: business planning strategy and process update	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/18/20	DS	Draft detailed agenda and key points for meeting with L. Donahue (AlixPartners)	0.80
02/18/20	DS	Assemble materials of charts and analyses for meeting on business plan	1.20
02/18/20	DS	Correspondence with Avrio CFO re: status and next steps	0.30
02/18/20	DS	Compile Customer Programs data for S. Lemack (AlixPartners)	0.30
02/18/20	DS	Review Purdue rebates manager's process comments on Customer Programs report and reply with detailed proposal	1.10
02/18/20	DS	Prepare analysis on economics and legal context of various settlements, per request of FTI Consulting	1.70
02/18/20	JD	Catch up call with E. Ruiz, D. Saussy (both Purdue), and J. DelConte (AlixPartners) re: auto injector.	0.50
02/18/20	JD	Call with L. Donahue, J. DelConte (both AlixPartners), and B. Weingarten (Purdue) re: life sciences projects.	0.40
02/18/20	JD	Call with L. Donahue, J. DelConte, D. Samikkannu, I. Arana, R. Sublett and K. McCafferty (all AlixPartners) re: business planning strategy and process update	3.20
02/18/20	JD	Finalize materials for internal business plan overview and strategy meeting.	0.80
02/18/20	IA	Partial attendance on call with L. Donahue, J. DelConte, D. Samikkannu, I. Arana, R. Sublett and K. McCafferty (all AlixPartners) re: business planning strategy and process update	0.80
02/18/20	IA	Review updated diligence tracker to be sent to management by PJT.	0.90
02/18/20	IA	Review Avrio internal dashboard.	0.70
02/18/20	IA	Update calculated LTRP 2020 payments by employee to reflect approved Purdue factor and final Rhodes individual	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		factors.	
02/18/20	IA	Review updated responses received from management to UCC questions to consolidate in one final document to be sent around for internal approvals.	1.70
02/18/20	IA	Review historical market share by product and consumption data to be incorporated in management scorecards for Avrio.	1.60
02/18/20	IA	Review Avrio innovation milestone information and update innovation templates.	2.30
02/18/20	IA	Review diligence materials submitted in response to UCC business plan questions.	2.30
02/18/20	HK	Review European country-level P&L data to update IAC business plan model.	1.90
02/18/20	HK	Review Asian country-level P&L data to update IAC business plan model.	1.10
02/18/20	MH	Create custom releases for several legal vendors.	0.80
02/18/20	MH	Create accounts payable release file.	0.70
02/18/20	GJK	LAM materials analysis and next steps	2.00
02/18/20	LJD	Call with L. Donahue, J. DelConte, D. Samikkannu, I. Arana, R. Sublett and K. McCafferty (all AlixPartners) re: business planning strategy and process update	3.20
02/18/20	LJD	Review Rhodes KPI report	1.50
02/18/20	LJD	Call with L. Donahue, J. DelConte (both AlixPartners), and B. Weingarten (Purdue) re: life sciences projects.	0.40
02/18/20	RDS	Call with V. Mancinelli, D. Fogel, M. Sisodia (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Levorphenol changes and NPV analysis	0.50
02/18/20	RDS	Partial attendance on call with L. Donahue, J. DelConte, D. Samikkannu, I. Arana, R. Sublett and K. McCafferty (all AlixPartners) re: business planning strategy and	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		process update	
02/18/20	RDS	Call into Rhodes Executive Leadership (D. Lundie, D. Fogel, R. Shamblen, V. Mancinelli) team meeting with K. McCafferty and R. Sublett (both AlixPartners) to review 2020 budget and restructuring implications	2.30
02/18/20	RDS	Call with D. Lundie (Purdue) and R. Sublett (AlixPartners) to debrief of RELT team meeting	0.70
02/18/20	RDS	Review updated Avrio dashboard and S&P allocation	0.80
02/18/20	KM	Call with V. Mancinelli, D. Fogel, M. Sisodia (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Levorphenol changes and NPV analysis	0.50
02/18/20	KM	Partial attendance on call with L. Donahue, J. DelConte, D. Samikkannu, I. Arana, R. Sublett and K. McCafferty (all AlixPartners) re: business planning strategy and process update	1.50
02/18/20	KM	Call into Rhodes Executive Leadership team meeting (D. Lundie, D. Fogel, R. Shamblen, V. Mancinelli) with K. McCafferty and R. Sublett (both AlixPartners) to review 2020 budget and restructuring implications	2.30
02/18/20	KM	Discussion with D. Lundie (Purdue) and K. McCafferty (AlixPartners) re: Rhodes opportunity assessment, implementation planning and roadblocks	0.70
02/18/20	ADD	Review of IAC with active intercompany agreements to identify missing agreements.	0.80
02/19/20	KM	Rhodes planning and workplan development	0.70
02/19/20	KM	Nc Tech Ops quality team structure analysis and review	0.70
02/19/20	KM	Review meeting with D. McGuire (Purdue) and K. McCafferty (AlixPartners) re: NC Tech Ops dashboard	0.50
02/19/20	KM	Call with R. Shamblen (Purdue), K. McCafferty, and R. Sublett (both AlixPartners re: Rhodes Tech dashboard	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		metrics and definitions	
02/19/20	KM	Analysis re: Rhodes Tech operating scenarios and options for divestiture	0.60
02/19/20	KM	Review and edits re: Rhodes performance dashboard	1.30
02/19/20	KM	Update dashboard with Rhodes Pharma Jan 31 metrics	0.40
02/19/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss changes to presentation for Rhodes Tech call and dashboard updates	1.70
02/19/20	KM	Call with V. Mancinelli, D. Fogel, M. Sisoda (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma financial results and pipeline projections	2.30
02/19/20	KM	Review and analysis re: Rhodes Tech operating scenarios and associated financial impact	0.60
02/19/20	KM	Dashboard update for Rhodes Tech and distribution to R. Shamblen (Purdue)	0.30
02/19/20	KM	Meeting and deck review with D. Lunide, D. Fogel (Purdue), and K. McCafferty (AlixPartners) re: Rhodes Tech scenarios	0.90
02/19/20	KM	Meeting with D. Lundie (Purdue) and K. McCafferty (AlixPartners) re: dashboard status and exceptions	0.40
02/19/20	RDS	Review RELT leadership presentation as sanitized to be shared with the broader leadership team	0.80
02/19/20	RDS	Rhodes Tech partnership framework development	0.20
02/19/20	RDS	Data analysis and presentation preparation - breadth of market participation in Oxy-APAP and Oxy-IR Markets	1.40
02/19/20	RDS	CPP and plant cost analysis and subsequent correspondence with J. Lowne (Purdue)	0.60
02/19/20	RDS	Call with R. Shamblem (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech dashboard metrics and definitions	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/19/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss changes to presentation for Rhodes Tech call and dashboard updates	1.70
02/19/20	RDS	Slide creation for Rhodes Tech plant rationalization analysis	0.90
02/19/20	RDS	Call with V. Mancinelli, D. Fogel, M. Sisoda (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma financial results and pipeline projections	2.30
02/19/20	RDS	Prepare for and attend status update call with I. Arana, D. Samikkannu, J. DelConte and R. Sublett (all AlixPartners) re: Avrio business plane	0.90
02/19/20	RDS	Review RALP consolidated FCF variance analysis and commentary for board dashboard.	0.20
02/19/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio meeting agenda for 2/20/20	0.10
02/19/20	LJD	Review and discuss update deck re: Mundipharma due diligence and next steps	0.80
02/19/20	GJK	Post LAM Meetings update deck	3.00
02/19/20	MH	Create accounts payable release file.	0.70
02/19/20	HK	Review Mundipharma country-level P&Ls to confirm product-level summaries.	1.40
02/19/20	IA	Update sample Betadine management scorecard template for review with management	1.40
02/19/20	IA	Populate Betadine sample template with budget information for review with management.	0.80
02/19/20	IA	Populate Betadine sample template with prior year information for review with management.	1.20
02/19/20	IA	Populate Betadine sample template with January actual information for review with management.	1.70
02/19/20	IA	Review updated PL allocations between base and	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		innovation for Avrio.	
02/19/20	IA	Update file showing employees holding insider titles since 2000 based on information received from Davis Polk.	1.60
02/19/20	IA	Review Avrio marketing materials received and information on market share and consumption.	2.30
02/19/20	JD	Meeting with C. Landau, J. Lowne (both Purdue), and J. DelConte (AlixPartners) re: managed care coverage.	1.10
02/19/20	JD	Review and provide comments on Avrio diligence materials.	1.00
02/19/20	JD	Finalize draft work plan to provide to PJT and management prior to Thursday meeting.	1.20
02/19/20	JD	Status update call with I. Arana, D. Samikkannu, J. DelConte and R. Sublett (all AlixPartners) re: Avrio business plane	0.50
02/19/20	JD	Discussion of business plan work plan with J. Lowne (Purdue) and J. DelConte (AlixPartners)	0.40
02/19/20	JD	Update work plan for J. Lowne (Purdue) comments.	0.90
02/19/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio meeting agenda for 2/20/20	0.10
02/19/20	DS	Correspondence with J. DelConte (AlixPartners) re: industry specialists and validation of industry data	0.30
02/19/20	DS	Review of OTC dashboard on Purdue's intranet system	1.30
02/19/20	DS	Compile business plan diligence files and send to I. Arana (AlixPartners)	0.50
02/19/20	DS	Analyze historical Avrio P&L to provided basis for historical spend	1.60
02/19/20	DS	Put together materials for deck on profitability metrics for sample products and overall business view	2.40
02/19/20	DS	Assemble outline of slides for presentation on 2/20 and	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		send to I. Arana (AlixPartners) for input	
02/19/20	DS	Assemble deck for 2/20 presentation which includes Avrio overview on process, profitability analyses, and current status / findings to-date	2.70
02/19/20	DS	Status update call with I. Arana, D. Samikkannu, J. DelConte and R. Sublett (all AlixPartners) re: Avrio business plane	0.50
02/19/20	NAS	Review raw data uploads for individual countries to be included in Mundipharma business plan model.	2.10
02/19/20	NAS	Review notes and presentation covering key take away from Mundipharma management meetings in Dubai.	1.30
02/19/20	IA	Status update call with I. Arana, D. Samikkannu, J. DelConte and R. Sublett (all AlixPartners) re: Avrio business plane	0.50
02/20/20	NAS	Coordinate with advisors to UCC and Ad-Hoc Committee regarding priority Mundipharma diligence requests.	0.60
02/20/20	NAS	Review data provided to determine optimal source for Mundipharma G&A figures.	0.80
02/20/20	NAS	Incorporate individual country P&L data for key markets into Mundipharma business plan model.	1.50
02/20/20	NAS	Review individual country P&Ls in Mundipharma business plan model for accuracy.	1.40
02/20/20	JD	Review analysis and accompanying presentation re: Rhodes Tech go forward business plan.	0.80
02/20/20	JD	Revise go forward business plan workplan from earlier discussion with management.	0.70
02/20/20	JD	Meeting with D. Lundie, J. Lowne, C. Landau, B. Weingarten, D. Fogel (all Purdue), J. DelConte, K. McCafferty, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Rhodes Tech scenarios executive review	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/20/20	JD	Meeting with C. Landau, J. Lowne, M. Kesselman (all Purdue), T. Coleman, J. Turner (both PJT), M. Huebner (Davis Polk), L. Donahue, and J. DelConte (both AlixPartners) re: go forward business plan strategy.	2.50
02/20/20	JD	Prepare for and attend meeting with J. Lowne, C. Chomiak (both Purdue), J. Turner, G. Sim (both PJT), J. DelConte, R. Sublett, D. Samikkannu, S. Lemack and I. Arana (all AlixPartners) re: Avrio business plan.	2.00
02/20/20	DS	Meeting with J. Lowne, C. Chomiak (both Purdue), J. Turner, G. Sim (both PJT), J. DelConte, R. Sublett, D. Samikkannu, S. Lemack and I. Arana (all AlixPartners) re: Avrio business plan.	1.60
02/20/20	DS	Meeting with D. Lundie, J. Lowne, C. Landau, B. Weingarten, D. Fogel (all Purdue), J. DelConte, K. McCafferty, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Rhodes Tech scenarios executive review	1.10
02/20/20	DS	Meeting with D. Samikkannu, I. Arana, J. DelConte, S. Lemack, and R. Sublett (all AlixPartners) re: S&P bridge in preparation of meeting later that day	0.70
02/20/20	DS	Meeting with D. Samikkannu (AlixPartners) and Avrio CFO re: meeting follow-ups and next steps	0.80
02/20/20	DS	Revise presentation materials for meeting	1.30
02/20/20	DS	Provide I. Arana (AlixPartners) with market share data on sub-product basis for dashboard	0.60
02/20/20	DS	Correspondence with A. DePalma and S. Lemack (both AlixPartners) re: process of next production	0.30
02/20/20	DS	Review of monthly flash report	0.40
02/20/20	DS	Update of profitability model for Avrio	1.40
02/20/20	JD	Meeting with D. Samikkannu, I. Arana, J. DelConte, S. Lemack, and R. Sublett (all AlixPartners) re: S&P bridge	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		in preparation of meeting later that day	
02/20/20	JD	Correspondence with E. Ruiz (Purdue) and M. Atkinson (Province) re: auto injector details.	0.30
02/20/20	JD	Review and redact previous business plan presentations to provide management with previous templates.	1.20
02/20/20	IA	Meeting with J. Lowne, C. Chomiak (both Purdue), J. Turner, G. Sim (both PJT), J. DelConte, R. Sublett, D. Samikkannu, S. Lemack and I. Arana (all AlixPartners) re: Avrio business plan.	1.60
02/20/20	IA	Meeting with D. Lundie, J. Lowne, C. Landau, B. Weingarten, D. Fogel (all Purdue), J. DelConte, K. McCafferty, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Rhodes Tech scenarios executive review	1.10
02/20/20	IA	Update Avrio scorecard template to incorporate edits from AlixPartners team and share data by product.	1.40
02/20/20	IA	Meeting with D. Samikkannu, I. Arana, J. DelConte, S. Lemack, and R. Sublett (all AlixPartners) re: S&P bridge in preparation of meeting later that day	0.70
02/20/20	IA	Update Avrio status update slides in preparation for meeting with management.	1.60
02/20/20	IA	Call with I. Arana (AlixPartners) and C. DeStefano (Purdue) to discuss AIP and LTRP payment timing and under terms approved by court.	0.70
02/20/20	IA	Review Rhodes Pharma and Rhodes Tech AIP calculations per employee.	1.40
02/20/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.90
02/20/20	HK	Review European country-level P&L data to update IAC business plan model.	1.20
02/20/20	SKL	Meeting with J. Lowne, C. Chomiak (both Purdue), J.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Turner, G. Sim (both PJT), J. DelConte, R. Sublett, D. Samikkannu, I. Arana and S. Lemack (all AlixPartners) re: Avrio business plan.	
02/20/20	SKL	Meeting with D. Samikkannu, I. Arana, J. DelConte, S. Lemack, and R. Sublett (all AlixPartners) re: S&P bridge in preparation of meeting later that day	0.70
02/20/20	GJK	Mundipharma diligence planning and next steps	2.00
02/20/20	GJK	Calls related to diligence follow up with B. Bromberg (FTI), I. McClatchey (Norton Rose), and G. Koch (AlixPartners)	1.80
02/20/20	GJK	Email exchanges related to Bates White inquiry re: Mundipharma	0.30
02/20/20	LJD	Meeting with C. Landau, J. Lowne, M. Kesselman (all Purdue), T. Coleman, J. Turner (both PJT), M. Huebner (Davis Polk), L. Donahue, and J. DelConte (both AlixPartners) re: go forward business plan strategy.	2.50
02/20/20	LJD	Update meeting with management to plan presentations for board meeting at end of February	0.60
02/20/20	LJD	Review templates for business plan meetings and comment	0.90
02/20/20	LJD	Call with L. Donahue (AlixPartners) and CEO re: scheduling strategy sessions	0.60
02/20/20	LJD	Work on staffing prospect for OTC expertise	0.40
02/20/20	RDS	Correspondence with D. Samikkannu and I. Arana (both AlixPartners) re: meeting agenda today for Avrio business plan	0.30
02/20/20	RDS	Meeting with D. Samikkannu, I. Arana, J. DelConte, S. Lemack, and R. Sublett (all AlixPartners) re: S&P bridge in preparation of meeting later that day	0.70
02/20/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners)	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		to discuss MKDT market share opportunity slides	
02/20/20	RDS	Update Rhodes Tech plant analysis to reflect one-time inventory adjustments	0.70
02/20/20	RDS	Meeting with J. Lowne, C. Chomiak (both Purdue), J. Turner, G. Sim (both PJT), J. DelConte, R. Sublett, D. Samikkannu, S. Lemack and I. Arana (all AlixPartners) re: Avrio business plan.	1.60
02/20/20	RDS	Walk through Aviro presentation materials with J. Tran, C. Chomiak (both Purdue), and R. Sublett (AlixPartners) ahead of meeting	1.10
02/20/20	RDS	Prepare for meeting with C. Chomiack, J. Tran, J. Lowne, D. Rosen (all Purdue), PJT and AlixPartners to discuss Avrio revenue rationalization	1.00
02/20/20	RDS	Conversation with J. Turner (PJT) and R. Sublett (AlixPartners) re: strategic API supply presentation	0.20
02/20/20	RDS	Meeting with D. Lundie, J. Lowne, C. Landau, B. Weingarten, D. Fogel (all Purdue), J. DelConte, K. McCafferty, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Rhodes Tech scenarios executive review	1.10
02/20/20	RDS	Review and update analysis of Coventry API site.	1.30
02/20/20	RDS	Review of Avrio historical and dashboard consumption data	0.60
02/20/20	KM	Analysis re: Rhodes Tech potential volume augmentation opportunity in event of Mallinckrodt closure	0.80
02/20/20	KM	Slide creation re: Executive summary + volume options + OxyContin CMO options of Rhodes Tech scenarios deck	1.90
02/20/20	KM	Slide edits and analysis re: payback period and WC inclusion for Rhodes Tech scenarios	0.50
02/20/20	KM	Analysis re: Rhodes Tech scenarios one-time cost impact	0.60
02/20/20	KM	Meeting with D. McGuire, J. Carlisle (both Purdue), and K.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty re: NC operations	
02/20/20	KM	Deck edits re: Rhodes Tech scenarios	0.80
02/20/20	KM	Dashboard updates for quality metrics	0.70
02/20/20	KM	Meeting with D. Lundie, J. Lowne, C. Landau, B. Weingarten, D. Fogel (all Purdue), J. DelConte, K. McCafferty, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Rhodes Tech scenarios executive review	1.10
02/20/20	KM	Slide creation re: scenario options and backup analysis	2.10
02/20/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss MKDT market share opportunity slides	0.30
02/21/20	KM	Review and update CPP approach and Rhodes Tech scenarios	0.50
02/21/20	KM	Slide edits and analysis re: Rhodes Tech scenarios	0.60
02/21/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss D. Lundie (Purdue) comments for next week board deck	0.50
02/21/20	KM	Meeting with N. Davis (Purdue) and K. McCafferty (AlixPartners) re: dashboard status and reporting requirements	0.80
02/21/20	KM	Meeting with K. McCafferty and R. Sublett (both AlixPartners) to implement changes to board deck for next week	2.10
02/21/20	KM	Dashboard refinement	0.50
02/21/20	RDS	Call with N. Davis (Purdue) and R. Sublett (AlixPartners) re: Rhodes dashboard updates	0.70
02/21/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to discuss headcount allocation for R&D resources by product	0.10
02/21/20	RDS	Meeting with K. McCafferty and R. Sublett (both AlixPartners) to implement changes to board deck for	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		next week	
02/21/20	RDS	Deck review / construction - D. Lundie (Purdue) comments for telephonic board meeting slides	0.60
02/21/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss D. Lundie (Purdue) comments for next week board deck	0.50
02/21/20	RDS	Meeting with I. Arana, D. Sammikkanu, and R. Sublett (all AlixPartners) to discuss Avrio business plan presentation and coordinate with PJT team	0.70
02/21/20	RDS	Comparative analysis of Rhodes Tech one-time closure cost	1.60
02/21/20	LJD	Update call with L. Donahue (AlixPartners) and T. Coleman (PJT) re: board decks and expectations for next week	0.80
02/21/20	GJK	Diligence coordination call with I. McClatchey (Norton Rose), G. Koch (AlixPartners) and advisors	1.00
02/21/20	GJK	Review current status of Mundipharma business plan model with G. Koch, N. Simon, and H. Ku (all AlixPartners).	0.50
02/21/20	GJK	Mundipharma project coordination and next steps, including data request planning and incorporation	2.00
02/21/20	MH	Create accounts payable release file.	0.70
02/21/20	HK	Review Asian country-level P&L data to update IAC business plan model.	1.60
02/21/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.40
02/21/20	HK	Review current status of Mundipharma business plan model with G. Koch, N. Simon, and H. Ku (all AlixPartners).	0.50
02/21/20	HK	Call with advisors on Mundipharma Diligence	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Coordination.	
02/21/20	IA	Call with J. DelConte, I. Arana (both AlixPartners), and D. Consla (Davis Polk) to discuss AIP payments as approved in wages order.	0.40
02/21/20	IA	Meeting with I. Arana, D. Sammikkanu, and R. Sublett (all AlixPartners) to discuss Avrio business plan presentation and coordinate with PJT team	0.70
02/21/20	IA	Call with J. DelConte, I. Arana (both AlixPartners), T. Melvin, J. Turner (both PJT), H. Schenk (Houlihan Lokey) and K. Knechtel (FTI) to discuss open items on diligence.	0.50
02/21/20	IA	Call with I. Arana (AlixPartners), C. DeStefano and D. Warren (both Purdue) to discuss calculations for AIP payments and timing.	0.60
02/21/20	JD	Call with J. Turner (PJT) and J. DelConte (AlixPartners) re: business plan presentations.	0.40
02/21/20	JD	Review and provide comments on redacted business plan presentations prior to providing them to management.	1.40
02/21/20	DS	Meeting with I. Arana, D. Sammikkanu, and R. Sublett (all AlixPartners) to discuss Avrio business plan presentation and coordinate with PJT team	0.70
02/21/20	JD	Call with J. DelConte, I. Arana (both AlixPartners), and D. Consla (Davis Polk) to discuss AIP payments as approved in wages order.	0.40
02/21/20	JD	Call with J. DelConte, I. Arana (both AlixPartners), T. Melvin, J. Turner (both PJT), H. Schenk (Houlihan Lokey), and K. Knechtel (FTI) to discuss open items on diligence.	0.50
02/21/20	NAS	Review and assess current status of Mundipharma diligence process.	0.80
02/21/20	NAS	Review current status of Mundipharma business plan model with G. Koch, N. Simon, and H. Ku (all AlixPartners).	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/21/20	NAS	Coordination call with G. Koch (AlixPartners) and advisors involved in Mundipharma diligence process (Norton Rose, Huron, PJT, FTI, Houlihan Lokey, Province, Jefferies) to prioritize remaining requests and meetings.	0.90
02/22/20	JD	Review work plan slides from PJT, create summary version of the business plan workplan to share with the Board, and draft main strategic questions to share with the Board.	2.50
02/22/20	LJD	Call with GC regarding info barrier and OTC issues	0.80
02/23/20	LJD	Call with M. Kesselman (Purdue) re: OTC resources and non-compete info	0.40
02/23/20	JD	Review and provide comments on draft business plan work plan Board slides to share with management.	0.40
02/23/20	JD	Create draft business plan shell to walk through with management and PJT.	2.50
02/23/20	RDS	Call with N. Davis (Purdue) to discuss Rhodes dashboard	0.50
02/23/20	RDS	Format changes to Rhodes board and operating unit dashboard	0.60
02/24/20	RDS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) re: business plan materials for Avrio	0.20
02/24/20	RDS	Turn comments to 2/27 board presentation materials for Rhodes	0.50
02/24/20	RDS	Assemble shell for consolidate business plan presentation - Avrio and Rhodes sections	2.70
02/24/20	RDS	Ongoing dashboard reporting discussions	1.10
02/24/20	RDS	Conversation with J. Lowne (Purdue) and R. Sublett (AlixPartners) re: business plan presentation	0.20
02/24/20	RDS	Conversation with D. Lundie (Purdue) and R. Sublett (AlixPartners) re: dashboard and implications of sharing Coventry site analysis with board ahead of meeting	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		without broader context	
02/24/20	RDS	Conversation with N. Davis (Purdue) and R. Sublett (AlixPartners) to discuss latest dashboard	0.20
02/24/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) re: dashboard and Rhodes Tech site planning	0.40
02/24/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) to discuss changes to board materials for Thursday meeting	0.20
02/24/20	RDS	Call with D. Samikkannu, J. DelConte, I. Arana, R. Sublett (all AlixPartners), Purdue CFO, and J. Turner (PJT) re: workplan for business plan deck.	0.30
02/24/20	RDS	Call with N. Davis, D. Fogel (both Purdue), and R. Sublett (AlixPartners) to discuss updates to dashboard	0.70
02/24/20	RDS	Meeting with D. Lundie, D. Fogel (both Purdue), and R. Sublett (AlixPartners) to discuss dashboard and Rhodes Tech board presentation slides	1.10
02/24/20	RDS	Presentation edits - board materials for Thursday Rhodes update	0.70
02/24/20	RDS	Meeting with N. Davis (Purdue) and R. Sublett (AlixPartners) to discuss dashboard issues	0.80
02/24/20	ADD	Conversation with A. DePalma and J. DelConte (both AlixPartners) re: Davis Polk request on diligence hours.	0.20
02/24/20	JD	Call with D. Samikkannu, J. DelConte, I. Arana, R. Sublett (all AlixPartners), Purdue CFO, and J. Turner (PJT) re: workplan for business plan deck.	0.30
02/24/20	JD	Call with D. Samikkannu, J. DelConte, I. Arana, and S. Lemack (all AlixPartners) re: cash reporting and Avrio business plan updates	0.30
02/24/20	JD	Conversation with G. Issa (Purdue) and J. DelConte (AlixPartners) re: ordinary course professional fee payments.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/24/20	JD	Conversation with A. DePalma and J. DelConte (both AlixPartners) re: Davis Polk request on diligence hours.	0.20
02/24/20	JD	Review and provide comments on latest draft work plan deck and management financial update for the board.	0.70
02/24/20	DS	Correspondence with K. Knechtel (FTI) re: surety bond / cash collateral	0.70
02/24/20	DS	Correspondence with J. Crockett (Province) and D. Samikkannu (AlixPartners) re: surety bond / cash collateral	0.60
02/24/20	DS	Call with D. Samikkannu, J. DelConte, I. Arana, R. Sublett (all AlixPartners), Purdue CFO, and J. Turner (PJT) re: workplan for business plan deck.	0.30
02/24/20	DS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) re: business plan materials for Avrio	0.20
02/24/20	DS	Call with D. Samikkannu, J. DelConte, I. Arana, and S. Lemack (all AlixPartners) re: cash reporting and Avrio business plan updates	0.30
02/24/20	DS	Correspondence with S. Lemack (AlixPartners) re: status of prior week's cash report in production process	0.30
02/24/20	DS	Draft detailed workplan re: Avrio metrics dashboard, S&P spend, media blocking charts	1.80
02/24/20	DS	Analyze Betadine media blocking chart	1.40
02/24/20	DS	Analyze Senokot and Colace media blocking charts	1.90
02/24/20	IA	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) re: business plan materials for Avrio	0.20
02/24/20	IA	Call with D. Samikkannu, J. DelConte, I. Arana, and S. Lemack (all AlixPartners) re: cash reporting and Avrio business plan updates	0.30
02/24/20	IA	Call with D. Samikkannu, J. DelConte, I. Arana, R. Sublett (all AlixPartners), Purdue CFO, and J. Turner (PJT) re:	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		workplan for business plan deck.	
02/24/20	NAS	Investigate open questions related to Mundipharma business plan model (G&A data consistency, open item tracking).	1.60
02/24/20	NAS	Discussion with G. Koch (AlixPartners) and N. Simon (AlixPartners) re: Mundipharma diligence priorities for week of 2/24.	0.40
02/24/20	LJD	Call with T. Coleman (PJT).	0.60
02/24/20	LJD	Review correspondence	0.40
02/24/20	GJK	Follow up with I McClatchey (Norton Rose) and E Kim (Davis Polk) re: coordinating call between Bates White and Management Revisions	0.30
02/24/20	GJK	G&A Review (comparing LEG LR to VDD to Country Product P&L)	1.50
02/24/20	MH	Create accounts payable release file.	0.70
02/24/20	IA	Review Paysource payments against rebates forecast for Purdue variance reporting and updated forecast.	1.30
02/24/20	IA	Review updated company short term Purdue collections forecast and discuss how to incorporate into latest Purdue weekly cash model.	1.30
02/24/20	IA	Set up terminations tracker and include first resignation information for AIP amounts.	0.60
02/24/20	IA	Review latest available versions and follow up on weekly sales reports and monthly flash reports with client for diligence purposes.	0.80
02/24/20	IA	Review internal draft of Avrio business plan presentation to be discussed with management and PJT.	1.60
02/24/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.70
02/24/20	SKL	Call with D. Samikkannu, J. DelConte, I. Arana, and S.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Lemack (all AlixPartners) re: cash reporting and Avrio business plan updates	
02/25/20	HK	Review EY Draft Consumer Health Vendor Due Diligence report.	2.10
02/25/20	HK	Meeting with G. Koch, H. Ku, and N. Simon (all AlixPartners) to discuss potential structure of Mundipharma diligence report and review initial take away from EY Consumer Health VDD report.	0.80
02/25/20	HK	Review new uploads to IAC diligence data site for requested information.	1.40
02/25/20	HK	Draft initial financial overview of the Mundipharma Consumer Health business.	1.70
02/25/20	HK	Draft preliminary questions for follow-up to Mundipharma on the Consumer Health business plan.	2.20
02/25/20	IA	Call with I. Arana, R. Sublett, and D. Sammikkanu (both AlixPartners) to discuss Avrio business plan slides for PJT meeting	0.20
02/25/20	IA	Conversation with I. Arana, J. DelConte and D. Samikkannu (all AlixPartners) re: Avrio business plan.	0.40
02/25/20	MH	Create list of documents and data sources used in the cash transfer investigation.	0.30
02/25/20	MH	Create accounts payable release file.	0.70
02/25/20	GJK	Meeting with G. Koch, H. Ku, and N. Simon (all AlixPartners) to discuss potential structure of Mundipharma diligence report and review initial take away from EY Consumer Health VDD report.	0.80
02/25/20	GJK	Consumer Health VDD report read through (1-49)	3.00
02/25/20	GJK	Consumer Health VDD Read Through (50-100)	3.00
02/25/20	LJD	Review and comment on board presentation	0.90
02/25/20	LJD	Review and comment on Rhodes KPI presentation	1.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/25/20	IA	Meeting with D. Samikkannu, I. Arana (both AlixPartners), Avrio President and CFO re: dashboard review and profitability analyses	1.20
02/25/20	IA	Review updated innovation trackers for Gummies and Gargle data.	0.70
02/25/20	IA	Update Purdue retention tracker for latest resignations and additions.	0.60
02/25/20	IA	Review draft outline slides to be discussed with PJT on Avrio business plan.	1.70
02/25/20	IA	Follow up on Purdue commercial leases assumptions/rejections in preparation for filing of motion.	0.70
02/25/20	IA	Review and consolidate responses to UCC business plan questions and follow up on internal approvals.	2.10
02/25/20	IA	Review updated Avrio allocated PLs by brand, by product.	1.60
02/25/20	IA	Update profitability and terminal value analysis for Avrio based on reallocated spend.	0.60
02/25/20	NAS	Meeting with G. Koch, H. Ku, and N. Simon (all AlixPartners) to discuss potential structure of Mundipharma diligence report and review initial take away from EY Consumer Health VDD report.	0.80
02/25/20	NAS	Review Mundipharma Consumer Health volume of EY Vendor Due Diligence Report.	1.30
02/25/20	NAS	Analyze current state of Mundipharma business plan model and list remaining open items.	0.90
02/25/20	NAS	Discussion with B. Bromberg (FTI) and N. Simon (AlixPartners) re: thoughts on how to approach Mundipharma model under current data constraints.	0.50
02/25/20	DS	Put together profitability analysis on innovation - adjacent categories	1.10
02/25/20	DS	Prepare valuation assessment on innovation (line	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		extensions and adjacent categories)	
02/25/20	DS	Meeting with D. Samikkannu, I. Arana (both AlixPartners), Avrio President and CFO re: dashboard review and profitability analyses	1.20
02/25/20	DS	Call with TXP and D. Samikkannu (AlixPartners) re: surety bond / cash collateral situation	0.60
02/25/20	DS	Follow up correspondence with J. Crockett (Province) re: surety bond / cash collateral situation	0.50
02/25/20	DS	Prepare analysis on base product S&P spend and cannibalization in context of net sales	1.50
02/25/20	DS	Put together profitability analysis on innovation - line extensions	1.40
02/25/20	DS	Call with I. Arana, R. Sublett, and D. Sammikkanu (both AlixPartners) to discuss Avrio business plan slides for PJT meeting	0.20
02/25/20	DS	Conversation with I. Arana, J. DelConte and D. Samikkannu (all AlixPartners) re: Avrio business plan.	0.40
02/25/20	JD	Correspondence with PJT re: business plan work plan board slides.	0.30
02/25/20	JD	Review Rhodes board presentation.	0.50
02/25/20	JD	Conversation with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan presentation.	0.20
02/25/20	JD	Conversation with R. Sublett and J. DelConte (both AlixPartners) re: Avrio business plan.	0.20
02/25/20	JD	Conversation with I. Arana, J. DelConte and D. Samikkannu (all AlixPartners) re: Avrio business plan.	0.40
02/25/20	JD	Call with J. Greenway and J. DelConte (both AlixPartners) re: OTC S&P spending.	0.40
02/25/20	JD	AlixPartners and PJT correspondence re: business plan presentation process go forward.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/25/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss dashboard changes	0.20
02/25/20	RDS	Assemble dashboard update slide for consideration ahead of board meeting	1.00
02/25/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss dashboard changes	0.20
02/25/20	RDS	Review business plan shell and make changes based upon team feedback	0.50
02/25/20	RDS	Conversation with R. Sublett and J. DelConte (both AlixPartners) re: Avrio business plan.	0.20
02/25/20	RDS	Call with I. Arana, R. Sublett, and D. Sammikkanu (both AlixPartners) to discuss Avrio business plan slides for PJT meeting	0.20
02/25/20	RDS	Assemble slide to articulate vision for Throat Gargle case study for Avrio	0.50
02/25/20	RDS	Edit Rhodes board material side	1.40
02/25/20	RDS	Design dashboard alternative for board meeting	1.80
02/25/20	RDS	Review Senokot Gummy market study and prepare slide for PJT meeting	0.70
02/25/20	RDS	Formalize Avrio presentation materials ahead of PJT discussion	1.20
02/26/20	RDS	Review Avrio business plan financial analysis.	1.30
02/26/20	RDS	Prepare for Avrio meetings with PJT - review team data collection efforts	0.80
02/26/20	RDS	Assemble updated shell presentation to present Avrio business plan to BoD	1.70
02/26/20	RDS	Assemble shell of Avrio April board presentation	1.00
02/26/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) to discuss Avrio business plan presentation next steps	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/26/20	RDS	Analysis of Avrio Gummy product for Senokot	1.30
02/26/20	RDS	Correspondence with D. Fogel (Purdue), R. Schnitzler, J. Turner (PJT) and K. McCafferty and J. DelConte (AlixPartners) about ten-year budget work plan.	0.40
02/26/20	RDS	Assemble work plan for ten-year budget work plan (Rhodes)	1.00
02/26/20	DS	Meeting with J. Turner, R. Schnitzler, T. Melvin (all PJT), R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) to discuss Avrio board presentation.	1.00
02/26/20	DS	Meeting with Purdue CFO, D. Samikkannu, and I. Arana (both AlixPartners) to discuss Avrio scorecard.	0.50
02/26/20	DS	Review prior year's analysis on Kiwi Balance	1.20
02/26/20	DS	Review updated tracker for Gummies and Gargle provided by Avrio CFO	1.70
02/26/20	DS	Update Avrio model for updated S&P allocations	2.80
02/26/20	JD	Meeting with J. Turner, R. Schnitzler, T. Melvin (all PJT), R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) to discuss Avrio board presentation.	1.00
02/26/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) to discuss Avrio business plan presentation next steps	0.30
02/26/20	JD	Conversation with J. Turner (PJT) and J. DelConte re: business plan presentation.	0.30
02/26/20	IA	Meeting with J. Turner, R. Schnitzler, T. Melvin (all PJT), R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) to discuss Avrio board presentation.	1.00
02/26/20	IA	Update net sales by product January information and innovation details included in Avrio scorecard file to be reviewed by Purdue management.	2.20
02/26/20	IA	Meeting with Purdue CFO, D. Samikkannu, and I. Arana (both AlixPartners) to discuss Avrio scorecard.	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/26/20	IA	Review calculated AIP by employee amounts for Rhodes Pharma employees, as specified in court order.	1.90
02/26/20	IA	Draft presentation outline to be shared with PJT for Avrio business plan.	1.60
02/26/20	IA	Review Massachusetts AG questions and proposed responses and follow up on internal approvals.	1.70
02/26/20	IA	Review December and January flash report source files received from Purdue finance team.	1.30
02/26/20	IA	Incorporate proposed edits and follow up on UCC business plan diligence open items and internal approvals.	2.30
02/26/20	NAS	Review Consumer Health volume of EY Vendor Due Diligence report.	1.70
02/26/20	NAS	Meeting with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review initial questions regarding Consumer Health EY VDD report and discuss preliminary report structure.	0.50
02/26/20	NAS	Assess current status of Mundipharma diligence process and key items still outstanding.	0.20
02/26/20	NAS	Review Mundipharma financials provided by Management Revisions and finalize question list for 2/28 meeting with them.	2.40
02/26/20	NAS	Call with I. McClatchey (Norton Rose), M. Diaz, B. Bromberg (both FTI), G. Koch, and N. Simon (both AlixPartners) to discuss diligence requests and timing	1.00
02/26/20	LJD	Prepare for and attend call with J. Dubel - board member	0.80
02/26/20	LJD	Prepare board presentation materials	2.50
02/26/20	GJK	Call with I. McClatchey (Norton Rose), M. Diaz, B. Bromberg (both FTI), G. Koch, and N. Simon (both AlixPartners) to discuss diligence requests and timing	1.00
02/26/20	GJK	Meeting with G. Koch, N. Simon, and H. Ku (all	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) to review initial questions regarding Consumer Health EY VDD report and discuss preliminary report structure.	
02/26/20	GJK	Consumer Health VDD read through and follow up question's coordination	2.50
02/26/20	MH	Create accounts payable release file.	0.70
02/26/20	MH	Call with supply chain manager to review issues with acquisition of customer rebate manager.	0.70
02/26/20	MH	Advise client on response to a vendor with unpaid pre-petition invoices.	0.40
02/26/20	HK	Update questions for follow-up to Mundipharma on the Consumer Health business plan.	1.70
02/26/20	HK	Additional review of Consumer Health financial information for follow-up diligence requests.	2.30
02/26/20	HK	Meeting with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review initial questions regarding Consumer Health EY VDD report and discuss preliminary report structure.	0.50
02/27/20	HK	Update questions for follow-up to Mundipharma on the Consumer Health business plan.	2.20
02/27/20	HK	Review IAC due diligence materials to update Davis Polk on status.	0.60
02/27/20	HK	Update IAC due diligence review status for discussion with Davis Polk.	1.30
02/27/20	MH	Create accounts payable release file.	0.70
02/27/20	GJK	Call with I. McClatchey (Norton Rose) and G. Koch (AlixPartners) re: follow-up	1.50
02/27/20	GJK	Consumer Health VDD follow up	3.00
02/27/20	GJK	Questions/follow up email with DWP re: status and open items	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/27/20	LJD	Prepare for and attend board meeting - first session - legal update	1.50
02/27/20	LJD	Prepare for and attend board meeting - second session - business update	2.10
02/27/20	LJD	Prepare for and attend board meeting - third session - Rhodes update	1.40
02/27/20	LJD	Debrief call with T. Coleman (PJT) regarding next steps from board meeting	0.70
02/27/20	NAS	Review Consumer Health volume of EY Vendor Due Diligence report.	2.50
02/27/20	NAS	Preparation for 2/28 meeting with S. Jamieson (Management Revisions).	0.40
02/27/20	NAS	Track current status of Mundipharma diligence process including key open items remaining.	0.50
02/27/20	IA	Follow up on R&D and other one-time payment amounts to be included in Purdue cash forecast model.	0.70
02/27/20	IA	Review Purdue cash forecast model and updated rebates and collections forecasts	2.40
02/27/20	IA	Follow up on and review voluntary terminations report	0.30
02/27/20	IA	Review volumetric data received for gargle product	0.70
02/27/20	IA	Update and format Avrio scorecard file to be reviewed by Purdue management.	0.40
02/27/20	IA	Prepare for meeting with Avrio management to discuss reallocated S&P spend, management scorecard, and other business plan items.	1.60
02/27/20	IA	Meeting with C. Chomiak, J. Tran (both Purdue), and I. Arana (AlixPartners) to discuss reallocated S&P spend, management scorecard, marketing mix, innovation case studies, and other items.	1.70
02/27/20	JD	Participate in Board meeting.	4.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/27/20	JD	Review draft business plan outline and provide comments to management re: same.	0.80
02/27/20	JD	Correspondence with R. Silbert (Purdue) and R. Collura (AlixPartners) re: distribution analysis.	0.30
02/27/20	JD	Review updated draft professional fee forecast against filings.	0.40
02/27/20	DS	Draft detailed Avrio business plan workplan for distribution	1.10
02/27/20	DS	Provide Avrio CEO and CFO with detailed agenda for working session later	0.70
02/27/20	DS	Draft update to AlixPartners team based on working session with Avrio management	0.40
02/27/20	DS	Meeting with Avrio CFO and CEO re: key issues in Avrio business plan and workplan	1.50
02/27/20	DS	Work through Avrio model to make dynamic based on high-level sensitivities	2.90
02/27/20	DS	Review Betadine Gargle Nielsen report	1.80
02/27/20	DS	Review marketing mix report provided by Avrio management	1.80
02/27/20	RDS	Purdue Board call for Rhodes discussion	1.20
02/27/20	RDS	Correspondence with D. Samikkannu and I. Arana (AlixPartners) regarding Avrio work plan.	0.40
02/27/20	RDS	Review latest progress update on Avrio analysis.	0.40
02/27/20	RDS	Review Avrio throat gargle Nielsen study	0.80
02/27/20	RDS	Call with D. Fogel (Purdue), R. Sublett (both AlixPartners) to discuss ten-year budget hi/base/lo scenarios	0.30
02/27/20	RDS	Avrio gargle report analysis - CAD market comparison	0.60
02/28/20	DS	Update Avrio model for revised budget	1.20
02/28/20	JD	Prepare for and participate in a call with J. DelConte	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners), J. Turner, R. Schnitzler (PJT) and J. Lowne (Purdue) re: business plan presentation.	
02/28/20	IA	Update weekly sales files for Purdue and Rhodes for review by management.	0.70
02/28/20	IA	Review AIP payments by employee files received from Human Resources for validation.	1.30
02/28/20	IA	Review marketing mix and gargle volumetric information received from Avrio management	2.40
02/28/20	IA	Review cash actuals and cash forecast reports and provide comments.	1.20
02/28/20	IA	Review of December flash report and provide comments	0.90
02/28/20	IA	Review and follow up on business plan diligence questions from committees and communications with management and legal to request approvals	2.90
02/28/20	NAS	Initial analysis of Mundipharma price/volume data.	1.00
02/28/20	NAS	Preparation for call with S. Jamieson (Management Revisions).	0.30
02/28/20	NAS	Call with G. Koch, N. Simon, H. Ku (all AlixPartners), S. Jamieson (Management Revisions), and Mundipharma diligence advisors to review open items related to financials provided.	2.00
02/28/20	LJD	Review correspondence	0.50
02/28/20	LJD	Board meeting debrief call with L. Donahue (AlixPartners) and J. Dubel (Board member)	1.00
02/28/20	GJK	Call with G. Koch, N. Simon, H. Ku (all AlixPartners), S. Jamieson (Management Revisions), and Mundipharma diligence advisors to review open items related to financials provided.	2.00
02/28/20	GJK	Coordinate with Norton Rose on follow up items	1.00
02/28/20	MH	Create accounts payable release file.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
02/28/20	HK	Call with G. Koch, N. Simon, H. Ku (all AlixPartners), S. Jamieson (Management Revisions), and Mundipharma diligence advisors to review open items related to financials provided.	1.90
02/29/20	LJD	Debrief call with management after board call, discuss next steps with OTC etc.	0.60
03/01/20	DS	Calculate unallocated base costs from client's model	0.80
03/02/20	DS	Discussion with I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re: presentation materials for Avrio board meeting	0.80
03/02/20	DS	Meeting with J. Tran (Purdue), D. Sammikkanu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio diligence questions	1.40
03/02/20	DS	Provide team with detailed workplan for day re: Avrio business plan	1.10
03/02/20	DS	Analyze Avrio operating model and provide comments to Avrio CFO	1.80
03/02/20	DS	Review Avrio CFO's cannibalization assumptions	1.60
03/02/20	DS	Develop format for high-level scenarios in Avrio model	1.30
03/02/20	DS	Meeting with Avrio CFO and K. McCafferty (AlixPartners) re: base S&P spend and marketing scenarios	2.30
03/02/20	DS	Review FFS data set provided by Purdue financial analyst	0.60
03/02/20	JD	Meeting with J. Turner (PJT), J. Lowne, P. Strassburger (both Purdue), and J. DelConte (AlixPartners) re: OxyContin LOE assumptions.	1.10
03/02/20	JD	Call with Associate General Counsel re: business planning progress.	0.30
03/02/20	JD	Call with C. Robertson (Davis Polk), K. McCarthy, R. Aleali (both Purdue), and J. DelConte (AlixPartners) re: reporting expectations.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/02/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business planning progress.	0.30
03/02/20	JD	Review detailed business planning materials and assumptions including product by product innovation forecasts and OTC market spending levels re: Avrio long term business plan.	2.80
03/02/20	JD	Partial attendance at meeting with J. Tran (Purdue), J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) re: Avrio business plan assumptions.	0.80
03/02/20	JD	Review and provide comments re: draft Avrio business plan presentation.	1.20
03/02/20	IA	Discussion with I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re: presentation materials for Avrio board meeting	0.80
03/02/20	NAS	Create plan for Mundipharma diligence priorities for week of 3/2.	0.60
03/02/20	NAS	Analysis of Purdue IQVIA data to determine what data should be requested for purposes of Mundipharma diligence.	0.80
03/02/20	NAS	Analysis of Mundipharma G&A costs by region outlined in financial statements provided by Management Revisions.	0.50
03/02/20	NAS	Analysis of price/volume data provided by Mundipharma to assess forward-looking projections.	2.80
03/02/20	NAS	Provide overview to J. DelConte (AlixPartners) of historical Mundipharma Consumer Health performance.	0.40
03/02/20	LJD	Review documents	0.70
03/02/20	LJD	Update call with J. Lowne (Purdue) and L. Donahue (AlixPartners)	0.50
03/02/20	GJK	Update and coordination of diligence for Mundipharma	1.50
03/02/20	MH	Create accounts payable release file.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/02/20	HK	Update IAC diligence project status report for discussion with Davis Polk.	1.20
03/02/20	HK	Analyze European IAC G&A data to update Mundipharma IAC financial model.	2.10
03/02/20	HK	Analyze LAM IAC G&A data to update Mundipharma IAC financial model.	2.60
03/02/20	HK	Analyze Canadian IAC G&A data to update Mundipharma IAC financial model.	0.30
03/02/20	HK	Analyze corporate G&A data to update Mundipharma IAC financial model.	0.70
03/02/20	IA	Follow up on commercial leases and support documents in preparation for upcoming hearing.	1.10
03/02/20	IA	Review updated Avrio PL allocations file between base business and innovations.	1.70
03/02/20	IA	Review company short term cash forecast to compare to 13 week forecast and update fee for service credit assumptions.	0.80
03/02/20	IA	Validate Purdue AIP payments by employee for Purdue and Rhodes based on court approval and latest active employee roster.	1.80
03/02/20	IA	Reconcile total AIP payments (Purdue and Purdue) to 2019 accruals and approved court amounts.	2.10
03/02/20	RDS	Prepare slides to talk through Senokot gummy Nilson analysis	2.10
03/02/20	RDS	Call with J. Turner (PJT), K. McCafferty, and R. Sublett (both AlixPartners) to discuss 10-year business plan assumptions	0.40
03/02/20	RDS	Meeting with J. Tran (Purdue), D. Sammikkanu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio diligence questions	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/02/20	RDS	Discuss sales consumption data from Nielsen for Betadine	1.80
03/02/20	RDS	Review Avrio Gummy Nilsen data	0.70
03/02/20	RDS	Discussion with I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re: presentation materials for Avrio board meeting	0.80
03/02/20	RDS	Review and amendments to PJT and AlixPartners presentation for BoD	1.30
03/02/20	KM	Meeting with Avrio CFO and D. Samikkannu (AlixPartners) re: base S&P spend and marketing scenarios	2.30
03/02/20	KM	Dashboard review	1.20
03/02/20	KM	Analysis re: forecasting models for generics portfolio long range planning	2.20
03/02/20	KM	Prepare suggested dashboard edits	0.40
03/02/20	KM	Research re: potential industry partners	1.70
03/02/20	KM	SWOT analysis re: potential industry partners	1.90
03/02/20	KM	Call with J. Turner (PJT), K. McCafferty, and R. Sublett (both AlixPartners) to discuss 10-year business plan assumptions	0.40
03/03/20	KM	Dashboard process planning	1.10
03/03/20	KM	Generics pipeline projections with SME	0.60
03/03/20	KM	Prepare Rhodes Tech scenario breakdown	1.40
03/03/20	KM	Call with D. Lundie, D. Fogel, J. Lowne (Purdue), J. Turner, R. Schnitzler (PJT), K. McCafferty and R. Sublett (both AlixPartners) to discuss strategic / sponsor steps for Rhodes Technology asset	0.90
03/03/20	KM	Discussion with SME re: Rhodes Tech closure model	0.80
03/03/20	KM	Rhodes performance tracking	0.60
03/03/20	KM	Discussion with SME re: long range forecasting models for generics industry	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/03/20	KM	Prepare for and attend meeting with J. Lowne, D. Fogel (both Purdue), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to discuss Rhodes ten-year budget changes	0.50
03/03/20	KM	Create preliminary 10-year plan budget scenarios for Rhodes	1.60
03/03/20	KM	Workstream planning	0.50
03/03/20	RDS	Work planning for Rhodes headcount reductions	0.60
03/03/20	RDS	Update market share analysis for Rhodes Gx products	0.70
03/03/20	RDS	Work through Rhodes Pharma implementation planning for R&D headcount	0.60
03/03/20	RDS	Meeting with D. Fogel (Purdue) and R. Sublett (AlixPartners) to discuss Rhodes implementation planning - Coventry site costs for budget base case	1.00
03/03/20	RDS	Conversation with D. Fogel (Purdue) to discuss Upside scenario for Coventry budget upside case	0.90
03/03/20	RDS	Call with D. Lundie, D. Fogel, J. Lowne (Purdue), J. Turner, R. Schnitzler (PJT), K. McCafferty (AlixPartners) to discuss strategic / sponsor steps for Rhodes Technology asset	0.90
03/03/20	RDS	Meeting with J. Lowne, D. Fogel (both Purdue), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to discuss Rhodes ten-year budget changes	0.50
03/03/20	RDS	Determine next steps for Avrio business plan	0.40
03/03/20	RDS	Review Rhodes Budget assumptions and Wilson, NC Assumptions	2.60
03/03/20	RDS	Call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes 10 year business plan.	0.40
03/03/20	RDS	Call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: long term planning for Rhodes.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/03/20	RDS	Revise workplan ahead of D. Lundie meeting 3/4/2020	0.40
03/03/20	IA	Call with C. Destefano (Purdue), J. Teo (Willis Towers Watson), and I. Arana (AlixPartners) to discuss data set provided on historical and estimated benefit payments by employee	0.60
03/03/20	IA	Call with C. Destefano (Purdue) and I. Arana (AlixPartners) and to discuss bonus files for AIP payments.	0.50
03/03/20	IA	Review Rhodes Tech and Rhodes Pharma calculated bonus by employee files to validate AIP 2020 approved payments.	1.90
03/03/20	IA	Follow up on reporting from HR and updated Purdue voluntary terminations report,	1.20
03/03/20	IA	Review questions received from Willis Towers Watson on court approved AIP and LTRP payments.	0.60
03/03/20	IA	Follow up on OCP spend reporting.	0.40
03/03/20	IA	Discuss and follow up on request for validation of 2019 benefit plan accruals and estimate for 2020 with C. Destefano (Purdue) and I. Arana (AlixPartners)	2.40
03/03/20	IA	Follow up on commercial leases requests in preparation for hearing.	1.30
03/03/20	IA	Review Avrio products - Kiwi and Ginger - study and results.	1.70
03/03/20	HK	Update IAC diligence project status report for discussion with Davis Polk.	1.20
03/03/20	HK	Update Mundipharma business plan analysis with revise product category sales trends.	2.60
03/03/20	MH	Create accounts payable release file.	0.70
03/03/20	MH	Attend call with legal operations to review changes to the invoice release process.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/03/20	MH	Arrange for a special hold on payments to an equipment lessor on advice from counsel.	0.40
03/03/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss current status of Mundipharma diligence process.	0.30
03/03/20	GJK	Call with I. McClatchey (Norton Rose) and G. Koch (AlixPartners) re: updates on London Mundipharma Deutsche Bank, LEK and exec meetings	1.00
03/03/20	GJK	Analysis re: price x volume information	2.00
03/03/20	LJD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: business planning progress and work plan going forward.	0.70
03/03/20	NAS	Analysis of Purdue IQVIA data to inform data request for Mundipharma diligence.	1.50
03/03/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss current status of Mundipharma diligence process.	0.30
03/03/20	JD	Meeting with J. Lowne, D. Fogel (both Purdue), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to discuss Rhodes ten-year budget changes	0.50
03/03/20	JD	Call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: long term planning for Rhodes.	0.30
03/03/20	JD	Review and provide comments on the latest professional fee forecast and check forecast against the docket and fee apps filed to date.	0.70
03/03/20	JD	Review draft business planning materials re: branded opioids, PHI and pipeline assets and update associated work plan and meeting timelines.	2.30
03/03/20	DS	Model base sales realization scenarios across product families	2.20
03/03/20	DS	Model benchmark S&P override toggle across product families	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/03/20	DS	Model cost of sales realization across product families	1.60
03/03/20	DS	Build scenario control panel for base products in Avrio model	1.90
03/03/20	JD	Partial participation in call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes 10 year business plan.	0.20
03/04/20	DS	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	DS	Correspondence with Rhodes financial analyst re: customer programs files sent	0.30
03/04/20	DS	Analyze Betadine Gargle data sent by Avrio	1.20
03/04/20	DS	Model upside scenarios for base products business	2.10
03/04/20	DS	Model downside and benchmark scenarios for base products business for Avrio	2.00
03/04/20	DS	Develop dynamic model for S&P fluctuations in Avrio model	2.40
03/04/20	DS	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	JD	Prepare for and participate in Managed Care marketing meeting with B. Shank, M. Ronning (both Purdue), J. DelConte, and S. Lemack (both AlixPartners).	1.20
03/04/20	JD	Catch up call with J. DelConte, N. Simon (both AlixPartners), J. Turner and R. Schnitzler (both PJT) re: business plan.	0.50
03/04/20	JD	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	JD	Call with J. Turner, J. O'Connell (both PJT), J. Lowne	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: Thursday meeting agenda.	
03/04/20	JD	Review and provide comments on draft branded opioid, PHI and pipeline asset slides for the ultimate business plan presentation.	1.70
03/04/20	JD	Correspondence with KCC and C. MacDonald (Purdue) re: vendor forms.	0.30
03/04/20	JD	Edit HRT overview presentation to share with the committee advisors.	0.80
03/04/20	JD	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	DS	Meeting with J. Lowne (Purdue), I. Arana, and D. Samikkannu (both AlixPartners) to review updated Avrio dashboard.	0.50
03/04/20	NAS	Assess current state of Mundipharma business plan model and additional modifications that can be made.	0.40
03/04/20	NAS	Catch up call with J. DelConte, N. Simon (both AlixPartners), J. Turner and R. Schnitzler (both PJT) re: business plan.	0.50
03/04/20	NAS	Initial analysis of Purdue business plan slides.	0.30
03/04/20	NAS	Analysis of data templates and subsequent correspondence with FTI re: Mundipharma IQVIA data requests.	0.40
03/04/20	IA	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	LJD	Review draft decks for business plan and comments	1.80
03/04/20	LJD	Prepare for and attend call with J. Turner, J. O'Connell (both PJT), J. Lowne (Purdue), L. Donahue, and J.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DelConte (both AlixPartners) re: Thursday meeting agenda.	
03/04/20	GJK	Coordination re: Mundipharma including open diligence items, and price x volume	2.00
03/04/20	MH	Advise client on vendor who threatened to end calibration support over nonpayment of pre-petition.	0.90
03/04/20	MH	Create accounts payable release file.	0.70
03/04/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.40
03/04/20	IA	Review and discuss final Purdue and Rhodes Pharma AIP payment files with C. Destefano (Purdue) and I. Arana (AlixPartners)	0.60
03/04/20	IA	Meeting with J. Lowne (Purdue), I. Arana, and D. Samikkannu (both AlixPartners) to review updated Avrio dashboard.	0.50
03/04/20	IA	Discuss and follow up on requests for information re: AIP and LTRP approved amounts with D. Sims (Willis Towers Watson) and I. Arana (AlixPartners)	1.30
03/04/20	IA	Follow up on pending payments to benefit vendors.	0.60
03/04/20	IA	Follow up on calculation questions re: Rhodes AIP bonus amounts.	0.80
03/04/20	IA	Update Avrio scorecard to incorporate comments from management.	1.30
03/04/20	IA	Follow up on weekly sales by product reports.	0.40
03/04/20	IA	Review updated January flash report.	1.10
03/04/20	IA	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	RDS	Outline and shell an investment teaser for Rhodes Tech asset	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/04/20	RDS	Changes to the Base/Lo/Hi scenarios for Rhodes business plan	0.40
03/04/20	RDS	Gather market research to position coventry asset within the wider API manufacturing landscape	0.30
03/04/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning for Rhodes turnaround plan	1.10
03/04/20	RDS	Review agenda for RELT meetings and prepare slides to discuss implementation progress for each workstream	0.60
03/04/20	RDS	Prepare for Avrio dashboard meeting with J. Lowne (Purdue) later today	0.20
03/04/20	RDS	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	RDS	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	KM	Prepare Rhodes Tech teaser outline	1.40
03/04/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: Rhodes Tech closure model options	0.60
03/04/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning for Rhodes turnaround plan	1.10
03/04/20	KM	Rhodes implementation planning with AlixPartners Partners team	1.10
03/04/20	KM	Deck planning and outline re: Rhodes Tech strategic partnerships	1.60
03/04/20	KM	Slides creation re: Rhodes Tech strategic partnerships	2.70
03/04/20	KM	Review of teaser deck with K. McCafferty, and R. Sublett (both AlixPartners)	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/04/20	KM	Market trends and forecast research and analysis	1.40
03/05/20	KM	Market trends and forecast research and analysis	1.70
03/05/20	KM	Slide creation re: Rhodes Tech strategic partnerships "teaser" deck	1.90
03/05/20	KM	Analysis and slides creation re: DEA quota trends for core opioids	2.10
03/05/20	KM	Edit and formatting re: Rhodes Tech strategic partnerships "teaser" deck	0.90
03/05/20	KM	Review of Rhodes Tech partnership opportunity	0.60
03/05/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss strategic partnerships presentation for Rhodes Tech	0.40
03/05/20	RDS	Review of RELT communication and provide commentary on the ten-year plan thoughts from D. Lundie (Purdue).	0.50
03/05/20	RDS	Meeting with D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), and J. Tran (Purdue) re: open items and status updates	0.20
03/05/20	RDS	Schedule turnaround team meetings for next week in Rhode Island	0.50
03/05/20	RDS	Correspondence with D. Fogel (Purdue) and J. DelConte (AlixPartners) re: Low/Base/High scenario analysis for Rhodes Pharma x	0.70
03/05/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to talk Low scenario implications	0.50
03/05/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss strategic partnerships presentation for Rhodes Tech	0.40
03/05/20	RDS	Review Rhodes RELT agenda	0.60
03/05/20	RDS	Slide preparation - Avrio Dulcolax case study	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/05/20	IA	Meeting with D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), and J. Tran (Purdue) re: open items and status updates	0.20
03/05/20	IA	Calculate estimated 2021 LTRP payments and outstanding grants by employee under current program.	2.70
03/05/20	IA	Create detailed file that shows insider and non-insider split for estimated and agreed 2020 LTRP payments, for comparison to estimated 2021 payments.	2.20
03/05/20	IA	Follow up on executive bio information requested by legal (R Aleali)	0.70
03/05/20	IA	Final review and updated summary of AIP payments to Purdue employees.	1.30
03/05/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.10
03/05/20	HK	Review current status of Mundipharma business plan model.	1.80
03/05/20	MH	Create accounts payable release file.	0.70
03/05/20	MH	Call with supply chain management to discuss treatment of vendors re: caps in their trade agreements.	0.30
03/05/20	MH	Research new pre-petition invoices for vendor with a trade agreement to determine proper treatment.	0.70
03/05/20	GJK	Calls with Brian Bromberg (FTI) and G. Koch (AlixPartners) re: follow up on P&V, model	2.00
03/05/20	LJD	Prepare for and participate in a meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), M. Huebner, T. Graulich (both Davis Polk), J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	2.40
03/05/20	LJD	Review draft slide deck for input into business plan	2.50
03/05/20	LJD	Review and comment on customer leave behind	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/05/20	NAS	Review draft Board presentation related to Purdue business plan.	2.20
03/05/20	NAS	Provide update to G. Koch (AlixPartners) re: status of Mundipharma diligence and business plan model.	0.30
03/05/20	JD	Review market access customer presentation, provide comments, and correspondence with Associate General Counsel re: same.	1.10
03/05/20	JD	Review unbilled and accrued professional fee amounts and correspondence with R. Brown (Purdue) re: same.	0.50
03/05/20	JD	Review and provide comments on draft Avrio business plan slides.	1.30
03/05/20	JD	Prepare for and participate in a meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), M. Huebner, T. Graulich (both Davis Polk), J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	2.00
03/05/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: open business plan questions.	0.60
03/05/20	JD	Call with J. Turner (PJT) and J. DelConte (AlixPartners) re: open business plan questions.	0.30
03/05/20	JD	Update and send out agenda prior to meeting with DPW, AlixPartners, PJT and management.	0.30
03/05/20	JD	Draft responses to questions from the UCC re: Avrio lease assumption and correspondence with Davis Polk and management re: same.	0.90
03/05/20	DS	Begin modeling innovation bottoms up data for Betadine innovation	2.30
03/05/20	DS	Begin modeling for Senokot the detailed innovation scenarios	1.40
03/05/20	DS	Meeting with D. Samikkannu, I. Arana, R. Sublett (all	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners), and J. Tran (Purdue) re: open items and status updates	
03/05/20	DS	Correspondence with R. Sublett (AlixPartners) re: Betadine Gargle data received from client	0.40
03/05/20	DS	Review category spending and retail dollars data provided by Avrio management	1.40
03/06/20	DS	Call with J. Tran, R. Brown (Purdue), D. Samikkannu, and R. Sublett (both AlixPartners) to discuss beta fine throat gargle case study	0.80
03/06/20	DS	Call with D. Samikkannu (AlixPartners), J. Tran (Purdue), and marketing analyst re: Betadine case study	0.80
03/06/20	DS	Review detailed Canadian Betadine Gargle data sent by Avrio management	1.70
03/06/20	DS	Analyze Rhodes budget files sent by Rhodes management	2.20
03/06/20	DS	Correspondence with S. Lemack (AlixPartners) re: next steps re: Rhodes budget files	0.30
03/06/20	DS	Review Gummy external comps and benchmarks	1.40
03/06/20	JD	Conversation with R. Schnitzler (PJT) and J. DelConte (AlixPartners) re: business plan and Avrio meeting on Monday.	0.50
03/06/20	JD	Update draft responses to UCC questions on Avrio lease and correspondence with management and Davis Polk re: same.	0.60
03/06/20	JD	Review draft pipeline slides and provide comments on missing elements and potential adjustments to existing slides.	1.80
03/06/20	JD	Review and provide comments on draft PHI slides and compare financial information in the slides back to the PHI diligence responses given to the various committee advisors.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/06/20	JD	Conversations with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: Rhodes business plan sensitivities. Correspondence with PJT re: same.	0.50
03/06/20	JD	Review and provide comments on final customer presentation.	0.30
03/06/20	JD	Review and provide comments on the latest Avrio scorecard.	0.40
03/06/20	LJD	Review various files for budget input and edit/comment	2.60
03/06/20	GJK	Call with I. McClatchey (Norton Rose) and G. Koch (AlixPartners) re: follow up on Friday legal calls	1.30
03/06/20	MH	Update status of legal vendors in all payment and reporting systems on advice from legal operations.	1.30
03/06/20	MH	Create accounts payable release file.	0.70
03/06/20	HK	Review new uploads to Mundipharma due diligence data site.	1.40
03/06/20	HK	Review draft business plan model to draft summaries on sales trends in Canada.	1.10
03/06/20	IA	Review actual and estimated amounts presented in benefit programs proposal to be reviewed with CEO and prepared by Willis Tower Watson	2.30
03/06/20	IA	Discuss Avrio open items for business plan presentation and assigned updates.	0.60
03/06/20	IA	Review received Avrio competitive Gummy data.	0.70
03/06/20	IA	Discuss draft Avrio scorecard with J. Lowne (Purdue) and I. Arana (AlixPartners)	0.50
03/06/20	IA	Update Avrio scorecard to incorporate latest comments from management.	1.70
03/06/20	IA	Call with C. DeStefano (Purdue), I. Arana (AlixPartners), and Willis Towers Watson to discuss numbers on benefit program proposal overview.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/06/20	RDS	Comments to updated Avrio dashboard	0.30
03/06/20	RDS	Call with J. Tran, R. Brown (Purdue), D. Samikkannu, and R. Sublett (both AlixPartners) to discuss beta fine throat gargle case study	0.80
03/06/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss customer and product profitability for Rhodes Pharma products	0.20
03/06/20	RDS	Correspondence with Rhodes team re: customer and product profitability analysis and corresponding implementation plan.	0.60
03/06/20	KM	Rhodes implementation planning for review sessions	0.80
03/06/20	KM	Analysis and market research re: SWOT analysis for Rhodes Tech strategic partnerships "teaser"	1.50
03/06/20	KM	Agendas and actions lists for Rhodes implementation planning for review sessions	1.20
03/06/20	KM	Key executives from potential partners analysis	1.70
03/06/20	KM	Slide creation re: Rhodes Tech strategic partnerships "teaser" deck	0.70
03/06/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss customer and product profitability for Rhodes Pharma products	0.20
03/07/20	DS	Follow up with Avrio management re: further Canadian Betadine Gargle data	0.30
03/08/20	DS	Refresh numbers for draft deck reflecting Avrio CFO's latest allocations	1.30
03/08/20	DS	Update cannibalization assumptions and re-run analysis on commercial products	1.60
03/08/20	DS	Correspondence with J. Tran (Purdue) re: gummy comps	0.30
03/08/20	DS	Draft introductory slides to frame discussion for presentation	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/08/20	IA	Update Avrio business plan slides for review with management.	1.80
03/08/20	RDS	Avrio Slide creation - observations, risks and opportunities	0.70
03/08/20	RDS	Avrio Slide creation - Betadyne case study	1.10
03/09/20	RDS	Meeting with J. Lowne, B. Weingarten, J. Tran (all Purdue), D. Samikkannu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) to discuss board presentation on Avrio health	2.00
03/09/20	RDS	Avrio slide creation - edits from meeting with J. Lowne (Purdue) and changes to the S&P bridge for legacy commercial products	1.60
03/09/20	RDS	Call with V. Mancinelli, K. Kolar, D. Ebere, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project management update for Rhodes Pharma pipeline turnaround plan	2.00
03/09/20	RDS	Meeting with R. Shamblen, J. Freidricksen, D. Fogel (all Purdue), R Sublett, and K. McCafferty (both AlixPartners) re: Rhodes Tech strategic partnerships "teaser"	1.90
03/09/20	RDS	Slide creation - Avrio analysis from Nielsen sensitivity on senokot and colace marketing spend	1.10
03/09/20	RDS	Slide creation - Avrio innovation payback and enterprise value creation	0.80
03/09/20	ADD	Update Purdue vendor master spreadsheet.	0.60
03/09/20	KM	Itinerary planning and adjustment	0.50
03/09/20	KM	API market research	0.40
03/09/20	KM	Call with K. McCafferty (AlixPartners) and D. Fogel (Purdue) re: implementation review process for this week	0.10
03/09/20	KM	Analysis and market research re: API forecast for core opioids	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/09/20	KM	Slide creation re: Rhodes Tech partnership teaser	0.90
03/09/20	KM	Review and analysis re: Rhodes Pharma resource allocation	0.90
03/09/20	KM	Slide creation re: Rhodes Tech partnership teaser	1.10
03/09/20	KM	Call with V. Mancinelli, K. Kolar, D. Ebere, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project management update for Rhodes Pharma pipeline turnaround plan	2.00
03/09/20	KM	Prepare for and attend meeting with R. Shamblen, J. Freidricksen, D. Fogel (all Purdue), R Sublett, and K. McCafferty (both AlixPartners) re: Rhodes Tech strategic partnerships "teaser"	1.90
03/09/20	KM	Document edits re: Rhodes Tech strategic partnerships "teaser"	0.80
03/09/20	IA	Review insider estimated approved benefit payments as requested by human resources to be submitted to WTW.	0.60
03/09/20	IA	Review latest version of Avrio allocated PL file showing the split of base business and innovations.	1.70
03/09/20	IA	Review Emerson savings backup presentation to inform restated Avrio historical financials.	0.80
03/09/20	IA	Meeting with J. Lowne, B. Weingarten, J. Tran (all Purdue), D. Samikkannu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) to discuss board presentation on Avrio health	2.00
03/09/20	IA	Edit slides to be reviewed with J. Lowne, B. Weingarten, J. Tran (all Purdue), R. Schnitzler, and J. Turner (both PJT)	1.20
03/09/20	MH	Create accounts payable release file.	0.70
03/09/20	MH	Create monthly analysis of pre-petition accounts payable for reclassification to "subject to compromise"	3.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/09/20	GJK	Call with N. Simon and G. Koch (both AlixPartners) to provide update on Mundipharma diligence status and set priorities for week of 3/9.	0.40
03/09/20	GJK	Call with I McClatchey (Norton Rose) to discuss Mundipharma diligence and next steps	1.00
03/09/20	GJK	Call with B. Bromberg (FTI) and G. Koch (AlixPartners) to discuss diligence requests	0.30
03/09/20	GJK	Mundipharma diligence - key questions, documents reviews, next steps	2.50
03/09/20	LJD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: business plan progress.	0.70
03/09/20	DS	Prepare for and attend meeting with J. Lowne, B. Weingarten, J. Tran (all Purdue), D. Samikkannu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) to discuss board presentation on Avrio health	2.00
03/09/20	DS	Review draft materials in preparation for meeting	1.40
03/09/20	DS	Updates to draft materials based on Purdue CFO's comments	0.60
03/09/20	DS	Correspondence with Aviro marketing manager re: Gargle data sent	0.30
03/09/20	DS	Analyze marketing spend scenarios provided by Nielsen	2.40
03/09/20	DS	Review Purdue CFO's list of comments to proposed materials	0.90
03/09/20	DS	Review and correspondence with Avrio CFO re: working capital assumptions	1.20
03/09/20	DS	Work on revised presentation (marketing spend scenarios, evaluating S&P spend)	2.10
03/09/20	DS	Update Avrio model with J. Tran's (Purdue) revised numbers	1.40
03/09/20	JD	Finalize Avrio lease assumption questions to be posted to	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		the data room.	
03/09/20	JD	Review and provide draft comments to PJT draft business plan board presentation.	1.10
03/09/20	JD	Review draft Rhodes Pharma and Rhodes Tech sensitivities for business plan presentation.	0.40
03/09/20	JD	Provide comments on draft Avrio presentation.	0.70
03/09/20	JD	Prepare for and attend meeting with J. Lowne, J. Tran (both Purdue), J. Turner, R. Schnitzler (both PJT), J. DelConte, D. Samikkannu, R. Sublett, and I. Arana (all AlixPartners) re: Avrio business plan presentation.	2.00
03/09/20	JD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: business plan progress.	0.70
03/09/20	JD	Meeting with J. Lowne, M. Kesselman, R. Brown (all Purdue), T. Melvin (PJT), and J. DelConte (AlixPartners) re: professional fee forecasts.	0.50
03/09/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business planning progress.	0.30
03/09/20	JD	Analysis of Avrio business plan and historical sales and promotion spend trends including creating sensitivity analyses at various different spend levels.	1.70
03/09/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to provide update on Mundipharma diligence status and set priorities for week of 3/9.	0.40
03/09/20	NAS	Review Purdue business plan slides for Board proposed by PJT.	0.50
03/10/20	NAS	Meeting with J. DelConte and N. Simon (both AlixPartners) to review Purdue business plan slides prepared by company and discuss revisions.	0.90
03/10/20	NAS	Discussion with J. DelConte, N. Simon (both AlixPartners), R. Schnitzler, and J. Turner (both PJT) re:	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		draft Purdue business plan presentation for Board.	
03/10/20	NAS	Updates to Mundipharma diligence process including country manager meetings and KPMG workplan status.	0.50
03/10/20	JD	Review and provide comments on draft materials for Rhodes Executive Leadership Team meeting.	0.90
03/10/20	JD	Call with R. Sublett and J. DelConte (both AlixPartners) re: RELT meeting and presentation.	0.20
03/10/20	JD	Follow up with the company re: open vendor payment issues.	0.40
03/10/20	JD	Review Adhanisa pre-read materials. Provide comments re: same.	1.30
03/10/20	JD	Review final Ad Hoc Committee diligence responses and diligence materials.	0.50
03/10/20	JD	Review comments from J. Lowne (Purdue) on the draft Avrio presentation and review Avrio analysis for potential responses.	0.60
03/10/20	JD	Call with I. McClatchey (Norton Rose), G. Koch, and J. Delconte (both AlixPartners) re: follow up (partial attendance)	0.20
03/10/20	JD	Meeting with N. Simon and J. DelConte (both AlixPartners) to review Purdue business plan slides prepared by company and discuss revisions.	0.90
03/10/20	JD	Discussion with N. Simon, J. DelConte (both AlixPartners), R. Schnitzler, and J. Turner (both PJT) re: draft Purdue business plan presentation for Board.	0.50
03/10/20	DS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to review and update draft slides	0.60
03/10/20	DS	Attend call with D. McGuire, D. Fogel, R. Shamblan, A. Soma (all Purdue), K. McCafferty, D Samikkannu, and R. Sublett (both AlixPartners) to discuss manufacturing	2.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		organizational changes implementation planning	
03/10/20	DS	Draft list of detailed follow up items on Avrio budget, based on model outputs	1.20
03/10/20	DS	Work on Betadine sub products part of Avrio model	2.70
03/10/20	DS	Make Avrio model dynamic re: S&P spend and innovation products detail	2.80
03/10/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: case progress.	1.10
03/10/20	GJK	Call with I. McClatchey (Norton Rose), G. Koch, and J. Delconte (both AlixPartners) re: follow up	1.10
03/10/20	GJK	Mundipharma P V review.	2.50
03/10/20	GJK	Budget sales comparison for Mundipharma (provided by T Martin - Huron)	1.00
03/10/20	MH	Create accounts payable release file.	0.70
03/10/20	MH	Update all professional release table to reflect updates from legal operations on retention status.	0.90
03/10/20	IA	Update Avrio business plan presentation slides.	2.10
03/10/20	IA	Review submitted files and follow up on questions re: Rhodes merit increases.	1.40
03/10/20	IA	Follow up on pending payments to benefit vendors.	0.50
03/10/20	IA	Review updated retention tracker for Purdue employees.	1.30
03/10/20	IA	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to review and update draft slides	0.60
03/10/20	IA	Call with AHC and I. Arana (AlixPartners) to discuss open diligence requests.	0.50
03/10/20	KM	Meeting with V. Mancinelli, B. Thebeau, D. Fogel (all Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma CPP implementation	1.50
03/10/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Sublett (both AlixPartners) re: overall implementation progress and 10-year budget	
03/10/20	KM	Document revisions re: Rhodes Tech strategic partnerships	1.10
03/10/20	KM	Preparation for Org structure discussions	0.40
03/10/20	KM	Attend call with D. McGuire, D. Fogel, R. Shamblan, A. Soma (all Purdue), K. McCafferty, D Samikkannu, and R. Sublett (both AlixPartners) to discuss manufacturing organizational changes implementation planning (partial attendance)	1.70
03/10/20	KM	Call with A. Soma, D. Fogel, R. Shamblan (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes tech R&D implementation planning.	1.40
03/10/20	KM	Review and analysis re: Rhodes Pharma partnership opportunities	0.90
03/10/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes Pharma R&D implementation planning and Rhodes board presentation materials	1.00
03/10/20	KM	Preparation for CPP meeting	0.30
03/10/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss aggregated implementation plans for Rhodes	0.50
03/10/20	KM	Deck pages re: Rhodes Tech teaser	1.60
03/10/20	RDS	Meeting with V. Mancinelli, B. Thebeau, D. Fogel (all Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma CPP implementation	1.50
03/10/20	RDS	Historical Avrio spend with combined Purdue previously unallocated costs	0.40
03/10/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: overall implementation	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		progress and 10-year budget	
03/10/20	RDS	Slide creation - Avrio historical financials	0.80
03/10/20	RDS	Slide creation - Avrio Colace & Senokot media / S&P spend / savings analysis	0.80
03/10/20	RDS	Attend call with D. McGuire, D. Fogel, R. Shamblan, A. Soma (all Purdue), K. McCafferty, D Samikkannu, and R. Sublett (both AlixPartners) to discuss manufacturing organizational changes implementation planning	2.20
03/10/20	RDS	Call with A. Soma, D. Fogel, R. Shamblan (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes tech R&D implementation planning.	1.40
03/10/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss aggregated implementation plans for Rhodes	0.50
03/10/20	RDS	Correspondence with D. Lundie (Purdue) re: work stream planning updates	0.40
03/10/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes Pharma R&D implementation planning and Rhodes board presentation materials	1.00
03/10/20	RDS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to review and update draft slides	0.60
03/10/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: RELT meeting and presentation.	0.20
03/11/20	RDS	Call with N. Davis, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss months two dashboard update status and commentary	0.80
03/11/20	RDS	Slide creation - Avrio valuation and cash flow over time	1.20
03/11/20	RDS	Slide creation - Avrio historical financial observations	0.90
03/11/20	RDS	Slide creation - Avrio commercial S&P bridge & financial projection observations	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/11/20	RDS	Slide creation - teaser for Rhodes Tech partnership and strategic opportunities conversations	2.00
03/11/20	RDS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss Avrio presentation materials	0.70
03/11/20	RDS	Slide creation - Avrio case study for senokot gummy	0.80
03/11/20	RDS	Coordination of Avrio slide preparation - AlixPartners team	0.40
03/11/20	RDS	Slide creation - Avrio summary of innovation product launches and time / line chart to profitability / ROI	2.00
03/11/20	RDS	Avrio business plan presentation edits	0.50
03/11/20	RDS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to finalize Avrio presentation materials before sharing with PJT	0.50
03/11/20	RDS	Correspondence with AlixPartners team about data requests from Mundipharma	0.20
03/11/20	KM	Review of February dashboard	0.20
03/11/20	KM	Call with N. Davis, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss months two dashboard update status and commentary	0.80
03/11/20	KM	Research and analysis re: partnership API locations and competitive advantages	1.70
03/11/20	KM	Document editing and slide creation re: Rhodes Tech teaser	2.10
03/11/20	KM	Slide creation re: Rhodes Tech teaser	1.30
03/11/20	KM	Key Execs list for partnerships discussions	1.40
03/11/20	KM	Dashboard edits	0.80
03/11/20	IA	Review Avrio February sales report to be incorporated into Dashboard.	0.60
03/11/20	IA	Update Avrio dashboard to incorporate comments from	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management.	
03/11/20	IA	Follow up on pending payments to benefit providers through third party vendor.	0.60
03/11/20	IA	Review updated employee demographic and bonuses file prepared by human resources.	1.70
03/11/20	IA	Review updated Avrio PL allocations file for base and innovation products.	1.00
03/11/20	IA	Update business plan slides for Avrio board presentation to include refreshed financials.	2.30
03/11/20	IA	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to finalize Avrio presentation materials before sharing with PJT	0.50
03/11/20	IA	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss Avrio presentation materials	0.70
03/11/20	HK	Diligence call with L. Lee (Mundipharma Korea), G. Koch, and N. Simon (both AlixPartners).	1.00
03/11/20	MH	Call with E. Ruiz (Purdue), M. Hartley, H. Ku (both AlixPartners), and other company representatives to discuss potential pre-petition royalties' obligations.	0.60
03/11/20	MH	Create accounts payable release file.	0.70
03/11/20	GJK	Mundipharma diligence coordination including discussions with FTI	1.50
03/11/20	GJK	Diligence call with L. Lee (Mundipharma Korea), G. Koch, and N. Simon (both AlixPartners).	1.00
03/11/20	GJK	Mundipharma sales comparisons, including file from FTI	2.50
03/11/20	LJD	Prepare for and attend business plan call for LOE, history on ANDA challenges and BP implications with C. Landau, J. Lowne, M. Ronning (Purdue), J. DelConte and L Donahue (both AlixPartners).	1.50
03/11/20	LJD	Prepare for and attend meeting with C. Landau, J. Lowne,	1.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		M. Ronning (all Purdue), R. Schnitzler, J. Turner (both PJT), J. DelConte, and L. Donahue (both AlixPartners) re: Adhansia projections.	
03/11/20	LJD	Review staffing protocol and comment	0.40
03/11/20	DS	Revise Avrio model for base products numbers and numerous tabs	1.50
03/11/20	DS	Revise analysis on cannibalization and assumed base growth	1.40
03/11/20	DS	Put together analysis on laxative market and market share / growth rates	2.20
03/11/20	DS	Tie-out Avrio model to Avrio CFO's latest budget to ensure balances	2.60
03/11/20	DS	Review latest draft of Avrio materials	0.20
03/11/20	DS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss Avrio presentation materials	0.70
03/11/20	DS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to finalize Avrio presentation materials before sharing with PJT	0.50
03/11/20	JD	Review of draft pipeline presentation for Board of Directors with J. Delconte, N. Simon, and S. Lemack (all AlixPartners).	0.60
03/11/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.30
03/11/20	JD	Conversation with J. Lowne, E. Ruiz (both Purdue), J. Turner, R. Schnitzler (both PJT), and J. DelConte (AlixPartners) re: business plan scenarios.	0.50
03/11/20	JD	Meeting with C. Landau, J. Lowne, M. Ronning (all Purdue), R. Schnitzler, J. Turner (both PJT), J. DelConte, and L. Donahue (both AlixPartners) re: Adhansia projections.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/11/20	JD	Meeting with J. Lowne, C. Landau, M. Ronning (all Purdue), and J. DelConte (AlixPartners) re: customer outreach.	0.50
03/11/20	JD	Attend business plan call for LOE, history on ANDA challenges and BP implications with C. Landau, J. Lowne, M. Ronning (all Purdue), J. DelConte and L Donahue (both AlixPartners).	1.00
03/11/20	JD	Review OxyContin LOE and Adhansia presentations prior to meetings later this afternoon. Provide comments re: same.	0.80
03/11/20	JD	Continue analysis of Avrio forecasted S&P spending. Review modeling to date.	0.70
03/11/20	NAS	Review of draft pipeline presentation for Board of Directors with J. Delconte, N. Simon, and S. Lemack (all AlixPartners).	0.60
03/11/20	NAS	Prepare for diligence call with L. Lee (Mundipharma Korea).	0.40
03/11/20	NAS	Diligence call with L. Lee (Mundipharma Korea), G. Koch, and N. Simon (both AlixPartners).	1.00
03/11/20	NAS	Review updates to Mundipharma diligence process including new data requests and KPMG tax workstream update.	0.70
03/12/20	NAS	Assess current status of Mundipharma diligence process and coordinate with other advisors.	1.00
03/12/20	NAS	Diligence call with F. Bernard (Mundipharma Central/Eastern Europe), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.00
03/12/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: current status of Mundipharma diligence process and takeaways from recent diligence calls.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/12/20	NAS	Compare sales data across iterations of Mundipharma business plan to assess changes in trends and categorizations.	0.80
03/12/20	JD	Call with R. Sublett and J. DelConte (both AlixPartners) re: go forward business plan process.	0.30
03/12/20	JD	Call with D. Consla (Davis Polk), and J. DelConte (AlixPartners) re: general Chapter 11 timeline.	0.20
03/12/20	JD	Review pipeline asset presentation and provide comments to management.	0.60
03/12/20	JD	Review draft Chapter 11 timeline and create Chp. 11 glossary page to be provided to various managed care customers.	1.50
03/12/20	JD	Call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio. Partial attendance.	1.10
03/12/20	JD	Meeting with B. Weingarten (Purdue) and J. DelConte (AlixPartners) re: Avrio business plan.	0.60
03/12/20	JD	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	DS	Meeting with J. Tran (Purdue), D. Samikkannu, J. DelConte, R. Sublett, and I. Arana (all AlixPartners) to review operating model for Avrio.	0.50
03/12/20	DS	Call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio.	1.70
03/12/20	DS	Meeting with marketing analyst re: Betadine Gargle	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/12/20	DS	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	DS	Correspondence with S. Lemack (AlixPartners) re: status of Customer Programs report	0.30
03/12/20	DS	Put together financial analysis on historical - transition - budget, explaining trends and implications	2.20
03/12/20	DS	Assemble analysis on projected business plan cut into 3 types of product families	2.40
03/12/20	DS	Revise slide on commercial products cannibalization and growth rates	1.10
03/12/20	LJD	Review decks for business plan presentation and comment	0.90
03/12/20	GJK	Follow up on Canada gargle product with I. McClatchey (Norton Rose) and also pull relevant info for business planning team	0.50
03/12/20	GJK	Diligence call with F. Bernard (Mundipharma Central/Eastern Europe), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.00
03/12/20	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) re: current status of Mundipharma diligence process and takeaways from recent diligence calls.	0.30
03/12/20	MH	Create accounts payable release file.	0.70
03/12/20	MH	Analyze reporting options for tracking of professional payments using different date sources.	2.40
03/12/20	MH	Call with M. Hartley (AlixPartners) and counsel to review options to finalize the Ordinary Course Professional report.	0.50
03/12/20	GJK	Mundipharma diligence planning	2.50
03/12/20	HK	Update IAC diligence tracker with additions to the	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence data site.	
03/12/20	HK	Diligence call with F. Bernard (Mundipharma Central/Eastern Europe), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.00
03/12/20	IA	Update executive bios presentation as requested by legal in response to DOJ request.	1.70
03/12/20	IA	Review September to February OCP spend report and follow up on open items.	1.80
03/12/20	IA	Follow up on pending payments through third party vendor Benefit focus.	0.40
03/12/20	IA	Update Avrio business plan presentation slides.	2.80
03/12/20	IA	Meeting with J. Tran (Purdue), D. Samikkannu, J. DelConte, R. Sublett, and I. Arana (all AlixPartners) to review operating model for Avrio.	0.50
03/12/20	IA	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	IA	Prepare for and attend call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio.	1.70
03/12/20	IA	Review competitive brand and market share data for Avrio category competitors.	1.40
03/12/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review implementation planning workstream progress and plan for board presentation materials	1.80
03/12/20	KM	Rhodes Tech partnership list and review to Rhodes Tech executive team	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/12/20	KM	Call with R. Shamblen, P. Cheng, A. Soma (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review implementation plans for Rhodes Tech turnaround	1.90
03/12/20	KM	Analysis re: Rhodes Tech implementation timeline	0.30
03/12/20	KM	Call with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: debrief and Rhodes Tech planning	0.20
03/12/20	KM	Outline of Rhodes presentation to Board slides	0.80
03/12/20	KM	CPP implementation sequencing	0.60
03/12/20	KM	CPP analysis for Rhodes Pharma	0.80
03/12/20	RDS	Assemble and communicate daily workplan for Avrio business planning team	0.10
03/12/20	RDS	Review Purdue Canada financials for input to US Avrio business plan	0.40
03/12/20	RDS	Rhodes board material outline and agenda for D. Lundie (Purdue) call to discuss	0.40
03/12/20	RDS	Review Rhodes Tech R&D Implementation planning workstream and assemble comments for call with management	0.60
03/12/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review implementation planning workstream progress and plan for board presentation materials	1.80
03/12/20	RDS	Call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio.	1.70
03/12/20	RDS	Call with Avrio management to discuss betadine gargle data.	0.30
03/12/20	RDS	Slide creation - Betadine throat gargle case study	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/12/20	RDS	Avrio workstream implementation planning and S&P cutbacks	0.40
03/12/20	RDS	Meeting with J. Tran (Purdue), D. Samikkannu, J. DelConte, R. Sublett, and I. Arana (all AlixPartners) to review operating model for Avrio.	0.50
03/12/20	RDS	Call with R. Shamblen, P. Cheng, A. Soma (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review implementation plans for Rhodes Tech turnaround	1.90
03/12/20	RDS	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	RDS	Communication with BIC re: Avrio data to support business plan assumptions	0.20
03/12/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: go forward business plan process.	0.30
03/12/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: go forward business plan process.	0.30
03/13/20	RDS	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest Avrio business plan deck.	0.60
03/13/20	RDS	Review of latest Avrio 3.11.2020 operating plan adjustments	1.00
03/13/20	RDS	Slide creations - Avrio opening methodology walk through	0.60
03/13/20	RDS	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Ebere (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes Pharma R&D turnaround plan	1.80
03/13/20	RDS	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Pharma CPP discussions	
03/13/20	RDS	Review latest slides for J. Lowne (Purdue) presentation	0.40
03/13/20	RDS	Aggregate Avrio slides and provide final edits for distribution to management team	1.50
03/13/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to recap implementation meetings and plan for next weeks	1.10
03/13/20	RDS	Review of market research for Avrio / consumer health businesses	1.10
03/13/20	KM	Analysis re: Rhodes Pharma allocation of resources and key execs	1.20
03/13/20	KM	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Ebere (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes Pharma R&D turnaround plan	1.80
03/13/20	KM	Review of CPP analysis	0.20
03/13/20	KM	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes Pharma CPP discussions	1.00
03/13/20	KM	Analysis re: CPP implementation plan	0.30
03/13/20	KM	Analysis and restructuring of the CPP implementation plan	0.90
03/13/20	KM	Summary of implementation progress for discussion with D. Lundie (Purdue)	0.70
03/13/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to recap implementation meetings and plan for next weeks.	1.10
03/13/20	IA	Review proposed benefit program overview presentation.	0.80
03/13/20	IA	Review updated employee demographic information source file submitted by human resources.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/13/20	IA	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest Avrio business plan deck.	0.60
03/13/20	IA	Update Avrio slides for business plan presentation to client.	1.60
03/13/20	IA	Review cash report for week ended 03/13.	1.30
03/13/20	IA	Review monthly flash report and follow up on open items for January.	1.40
03/13/20	HK	Diligence call with S. Kimura (GM, Mundipharma Japan), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.50
03/13/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.70
03/13/20	GJK	Mundipharma model review and coordination	2.20
03/13/20	MH	Create accounts payable release file.	0.70
03/13/20	MH	Call with M. Hartley (AlixPartners) and legal operations to discuss ordinary course exceptions and identify better data source.	0.70
03/13/20	MH	Revise all professional payment reporting to align with Team Connect data source.	2.70
03/13/20	GJK	Diligence call with S. Kimura (GM, Mundipharma Japan), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.50
03/13/20	LJD	Call with company management re: staffing update and working on locations	0.30
03/13/20	LJD	Coordination call with T. Coleman (PJT)	0.60
03/13/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners)	0.40
03/13/20	DS	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Avrio business plan deck.	
03/13/20	DS	Refine consumer health comparative analysis, utilizing CapIQ data	1.10
03/13/20	DS	Edit Senokot Kiwi scenario analysis for Avrio business plan	0.90
03/13/20	DS	Enhance Avrio working capital analysis for use of business plan presentation	1.20
03/13/20	DS	Enhance Avrio working capital analysis for use of business plan Create appendix detailed pro forma historical analysis of gross profit and S&P components	2.20
03/13/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business planning progress.	0.20
03/13/20	JD	Call with J. Lowne and others (all Purdue) and J. DelConte (AlixPartners) re: business planning open items and scheduled time to finish.	0.50
03/13/20	JD	Prepare for and participate in a call with R. Aleali, E. Ruiz (both Purdue), S. Brecher (Davis Polk), and J. DelConte (AlixPartners) re: PBGC response.	0.50
03/13/20	JD	Review historical PBGC correspondence and open diligence questions.	0.70
03/13/20	JD	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest Avrio business plan deck.	0.60
03/13/20	JD	Review and provide comments to management on the updated Adhansia slides.	0.50
03/13/20	JD	Review, provide comments and edit the latest Avrio business plan slides.	1.40
03/13/20	JD	Review and provide comments on the January flash report.	0.40
03/13/20	NAS	Prepare for Mundipharma Japan diligence call.	0.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/13/20	NAS	Diligence call with S. Kimura (GM, Mundipharma Japan), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.50
03/14/20	JD	Review comments from J. Lowne (Purdue) to draft Avrio business plan presentation.	0.60
03/14/20	RDS	Review Rhodes quality organization implementation plans	0.60
03/14/20	RDS	Review J. Lowne (Purdue) comments to Avrio presentation materials	0.30
03/15/20	RDS	Review PJT slides for Avrio presentation	0.30
03/15/20	RDS	Slide presentation edits for Monday Avrio presentation	0.90
03/15/20	RDS	Review latest comments from Purdue CFO to Avrio materials	0.30
03/15/20	DS	Correspondence with J. DelConte (AlixPartners) re: cannibalization assumptions in analysis	0.20
03/15/20	DS	Follow up with Head of Finance (Purdue) re: G&A assumptions in business plan beyond 2020	0.30
03/15/20	DS	Incorporate Purdue CFO's comments into Avrio business plan deck	2.40
03/15/20	LJD	Review correspondence	0.30
03/15/20	LJD	Review and discuss Oxycontin patent overview slides	0.70
03/15/20	IA	Update Avrio business plan slides to reflect latest comments from management.	2.40
03/15/20	IA	Update Avrio dashboard to show February net sales by brand by product.	1.10
03/15/20	IA	Consolidate update slides from AlixPartners and PJT for Avrio business plan presentation for review by management.	0.70
03/16/20	IA	Draft executive committee bios and job history as requested by DOJ.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/16/20	IA	Update Purdue retention tracker to include updated demographic information and latest additions to program.	1.80
03/16/20	IA	Update AIP and LTRP database to include updated 2020 demographic data by employee, as requested by WTW.	1.40
03/16/20	IA	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	1.20
03/16/20	HK	Review IAC projected balance sheet data.	1.60
03/16/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.20
03/16/20	LJD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: case work stream coordination and business plan progress.	0.40
03/16/20	LJD	Review and comment on interim fee app	0.60
03/16/20	LJD	Review draft avrio business plan presentation and comment	1.50
03/16/20	MH	Create accounts payable release file.	0.70
03/16/20	GJK	Call with I. McClatchy (Norton Rose) re: Mundipharma diligence	2.50
03/16/20	GJK	Mundipharma document review	1.00
03/16/20	DS	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	1.20
03/16/20	DS	Working session with D. Samikkannu and S. Lemack (both AlixPartners) re: allocation of 3rd party rebate funding's and payments	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/16/20	DS	Update Avrio business plan draft materials with comments from Purdue CFO	0.80
03/16/20	DS	Correspondence with Head of Finance (Purdue) re: historical period needed for market share data	0.20
03/16/20	DS	Draft workplan and share with I. Arana (AlixPartners) and Head of Finance (Purdue) re: completing draft of Avrio business plan materials	0.50
03/16/20	DS	Review of historical market share data sent by Head of Finance Avrio	0.70
03/16/20	DS	Draft detailed list of to-do items based on Avrio business plan meeting	1.30
03/16/20	JD	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	1.20
03/16/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio and Rhodes business plan progress.	0.40
03/16/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: Avrio business plan.	0.20
03/16/20	JD	Correspondence with J. Tran and J. Lowne (both Purdue) re: open Avrio questions.	0.40
03/16/20	JD	Review and provide comments on draft Avrio business plan analysis and presentation.	2.00
03/16/20	JD	Correspondence with C. Robertson (Davis Polk) and J. Turner (PJT) re: Nalmefene consultant.	0.30
03/16/20	JD	Create tracker and forecast for restructuring professional fees and compare to latest business plan forecast.	2.10
03/16/20	JD	Review draft Oncology business plan presentation.	1.10
03/16/20	RDS	Meeting with J. Norhtington, D. Fogel (both Purdue), K.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty, and R. Sublett (both AlixPartners) re: Quality organization implementation plan.	
03/16/20	RDS	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updated CPP implementation plan	0.50
03/16/20	RDS	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	1.20
03/16/20	RDS	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Ebere, (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updates to implementation planning for Rhodes Pharma R&D turnaround plan	1.10
03/16/20	RDS	Assemble AlixPartners version of shortened Avrio business plan presentation	0.30
03/16/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	0.60
03/16/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	1.70
03/16/20	RDS	Call with R. Haberlin, D. Fogel, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Hydromorphone CPP analysis needs and requirements	0.80
03/16/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio and Rhodes business plan progress.	0.40
03/16/20	RDS	Analysis of Dilaudid AG CPP (Purdue)	0.80
03/16/20	RDS	Assemble slides for RELT meeting to discuss Rhodes Pharma CPP	0.60
03/16/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners)	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: customer classification for hydroprophone analysis	
03/16/20	KM	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updated CPP implementation plan	0.50
03/16/20	KM	Analysis re: hydromorphone volume by customer	1.10
03/16/20	KM	Gap analysis re: Rhodes Pharma R&D implementation plan	0.70
03/16/20	KM	Coordination and correspondence re: status of Rhodes turnaround implementation planning	0.20
03/16/20	KM	Meeting with J. Norhtington, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Quality organization implementation plan.	1.00
03/16/20	KM	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Ebere, (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updates to implementation planning for Rhodes Pharma R&D turnaround plan	1.10
03/16/20	KM	Analysis and slide creation re: CPP implementation plan	0.80
03/16/20	KM	Meeting with V. Mancinelli, K. Kolar, D. Ebere, D. Fogel (all Purdue), and K. McCafferty (AlixPartners) re: Rhodes Pharma implementation plan review	1.10
03/16/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	0.60
03/16/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	1.70
03/16/20	KM	Call with R. Haberlin, D. Fogel, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Hydromorphone CPP analysis needs and requirements	0.80
03/16/20	KM	Slide creation re: CPP implementation plan	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/16/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) re: customer classification for hydroprophone analysis	0.10
03/17/20	KM	Analysis re: CPP approach and impact	1.20
03/17/20	KM	Slide creation re: CPP approach and impact	0.90
03/17/20	KM	Meeting with K. McCafferty and R. Sublett (both AlixPartners) re: implementation planning	0.70
03/17/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning workstreams ahead of RELT workshop Wednesday / Thursday	1.80
03/17/20	KM	Meeting with R. Haberin, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: CPP analysis and financial impact	0.70
03/17/20	KM	Slide edits re: CPP financial impact	0.30
03/17/20	KM	Meeting with K. McCafferty and R. Sublett (both AlixPartners) to assemble questions for RELT meetings for D. Lundie (Purdue)	2.40
03/17/20	KM	Reconciliation re: Rhodes Pharma R&D implementation plan	0.40
03/17/20	ADD	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan due diligence responses.	1.10
03/17/20	RDS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss changes to Avrio business plan presentation	0.40
03/17/20	RDS	Work on RELT meeting presentation for Rhodes Pharma CPP	0.80
03/17/20	RDS	Slide creation - Avrio presentation S&P, net sales CAGR	0.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		bridge	
03/17/20	RDS	Meeting with K. McCafferty and R. Sublett (both AlixPartners) re: implementation planning	0.70
03/17/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning workstreams ahead of RELT workshop Wednesday / Thursday	1.80
03/17/20	RDS	Review latest turn of Avrio presentation materials and aggregate comments	0.20
03/17/20	RDS	Meeting with R. Haberin, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: CPP analysis and financial impact	0.70
03/17/20	RDS	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	RDS	Modeling of CPP scenarios for Rhodes	0.30
03/17/20	RDS	Analysis of pro forma bridge for historical Avrio financials	0.50
03/17/20	RDS	Meeting with K. McCafferty and R. Sublett (both AlixPartners) to assemble questions for RELT meetings for D. Lundie (Purdue)	2.40
03/17/20	RDS	Avrio presentation tweaks ahead of pre-read	1.60
03/17/20	JD	Review and work on latest Avrio business plan presentation.	1.00
03/17/20	JD	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	JD	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan due diligence responses.	1.10
03/17/20	JD	Review Ad Hoc committee due diligence questions,	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		proposed responses and materials provided to date.	
03/17/20	JD	Call with J. DelConte (AlixPartners) and J. Lowne (Purdue) re: Avrio business plan presentation progress.	0.60
03/17/20	JD	Update and finalize generic Chapter 11 timeline for the commercial group and their customer outreach.	1.50
03/17/20	JD	Review draft version of the Oncology asset analysis. Review draft Oncology presentation. Provide comments re: same.	0.70
03/17/20	DS	Revise Avrio business plan materials for revised numbers	1.80
03/17/20	DS	Review analysis on SG&A and G&A changes to plan	0.80
03/17/20	DS	Create a "Pre-Read" version of Avrio business plan materials and send to Purdue CFO	0.80
03/17/20	DS	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	DS	Prepare pro forma historical Avrio analysis incorporating adjustments along the P&L	2.40
03/17/20	DS	Call with Head of Finance (Purdue) re: pro forma historical adjustments	0.80
03/17/20	DS	Revise Avrio working capital / free cash flow analysis for updated working capital assumptions developed with Purdue CFO	1.30
03/17/20	DS	Revise AlixPartners's Avrio model for new set of numbers	0.60
03/17/20	DS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss changes to Avrio business plan presentation	0.40
03/17/20	DS	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan due diligence responses.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/17/20	NAS	Revise branded opioid and Adhansia business plan slides in advance of Board meeting.	2.60
03/17/20	GJK	Mundipharma diligence, planning and analysis including next steps with/without Deutsche Bank meetings	3.00
03/17/20	MH	Create accounts payable release file.	0.70
03/17/20	MH	Prepare for call with legal operations on Ordinary Course Professional tracking.	1.10
03/17/20	MH	Research signed trade agreement to ensure proper UCC approval and correct accounts payable controls.	0.40
03/17/20	MH	Rebuild the Ordinary Course Professional report to tie to details from Team Connect.	2.90
03/17/20	MH	Build algorithm to assign correct period and category to Team Connect billing details for Ordinary Course Professional tracking.	2.70
03/17/20	LJD	Review deck for Wednesday presentation and discussion	1.50
03/17/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.20
03/17/20	HK	Review IAC projected cash flow data.	2.10
03/17/20	IA	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	IA	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan due diligence responses.	1.10
03/17/20	IA	Follow up on pending payments to benefit vendors.	0.30
03/17/20	IA	Update Avrio slides to reflect changes requested by management.	1.90
03/17/20	IA	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss changes to Avrio business plan	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		presentation	
03/18/20	IA	Follow up on pending payments to benefit vendors.	0.40
03/18/20	IA	Update Executive committee bios and job history based on job descriptions provided by human resources, as requested by DOJ.	1.90
03/18/20	IA	Follow up on updated Purdue budget files to be incorporated into Purdue cash forecast.	0.30
03/18/20	IA	Update Avrio business plan slides to include latest updated financials.	1.40
03/18/20	IA	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60
03/18/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.10
03/18/20	LJD	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback.	0.60
03/18/20	LJD	Participate in call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, M. Ronning (all Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: Oncology asset forecast.	1.60
03/18/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: catch up on business planning and case progress.	0.40
03/18/20	LJD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau (both Purdue), J. DelConte and L. Donahue (AlixPartners) re: PHI and Pipeline asset forecasts.	1.10
03/18/20	MH	Create accounts payable release file.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/18/20	MH	Research new pre-petition invoice for trade agreement vendor to determine correct payment treatment.	0.50
03/18/20	GJK	Court call re: Purdue filing and implications for IAC diligence	3.00
03/18/20	GJK	Follow up post Court call, including priority steps and messaging	1.00
03/18/20	MH	Call with M. Hartley and K. McCafferty (both AlixPartners) re: Rhodes EI program activities	0.30
03/18/20	NAS	Revise branded opioid and Adhansia business plan slides for Board presentation.	0.70
03/18/20	DS	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60
03/18/20	DS	Conform CFO's latest version of Avrio business plan deck with March 17 numbers	1.90
03/18/20	JD	Participate in call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, M. Ronning (all Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: Oncology asset forecast.	1.60
03/18/20	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne (Purdue), and J. DelConte (AlixPartners) re: Oncology forecast.	0.50
03/18/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: catch up on business planning and case progress.	0.40
03/18/20	JD	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/18/20	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau (both Purdue), J. DelConte and L. Donahue (AlixPartners) re: PHI and Pipeline asset forecasts.	0.70
03/18/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: Oncology forecast.	0.30
03/18/20	JD	Review updated Avrio business plan presentation.	0.80
03/18/20	JD	Call with R. Schnitzler (PJT) and J. DelConte (AlixPartners) re: business plan issues.	0.20
03/18/20	JD	Review draft customer programs motion and provide comments.	0.30
03/18/20	RDS	Assemble Gantt chart to guide budget variance discussion with RELT	1.70
03/18/20	RDS	Meeting with D. Fogel (Purdue) K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes implementation milestones and budgeted impact	0.50
03/18/20	RDS	Rhodes Executive Leadership Team (RELT) R&D meeting (virtual/WebEx)	3.60
03/18/20	RDS	Assemble summary document for D. Lundie (Purdue) to guide discussions at day 2 of the RELT	1.00
03/18/20	RDS	Address Avrio presentation questions	0.60
03/18/20	RDS	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60
03/18/20	RDS	Recap D. Lundie (Purdue) and RELT R&D Discussion	0.20
03/18/20	RDS	Call with J. Lowne, D. Fogel, W. DiNicola, R. Haberman (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to preview updated scenario planning for five-year plan	0.60
03/18/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners)	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		to discuss board slide outline	
03/18/20	KM	RELT implementation planning	1.00
03/18/20	KM	Call with M. Hartley and K. McCafferty (both AlixPartners) re: Rhodes EI program activities	0.30
03/18/20	KM	Rhodes implementation milestones and budgeted impact summary	0.90
03/18/20	KM	Meeting with D. Fogel (Purdue) K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes implementation milestones and budgeted impact	0.50
03/18/20	KM	Review Rhodes project review meeting materials	0.30
03/18/20	KM	Rhodes project review meeting hosted by D. Lundie (Purdue)	4.00
03/18/20	KM	Meeting with D. Lundie (Purdue) and K. McCafferty (AlixPartners) re: RELT meeting preparation	0.50
03/18/20	KM	Background and incremental analyses re: RELT meeting preparation	0.40
03/18/20	KM	Call with J. Lowne, D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to preview updated scenario planning for five-year plan	0.60
03/19/20	KM	Coordination and correspondence re: status of Rhodes turnaround implementation planning	1.30
03/19/20	KM	Rhodes Executive Leadership Team meeting with R. Shamblen, V. Mancinelli, D. Fogel, D. McGuire, J. Northington (all Purdue), K. McCafferty and R. Sublett (AlixPartners) to discuss turnaround implementation plans.	3.90
03/19/20	KM	Recap on RELT meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) and design next steps for big four management meetings	1.00
03/19/20	KM	Deck outline and storyline re: Rhodes presentation to the	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Board	
03/19/20	KM	Analysis and slide creation re: Rhodes presentation to the Board	1.40
03/19/20	KM	Analysis variance re: Rhodes presentation to the Board	1.60
03/19/20	RDS	Rhodes Executive Leadership Team meeting with R. Shamblen, V. Mancinelli, D. Fogel, D. McGuire, J. Northington (all Purdue), K. McCafferty and R. Sublett (both AlixPartners) to discuss turnaround implementation plans	3.90
03/19/20	RDS	Updated RELT review slides for David Lundie	0.30
03/19/20	RDS	Recap on RELT meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) and design next steps for big four management meetings	1.00
03/19/20	RDS	Slide creation - shell for Rhodes Board materials, dashboard and Appendix slides	2.20
03/19/20	RDS	Correspondence with R. Schnitzler (PJT) re: Avrio financials	0.30
03/19/20	RDS	Slide creation - Rhodes board presentation; Butrans market share and impact to Rhodes budget	1.80
03/19/20	RDS	Slide creation - Rhodes board presentation financial scenario modeling and bridges	0.90
03/19/20	DS	Update Avrio business plan deck for latest numbers	1.10
03/19/20	DS	Call with Head of Finance (Purdue) re: cost structure prior to current sales/operations provider	0.40
03/19/20	DS	Correspondence with PJT re: providing latest numbers in business plan	0.30
03/19/20	NAS	Review of new files posted in Mundipharma diligence data room, including guide to accounting treatment.	1.30
03/19/20	NAS	Correspondence with B. Bromberg (FTI) and analysis of data provided re: new data from Mundipharma/Huron.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/19/20	NAS	Meeting with J. DelConte, N. Simon, and S. Lemack (all AlixPartners) to discuss revisions to Purdue business plan slides for upcoming Board meeting.	0.90
03/19/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to provide update on latest developments in Mundipharma diligence process.	0.40
03/19/20	NAS	Inventory of available Mundipharma data and analysis of how data can be incorporated into Mundipharma business plan model.	0.90
03/19/20	NAS	Revise Purdue business plan slides for upcoming Board meeting following discussion with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	0.40
03/19/20	JD	Meeting with J. DelConte, N. Simon, and S. Lemack (all AlixPartners) to discuss revisions to Purdue business plan slides for upcoming Board meeting	0.90
03/19/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: open business plan questions.	0.20
03/19/20	JD	Review draft Opioid, PHI and Pipeline presentation edits. Provide comments re: same.	1.00
03/19/20	JD	Review and edit draft HRT presentation and draft court declaration in order to prepare it to be shared with outside advisors.	1.80
03/19/20	JD	Participate in a call with C. Landau, M. Kesselman, J. Lowne (all Purdue), M. Huebner, T. Graulich (both Davis Polk), T. Coleman, J. O'Connell (both PJT), J. DelConte, and L. Donahue (both AlixPartners) re: case update and go forward planning call.	1.20
03/19/20	JD	Review and provide comments re: draft January flash report.	0.70
03/19/20	JD	Call with J. Turner (PJT) and J. DelConte (AlixPartners) re: go forward Thursday meetings.	0.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/19/20	GJK	Call with G. Koch (AlixPartners), I. McClatchy (Norton Rose), and B. Bromberg (FTI) re: Mundipharma diligence process	2.00
03/19/20	GJK	Follow up and document review per FTI and Huron emails	1.60
03/19/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to provide update on latest developments in Mundipharma diligence process.	0.40
03/19/20	MH	Create accounts payable release file.	0.70
03/19/20	MH	Call with counsel to discuss next steps on legal firm that may have exceeded the OCP cap.	0.40
03/19/20	LJD	Prepare for and attend update call with advisors and management	1.20
03/19/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.30
03/19/20	SKL	Meeting with J. Delconte, S. Lemack, and N. Simon (all AlixPartners) to discuss revisions to Purdue business plan slides for upcoming Board meeting.	0.90
03/19/20	SKL	Begin review of the latest version of the Purdue business plan slides and begin updating accordingly to ensure consistent format throughout.	2.10
03/19/20	IA	Review follow up questions on Avrio business plan slides received from management.	1.10
03/19/20	IA	Review position history and job descriptions submitted for executive committee members as requested by legal in response to DOJ request.	1.20
03/19/20	IA	Update Avrio business plan slides to reflect financials adjusted for innovation growth in outer years of forecast.	1.80
03/19/20	IA	Review updated Avrio business plan presentation, now including updated slides showing latest financials	1.60
03/20/20	IA	Review updated AIP and LTRP database created for Willis	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Towers Watson and update with new hires eligible for payments in 2021	
03/20/20	IA	Review submitted additional job descriptions for executive committee members and update summary file in response to DOJ diligence request	2.40
03/20/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.60
03/20/20	LJD	Prepare for and attend opioid assumptions for revenue sensitivities call with management and advisors	1.10
03/20/20	MH	Create accounts payable release file.	0.70
03/20/20	GJK	Catch up call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence.	0.20
03/20/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: key outputs from Mundipharma business plan model for interim report.	0.80
03/20/20	GJK	Mundipharma diligence and analysis	2.30
03/20/20	GJK	Mundipharma diligence coordination and planning	1.50
03/20/20	NAS	Revise Mundipharma business plan model to incorporate G&A and indirect R&D.	2.30
03/20/20	NAS	Reconcile P&L line items included in two types of Mundipharma P&Ls provided by Management Revisions and incorporate those which are missing in business plan model.	3.40
03/20/20	NAS	Summarize findings from revisions to-date to Mundipharma business plan model for G. Koch (AlixPartners).	0.50
03/20/20	NAS	Assess data received from Mundipharma to-date and determine how to bridge between data sources in business plan model.	1.10
03/20/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners)	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: key outputs from Mundipharma business plan model for interim report.	
03/20/20	NAS	Create list of action items and determine best approach towards revising Mundipharma model following discussion with G. Koch (AlixPartners).	0.40
03/20/20	NAS	Conference call with J. DelConte, N. Simon (both AlixPartners), J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, and M. Kesselman (all Purdue) to review branded opioid business plan.	1.20
03/20/20	DS	Review latest draft of Avrio deck and provide revised copy to management, PJT	1.30
03/20/20	DS	Update Avrio deck to include detail on retail sales	0.20
03/20/20	DS	Further revise Avrio business plan deck based on comments from Head of Finance (Purdue)	1.50
03/20/20	JD	Call with J. Lowne, D. Fogel, D. Lundie (all Purdue), J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) to preview board presentation materials.	1.10
03/20/20	JD	Review and provide comments on the branded opioid business plan presentation.	0.70
03/20/20	JD	Review and provide comments on the Rhodes business plan presentation and analysis.	0.70
03/20/20	JD	Review final January flash report to send out for approval to post.	0.40
03/20/20	JD	Conference call with J. DelConte, N. Simon (both AlixPartners), J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, and M. Kesselman (all Purdue) to review branded opioid business plan.	1.20
03/20/20	JD	Call with J. DelConte (AlixPartners), J. Lowne (Purdue), J. Turner, R. Schnitzler (both PJT) re: Adhansia LOE.	0.50
03/20/20	JD	Catch up call with G. Koch and J. DelConte (both	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: IAC diligence.	
03/20/20	RDS	Slide creation - Rhodes board presentation; Butrans Appendix detail	1.00
03/20/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss revised board presentation	1.40
03/20/20	RDS	Slide creation - low/base/high and plant closure slides	0.50
03/20/20	RDS	Call with N. Davis (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss dashboard updates	0.40
03/20/20	RDS	Review and changes to Avrio board presentation per updated 3.17.20 financial update	0.60
03/20/20	RDS	Call with J. Lowne, D. Fogel, D. Lundie (all Purdue), J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) to preview board presentation materials	1.10
03/20/20	RDS	Continue edits to board presentation for Rhodes board materials and Rhodes Tech partnership update and implementation Gantt chart	2.20
03/20/20	KM	Storyboard and planning re: Rhodes presentation to the Board	0.60
03/20/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss revised board presentation.	1.40
03/20/20	KM	Butrans edits re: Rhodes presentation to the Board	0.70
03/20/20	KM	Call with N. Davis (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss dashboard updates	0.40
03/20/20	KM	Coordination and correspondence re: status of Rhodes turnaround implementation planning	0.30
03/20/20	KM	Deck edits re: Rhodes presentation to the Board	0.50
03/20/20	KM	Call with J. Lowne, D. Fogel, D. Lundie (all Purdue), J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) to preview board presentation materials	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/20/20	KM	Dashboard slide creation and updates re: Rhodes presentation to the Board	0.40
03/20/20	KM	Deck edits and improvements re: Rhodes presentation to the Board	0.60
03/20/20	KM	Partnership analysis re: Rhodes presentation to the Board	0.60
03/21/20	RDS	Updates to Avrio board presentation including J. Lowne, J. Tran (both Purdue) updates to language and projections	0.90
03/21/20	DS	Further revise Avrio business plan deck and send to management and PJT	1.10
03/21/20	IA	Review April retention payments information by employee to be submitted by HR to payroll.	0.60
03/22/20	IA	Update executive bios and add position timeline tables to slides in executive committee summary file in response to DOJ diligence request	1.70
03/22/20	DS	Review CFO's comments on Avrio draft deck	0.50
03/22/20	JD	Review and provide comments on the latest Adhansia presentation before tomorrow's meetings.	1.10
03/23/20	DS	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and Avrio VP Finance re: updating business plan numbers	0.30
03/23/20	DS	Create schedule summarizing topline changes to prior plan	1.20
03/23/20	DS	Update model for revised numbers	2.70
03/23/20	DS	Review revised numbers in detail providing comments to VP Finance	2.90
03/23/20	DS	Review and provide comments to S. Lemack (AlixPartners) on weekly cash report	0.90
03/23/20	DS	Draft detailed email to VP Finance (Purdue) re: further changes needed to be made with revised numbers	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/23/20	JD	Review and provide comments on different Adhansia financial sensitivities.	0.80
03/23/20	JD	Review and provide comments on updated Avrio analysis and forecast.	0.80
03/23/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.30
03/23/20	JD	Call with J. Lowne (Purdue), J. Turner, R. Schnitzler (both PJT), and J. DelConte (AlixPartners) re: Adhansia business plan.	0.50
03/23/20	JD	Call with J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner, R. Schnitzler, J. O'Connell (all PJT), L. Donahue, and J. DelConte (both AlixPartners) re: Adhanisa business plan.	0.70
03/23/20	JD	Call with J. Lowne, C. Landau, D. Lundie (all Purdue), J. Turner, R. Schnitzler (both PJT), R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes business plan.	1.00
03/23/20	JD	Meeting with J. Lowne (Purdue), J. Turner, R. Schnitzler (both PJT), and J. DelConte (AlixPartners) re: final business plan presentation.	0.30
03/23/20	JD	Review latest Rhodes slides.	0.20
03/23/20	JD	Call with C. Landau, D. Lundie, M. Kessleman, J. Lowne, D. Fogel (all Purdue), J. DelConte, and R. Sublett (all AlixPartners) to present the Gx business plan.	1.40
03/23/20	JD	Review and comment on Adhansia projections, scenario analyses and draft presentation.	1.30
03/23/20	JD	Review final January flash report and correspondence with R. Aleali (Purdue) re: same.	0.40
03/23/20	NAS	Set priorities and action items related to Mundipharma diligence for week of 3/23.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/23/20	NAS	Review prior Purdue business plan presentations to Board for purposes of drafting materials for upcoming Board meeting.	0.30
03/23/20	NAS	Draft and send follow-up questions to S. Jamieson (Management Revisions) re: Mundipharma data provided.	1.20
03/23/20	NAS	Pull data from source files and revise Mundipharma business plan model to include functionality for intercompany eliminations.	2.10
03/23/20	NAS	Add P&Ls for adjusting journal entries and central functions to Mundipharma business plan model.	3.00
03/23/20	IA	Update executive bios and employment history overview deck in response to DOJ request.	1.70
03/23/20	IA	Review updated innovation PLs for Avrio reallocating growth reductions to Senokot gummies.	1.20
03/23/20	IA	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and Avrio VP Finance re: updating business plan numbers	0.30
03/23/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.60
03/23/20	MH	Create accounts payable release file.	0.70
03/23/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: business plan and team coordination.	0.70
03/23/20	LJD	Preview adhansia plan	1.10
03/23/20	LJD	Review correspondence	0.50
03/23/20	GJK	Mundipharma diligence and projection planning	3.00
03/23/20	GJK	Mundipharma sales trends and markets review	2.50
03/23/20	RDS	Update dashboard and sensitivity analysis for Rhodes business plan	0.90
03/23/20	RDS	Correspondence re: updated Rhodes budget figures	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/23/20	KM	Edits for Rhodes deck for Board meeting	0.70
03/23/20	KM	Analysis of recent IQVIA data and methylphenidate market share data	0.60
03/23/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: methylphenidate analysis	0.40
03/23/20	KM	Analysis and slide creation re: change in methylphenidate market	1.90
03/23/20	KM	Call with D. Fogel, D. Lundie (both Purdue), R. Sublett and K. McCafferty (AlixPartners) re. Rhodes presentation to the Board and C. Landau (Purdue) discussion	1.80
03/23/20	KM	Update presentation re: Rhodes presentation to the Board and C. Landau (Purdue) discussion	0.90
03/23/20	KM	Dashboard slide development re: Rhodes presentation to the Board and C. Landau (Purdue) discussion	1.30
03/23/20	KM	Call with D. Fogel, D. Lundie, J. Lowne, C. Landau, M. Kesselman, B. Weingarten (all Purdue), and K. McCafferty (AlixPartners) re: Rhodes deck for presentation to the Board	1.00
03/23/20	KM	Board deck edits re: Rhodes deck for presentation to the Board	0.90
03/23/20	RDS	Update to Rhodes board presentation to reflect Methylphenidate and changes to the pipeline	0.50
03/23/20	RDS	Avrio financial restatements	0.20
03/23/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to discuss Methylphenidate	0.50
03/23/20	RDS	Update presentation to reflect Methylphenidate forecast updates	2.30
03/23/20	RDS	Call with D. Fogel, D. Lundie (both Purdue), R. Sublett and K. McCafferty (both AlixPartners) re. Rhodes presentation to the Board and C. Landau (Purdue)	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		discussion	
03/23/20	RDS	Call with J. Lowne, C. Landau, D. Lundie (all Purdue), J. Turner, R. Schnitzler (both PJT), R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes business plan.	1.00
03/23/20	RDS	Assemble materials for call with C. Landau (Purdue)	1.10
03/23/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: methylphenidate analysis	0.40
03/23/20	RDS	Call with C. Landau, D. Lundie, M. Kessleman, J. Lowne, D. Fogel (all Purdue), J. DelConte, and R. Sublett (all AlixPartners) to present the Gx business plan	1.40
03/24/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss management changes to board presentation	1.50
03/24/20	KM	Coordination of Rhodes partnership planning effort	0.50
03/24/20	KM	Analysis and review of Butrans and Methylphenidate impact to budget	1.90
03/24/20	KM	Board deck edits re: Rhodes deck for presentation to the Board	0.80
03/24/20	KM	Slide editing for Board deck	0.80
03/24/20	KM	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	KM	Deck edits re: Rhodes implementation progress and Board report	0.50
03/24/20	KM	Rhodes org synergies implementation plan and targeting	0.60
03/24/20	KM	Rhodes budget cash flow bridge analysis	0.90
03/24/20	KM	Slide edits re: Rhodes implementation progress and Board report	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/24/20	RDS	Review changes to board presentation by D. Lundie (Purdue)	0.50
03/24/20	RDS	Execute D. Lundie (Purdue) edits to Rhodes board presentation	0.40
03/24/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to review changes to Rhodes board presentation	0.40
03/24/20	RDS	Draft email outreach drafts for potential strategic partners to Rhodes Tech	1.60
03/24/20	RDS	Changes to Rhodes Tech teaser presentation	0.80
03/24/20	RDS	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	RDS	Review Rhodes business plan assumptions	0.50
03/24/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss management changes to board presentation	1.50
03/24/20	RDS	Edits to board presentation for Rhodes	1.20
03/24/20	RDS	Review amended Avrio board presentation and update executive summary version	1.50
03/24/20	LJD	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	MH	Create accounts payable release file.	0.70
03/24/20	MH	Research petition status on bonus payments to contracted sales force.	0.80
03/24/20	GJK	Mundipharma report outline review	1.50
03/24/20	GJK	Mundipharma trends analysis	2.00
03/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, R. Schnitzler, and J. Arsic (all PJT) to discuss status of	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma diligence/model and discuss scenarios to run.	
03/24/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.30
03/24/20	IA	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Wang (PJT) re: revised numbers	0.30
03/24/20	IA	Review insider payments based on latest estimate of LTI grant factors.	0.60
03/24/20	IA	Review latest Avrio PL allocations by innovation adjusted for Gummies growth.	1.40
03/24/20	IA	Update Avrio slides based on latest Avrio PL allocations by innovation adjusted for Gummies growth.	1.40
03/24/20	NAS	Evaluate current state of Mundipharma business plan model and plan out revisions.	0.40
03/24/20	NAS	Review latest draft of Adhansia presentation for Purdue management for summary slides to go to Board.	0.60
03/24/20	NAS	Create consolidated tab in Mundipharma business plan model for all commercial regions, central costs, and intercompany eliminations/adjustments.	1.20
03/24/20	NAS	Document data sources for all inputs to Mundipharma business plan model, build check functionality relative to raw data, and resolve all discrepancies.	2.80
03/24/20	NAS	Prepare for Mundipharma diligence status update call with PJT.	0.30
03/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, R. Schnitzler, and J. Arsic (all PJT) to discuss status of Mundipharma diligence/model and discuss scenarios to run.	0.50
03/24/20	NAS	Create plan to implement specific scenarios in Mundipharma business plan model following discussion	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		with PJT.	
03/24/20	JD	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	JD	Review and provide comments on final branded opioid presentation.	1.00
03/24/20	JD	Review latest draft PHI and pipeline slides for incorporation into the overall board business plan presentation.	0.80
03/24/20	DS	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Wang (PJT) re: revised numbers	0.30
03/24/20	DS	Incorporate next draft of numbers into business plan model	2.20
03/24/20	DS	Bridge changes in last 3 set of management's numbers and provide to PJT	1.80
03/24/20	DS	Draft analysis supporting topline change in Avrio business plan	1.10
03/24/20	DS	Revise latest version of Avrio deck and send for internal review	1.00
03/24/20	JD	Review 3 statement model incorporating the latest updated business plans to analyze the consolidated cash flows in conjunction with public health initiatives layered in in order to compare plan to January forecast.	1.80
03/24/20	JD	Review updated draft Adhansia slides and provide comments re: same.	0.50
03/24/20	JD	Correspondence with C. Landau and J. Lowne (both Purdue) re: questions from Duff & Phelps.	0.70
03/25/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.20
03/25/20	JD	Review diligence materials re: third party valuations.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/25/20	JD	Review Syneos master service agreement re: force majeure clause.	0.30
03/25/20	JD	Review and reconcile Rhodes presentation against financial model.	0.60
03/25/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: business plan update.	0.60
03/25/20	JD	Review latest Rhodes business plan updates.	1.00
03/25/20	JD	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: updated Rhodes business plan slides.	0.90
03/25/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: DOJ responses.	0.50
03/25/20	JD	Review updated Avrio slides.	0.50
03/25/20	DS	Review latest draft of Avrio deck and send to fellow advisors	1.10
03/25/20	DS	Call with VP Finance (Purdue) and D. Samikkannu (AlixPartners) re: previous sales broker and cost structure	0.50
03/25/20	NAS	Review and revise Adhansia slides provided by Purdue for materials related to upcoming Board meeting.	1.20
03/25/20	NAS	Review and revise branded opioid business plan slides provided by Purdue in advance of Board meeting.	2.80
03/25/20	NAS	Revise Public Health Initiatives business plan slides in advance of Purdue Board meeting.	0.30
03/25/20	IA	Review wages motion agreement documents and summarize backup to non-executive retention payments by employee per management's request.	1.30
03/25/20	IA	Review voluntary resignations report submitted by human resources.	0.30
03/25/20	IA	Review and update Avrio business plan presentation based on comments from AlixPartners team.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/25/20	IA	Review comments received from J. Lowne (Purdue) on Avrio business plan presentation.	0.90
03/25/20	IA	Review updated P&L file for Avrio and update board presentation to include latest comments from management.	1.70
03/25/20	IA	Follow up on PJT questions related to adjacent innovations in Avrio business plan.	0.40
03/25/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.80
03/25/20	GJK	Project coordination and planning	1.00
03/25/20	GJK	Mundipharma diligence and analysis	2.00
03/25/20	GJK	Mundipharma report notes and scenario planning	2.00
03/25/20	MH	Create accounts payable release file.	0.70
03/25/20	MH	Add insurance vendor to approved release list.	0.30
03/25/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: business plan update.	0.60
03/25/20	LJD	Review and comment on Rhodes partnership teaser	0.70
03/25/20	RDS	Update Rhodes work stream workplan	0.40
03/25/20	RDS	Implementation gantt chart creation	0.60
03/25/20	RDS	Further edits to board slides for Rhodes presentation	1.50
03/25/20	RDS	Call with D. Fogel, N. Davis (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss latest updates to Rhodes board presentation	1.90
03/25/20	RDS	Call with D. Lundie, R. Shamblan, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) for update on Rhodes Tech partnership workstream	1.50
03/25/20	RDS	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: updated Rhodes business plan slides.	0.90
03/25/20	RDS	Assemble longer form board presentation for contextual	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		backup	
03/25/20	RDS	Call with R. Schnitzler (PJT) and R. Sublett (AlixPartners) to discuss Avrio and Rhodes business plan presentation	0.40
03/25/20	RDS	Review Rhodes Tech partnership rationale	1.40
03/25/20	RDS	Review and provide thoughts against J. Lowne (Purdue) commentary to the Avrio board presentation slides.	0.30
03/25/20	KM	Creation of Smartsheet implementation tracker	0.40
03/25/20	KM	Deck edits and improvements re: Rhodes presentation to the Board for D. Lundie	0.40
03/25/20	KM	Rhodes cash flow bridge revisions	0.90
03/25/20	KM	Rhodes R&D implementation plan update and analysis	0.80
03/25/20	KM	Call with D. Fogel, N. Davis (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss latest updates to Rhodes board presentation	1.90
03/25/20	KM	Call with D. Lundie, R. Shamblan, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) for update on Rhodes Tech partnership workstream	1.50
03/25/20	KM	Rhodes Tech implementation plan update and analysis - 5x24 ops	0.50
03/25/20	KM	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: updated Rhodes business plan slides.	0.90
03/25/20	KM	Build Rhodes presentation to the Board for D. Lundie (Purdue)	2.10
03/26/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: edits and financial update for Rhodes presentation to the Board for D. Lundie	0.40
03/26/20	KM	Rhodes Tech workforce reduction Smartsheet implementation plan development	0.80
03/26/20	KM	Meeting with D. Fogel, M. Sisoda, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re:	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Rhodes Pharma market dynamics / forecasting / competitive landscape	
03/26/20	KM	Rhodes Tech 5x24 operations implementation plan development on smartsheet	0.50
03/26/20	KM	Meeting with D. Lundie, D. McGuire, D. Fogel, R. Shamblen, V. Mancinelli, J. Doyle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes deck and initiatives for BOD	1.50
03/26/20	KM	Rhodes Tech implementation plan health and status updates	0.30
03/26/20	KM	Edits to Rhodes BOD presentation	0.40
03/26/20	KM	Research and analysis for Rhodes Tech teaser	1.80
03/26/20	KM	Rhodes Tech teaser for Noramco partnership discussion	0.70
03/26/20	KM	Partnership teaser analysis and development	2.30
03/26/20	KM	Call with J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: aggregated Purdue business plan	0.80
03/26/20	RDS	Meeting with D. Lundie, D. McGuire, D. Fogel, R. Shamblen, V. Mancinelli, J. Doyle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes deck and initiatives for BOD	1.50
03/26/20	RDS	Call with Rhodes senior leadership team R. Shamblen, D. Lundie, V. Mancinelli, D. Fogel, D. McGuire, J. Northington (all Purdue) and R. Sublett (AlixPartners) to present board slides	1.50
03/26/20	RDS	Prepare presentation breakdown for Rhodes board deck	0.60
03/26/20	RDS	Correspondence with PJT re: board presentation to discuss business planning	0.40
03/26/20	RDS	Partnership presentation for Noramco teaser	2.80
03/26/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners)	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		to discuss headcount reductions targets for Rhodes organization	
03/26/20	RDS	Assemble board backup story to bridge from various approved budget approvals	1.60
03/26/20	RDS	Call with J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: aggregated Purdue business plan	0.80
03/26/20	RDS	Call with D. Fogel, D. Lundie (both Purdue), and R. Sublett (AlixPartners) to discuss headcount reductions	0.20
03/26/20	RDS	Meeting with D. Fogel, M. Sisoda, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma market dynamics / forecasting / competitive landscape	1.00
03/26/20	LJD	Prepare for and attend call with J. O'Connell, R. Schnitzler, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman (both Purdue), L. Donahue, G. Koch, J. DelConte (all AlixPartners) re: case progress update and planning call.	1.20
03/26/20	LJD	Update call with J. Dubel (board member)	0.50
03/26/20	GJK	Mundipharma diligence process discussion with Huron (financial advisor to Mundipharma), G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic (both PJT), and other Mundipharma diligence advisors (FTI, HL, Province, Jefferies).	0.60
03/26/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to prepare for Mundipharma diligence discussion with Huron and other Mundipharma diligence advisors	0.30
03/26/20	GJK	Call with J. O'Connell, R. Schnitzler, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman (both Purdue), L. Donahue, G. Koch, J. DelConte (all AlixPartners) re: case progress update and	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		planning call.	
03/26/20	GJK	Mundipharma project coordination, including prep for calls and alignment with other advisors	2.50
03/26/20	MH	Create accounts payable release file.	0.70
03/26/20	MH	Research vendor with additional invoices beyond trade agreement amount.	0.80
03/26/20	GJK	Mundipharma sales trends/analysis	2.00
03/26/20	SKL	Prepare for walk-through of latest draft of Purdue business plan slides with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.00
03/26/20	SKL	Walk-through of latest draft of Purdue business plan slides for Board of Directors with J. DelConte, S. Lemack, and N. Simon (all AlixPartners).	1.20
03/26/20	SKL	Continue to update the latest version of the Business Planning/Pipeline deck in preparation for tomorrow's discussion with J. DelConte and N. Simon (both AlixPartners)	2.50
03/26/20	NAS	Prepare for walk-through of latest draft of Purdue business plan slides with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.00
03/26/20	NAS	Revise list of Mundipharma diligence requests to be sent to Huron (Mundipharma financial advisor).	0.60
03/26/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to prepare for Mundipharma diligence discussion with Huron and other Mundipharma diligence advisors.	0.30
03/26/20	NAS	Mundipharma diligence process discussion with Huron (financial advisor to Mundipharma), G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic (both PJT), and other Mundipharma diligence advisors (FTI, HL, Province, Jefferies).	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/26/20	NAS	Walk-through of latest draft of Purdue business plan slides for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.20
03/26/20	NAS	Revise Mundipharma business plan model to incorporate price/volume data provided by company.	2.10
03/26/20	IA	Update operating expenses assumptions in Purdue cash forecast based on run rates.	1.20
03/26/20	IA	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Tran (Purdue) to discuss latest version of board presentation	0.40
03/26/20	IA	Review updated Avrio model and CAGR breakeven point.	0.70
03/26/20	IA	Draft Avrio innovation break even analysis per requests by management to be included in business plan presentation.	1.80
03/26/20	DS	Call with VP Finance (Purdue) and D. Samikkannu (AlixPartners) to review revised numbers	0.80
03/26/20	JD	Prepare for walk-through of latest draft of Purdue business plan slides with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.00
03/26/20	DS	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Tran (Purdue) to discuss latest version of board presentation	0.40
03/26/20	JD	Call with J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: aggregated Purdue business plan	0.80
03/26/20	JD	Walk-through of latest draft of Purdue business plan slides for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.20
03/26/20	JD	Review updated and edited branded opioid, adhansia, pipeline and PHI slides prior to call with team and	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		compare against previous versions.	
03/26/20	JD	Review additional Rhodes background business plan slides.	0.60
03/26/20	JD	Review and update Avrio innovation breakeven analysis.	0.80
03/26/20	JD	Review final version of HRT Naloxone agreement prior to distribution.	0.50
03/27/20	JD	Catch up with J. Lowne (Purdue), R. Schnitzler, J. Turner (both PJT), and J. DelConte (AlixPartners) re: business plan progress.	0.50
03/27/20	JD	Review the latest version of the Board presentation from David Lundie.	0.60
03/27/20	JDH	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	NAS	Build revised Mundipharma sales scenario (through Product Contribution line) for Europe, LAM, and Canada regions.	2.90
03/27/20	NAS	Build revised sales scenario in Mundipharma business plan model below Product Contribution line item.	1.90
03/27/20	NAS	Check and reconcile figures resulting from revised sales case scenario in Mundipharma business plan model.	2.10
03/27/20	NAS	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	NAS	Summarize findings from revised sales case scenario in Mundipharma business plan model for G. Koch (AlixPartners).	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/27/20	RC	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	SKL	Finalize updates to the Purdue Business Plan/Pipeline slides and circulate to the AlixPartners team for final sign-off.	1.30
03/27/20	HK	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	IA	Discussion with J. Wang (PJT) and I. Arana (both AlixPartners) on Avrio updated financials.	0.40
03/27/20	IA	Review and update innovation break even analysis for Avrio.	1.10
03/27/20	IA	Update Avrio slides to include latest comments from management and updated financials.	1.40
03/27/20	IA	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	GJK	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	GJK	IAC update with PJT and DPW to discuss DPW reaching out to family counsel re: DB meetings	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/27/20	GJK	Mundipharma model review and planning	3.20
03/27/20	GJK	Mundipharma consumer products review	2.50
03/27/20	MH	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	MH	Create accounts payable release file.	0.70
03/27/20	MFR	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	LJD	Call with J. Dubel (board member)	0.40
03/27/20	LJD	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	RDS	Review headcount reductions from finance reductions with D. Fogel (Purdue)	0.30
03/27/20	RDS	Meeting with R. Shamblen, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech partnership outreach - general and noramco	2.00
03/27/20	RDS	Review and correct presentation changes to the Rhodes Board presentation from J. Lowne (Purdue)	1.30
03/27/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes BOD presentation	1.50
03/27/20	RDS	Review and send board presentation slides to Purdue aggregator	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/27/20	RDS	Assemble partnership discussion emails with strategic insights to tease conversation	1.50
03/27/20	RDS	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	RDS	Correspondence with J. Tran (Purdue) re: Betadine throat gargle	0.20
03/27/20	RDS	PowerPoint edits to teaser presentation framing Rhodes Tech	0.50
03/27/20	KM	Storyboard and planning re: Rhodes presentation to the Board	1.20
03/27/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: Rhodes business plan slides for the board	0.80
03/27/20	KM	Meeting with R. Shamblen, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech partnership outreach - general and noramco	2.00
03/27/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes BOD presentation	1.50
03/27/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: Rhodes headcount and organizational restructuring targets	0.80
03/27/20	KM	Rhodes Tech partnership outreach - edits and outreach for Cambrex, Alcaliber and Hikma	1.60
03/27/20	KM	Rhodes Tech partnership outreach - master teaser improvement	1.00
03/27/20	KM	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	
03/27/20	ADD	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/28/20	KM	Participate in a call with R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty, I. Arana and R. Sublett (all AlixPartners) re: draft Board deck (Partial Participation).	0.60
03/28/20	RDS	Review and provide comments to the PJT aggregated board business plan presentation	0.70
03/28/20	RDS	Call with J. Turner, R. Schnitzler (both PJT), J. DelConte, K. McCafferty, I. Arana and R. Sublett (all AlixPartners) to discuss aggregated board presentation	0.80
03/28/20	GJK	Mundipharma diligence - balance sheet/cash forecast	2.00
03/28/20	IA	Call with J. Turner, R. Schnitzler (both PJT), J. DelConte, R. Sublett, K. McCafferty, and I. Arana (all AlixPartners) to discuss updated board deck.	0.80
03/28/20	NAS	Revise Purdue opioid business plan slides for Board of Directors following discussion with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.20
03/28/20	JD	Review and provide comments on initial PJT draft of Board business plan presentation.	2.50
03/28/20	JD	Participate in a call with R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty, I. Arana and R. Sublett (all AlixPartners) re: draft Board deck.	0.80
03/29/20	JD	Create slides for the Board deck on G&A and Medical Affairs.	2.70
03/29/20	NAS	Revise Adhansia business plan slides for Board of	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Directors following discussion with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	
03/29/20	NAS	Build full P&L split by Consumer Health and Ethical businesses in Mundipharma business plan model.	1.90
03/29/20	RDS	Review of updated board slides and correspondence with PJT advisors	0.60
03/30/20	RDS	Construct new slides for aggregated business plan deck that encompasses better context for Rhodes business plan	1.70
03/30/20	RDS	Conversation with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan slides.	0.60
03/30/20	KM	Revenue analysis re: Project Windsor - Rhodes business plan outline for Board	1.90
03/30/20	KM	Deck creation re: Project Windsor - Rhodes business plan outline for Board	2.70
03/30/20	KM	Slide creation re: Project Windsor - Rhodes business plan outline for Board	1.10
03/30/20	KM	Rhodes implementation planning follow up and progress tracking	0.80
03/30/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project Windsor financials and forecasting performance	1.10
03/30/20	KM	Board deck review with Purdue executive team	1.00
03/30/20	KM	Conversation with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan slides.	0.60
03/30/20	KM	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: discuss next steps and coordinate plan post business plan meeting.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/30/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project Windsor financials and forecasting performance	1.10
03/30/20	RDS	Slide creation - industry overview of generics and impact on Rhodes business	1.80
03/30/20	RDS	Slide creation - historical Rhodes revenue execution against budget	0.90
03/30/20	RDS	Slide creation - update management levers to implement turnaround plan and impact on the budget	2.10
03/30/20	RDS	Meeting with T. Coleman, J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, J. DelConte, R. Sublett (all AlixPartners), C. Landau, J. Lowne, M. Kesselman, and D. Lundie (all Purdue) re: Board business plan presentation review.	1.70
03/30/20	RDS	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: discuss next steps and coordinate plan post business plan meeting.	0.70
03/30/20	NAS	Build standalone product class scenarios in Mundipharma business plan model in advance of conversation with PJT.	2.40
03/30/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) re: Mundipharma model walk through and variance on sales	1.40
03/30/20	NAS	Build comparison of Mundipharma management's revised sales forecast relative to December 2019 version and analyze key takeaways.	2.50
03/30/20	NAS	Review Mundipharma product classifications in data provided to ensure alignment across data sources.	0.50
03/30/20	NAS	Prepare product line-level standalone case in Mundipharma business plan model for 3/31 discussion with PJT.	1.80
03/30/20	JD	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: discuss next steps and coordinate plan	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		post business plan meeting.	
03/30/20	JD	Conversation with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan slides.	0.60
03/30/20	JD	Conversation with L. Donahue and J. DelConte (both AlixPartners) re: business plan update and case planning.	0.50
03/30/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan presentation.	0.30
03/30/20	JD	Meeting with T. Coleman, J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, J. DelConte, R. Sublett (all AlixPartners), C. Landau, J. Lowne, M. Kesselman, and D. Lundie (all Purdue) re: Board business plan presentation review.	1.70
03/30/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: sync up post business plan review meeting.	0.10
03/30/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: open business plan issues.	0.40
03/30/20	JD	Correspondence with C. MacDonald (Purdue) re: professional fee payments.	0.20
03/30/20	JD	Correspondence with E. Kardos (AlixPartners) re: Purdue confidentiality agreements.	0.20
03/30/20	JD	Review and provide comments to the consolidated business plan presentation.	3.30
03/30/20	JD	Review and provide comments on the latest weekly sales report update and compare sales levels to previous versions.	0.50
03/30/20	JD	Review R&D and legal fee forecasts for 2020-2024 period and provide comments re: same.	0.70
03/30/20	JD	Review OCP payment tracking information prior to filing a report with the court, compare amounts against original	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		forecasts and provide comments re: same.	
03/30/20	IA	Draft Purdue corporate operating expense overview slides including details on R&D, legal, and bankruptcy costs.	2.60
03/30/20	IA	Review comments from J. Lowne (Purdue) to Avrio board deck slides.	0.80
03/30/20	IA	Follow up on March source data (invoiced sales, consumption, market share) for Avrio Dashboard, to be shown as part of Avrio board update.	0.30
03/30/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) re: Mundipharma model walk through and variance on sales	1.40
03/30/20	GJK	Document review for opportunities to utilize balance sheet and cash flow info	2.00
03/30/20	MH	Call with M. Hartley (AlixPartners), legal operations, and Canadian counsel to review changes to payments to ensure compliance with Ordinary Course Professional limits.	0.80
03/30/20	MH	Create accounts payable release file.	0.70
03/30/20	LJD	Prepare for and attend meeting with T. Coleman, J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, J. DelConte, R. Sublett (all AlixPartners), C. Landau, J. Lowne, M. Kesselman, and D. Lundie (all Purdue) re: Board business plan presentation review.	2.50
03/30/20	LJD	Conversation with L. Donahue and J. DelConte (both AlixPartners) re: business plan update and case planning.	0.50
03/30/20	GJK	Review of VDD documents re: Ethical breakdown	2.00
03/30/20	GJK	Product analysis - analgesics and CH	2.50
03/31/20	GJK	Mundipharma diligence report planning	2.20
03/31/20	MH	Call with M. Hartley (AlixPartners), supply chain manager, and large sales force contractor to review pre-petition invoices.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/31/20	MH	Create accounts payable release file.	0.70
03/31/20	MH	Create second accounts payable release file on request.	0.50
03/31/20	MH	Advise purchasing manager of procedure to amend the existing trade agreement with a vendor.	0.40
03/31/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to prep for PJT walk through and review of Mundipharma diligence responses on variances between March 2020 and OB sales	1.00
03/31/20	GJK	Call with PJT to review draft of model	1.00
03/31/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to align on discussion topics and prepare for 3/31 Mundipharma model and sales update meeting with PJT.	0.30
03/31/20	IA	Update corporate slides in business plan board presentation based on comments from J. Lowne (Purdue)	1.60
03/31/20	IA	Update Purdue 13 week cash forecast customer collections, restructuring fees and retained professional fees.	2.70
03/31/20	IA	Update Avrio dashboard for March invoiced sales data.	1.10
03/31/20	IA	Update Avrio dashboard for March consumption and market share data.	1.80
03/31/20	JD	Review proposed diligence responses to various outstanding UCC requests.	0.30
03/31/20	JD	Conversation with J. DelConte (AlixPartners) and R. Silbert (Purdue) re: PHI plans and disclosure to various stakeholders.	0.20
03/31/20	JD	Conversation with J. DelConte (AlixPartners) and J. Lowne (Purdue) re: business plan presentation.	0.10
03/31/20	JD	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.20
03/31/20	JD	Correspondence with R. Schnitzler (PJT) re: Rhodes	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		slides.	
03/31/20	JD	Review corporate expense forecasts and create presentation slides and create summary slide for Board presentation.	1.50
03/31/20	JD	Review updated Rhodes business plan slides and provide comments re: same.	0.80
03/31/20	JD	Review updated draft corporate expense slides and provide comments re: same.	0.60
03/31/20	JD	Review and provide comments to the updated Avrio business plan presentation.	0.50
03/31/20	JD	Review and provide comments on updated Opioid section of the business plan presentation.	0.70
03/31/20	JD	Review and provide comments on the updated Adhansia section of the business plan presentation and review previous iterations of that section and previous Adhansia Board presentations.	1.10
03/31/20	JD	Review latest inbound requests from the Ad Hoc Committee and proposed responses and review correspondence from T. Melvin (PJT) and E. Ruiz (Purdue) re: same.	0.60
03/31/20	JD	Review proposed UCC diligence responses and proposed responses to HRT specific questions.	0.40
03/31/20	JD	Review mark up of pipeline assets section of the business plan presentation and provide comments re: same.	0.50
03/31/20	JD	Review comments to Board presentation executive summary.	0.50
03/31/20	JD	Review updated Adhansia section.	0.40
03/31/20	NAS	Build product line-level standalone case in Mundipharma business plan model for 3/31 discussion with PJT.	1.10
03/31/20	NAS	Check product line-level standalone case in Mundipharma	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan model against management forecast and resolve any discrepancies.	
03/31/20	NAS	Prepare region-level standalone case in Mundipharma business plan model for 3/31 discussion with PJT.	1.40
03/31/20	NAS	Prepare agenda and discussion points related to Mundipharma model and management's sales update for 3/31 call with PJT.	1.80
03/31/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to align on discussion topics and prepare for 3/31 Mundipharma model and sales update meeting with PJT.	0.30
03/31/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to prep for PJT walk through and review of Mundipharma diligence responses on variances between March 2020 and OB sales	1.00
03/31/20	NAS	Build list of action items following 3/31 Mundipharma discussion with PJT.	0.30
03/31/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: impact of Oxy-APAP and Oxy-IR rebid	2.00
03/31/20	RDS	Update board presentation	1.50
03/31/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation for Rhodes	1.10
03/31/20	RDS	Meeting with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Board deck refinement	0.60
03/31/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation executive summary for Rhodes	1.00
03/31/20	RDS	Review customer, product profitability analysis for additional marginal products	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/31/20	RDS	Turn comments from J. Lowne (Purdue) to board presentation slides for Rhodes	0.90
03/31/20	RDS	Review and turn comments to new format board presentation on Avrio business plan	0.10
03/31/20	KM	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.20
03/31/20	KM	Rhodes implementation strategy and impact to budget for Board presentation	0.60
03/31/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: impact of Oxy-APAP and Oxy-IR rebid	2.00
03/31/20	KM	Meeting with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Board deck refinement	0.60
03/31/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation executive summary for Rhodes	1.00
03/31/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation for Rhodes	1.10
03/31/20	KM	Rhodes Board deck restructuring for executive team	1.90
03/31/20	KM	Rhodes implementation plan timeline update	0.40
03/31/20	KM	Rhodes Board deck edits	0.90
03/31/20	RDS	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.20
04/01/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: partnership discussions.	1.00
04/01/20	RDS	Preparation for call re: partnerships.	0.40
04/01/20	RDS	Build storyboard for Rhodes section of board presentation and shared updated draft.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/01/20	RDS	Review RT partnership follow up materials.	1.40
04/01/20	RDS	Call with D. Fogel (Purdue) re: partnerships.	0.40
04/01/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: supply analysis.	2.00
04/01/20	RDS	Call with D. Lundie, J. Lowne (Purdue), D. Fogel (Purdue), K. McCafferty, J. DelConte, R. Sublett (all AlixPartners) re: partnership discussions.	1.10
04/01/20	KM	Update Rhodes Board deck and implementation plan changes.	1.10
04/01/20	KM	Rhodes turnaround planning -- CPP + forecasting.	0.80
04/01/20	KM	Analysis and review of supply proposal.	0.70
04/01/20	KM	Discussion with D. Fogel (Purdue) and D. Lundie (Purdue) re: partnership options.	0.40
04/01/20	KM	Analysis of partnership options.	0.50
04/01/20	KM	RT cost-volume sensitivity analysis.	0.50
04/01/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: supply analysis.	2.00
04/01/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: partnership discussions.	1.00
04/01/20	KM	Call with D. Lundie, J. Lowne (Purdue), D. Fogel (Purdue), K. McCafferty, J. DelConte, R. Sublett (all AlixPartners) re: partnership discussions.	1.10
04/01/20	KM	Rhodes partnership strategy and impact to budget.	0.40
04/01/20	NAS	Draft list of outstanding Mundipharma diligence items by priority level.	0.40
04/01/20	NAS	Incorporate edits from 3/31 discussion with PJT in Mundipharma business plan model.	0.50
04/01/20	NAS	Revise product categories in Mundipharma business plan model to conform across data sources.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/01/20	NAS	Add remaining line items to individual country P&Ls in Mundipharma business plan model.	2.30
04/01/20	NAS	Add check functionality to individual country P&Ls in Mundipharma business plan model.	0.40
04/01/20	NAS	Share findings from individual country P&Ls in Mundipharma business plan model with G. Koch (AlixPartners).	0.40
04/01/20	NAS	Draft discussion topics and supporting information for Mundipharma modeling methodology discussion with advisors involved in diligence process.	2.10
04/01/20	IA	Compare January and March Avrio consumption and market share data to inform performance commentary in Covid context.	1.70
04/01/20	IA	Update corporate slides in business plan board presentation based on comments.	2.10
04/01/20	IA	Update Avrio Dashboard slides with tables showing March performance and circulate to Avrio management for commentary.	1.40
04/01/20	JD	Review and comment on updated executive summary slides for the Board presentation.	1.00
04/01/20	JD	Review changes to Adhansia presentation compared against previous version.	0.40
04/01/20	JD	Review and comment on COVID-19 business plan impact slides for the Board presentation.	0.50
04/01/20	JD	Review comments from M. Kesselman (Purdue) on draft business plan presentation.	1.10
04/01/20	JD	Review updated Rhodes business plan slides from K. McCafferty and R. Sublett (both AlixPartners).	0.80
04/01/20	JD	Review updated Avrio business plan slides.	0.40
04/01/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners) re:	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan and Board presentation update.	
04/01/20	JD	Meeting with D. Lundie, D. Fogel, J. Lowne (all Purdue), J. Turner and R. Schnitzler (both PJT) re: Rhodes partnership opportunity.	1.10
04/01/20	JD	Call with R. Schnitzler, J. Turner (both PJT) and J. Lowne (Purdue) re: Rhodes business plan.	0.30
04/01/20	JD	Call with D. Lundie, J. Lowne (Purdue), D. Fogel (Purdue), K. McCafferty, J. DelConte, R. Sublett (all AlixPartners) re: partnership discussions.	1.10
04/01/20	JD	Call with J. Turner (PJT) re: business plan presentation.	0.40
04/01/20	JD	Call with J. Lowne (Purdue) re: Rhodes business plan.	0.20
04/01/20	JD	Review comments from management on the Avrio business plan.	0.80
04/01/20	JD	Review correspondence from E. Kardos (AlixPartners) re: Purdue relationships.	0.20
04/01/20	DS	Call with head of Finance (Avrio) re: 2018 historical pro forma adjustments.	0.30
04/01/20	GJK	Call with N. Simon, G. Koch (both AlixPartners) re: review findings from individual country P&Ls in Mundipharma business plan model.	0.40
04/01/20	MH	Create accounts payable release file.	0.70
04/01/20	GJK	Preparation of Mundipharma diligence discussion topic list review for advisor call.	0.30
04/01/20	GJK	China review and potential dial drivers of value (up or down).	2.00
04/01/20	GJK	Continue LAM review for diligence.	2.50
04/01/20	LJD	Call with J. DelConte, L. Donahue (both AlixPartners) re: business plan and Board presentation update.	0.70
04/01/20	LJD	Review and comment on preliminary board presentations.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/01/20	LJD	Strategy update call with PJT regarding Adhansia.	0.60
04/02/20	LJD	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/02/20	GJK	Call with I. McClatchy (Norton Rose), update and discuss diligence options.	1.00
04/02/20	GJK	Plan and coordinate advisor diligence	2.00
04/02/20	GJK	Review and analysis of Mundipharma model.	3.00
04/02/20	MH	Create accounts payable release file.	0.70
04/02/20	JD	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/02/20	JD	Call with J. Turner (PJT) re: updated business plan.	0.20
04/02/20	JD	Correspondence with R. Sublett and K. McCafferty (both AlixPartners) re: Rhodes business plan updates.	1.20
04/02/20	JD	Review final business plan presentation prior to management meeting. Provide comments re: same.	1.50
04/02/20	JD	Correspondence with R. Schnitzler (PJT) re: Avrio business plan slides.	0.40
04/02/20	IA	Review Avrio dashboard commentary prepared by management J. Tran and T. Garvey (both Avrio).	1.80
04/02/20	IA	Update Purdue opex rationalization slide to include updated consolidated numbers and reconciled opex amounts show to the rest of the draft board presentation.	2.20
04/02/20	IA	Validated consumption and market share trend commentary included in Avrio March dashboard slides.	1.20
04/02/20	IA	Review updated board business plan presentation slides.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/02/20	KM	Analysis re: strategic plans go forward.	0.40
04/02/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Board deck walk through and call prep.	1.30
04/02/20	KM	RT cost-volume sensitivity analysis.	0.40
04/02/20	KM	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/02/20	KM	Rhodes partnership analysis and outreach.	0.30
04/02/20	KM	Prepare Rhodes strategic analysis.	0.80
04/02/20	KM	Meeting with D. Lundie, J. Lowne (Purdue), R. Shamblen, D. Fogel, J. Doyle (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Partnership analysis and response process.	1.10
04/02/20	KM	Meeting with D. Fogel, R. Haberlin (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma stand-alone P&L analysis.	1.00
04/02/20	RDS	Review RP standalone operating financials.	0.60
04/02/20	RDS	Call with D. Fogel (Purdue) re: stand along RP financial profile.	1.30
04/02/20	RDS	Construct strategic diligence list.	0.50
04/02/20	RDS	Meeting with D. Fogel, R. Haberlin (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma stand-alone P&L analysis.	1.00
04/02/20	RDS	Review latest updated Purdue board presentation for comments.	0.60
04/02/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Board deck walk through and call prep.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/02/20	RDS	Respond to questions on Avrio presentations.	0.50
04/02/20	RDS	Changes to updated presentation materials for Project Catalyst.	1.30
04/02/20	RDS	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/02/20	RDS	Update partnership analysis and correspondence with Purdue and Rhodes management team.	0.70
04/02/20	RDS	Meeting with D. Lundie, J. Lowne (Purdue), R. Shamblen, D. Fogel, J. Doyle (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Partnership analysis and response process.	1.10
04/03/20	RDS	Call with J. DelConte, R. Sublett (both AlixPartners) re: Rhodes updated forecast.	0.20
04/03/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.50
04/03/20	RDS	Call with D. Fogel (Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.60
04/03/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.90
04/03/20	RDS	Meeting with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: updated Rhodes forecast.	1.10
04/03/20	RDS	Review Rhodes Pharma - RALP consolidated P&L statement.	1.00
04/03/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), R. Sublett, K. McCafferty (both AlixPartners) re: Rhodes Pharma stand-alone financials.	1.60
04/03/20	RDS	Reconcile Rhodes Pharma financials and RALP	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		reconciliation.	
04/03/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma and RALP financial reconciliation.	3.80
04/03/20	RDS	Assemble presentation materials to explain the bridge of Rhodes Pharma to RALP consolidation.	1.00
04/03/20	RDS	Update presentation for amended RALP numbers.	2.00
04/03/20	ADD	Research vendor payment history to prepare for meeting.	2.20
04/03/20	ADD	Compile and prepare files to send to David Polk for review, processing and designation.	1.60
04/03/20	KM	Slide edits and analysis re: Rhodes deck for presentation to Purdue Board.	1.80
04/03/20	KM	Financial analysis in support re: Rhodes deck for presentation to Purdue Board.	1.20
04/03/20	KM	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), R. Sublett, K. McCafferty (both AlixPartners) re: Rhodes Pharma stand-alone financials.	1.60
04/03/20	KM	Financial revisions re: Rhodes deck for presentation to Purdue Board.	0.90
04/03/20	KM	Slide edits in support of Rhodes presentation to Purdue Board.	0.50
04/03/20	KM	Meeting with D. Fogel (Purdue) re: Rhodes Pharma and RALP financial restatement.	1.50
04/03/20	KM	Analysis and review of Rhodes detailed financial reporting.	0.80
04/03/20	KM	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty (partial attendance), R. Sublett (both AlixPartners) re: Rhodes Pharma and RALP financial reconciliation.	2.10
04/03/20	KM	Rhodes financials tracking.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/03/20	KM	Rhodes Board deck re-statement of financial projections.	1.90
04/03/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.50
04/03/20	KM	Call with D. Fogel (Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.60
04/03/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.90
04/03/20	KM	Meeting with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: updated Rhodes forecast.	1.10
04/03/20	JD	Review updated flash report to provide to all parties.	0.60
04/03/20	JD	Call with M. Huebner and E. Vonnegut (both Davis Polk) re: HRT discussions.	0.20
04/03/20	JD	Call with D. Fogel (Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.60
04/03/20	JD	Conversation with J. Turner (PJT) re: Rhodes forecast.	0.20
04/03/20	JD	Meeting with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: updated Rhodes forecast.	1.10
04/03/20	JD	Call with J. Lowne (Purdue) re: Rhodes forecast update.	0.30
04/03/20	JD	Call with J. DelConte, R. Sublett (both AlixPartners) re: Rhodes updated forecast.	0.20
04/03/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.90
04/03/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.50
04/03/20	JD	Review and provide comments on latest draft Board business plan presentation.	2.20
04/03/20	JD	Correspondence with R. Aleali (Purdue) and S. Lemack	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners) re: January flash report and latest MOR.	
04/03/20	JD	Review analysis of historical consulting fee payments.	0.40
04/03/20	JD	Review and provide comments on updated Avrio dashboard slides.	0.30
04/03/20	JD	Review and provide comments on updated opex cost slides for the Board presentation.	0.30
04/03/20	MH	Create accounts payable release file.	0.70
04/03/20	MH	Add professional firms to AP control process and monthly reporting process.	0.60
04/03/20	GJK	Follow up with B. Bromberg (FTI) re: approach to country diligence in absence of further calls with country managers.	1.90
04/03/20	LJD	Review business plan iterations.	0.90
04/03/20	IA	Reconcile updated consolidated PL numbers and reflected changes in opex rationalization slide.	1.40
04/03/20	IA	Update Avrio dashboard commentary to be discussed with J. Tran (Avrio).	0.80
04/03/20	IA	Update case update agenda in preparation for AlixPartners weekly team update call.	0.30
04/03/20	IA	Review latest version of business plan board presentation.	0.80
04/03/20	IA	Call with J. Tran (Avrio) re: dashboard slides and March results commentary.	0.50
04/03/20	IA	Call with J. Lowne (Purdue) re: Avrio dashboard slides and March results commentary.	0.20
04/03/20	IA	Update Avrio dashboard model to reflect comments on market share data and innovation trackers per discussions with Purdue and AlixPartners teams.	2.10
04/04/20	IA	Review updated business plan presentation ahead of 04/07 meeting.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/04/20	IA	Review restructuring fees tracker for 20% holdback fee payment assumptions.	0.60
04/04/20	IA	Provide comments to PJT on Avrio section of business plan presentation ahead of 04/07 meeting.	1.00
04/04/20	LJD	Review schedules and financial bridges for business plan for board meeting next week.	0.90
04/04/20	JD	Review and provide comments on latest draft business plan presentation. Check numbers throughout the presentation.	2.60
04/04/20	JD	Correspondence with J. Turner and R. Schnitzler (both PJT) re: latest draft business plan.	0.50
04/04/20	JD	Review and provide comments on the Rhodes section of the Board presentation.	0.40
04/04/20	JD	Review questions from FTI on the HRT funding request. Review information to be responsive.	0.70
04/04/20	KM	Call with D. Fogel, R. Haberin (Purdue), R. Sublett (AlixPartners) to tie out manufacturing makeup of Rhodes Pharma gross profit.	0.40
04/04/20	KM	Meeting with D. Fogel, W. DiNicola, R. Haberin (Purdue), J. Carlisle (Purdue) and R. Sublett (AlixPartners) re: Rhodes Pharma and RALP financials.	2.00
04/04/20	KM	Financial analysis in support of Rhodes deck for presentation to Purdue Board.	0.90
04/04/20	KM	Meeting with D. Fogel, W. DiNicola, R. Haberin, J. Carlisle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes financials for the Board deck.	0.90
04/04/20	RDS	Review Purdue management comments to board presentation draft.	0.30
04/04/20	RDS	Update to underlying RALP budget model to reflect AlixPartners comments.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/04/20	RDS	Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue) and K. McCafferty (AlixPartners) re: Rhodes Pharma and RALP financials.	2.00
04/04/20	RDS	Call with D. Fogel, R. Haberlin (Purdue), K. McCafferty (AlixPartners) to tie out manufacturing makeup of Rhodes Pharma gross profit.	0.40
04/04/20	RDS	Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes financials for the Board deck.	0.90
04/04/20	RDS	Final PPT changes to reflect PJT and management comments to board slides for Rhodes.	1.30
04/04/20	RDS	Post comments to full PPLP business plan deck.	0.10
04/04/20	RDS	Call with J. Wang (PJT) to articulate estimated savings from plant closure scenario to five-year cash flow.	0.50
04/04/20	ADD	Research vendor payment history to prepare for meeting.	2.50
04/05/20	RDS	Review senior management comments to PPLP business plan presentation.	0.40
04/05/20	JD	Review comments on and updated slides re: Adhansia.	0.50
04/05/20	JD	Review correspondence re: Pinney Associates and Purdue history.	0.30
04/05/20	JD	Review comments from E. Ruiz (Purdue) re: Avrio business plan. Review underlying analysis.	0.60
04/05/20	LJD	Review and comment on business plan deck before final send off to board.	1.80
04/06/20	LJD	Prepare for and attend board meeting.	2.10
04/06/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.80
04/06/20	MH	Create accounts payable release file.	0.70
04/06/20	GJK	Calls with N. Simon (AlixPartners) re: diligence process	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/06/20	GJK	including preparation for Review IQvia data feedback. Discussion with N. Simon (AlixPartners) re: goals for 4/7 call with other Mundipharma diligence advisors and key discussion topics.	0.40
04/06/20	GJK	Review OxyContin market for Mundipharma advisor call prep.	3.00
04/06/20	GJK	Preparation for advisor discussion re: China and ANZ projections.	2.00
04/06/20	IA	Call with J. Turner, R. Schnitzler (PJT), J. Lowne, J. Tran (Purdue), J. DelConte, I. Arana (both AlixPartners) re: Avrio business plan board presentation.	0.70
04/06/20	IA	Preparation of updated post-filing voluntary separations report for Purdue and Rhodes.	0.80
04/06/20	IA	Call with J. Tran (Purdue) re: questions and comments received from J. Lowne (Purdue) on business plan slides to be presented to the board.	0.40
04/06/20	IA	Call re: HRT agreement with committees.	0.70
04/06/20	JD	Call with R. Aleali (Purdue) re: board presentation.	0.40
04/06/20	JD	Call with C. Robertson (Davis Polk) re: HRT diligence questions.	0.20
04/06/20	JD	Call with R. Aleali (Purdue) re: HRT diligence.	0.20
04/06/20	JD	Prepare for and participate in a call with all committee advisors, state AG's, Davis Polk, PJT and J. DelConte, I. Arana (both AlixPartners) re: HRT diligence questions.	1.00
04/06/20	JD	Preparation for and participate in Purdue Board meeting.	2.00
04/06/20	JD	Review Avrio business plan presentation prior to preparation call.	0.50
04/06/20	JD	Call with J. Turner, R. Schnitzler (PJT), J. Lowne, J. Tran (Purdue), J. DelConte, I. Arana (both AlixPartners) re: Avrio business plan board presentation.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/06/20	JD	Correspondence with C. Robertson (Davis Polk) re: HRT diligence questions.	0.40
04/06/20	JD	Research Oncology business plan spending and questions re: board presentation. Correspondence with R. Aleali and E. Ruiz (both Purdue) re: same.	0.80
04/06/20	NAS	Outline Mundipharma diligence priorities for week of April 6th.	0.80
04/06/20	NAS	Review new Mundipharma diligence documents and responses provided by Huron.	1.30
04/06/20	NAS	Review Mundipharma IQVIA data and compare to price/volume projections provided by management.	1.90
04/06/20	NAS	Draft discussion points for diligence update call with other advisors involved in Mundipharma diligence process.	1.70
04/06/20	NAS	Discussion with G. Koch (AlixPartners) re: goals for 4/7 call with other Mundipharma diligence advisors and key discussion topics.	0.40
04/06/20	NAS	Review initial draft of Mundipharma diligence report outline provided by PJT.	0.50
04/06/20	RDS	Preparation of page-flip questions for the board presentation.	1.30
04/06/20	RDS	Call with D. Fogel (Purdue) on utilization of CPP tool.	0.30
04/06/20	RDS	Meeting with D. Fogel, W. DiNicola (both Purdue) and K. McCafferty (AlixPartners) re: Rhodes Tech stand-alone financials.	1.10
04/06/20	RDS	Updates to board presentation notes for AlixPartners team.	1.40
04/06/20	RDS	Preparation of break-even financial analysis for Rhodes Tech facility sale / supply agreement.	1.90
04/06/20	RDS	Review distributed board presentation.	0.80
04/06/20	RDS	Updates and slide creation for Avrio board presentation.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/06/20	KM	Coordination of Rhodes partnership implementation effort.	1.60
04/06/20	KM	R&D program efficiency research and preparation.	2.00
04/06/20	KM	Analysis re: Rhodes R&D re-engineering case for change.	1.20
04/06/20	KM	Meeting with D. Fogel, W. DiNicola (both Purdue) and R. Sublett (AlixPartners) re: Rhodes Tech stand-alone financials.	1.10
04/07/20	KM	Rhodes next phase implementation planning.	1.30
04/07/20	KM	Rhodes R&D project slip-chart analysis.	0.70
04/07/20	KM	Rhodes R&D re-engineering approach development.	1.00
04/07/20	KM	Purdue Board meeting re: Rhodes and Avrio business plans.	0.60
04/07/20	KM	Analysis re: Rhodes pipeline forecasting.	1.00
04/07/20	KM	Call with D. Lundie (Purdue) and R. Sublett (AlixPartners) re: Rhodes next phase transformation.	1.10
04/07/20	KM	Rhodes R&D and Financial re-engineering roadmap development.	0.90
04/07/20	KM	Deck development re: Rhodes R&D restructuring roll-out.	0.70
04/07/20	RDS	Call with D. Lundie (Purdue), K. McCafferty (AlixPartners) re: Rhodes next phase transformation.	1.10
04/07/20	RDS	Construct materials to update management on current work stream progress and next steps.	1.10
04/07/20	RDS	Analysis of Avrio business plan changes.	0.70
04/07/20	RDS	Review and prepare materials for an R&D turnaround effort at Rhodes.	2.20
04/07/20	RDS	Purdue Board meeting for RALP and Avrio presentation points.	1.80
04/07/20	IA	Review final draft of business plan presentation to the board.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/07/20	NAS	Review draft of Mundipharma report outline provided by PJT and provide feedback.	0.80
04/07/20	NAS	Review responses provided by Huron to Mundipharma diligence questions.	0.40
04/07/20	NAS	Prepare for Mundipharma diligence methodology discussion with other debtor advisors - AlixPartners and PJT, AHC advisors - FTI and HL, UCC advisors - Province and Jefferies.	1.20
04/07/20	NAS	Call with G. Koch (AlixPartners) to prepare for Mundipharma diligence methodology discussion with debtor advisors - AlixPartners and PJT, AHC advisors - FTI and HL, UCC advisors - Province and Jefferies.	1.30
04/07/20	NAS	Discussion with N. Simon, G. Koch (both AlixPartners), other debtor advisors, AHC advisors, and UCC advisors re: Mundipharma diligence methodology.	1.00
04/07/20	NAS	Follow up items (including request list and key takeaways) following Mundipharma methodology discussion with advisors to debtor, AHC, and UCC.	0.90
04/07/20	NAS	Call with J. Arsic (PJT) to provide background on Mundipharma diligence process and divide responsibilities for sections of interim report.	0.90
04/07/20	NAS	Add additional KPIs (e.g. growth rates, ratios) to Mundipharma business plan model.	1.30
04/07/20	JD	Prepare for and participate in Purdue Board meeting.	6.80
04/07/20	JD	Conversation with R. Aleali (Purdue) re: post Board meeting follow up.	0.40
04/07/20	JD	Review and write up notes prior to board call.	1.00
04/07/20	GJK	Discussion with N. Simon, G. Koch (both AlixPartners), other debtor advisors, AHC advisors, and UCC advisors re: Mundipharma diligence methodology.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/07/20	GJK	Call with N. Simon (AlixPartners) to prepare for Mundipharma diligence methodology discussion with debtor advisors - AlixPartners and PJT, AHC advisors - FTI and HL, UCC advisors - Province and Jefferies.	1.30
04/07/20	GJK	Review diligence document and diligence planning post Advisor call.	2.50
04/07/20	GJK	Review price x volume and forecast planning.	1.60
04/07/20	MH	Create accounts payable release file.	0.70
04/07/20	MH	Update legal release files and OCP control files based on revised information from legal operations.	1.40
04/07/20	MH	Respond to client questions about prepetition for a marketing vendor.	0.40
04/07/20	LJD	Prepare for and attend Purdue board meeting.	7.20
04/08/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.50
04/08/20	MH	Create accounts payable release file.	0.70
04/08/20	GJK	Discussion with N. Simon (AlixPartners) to review analysis of Mundipharma cash flow information and share takeaways from call with PJT.	0.50
04/08/20	GJK	Call with N. Simon (AlixPartners), J. Turner, R. Schnitzler, and J. Arsic (all PJT) re: interim report outline and other deliverables.	0.70
04/08/20	GJK	Discussion with N. Simon (AlixPartners) regarding revisions to Mundipharma business plan model.	0.90
04/08/20	GJK	Review cash flows analysis.	1.20
04/08/20	GJK	Conduct Mundipharma markets diligence/balance sheet and VDD.	2.00
04/08/20	GJK	Plan for Mundipharma diligence including preparation for team call.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/08/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.50
04/08/20	JD	Call with J Turner, R Schnitzler (both PJT) and I. Arana, J. DelConte (both AlixPartners) re: creditor business plan presentation.	0.50
04/08/20	JD	Review and provide comments on latest weekly sales reports.	0.40
04/08/20	JD	Review board presentation in order to determine what work needs to be done to convert it to a creditor advisor presentation.	2.10
04/08/20	JD	Review and provide comments on the latest customer report.	0.60
04/08/20	JD	Preparation of analysis of costs for contract assumption.	0.80
04/08/20	JD	Review correspondence from J. Lowne and J. Tran (both Purdue) re: Avrio Board follow up questions.	0.30
04/08/20	JD	Correspondence with R. Brown (Purdue) re: professional fee accruals for March.	0.70
04/08/20	JD	Review and make notes on the first cut of the creditor presentation outline from PJT.	1.10
04/08/20	JD	Review latest IMS data pulls prior to sharing with creditors.	0.40
04/08/20	JD	Partial review draft board materials prior to them being shared with various creditor advisors.	0.70
04/08/20	IA	Call with J Turner, R Schnitzler (both PJT) and I. Arana, J. DelConte (both AlixPartners) re: creditor business plan presentation.	0.50
04/08/20	IA	Review customer programs report for February.	1.10
04/08/20	IA	Provide comments and a proposed outline for creditor business plan presentation based on board presentation.	2.90
04/08/20	IA	Review updated Purdue and Rhodes weekly sales reports	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		to be sent to management for review.	
04/08/20	NAS	Translate Mundipharma cash flow information (provided by management) from a legal entity basis to a region/functional basis to assess liquidity profile.	2.40
04/08/20	NAS	Discussion with G. Koch (AlixPartners) re: revisions to Mundipharma business plan model.	0.90
04/08/20	NAS	Draft findings from analysis of Mundipharma cash flow information and provide for G. Koch (AlixPartners).	0.80
04/08/20	NAS	Add additional growth and profitability metrics to all scenarios in Mundipharma business plan model.	2.20
04/08/20	NAS	Prepare for call with PJT re: interim report outline and other deliverables.	0.40
04/08/20	NAS	Call with G. Koch (AlixPartners), J. Turner, R. Schnitzler, and J. Arsic (all PJT) re: interim report outline and other deliverables.	0.70
04/08/20	NAS	Discussion with G. Koch (AlixPartners) to review analysis of Mundipharma cash flow information and share takeaways from call with PJT.	0.50
04/08/20	NAS	Draft to-do list with respect to Mundipharma business plan model and requested diligence items.	0.40
04/08/20	RDS	Preparation of materials for FP&A transformation at Rhodes.	0.60
04/08/20	RDS	Call with D. Fogel, W. DiNicola (both Purdue), K. McCafferty (AlixPartners) re: Rhodes Tech P&L breakdown for stand-alone financials.	1.20
04/08/20	RDS	Amend historical and forecast Rhodes Tech revenues to conform to true third-party pricing.	1.10
04/08/20	RDS	Construct product development committee meeting presentation slides.	2.00
04/08/20	RDS	Call with D. Fogel, W. DiNicola (both Purdue), K.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty (AlixPartners) re: Rhodes Tech standalone financials.	
04/08/20	RDS	Assemble budget model for standalone Rhodes Tech plant.	1.40
04/08/20	RDS	Review Rhodes Tech intercompany allocations and alternative suggested costs.	1.40
04/08/20	RDS	Review of Project Catalyst materials.	0.40
04/08/20	KM	Rhodes next phase implementation planning.	0.60
04/08/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) and R. Sublett (AlixPartners) re: Rhodes Tech P&L breakdown for stand-alone financials.	1.20
04/08/20	KM	Analysis re: Rhodes Tech past/forecast financials for partnership discussions.	1.00
04/08/20	KM	R&D process re-engineering process development and discussion with AlixPartners SMEs.	0.60
04/08/20	KM	Continue analysis re: Rhodes Tech past/forecast financials for partnership discussions.	0.40
04/08/20	KM	Analysis re: Rhodes Tech P&L breakdown for stand-alone financials.	0.40
04/08/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) and R. Sublett (AlixPartners) re: Rhodes Tech standalone financials.	1.00
04/09/20	KM	Analysis of partnership opportunities.	2.00
04/09/20	KM	Analysis re: RT stand-alone financials.	2.60
04/09/20	KM	Project Catalyst slide preparation	0.60
04/09/20	KM	Call with D. Fogel, R. Haberin, W. DiNicola, N. Davis, J. Carlisle (all Purdue) and R. Sublett (AlixPartners) re: next phase CPP analysis.	1.00
04/09/20	KM	Call with D. Fogel, W. DiNicola (both Purdue), R. Sublett	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners) re: RT standalone financials.	
04/09/20	KM	Continue analysis re: RT stand-alone financials.	0.20
04/09/20	KM	Analysis and presentations re: partnership opportunities.	1.40
04/09/20	RDS	Assemble presentation on generic product development best practices.	0.30
04/09/20	RDS	Call with D. Fogel (Purdue) re: supply options.	2.30
04/09/20	RDS	Construction of a stand-alone API manufacturing plant financial model.	2.20
04/09/20	RDS	Create model for different strategic options.	1.30
04/09/20	RDS	Create presentation for management of differing go forward strategic options.	1.90
04/09/20	RDS	Call with D. Fogel, R. Haberman, W. DiNicola, N. Davis, J. Carlisle (all Purdue), K. McCafferty (AlixPartners) re: next phase CPP analysis.	1.00
04/09/20	RDS	Call with D. Fogel, W. DiNicola (both Purdue), K. McCafferty (AlixPartners) re: RT standalone financials.	1.60
04/09/20	IA	Incorporate comments from PJT and AlixPartners to creditor business plan presentation to be discussed with management.	1.90
04/09/20	IA	Review PJT comments to business plan presentation to create creditor draft.	1.40
04/09/20	IA	Consolidate PJT and AlixPartners comments to business plan presentation to create creditor draft.	1.70
04/09/20	IA	Review management comments to latest cash report and forecast for week ended 03/27.	0.60
04/09/20	IA	Review operational scorecard slide update for February flash report.	0.60
04/09/20	NAS	Prioritize revisions to Mundipharma model and other follow-ups from 4/8 discussion with PJT.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/09/20	NAS	Review prior materials created re: key Mundipharma products to provide overview for PJT.	0.50
04/09/20	NAS	Review EY Mundipharma VDD report in order to classify costs in P&L as variable or fixed for model.	1.40
04/09/20	NAS	Update revised sales scenario in Mundipharma model to be dynamic with respect to fixed/variable cost toggles.	2.50
04/09/20	NAS	Review Mundipharma market-level diligence questions sent by FTI.	0.40
04/09/20	NAS	Build check functionality in Mundipharma model for revised sales case with fixed/variable cost toggles.	0.60
04/09/20	NAS	Update region standalone scenario in Mundipharma model to use new sales case methodology instead of 2020 original budget.	1.30
04/09/20	NAS	Calls with G. Koch (AlixPartners) re: diligence coordination.	0.40
04/09/20	JD	Continue review of draft board materials to provide to creditors.	1.50
04/09/20	JD	Call with J. Lowne (Purdue) re: cost allocations.	0.30
04/09/20	JD	Call with C. Robertson (Davis Polk) re: asset sale procedures and HRT contract diligence.	0.40
04/09/20	JD	Correspondence with R. Aleali (Purdue) and T. Melvin (PJT) re: DOJ requests.	0.50
04/09/20	JD	Finalize contract assumption calculations.	0.30
04/09/20	JD	Review Avrio overview presentation provided to the Board as follow up to the business plan presentation.	0.60
04/09/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.30
04/09/20	GJK	Meeting with J. DelConte, M. Hartley, L. Donahue (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	
04/09/20	GJK	Review China diligence.	2.50
04/09/20	GJK	Draft China market diligence questions.	2.50
04/09/20	GJK	Calls with N. Simon (AlixPartners) re: diligence coordination.	0.40
04/09/20	GJK	Review cost allocation.	0.30
04/09/20	GJK	Mundipharma diligence coordination and planning.	1.00
04/09/20	MH	Create accounts payable release file.	0.70
04/09/20	MH	Reconcile payments to approved critical vendor to determine treatment of new prepetition invoice.	0.50
04/09/20	LJD	Prepare for and attend meeting with G. Koch, M. Hartley, J. DelConte (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	0.70
04/09/20	LJD	Review Avrio updated presentation.	0.60
04/10/20	LJD	Debrief call with K. Buckfire (Board member) re: board meeting.	0.60
04/10/20	LJD	Review staffing needs.	0.30
04/10/20	LJD	Call with J. Dubel (Board Member) re: subsidiaries and allocation methodology.	0.70
04/10/20	LJD	Review correspondence and analysis re: allocation of shared services and subsidiary costs.	0.90
04/10/20	MH	Create monthly analysis of open prepetition balances not eligible for payment under motion.	1.00
04/10/20	MH	Create accounts payable release file.	0.70
04/10/20	GJK	Calls with N. Simon (AlixPartners) on coordination and model priorities.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/10/20	GJK	Continue review of diligence questions for Europe, including call/email exchange with B. Bromberg (FTI).	2.00
04/10/20	GJK	Review Canada and Europe (continued) for Mundipharma diligence.	2.00
04/10/20	JD	Call with R. Aleali (Purdue), J. DelConte, I. Arana (both AlixPartners) re: creditor business plan presentation.	1.00
04/10/20	JD	Review inbound interested parties log.	0.30
04/10/20	JD	Review 2004 discovery motion and subpoena.	0.40
04/10/20	JD	Review latest version of the creditor business plan presentation.	0.70
04/10/20	JD	Review correspondence between J. Turner (PJT) and J. Lowne (Purdue) re: cost allocation.	0.30
04/10/20	JD	Review correspondence from J. Lowne (Purdue) re: LTRP details. Review details re: same.	0.50
04/10/20	JD	Partial participation in call with D. Lundie, D. Fogel, J. Lowne, P. Strassburger, J. Doyle R. Shamblen, R. Aleali (all Purdue), R. Sublett, J. DelConte, K. McCafferty (all AlixPartners), J. Turner, R. Schnitzler (both PJT) re: Project Catalyst.	1.10
04/10/20	JD	Review article re: opioid shortages and correspondence with J. Lowne (Purdue) and R. Sublett (AlixPartners) re: same.	0.30
04/10/20	NAS	Calls with G. Koch (AlixPartners) on coordination and model priorities.	0.30
04/10/20	IA	Call with C DeStefano (Purdue) re: 2020 to 2022 LTRP payments bridge detail to support business plan presentation.	0.50
04/10/20	IA	Incorporate comments from PJT and AlixPartners to creditor business plan presentation to be discussed with management.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/10/20	IA	Call with R. Aleali (Purdue), J. DelConte, I. Arana (both AlixPartners) re: creditor business plan presentation.	1.00
04/10/20	IA	Follow up with Purdue Legal on specific slides containing third party data that are included in creditor business plan presentation.	0.80
04/10/20	NAS	Review market-level Mundipharma diligence questions drafted by G. Koch (AlixPartners) and suggest additions.	1.10
04/10/20	NAS	Draft weekly update for Mundipharma diligence workstream and prepare for AlixPartners engagement team update call.	0.90
04/10/20	NAS	Modify Mundipharma business plan model for scenarios to consider March 2020 sales update provided by management.	1.10
04/10/20	RDS	Correspondence with D. Fogel (Purdue) re: strategic planning.	0.30
04/10/20	RDS	Call with D. Lundie, D. Fogel, J. Lowne, P. Strassburger, J. Doyle R. Shamblen, R. Aleali (all Purdue), R. Sublett, J. DelConte, K. McCafferty (all AlixPartners), J. Turner, R. Schnitzler (both PJT) re: Project Catalyst.	2.00
04/10/20	KM	Meeting with R. Shamblen (Purdue) re: review AlixPartners slides for Project Catalyst meeting.	0.30
04/10/20	KM	Analysis and slide preparation re: Project Catalyst meeting.	1.00
04/10/20	KM	Call with D. Lundie, D. Fogel, J. Lowne, P. Strassburger, J. Doyle R. Shamblen, R. Aleali (all Purdue), R. Sublett, J. DelConte, K. McCafferty (all AlixPartners), J. Turner, R. Schnitzler (both PJT) re: Project Catalyst.	2.00
04/10/20	KM	Meeting with D. Fogel (Purdue) re: strategic planning.	0.10
04/10/20	KM	Analysis re: Project Catalyst.	0.20
04/10/20	RDS	Aggregate forecast volume data.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/10/20	RDS	Preparation of Rhodes finance transformation.	1.30
04/10/20	RDS	Review of COVID response at Rhodes in the scope of GE pharmaceuticals.	0.50
04/11/20	LJD	Call with board members regarding revised reporting for subsidiary cash flows and balance sheets.	1.20
04/12/20	RDS	Update board level KPI reporting formatting for March actuals.	0.80
04/12/20	RDS	Correspondence with D. Fogel (Purdue) re: latest consolidated RALP financial presentation for April business plan board meeting.	0.30
04/12/20	RDS	Work toward consolidated financial plan.	0.10
04/13/20	RDS	Call with N. Davis (Purdue), K. McCafferty (AlixPartners) re: latest turnaround implementation plan and monthly dashboard.	0.30
04/13/20	RDS	Call with D. Fogel (Purdue) re: Project Windsor financial update.	0.20
04/13/20	RDS	Edits to Project Catalyst teaser materials.	1.40
04/13/20	RDS	Update March dashboard implementation progress tracker.	1.10
04/13/20	RDS	Preparation of materials for portfolio review meeting with D. Lundie (Purdue).	1.50
04/13/20	RDS	Call re: consolidated PPLP consolidated budget with D. Fogel, W. DiNicola, R. Haberin (all Purdue), T. Melvin, G. Sim (both PJT), K. McCafferty (AlixPartners).	0.40
04/13/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
04/13/20	KM	Meeting with N. Davis (Purdue) and R. Sublett (AlixPartners) re: implementation dashboard.	0.30
04/13/20	KM	Preparation of the March Rhodes implementation dashboard.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/13/20	KM	Rhodes implementation plan review.	0.60
04/13/20	KM	Rhodes R&D and pipeline re-engineering requirements.	1.30
04/13/20	KM	Analysis re: Rhodes Tech volume forecast.	0.70
04/13/20	KM	Analysis re: Rhodes CPP expansion.	0.90
04/13/20	KM	Analysis re: Rhodes personnel and reporting, spans and layers analysis refresh.	1.10
04/13/20	KM	Call re: consolidated PPLP consolidated budget with D. Fogel, W. DiNicola, R. Haberin (all Purdue), T. Melvin, G. Sim (both PJT), R. Sublett (AlixPartners).	0.40
04/13/20	LJD	Call with J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.20
04/13/20	LJD	Prepare for and attend call with J. Lowne (Purdue), T. Coleman, J. O'Connell, J. Turner (PJT), J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.70
04/13/20	LJD	Prepare for call with AP team in advance of call with management on Monday.	0.30
04/13/20	LJD	Call with T. Coleman, R. Schnitzler, J. Turner (PJT), B. Bartell, S. Lyman (Duff & Phelps) and J. DelConte (AlixPartners) re: strategic plans.	1.10
04/13/20	LJD	Review and edit fee app.	0.30
04/13/20	GJK	Review advisor questions and analysis.	2.50
04/13/20	GJK	Coordinate and plan for Mundipharma diligence report.	2.00
04/13/20	GJK	Review of S. Jamieson responses and files to diligence question.	2.80
04/13/20	MH	Update vendor release list with new trade agreement.	0.40
04/13/20	MH	Create accounts payable release file.	0.70
04/13/20	IA	Follow up on third party consent to share third party product analytics for Avrio.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/13/20	NAS	Revise product line standalone cases in Mundipharma business plan model to reflect March 2020 sales update and corresponding allocation methodology.	2.10
04/13/20	NAS	Build check functionality in Mundipharma business plan model for revised product line standalone cases following March 2020 sales update.	0.80
04/13/20	NAS	Build additional product line standalone cases in Mundipharma business plan model for Biosimilars, Diabetes, Oncology, Respiratory, and Other Ethical business lines.	2.60
04/13/20	NAS	Review Mundipharma diligence questions drafted by FTI and revise additional follow-up questions drafted by G. Koch (AlixPartners).	1.50
04/13/20	NAS	Draft list of Mundipharma diligence priority items for week of April 13th.	0.20
04/13/20	NAS	Build check functionality for region standalone scenarios in Mundipharma business plan model and resolve discrepancy.	1.20
04/13/20	JD	Call with J. Lowne (Purdue), T. Coleman, J. O'Connell, J. Turner (PJT), J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.50
04/13/20	JD	Call with T. Coleman, R. Schnitzler, J. Turner (PJT), B. Bartell, S. Lyman (Duff & Phelps) and L. Donahue (AlixPartners) re: strategic plans.	1.10
04/13/20	JD	Call with J. Lowne (Purdue) re: business plan follow ups and creditor presentation.	0.20
04/13/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.20
04/13/20	JD	Review strategic side by side analysis prior to call with Duff and Phelps.	0.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/13/20	JD	Review and provide comments on February flash report. Compare report against last month's report.	1.80
04/13/20	JD	Research federal and state funding of Naloxone and other opioid antagonists.	2.00
04/14/20	JD	Review materials in advance of this morning's board meeting.	0.50
04/14/20	JD	Participate in PPI board meeting.	1.00
04/14/20	JD	Call with J. Turner (PJT) re: post-board meeting follow up.	0.20
04/14/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes next steps.	0.40
04/14/20	JD	Review diligence request from FTI and associated files.	0.70
04/14/20	JD	Review analysis of year over year changes in bonus compensation structures and amounts.	0.80
04/14/20	JD	Review final Nalmafene report per court filing.	0.20
04/14/20	JD	Review finance and R&D re-engineering proposal for Rhodes.	0.60
04/14/20	NAS	Revise standalone Consumer Health and Ethical P&Ls in Mundipharma business plan model to reference March 2020 sales update.	2.30
04/14/20	NAS	Review latest draft of Mundipharma business plan model with G. Koch (AlixPartners) and discuss next steps for diligence report.	1.40
04/14/20	NAS	Brainstorm structure of Mundipharma Ethical business overview presentation for PJT.	1.00
04/14/20	NAS	Draft Mundipharma Ethical business overview presentation for PJT.	2.70
04/14/20	IA	Draft LTRP 2020 to 2022 payments bridges for Rhodes to support long term plan forecast.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/14/20	IA	Summarize projected LTRP 2020 to 2022 payments by employee for Purdue and Rhodes and reconciled to Finance accrual amounts.	2.60
04/14/20	IA	Draft LTRP 2020 to 2022 payment bridges to support payment assumptions in long term plan forecast.	1.70
04/14/20	IA	Review OCP monthly reporting process and reports in preparation for transition call with AlixPartners team.	0.80
04/14/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.40
04/14/20	MH	Adjust automatic accounts payable hold lists to reflect updated risk assessment.	0.90
04/14/20	MH	Create accounts payable release file.	0.70
04/14/20	GJK	Review latest draft of Mundipharma business plan model with N. Simon (AlixPartners) and discuss next steps for diligence report.	1.40
04/14/20	GJK	Coordination of Mundipharma diligence including follow ups and email exchanges with larger advisory group.	2.00
04/14/20	GJK	Analysis of updates from Mundipharma diligence questions.	2.80
04/14/20	LJD	Prepare for and attend board meeting.	1.20
04/14/20	LJD	Call with J. Dubel (Purdue) re: debriefing	0.60
04/14/20	LJD	Review and discuss Rhodes workplan with team.	0.90
04/14/20	KM	Finance re-engineering workplan development.	0.80
04/14/20	KM	R&D re-engineering workplan development.	0.70
04/14/20	KM	Analysis re: Rhodes personnel.	0.30
04/14/20	KM	Analysis re: Rhodes Pharma product launch plans.	1.00
04/14/20	KM	Analysis re: Rhodes reporting spans and layers.	1.60
04/14/20	KM	Slides for Rhodes product launch plan.	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/14/20	KM	Call with D. Fogel, N. Davis (both Purdue), R. Sublett (AlixPartners) re: updated dashboard.	1.40
04/14/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes next steps.	0.40
04/14/20	RDS	Assemble scope and overview of process implementation for product development and finance transformation.	1.50
04/14/20	RDS	Communication of strategy for FP&A and product development implementations.	0.60
04/14/20	RDS	Assemble teaser for Rhodes Pharma and Wilson sites.	1.90
04/14/20	RDS	Call with D. Fogel, N. Davis (both Purdue), K. McCafferty (AlixPartners) re: updated dashboard.	1.40
04/14/20	RDS	Updates to work plan for Rhodes turnaround implementation plan.	0.30
04/14/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes next steps.	0.40
04/15/20	RDS	Review of teaser documentation.	0.70
04/15/20	RDS	Update PMO plan for Rhodes initiatives.	0.20
04/15/20	RDS	Implement changes to Rhodes and Avrio dashboards.	1.10
04/15/20	KM	Rhodes Dashboard.	1.10
04/15/20	KM	Rhodes turnaround initiatives program management.	0.90
04/15/20	LJD	Call with K. Buckfire (Board member)	0.70
04/15/20	LJD	Coordination call with PJT.	0.50
04/15/20	GJK	PV analysis and exchanges based on N. Simon (AlixPartners) analysis.	2.40
04/15/20	GJK	Draft follow up email with Advisors to Mundipharma re: open diligence items.	0.40
04/15/20	MH	Release new critical vendor for accounts payable.	0.40
04/15/20	MH	Create accounts payable release file.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/15/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.10
04/15/20	IA	Update board business plan presentation materials to be shared with creditors.	2.10
04/15/20	IA	Call with C DeStefano and J. Lowne (both Purdue) re: 2020 to 2022 LTRP bridges to support budget financials.	0.40
04/15/20	IA	Update LTRP 2020 bridges to include comments from management and reconciled amounts to latest tracker.	1.30
04/15/20	NAS	Prioritize Mundipharma diligence requests currently outstanding.	0.50
04/15/20	NAS	Review new diligence files provided by Mundipharma and Huron on 4/10, 4/13, and 4/14.	2.00
04/15/20	NAS	Analysis of 2019 price/volume information provided by Mundipharma to establish baseline for 2020-2024 projections.	2.60
04/15/20	NAS	Begin update of individual country P&Ls in Mundipharma business plan model to use March 2020 revised sales case.	0.30
04/15/20	JD	Call with J. Lowne, D. Fogel and D. Lundie (all Purdue) re: Rhodes dashboard.	0.50
04/15/20	JD	Review draft Rhodes dashboard.	0.60
04/15/20	JD	Preparation of draft agenda for review for tomorrow morning's call with DPW, PJT, AlixPartners and the company.	0.50
04/15/20	JD	Review comments from R. Aleali (Purdue) re: proposed board materials to be shared. Review draft board materials along with comments.	1.50
04/15/20	JD	Review Nielsen data and agreement to determine what can be shared with third parties.	0.70
04/15/20	JD	Review latest draft presentation to provide to the various	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		creditor groups re: updated business plan. Provide comments re: same.	
04/16/20	JD	Review updated incentive compensation bridges.	0.30
04/16/20	JD	Update case professional fee tracker for recently filed fee applications. Compare to budget and update YTD trend.	0.80
04/16/20	JD	Review new batch of minutes and resolutions to be shared with the various creditor advisors.	1.30
04/16/20	JD	Review updated information re: Purdue pension plan performance.	0.60
04/16/20	JD	Review consolidated financial statements provided by E. Ruiz (Purdue) to be included in the dynamic financial model.	1.00
04/16/20	JD	Review non-consenting state subpoena.	0.30
04/16/20	JD	Call with J. Lowne and M. Ronning (both Purdue) re: Adhansia board update.	0.50
04/16/20	JD	Correspondence with D. Rosen (Purdue) and K. Benedict (Davis Polk) re: RxPricing information and ability to share.	0.70
04/16/20	NAS	Coordination with J. Arsic (PJT) re: draft of Mundipharma diligence report.	0.70
04/16/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma Ethical overview presentation for PJT and takeaways from new diligence files provided.	0.70
04/16/20	NAS	Revise overview of Mundipharma Ethical business following discussion with G. Koch (AlixPartners) and prepare supporting materials for PJT.	2.00
04/16/20	NAS	Discussion with G. Koch (AlixPartners) re: current status of Mundipharma diligence process.	0.40
04/16/20	NAS	Review source data (Mundipharma Board/budget books) for assumptions around net working capital (DSO and	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DIOH).	
04/16/20	NAS	Project Mundipharma accounts receivable by market cluster using DSO assumptions and revenue projections from business plan model.	1.20
04/16/20	NAS	Project Mundipharma inventory by market cluster using DIOH assumptions and COGS projections from business plan model.	1.30
04/16/20	NAS	Preliminary assessment of Mundipharma days payable outstanding using accounts payable data on legal entity balance sheets.	0.70
04/16/20	NAS	Share current status of and preliminary findings from net working capital (DSO, DIOH, DPO) with G. Koch (AlixPartners).	0.50
04/16/20	IA	Reconcile 2020 to 2023 amounts submitted by Purdue to finance using latest version of LTRP trackers for payments by employee.	1.40
04/16/20	IA	Update LTRP 2020-2020 Purdue and Rhodes bridges to reflect comments from Purdue management.	0.90
04/16/20	IA	Review consolidated financials for 2020 April budget file with PL allocations by segment to be incorporated to draft creditor presentation.	2.20
04/16/20	IA	Format consolidated and segment financials to be included in creditor draft presentation slides.	1.80
04/16/20	IA	Meeting with M. Hartley, I. Arana, S. Lemack (all AlixPartners) re: professional payment tracking process.	0.50
04/16/20	SKL	Meeting with M. Hartley, I. Arana, S. Lemack (all AlixPartners) re: professional payment tracking process.	0.50
04/16/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: accounts payable and critical vendor process.	0.60
04/16/20	MH	Meeting with M. Hartley, I. Arana, S. Lemack (all	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: professional payment tracking process.	
04/16/20	MH	Create accounts payable release file.	0.70
04/16/20	GJK	Call with N. Simon (AlixPartners) re: current status of Mundipharma diligence process.	0.40
04/16/20	GJK	Analysis of Mundipharma 2019A vs 2019 YEE comparison.	2.00
04/16/20	GJK	Review of Mundipharma NWC based on N. Simon (AlixPartners) analysis and VDD.	1.00
04/16/20	GJK	Call with I. McClatchy (Norton Rose) re Mundipharma - overall diligence process.	1.00
04/16/20	GJK	Discussion with N. Simon (AlixPartners) regarding Mundipharma Ethical overview presentation for PJT and takeaways from new diligence files provided.	0.70
04/16/20	GJK	Call with B. Bromberg (FTI) re: Mundipharma diligence.	0.30
04/16/20	GJK	Analysis of Mundipharma P&L.	2.50
04/16/20	LJD	Prepare for and participate in call with E. Vonnegut, T. Graulich (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte (both AlixPartners) re: case update and team coordination.	1.30
04/16/20	KM	Analysis re: Rhodes Tech filings and COA for partnership discussions.	0.50
04/16/20	KM	Meeting with D. Fogel, W. DiNicola (Purdue) and R. Sublett (AlixPartners) re: standalone RT financials.	1.30
04/16/20	KM	Document preparation re: strategic options with updated volumes and financials.	0.90
04/16/20	KM	RT volume breakdown and COA alignment.	1.80
04/16/20	RDS	Correspondence with Rhodes management team about asset teaser.	0.80
04/16/20	RDS	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners).	
04/16/20	RDS	Update teaser presentation for latest financial information.	1.10
04/17/20	RDS	Update presentation for latest financial information.	0.80
04/17/20	KM	Meeting with R. Shamblen and S. Yates (both Purdue) re: Forecast RT volume and associates COAs.	1.00
04/17/20	KM	Analysis re: forecast RT volume.	0.30
04/17/20	KM	Analysis re: forecast RT volume.	0.40
04/17/20	KM	Rhodes implementation planning - Rhodes CPP.	0.40
04/17/20	LJD	Update call with K. Buckfire (Board member)	0.40
04/17/20	LJD	Coordination call with PJT.	0.60
04/17/20	GJK	Discussion with N. Simon (AlixPartners) re: Mundipharma net working capital analysis and key takeaways from week of 4/13.	1.10
04/17/20	GJK	Call N. Simon (AlixPartners), KPMG, and advisors re: current status of tax workstream.	0.60
04/17/20	GJK	Call with J. Turner (PJT) re Mundipharma diligence.	0.30
04/17/20	GJK	Continue review of Mundipharma FCF component.	2.00
04/17/20	GJK	Review of Mundipharma FCF component review - by regions.	3.00
04/17/20	GJK	Review and comment on UCC subpoena.	1.20
04/17/20	MH	Create accounts payable release file.	0.70
04/17/20	MH	Evaluate vendor invoice for sales team bonuses to determine petition status.	0.60
04/17/20	MH	Create an action map for accounts payable controls to document correct actions for each event.	0.70
04/17/20	IA	Update 2020-2022 Purdue LTRP bridge details to tie to accrual amounts submitted to finance in support of 2020	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		long term plan financials.	
04/17/20	IA	Review outline of Avrio board update re: Kiwi product removal from budget.	0.70
04/17/20	NAS	Analysis of Mundipharma net working capital by commercial region.	0.60
04/17/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma net working capital analysis and key takeaways from week of 4/13.	1.10
04/17/20	NAS	Call G. Koch (AlixPartners), KPMG, and advisors re: current status of tax workstream.	0.60
04/17/20	NAS	Draft Mundipharma data request related to days of payables outstanding (DPO) and coordinate with other advisors.	1.40
04/17/20	NAS	Review UCC subpoenas for requests applicable to Mundipharma entities.	0.90
04/17/20	NAS	Analysis of key drivers of discrepancy between Mundipharma year-end estimate of results and actual results.	0.50
04/17/20	IA	Call with J. Tran (Avrio) re: changes to Avrio business plan related to Senokot Kiwi products.	0.30
04/17/20	JD	Correspondence with R. Aleali (Purdue) and J. Turner (PJT) re: creditor presentation.	0.80
04/17/20	JD	Review creditor presentation comments from J. Lowne (Purdue) and provide comments. Correspondence with J. Lowne (Purdue) and J. Turner (PJT) re: same.	1.00
04/17/20	JD	Review and provide comments on March flash report in new format for 4/30 Board meeting.	2.40
04/18/20	JD	Call with J. Turner (PJT) re: business plan presentation.	0.30
04/18/20	JD	Draft executive summary for the creditor business plan presentation.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/18/20	IA	Update Purdue creditor business plan draft presentation to redact slides based on comments from Purdue legal and remove unnecessary details.	1.60
04/18/20	RDS	Review COA for Rhodes Tech.	0.80
04/19/20	RDS	Review correspondence with Rhodes leadership team regarding cost out opportunities.	0.30
04/19/20	JD	Review latest version of the creditor presentation. Provide comments re: same.	0.80
04/19/20	JD	Correspondence with J. Turner (PJT) and M. Kesselman (Purdue) re: latest creditor presentation.	0.70
04/19/20	JD	Correspondence with R. Aleali (Purdue) re: creditor presentation.	0.40
04/19/20	IA	Correspondence with AlixPartners team re: latest draft of creditor presentation and updated to business plan.	0.60
04/19/20	IA	Update creditor draft business plan presentation to include comments received from PJT and AlixPartners teams, for distribution to company for comments.	0.90
04/20/20	MH	Call with vendor to review petition status of invoices and explain claims options.	0.70
04/20/20	MH	Create accounts payable release file.	0.70
04/20/20	GJK	Call with N. Simon (AlixPartners) re: Mundipharma diligence priorities for week of 4/20.	0.50
04/20/20	GJK	Call with N. Simon (AlixPartners) to review free cash flow assumptions and methodology in Mundipharma model.	0.70
04/20/20	GJK	Coordinate and plan for Mundipharma diligence report.	3.00
04/20/20	GJK	Asses Mundipharma diligence balance sheets between key markets.	2.50
04/20/20	JD	Review latest designation data against last previously disclosed data.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/20/20	JD	Review latest weekly sales data for Purdue and Rhodes.	0.40
04/20/20	JD	Review latest draft creditor business plan presentation.	0.50
04/20/20	JD	Review draft board deck for removal of Senokot Kiwi from the business plan.	1.00
04/20/20	JD	Correspondence with J. Lowne (Purdue) and J. Turner (PJT) re: draft creditor presentation and update to the Avrio plan.	0.50
04/20/20	JD	Review latest materials re: Rhodes strategic plan.	0.60
04/20/20	JD	Review comments from R. Aleali (Purdue) re: latest creditor presentation.	0.50
04/20/20	IA	Review March results draft report and pull slides to be incorporated in updated draft creditor deck.	1.10
04/20/20	IA	Update Avrio PL allocations file for removal of Senokot Kiwi products and adjustments to S&P spend.	1.80
04/20/20	IA	Update creditor draft business plan presentation based on comments received from Purdue management and PJT.	1.90
04/20/20	IA	Follow up on requests for consent to share third party data on creditor presentation and update summary of data to be disclosed for discussion with third party vendor's Counsel.	1.20
04/20/20	IA	Summarize latest set of questions received from UCC on 2020 business plan and status or reports to be discussed with company and PJT.	0.70
04/20/20	NAS	Finalize Mundipharma request for additional information related to working capital and coordinate with other advisors re: diligence materials received.	0.50
04/20/20	NAS	Call with G. Koch (AlixPartners) re: Mundipharma diligence priorities for week of 4/20.	0.50
04/20/20	NAS	Revise standalone country P&L in Mundipharma business plan model to use March 2020 sales update methodology.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/20/20	NAS	Incorporate free cash flow source data and assumptions in Mundipharma business plan model.	0.80
04/20/20	NAS	Call with G. Koch (AlixPartners) to review free cash flow assumptions and methodology in Mundipharma model.	0.70
04/20/20	NAS	Continue to build free cash flow projections in Mundipharma business plan model for management's projections.	1.20
04/20/20	NAS	Build free cash flow projections in Mundipharma business plan model for region, business line, and product line standalone scenarios.	2.80
04/20/20	RDS	Review updated RT partnership process.	0.30
04/20/20	KM	Review RT partnership process.	0.50
04/20/20	KM	Analysis re: CPP.	1.00
04/20/20	KM	API and COA analysis.	1.50
04/20/20	KM	COA analysis and report.	0.30
04/21/20	KM	Rhodes turnaround planning -- CPP + forecasting.	1.60
04/21/20	KM	Meeting with D. Fogel and D. Lundie (both Purdue) re: Project Catalyst.	0.70
04/21/20	KM	Analysis re: Project Catalyst.	1.70
04/21/20	RDS	Assemble work plans for implementation planning for turnaround initiatives at Rhodes.	0.50
04/21/20	IA	Correspondence with PJT re: updated Avrio PL backup files.	0.30
04/21/20	IA	Provide comments to J. Tran (Avrio) re: updated PL allocations file by product.	1.20
04/21/20	IA	Review updated PLs by product for Avrio, compare to prior versions, and summarize adjustments to be incorporated to latest draft of creditor presentation.	2.70
04/21/20	NAS	Prepare for walk-through of Mundipharma FCF model with	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		J. Arsic (PJT).	
04/21/20	NAS	Call with J. Arsic (PJT) to review latest draft of Mundipharma FCF model.	0.90
04/21/20	NAS	Respond to follow-up requests and revise Mundipharma FCF assumptions following discussion with J. Arsic (PJT).	1.60
04/21/20	NAS	Discussion with G. Koch (AlixPartners) to provide update on Mundipharma FCF model review with PJT, discuss follow-up requests, and plan diligence priorities.	1.00
04/21/20	NAS	Draft summary for PJT of underlying methodology for base case and standalone scenarios in Mundipharma business plan/FCF model.	2.00
04/21/20	JD	Review Project Catalyst board update materials.	0.60
04/21/20	JD	Catch up call with J. Turner (PJT) and R. Aleali (Purdue) re: creditor presentation.	0.50
04/21/20	GJK	Discussion with N. Simon (AlixPartners) to provide update on Mundipharma FCF model review with PJT, discuss follow-up requests, and plan diligence priorities.	1.00
04/21/20	GJK	Analysis of NWC comparison between model and the Arnaud Breabout (Mundipharma) Nov presentation.	2.00
04/21/20	GJK	Walkthrough of Mundipharma model process and EBIT comparison.	3.00
04/21/20	GJK	Review Mundipharma diligence allocations.	2.00
04/21/20	MH	Create accounts payable release file.	0.70
04/21/20	MH	Redesign accounts payable release program to effect transition to another consultant.	0.30
04/22/20	MH	Create accounts payable release file.	0.70
04/22/20	GJK	Review Mundipharma updated model.	2.50
04/22/20	GJK	Compare Mundipharma 2018 YEE to Actuals.	1.50
04/22/20	GJK	Compare Model FCF vs Evercore FCF.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/22/20	GJK	Discussion with N. Simon (AlixPartners) re: Mundipharma diligence priorities for remainder of week.	0.30
04/22/20	GJK	Review and Analysis of Mundipharma current model of product by regions.	2.00
04/22/20	IA	Call with J. Tran (Avrio) re: PL allocation file and adjustments to innovations.	0.30
04/22/20	IA	Review updated board deck including updated slides from PJT after Avrio adjustments.	1.70
04/22/20	IA	Update Avrio slides in board presentation to exclude Senokot Kiwi products.	2.80
04/22/20	IA	Update expense rationalization slide in board presentation based on latest consolidated numbers.	0.90
04/22/20	IA	Review and response to request from R. Aleali (Purdue) to provide job description for Avrio employee.	0.40
04/22/20	IA	Review updated voluntary separations report received from Purdue HR.	0.40
04/22/20	JD	Review long term plan model from the Company.	0.70
04/22/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma diligence priorities for remainder of week.	0.30
04/22/20	NAS	Build net working capital assumption toggle in Mundipharma business plan model and provide latest update to PJT.	1.40
04/22/20	NAS	Finalize standalone country case in Mundipharma business plan model using updated sales methodology.	2.90
04/22/20	NAS	Build check functionality in Mundipharma business plan model for revised individual country case.	1.70
04/22/20	NAS	Draft new Mundipharma diligence request list for Huron following discussion with PJT.	0.60
04/22/20	NAS	Review and revise Mundipharma model methodology document for PJT.	1.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/22/20	RDS	Call with D. Fogel (Purdue), K. McCafferty (AlixPartners) re: modeling and presentation for strategic partnerships.	1.00
04/22/20	RDS	Update volume / pricing model for strategic partnerships.	1.40
04/22/20	RDS	Create slides re: strategic partnership financial model.	1.10
04/22/20	KM	Business Development: API research.	1.50
04/22/20	KM	Analysis re: Project Catalyst.	1.30
04/22/20	KM	Analysis re: strategic partnership opportunities.	0.50
04/22/20	KM	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) re: modeling and presentation of strategic partnerships.	1.00
04/23/20	KM	Analysis re: Catalyst partnership opportunities.	0.60
04/23/20	KM	Call with D. Lundie, D. Fogel (both Purdue), R. Sublett (AlixPartners) re: Project Catalyst analysis.	1.10
04/23/20	KM	Analysis re: Project Catalyst financials.	1.00
04/23/20	KM	Call with R. Schnitzler, J. Turner (both PJT), P. Strassburger, D. Lundie, J. Lowne, (all Purdue), R. Sublett (AlixPartners) re: Project Catalyst	0.50
04/23/20	KM	Analysis re: Project Catalyst materials.	0.60
04/23/20	NAS	Consolidate open items from Mundipharma business plan model prior to discussion with G. Koch (AlixPartners).	0.90
04/23/20	NAS	Call with G. Koch (AlixPartners) to conduct full review of Mundipharma business plan model, determine next revisions, and discuss key takeaways.	2.50
04/23/20	NAS	Revise Mundipharma business plan model (including price/volume build and COGS/unit) following discussion with G. Koch (AlixPartners).	2.60
04/23/20	NAS	Call with G. Koch (AlixPartners) re: revised price/volume build in Mundipharma business plan model.	0.40
04/23/20	NAS	Build high-level Mundipharma COGS per unit analysis at market-by-market level.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/23/20	JD	Correspondence with R. Aleali (Purdue) re: PwC.	0.20
04/23/20	JD	Review side by side analysis prior to mediation meeting.	0.80
04/23/20	IA	Meeting with E. Nowakowski (Purdue) and I. Arana, S. Lemack (both AlixPartners) to review the 2020 Purdue P&L and Balance Sheet.	1.00
04/23/20	GJK	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case progress and go forward planning.	0.70
04/23/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence.	0.30
04/23/20	GJK	Call with N. Simon (AlixPartners) to conduct full review of Mundipharma business plan model, determine next revisions, and discuss key takeaways.	2.50
04/23/20	GJK	Call with N. Simon (AlixPartners) re: revised price/volume build in Mundipharma business plan model.	0.40
04/23/20	GJK	Review price and cost drivers for adjusted analysis in Purdue model.	2.00
04/23/20	GJK	Follow up with Mundipharma and other advisors on working capital.	2.50
04/23/20	MH	Create accounts payable release file.	0.70
04/24/20	MH	Create accounts payable release file.	0.70
04/24/20	GJK	Review Mundipharma model including by country by product.	2.80
04/24/20	GJK	Analysis of Mundipharma model - sales and promotion.	2.50
04/24/20	GJK	Preparation for AlixPartners call including exchanges with I. McClatchy (Norton Rose).	1.00
04/24/20	GJK	Call with N. Simon (AlixPartners) to review unit COGS analysis, discuss next steps for model, and summarize	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		activities for week in advance of team update call.	
04/24/20	JD	Review draft Mundipharma IAC model.	1.00
04/24/20	JD	Review diligence requests from C. Cabello and M. Atkinson (Province).	0.40
04/24/20	JD	Review correspondence re: Province diligence requests.	0.30
04/24/20	JD	Review and provide comments related to comments from M. Kesselman (Purdue) re: creditor presentation.	0.50
04/24/20	JD	Review Wilson and Coventry site utilization stats.	0.80
04/24/20	JD	Call with J. Turner, T. Melvin (both PJT), J. DeConte, A. DePalma (both AlixPartners) re: open diligence items.	0.60
04/24/20	NAS	Build gross margin by product and market functionality in Mundipharma business plan model.	2.60
04/24/20	NAS	Build analysis of Mundipharma COGS per unit by market.	2.10
04/24/20	NAS	Review follow-up diligence items provided by Huron/Mundipharma.	0.40
04/24/20	NAS	Call with G. Koch (AlixPartners) to review unit COGS analysis, discuss next steps for model, and summarize activities for week in advance of team update call.	0.80
04/24/20	JD	Review Intralinks re: materials provided to date.	0.40
04/24/20	KM	Analysis re: continued hydromorphone CPP analysis.	0.70
04/24/20	KM	Meeting with D. Fogel (Purdue) and R. Sublett (AlixPartners) re: Project Catalyst insourcing assumptions.	0.50
04/24/20	KM	Analysis re: hydromorphone CPP analysis and re-bidding needs.	1.50
04/24/20	KM	Slide preparation and updating re: Project Catalyst.	0.40
04/24/20	KM	Analysis re: Project Catalyst insourcing opportunities.	1.40
04/24/20	KM	Call with D. Fogel (Purdue), R. Sublett (AlixPartners) re: API market potential.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/24/20	ADD	Call with J. Turner, T. Melvin (both PJT), J. DelConte, A. DePalma (both AlixPartners) re: open diligence items.	0.60
04/24/20	RDS	Call with D. Fogel (Purdue), K. McCafferty (AlixPartners) re: API market potential.	2.20
04/24/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: Project Catalyst insourcing assumptions.	0.50
04/25/20	RDS	Correspondence with D. Fogel (Purdue) re: CPP process.	0.20
04/25/20	JD	Review updated executive summary language in the creditor presentation. Provide comments re: same.	0.40
04/25/20	GJK	Set-up Mundipharma Diligence Interim Report.	2.50
04/25/20	GJK	Analysis of Mundipharma product category for interim report.	2.50
04/26/20	GJK	Analysis of Mundipharma analgesics by country for interim report.	2.50
04/26/20	GJK	Analysis of Mundipharma base case P&L updates.	2.50
04/26/20	JD	Final review of draft creditor presentation. Provide comments re: same.	1.30
04/27/20	JD	Review updated February flash report prior to uploading.	0.40
04/27/20	JD	Correspondence with J. Lowne and S. Robertson (Purdue) re: corporate social responsibility budget and spending year to date.	0.70
04/27/20	JD	Review forecast of restricted cash balances from 2020-2029 and correspondence with J. Lowne and E. Ruiz (both Purdue) re: same.	0.80
04/27/20	JD	Correspondence with M. Huebner (Davis Polk), B. Weingarten and M. Kesselman (Purdue) re: UCC and AHC questions re: COVID donations.	0.80
04/27/20	JD	Call with B. Weingarten (Purdue) re: COVID donations.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/27/20	JD	Call with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: non-PEO monthly flash report disclosures.	0.40
04/27/20	JD	Call with J. DelConte, I. Arana (both AlixPartners), R. Aleali, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, F. Bivens (both Davis Polk) and S. Birnbaum (Dechert) re: UCC business plan scenario request.	0.60
04/27/20	JD	Review materials and analysis re: COVID donations.	2.00
04/27/20	JD	Review Rhodes depreciation and amortization forecast from 2020-2024 in order to answer questions re: same.	0.60
04/27/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: finance and R&D transformation for Rhodes.	0.30
04/27/20	JD	Follow up call with B. Weingarten (Purdue) re: COVID donations.	0.30
04/27/20	JD	Call with J. Lowne (Purdue) re: business plan scenarios.	0.50
04/27/20	IA	Review final version of business plan presentation shared with the committees.	1.10
04/27/20	IA	Call with Purdue Human Resources team re: employee roster data request for PHI cash flow analysis.	0.30
04/27/20	NAS	Build check functionality in Mundipharma business plan model for gross margin and unit COGS analyses.	1.40
04/27/20	NAS	Call with G. Koch (AlixPartners) re: Mundipharma diligence priorities for week of 4/27.	0.40
04/27/20	NAS	Create revised priority list in advance of Mundipharma market/product review with G. Koch (AlixPartners).	0.90
04/27/20	NAS	Call with G. Koch (AlixPartners) to review sales, gross margin, and selling & promotion cost assumptions for key Mundipharma product/market pairs.	3.50
04/27/20	NAS	Build selling & promotion expense benchmarks in	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma business plan model following market/product review with G. Koch (AlixPartners).	
04/27/20	GJK	Call with N. Simon (AlixPartners) re: Mundipharma diligence priorities for week of 4/27.	0.40
04/27/20	GJK	Call with N. Simon (AlixPartners) to review sales, gross margin, and selling & promotion cost assumptions for key Mundipharma product/market pairs.	3.50
04/27/20	GJK	Update call with J. Turner (PJT).	0.40
04/27/20	GJK	Review Mundipharma model, margin by market and product.	2.50
04/27/20	GJK	Conduct planning for Mundipharma interim report including identifying key limitations.	3.00
04/27/20	MH	Call with supply chain on vendor invoice re: petition status.	0.50
04/27/20	MH	Review invoice to determine correct petition status.	0.40
04/27/20	MH	Meet with analyst to transition accounts payable process.	0.60
04/27/20	MH	Create accounts payable release file.	0.70
04/27/20	IA	Call with J. DelConte, I. Arana (both AlixPartners), R. Aleali, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, F. Bivens (both Davis Polk) and S. Birnbaum (Dechert) re: UCC business plan scenario request.	0.60
04/27/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: finance and R&D transformation for Rhodes.	0.30
04/27/20	RDS	Preparation of kick-off materials for finance transformation discussion with Rhodes management.	2.50
04/27/20	RDS	Call with D. Fogel (Purdue), K. McCafferty (AlixPartners) re: finance transformation.	0.80
04/27/20	RDS	Call re: financial transformation work plan with S.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Rayburn, K. McCafferty, R. Sublett (all AlixPartners).	
04/27/20	RDS	Review of creditor presentation and edits to presentation of free cash flow for one-time items.	0.40
04/27/20	KM	Prepare next phase planning for Rhodes R&D and Finance initiatives.	0.70
04/27/20	KM	Analysis re: IQVIA API volumes.	1.70
04/27/20	KM	Call with D. Fogel (Purdue), R. Sublett (AlixPartners) re: finance transformation.	0.80
04/27/20	KM	Project Catalyst planning.	0.10
04/27/20	KM	Workplan development for Rhodes finance re-engineering.	0.90
04/27/20	KM	Project Catalyst strategic planning analysis.	0.70
04/27/20	KM	Re-engineering rollout plan development.	1.30
04/27/20	KM	Develop financial re-engineering program materials.	1.00
04/27/20	KM	API insourcing rollout materials.	0.50
04/27/20	KM	Call re: financial transformation work plan with S. Rayburn, K. McCafferty, R. Sublett (all AlixPartners).	0.70
04/27/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: finance and R&D transformation for Rhodes.	0.30
04/28/20	KM	Rhodes Finance re-engineering analysis.	1.00
04/28/20	KM	Workplan development re: re-engineering.	0.50
04/28/20	KM	Call with R. Sublett (AlixPartners), D. Fogel (Purdue) and re: finance re-engineering.	1.60
04/28/20	KM	API insourcing analysis.	2.00
04/28/20	KM	Meeting with J. DelConte (AlixPartners) re: Rhodes finance re-engineering plan.	0.30
04/28/20	KM	API insourcing analysis (continued).	0.70
04/28/20	KM	Meeting with W. DiNicola, D. Fogel (both Purdue) re:	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Project Catalyst.	
04/28/20	KM	Analysis re: go forward strategic options.	0.30
04/28/20	KM	Call with R. Sublett (AlixPartners) re: Catalyst analysis.	0.20
04/28/20	KM	Analysis and slide creation re: Project Catalyst analysis and synopsis.	1.20
04/28/20	RDS	Assemble finance transformation materials for meeting with management.	0.60
04/28/20	RDS	Call with K. McCafferty (AlixPartners), D. Fogel (Purdue) re: finance re-engineering.	1.60
04/28/20	RDS	Analysis of latest Project Catalyst materials.	2.20
04/28/20	RDS	Call with K. McCafferty (AlixPartners) re: Catalyst analysis.	0.20
04/28/20	IA	Review updated employee roster for severance analysis in PHI costs scenarios requested by committees.	1.40
04/28/20	IA	Calculate severance for current employee roster and rolled out estimates through 2025 for PHI scenario analysis.	2.10
04/28/20	IA	Calculate retention estimates based on latest retention trackers and rolled that out through 2025 for PHI scenario analysis.	1.70
04/28/20	MH	Advise on hold codes required for accounts payable in light of new situations.	0.20
04/28/20	MH	Create accounts payable release file.	0.70
04/28/20	GJK	Discussion with N. Simon (AlixPartners) re: Mundipharma Selling & Promotion expense benchmarks.	1.20
04/28/20	GJK	Mundipharma product- and market-level review session with N. Simon (AlixPartners) to assess potential adjustments to management forecast.	2.80
04/28/20	GJK	Analysis of Mundipharma Rezafungin product.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/28/20	GJK	Review of Mundipharma model and identification of further adjustments needed for base case.	2.80
04/28/20	GJK	Draft Mundipharma interim diligence report - slide updates, including CH slide.	2.00
04/28/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma Selling & Promotion expense benchmarks.	1.20
04/28/20	NAS	Add new Selling & Promotion expense benchmarks to Mundipharma business plan model.	2.90
04/28/20	NAS	Review new Mundipharma diligence files provided by Huron.	0.50
04/28/20	NAS	Mundipharma product- and market-level review session with G. Koch (AlixPartners) to assess potential adjustments to management forecast.	2.80
04/28/20	NAS	Analysis of Mundipharma historical reporting segment/classification for Rezafungin.	0.80
04/28/20	JD	Call with R. Aleali (Purdue) re: process update and go forward planning.	0.50
04/28/20	JD	Review materials provided by Purdue management re: scenario analysis.	0.80
04/28/20	JD	Correspondence with M. Huebner (Davis Polk) re: COVID donations.	0.50
04/28/20	JD	Meeting with K. McCafferty (AlixPartners) re: Rhodes finance re-engineering plan.	0.30
04/29/20	JD	Review responses from management re: open diligence questions.	1.00
04/29/20	JD	Review revised Mundipharma budget file.	1.50
04/29/20	JD	Call with J. DelConte, I. Arana (both AlixPartners), J. Lowne (Purdue), J. Turner and R. Schnitzler (both PJT) re: business planning scenarios.	0.80
04/29/20	JD	Review and provide comments on analysis for UCC	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business planning scenarios.	
04/29/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) re: update on IAC diligence.	0.50
04/29/20	JD	Review historical liquidation analyses related to wind down assumptions.	2.30
04/29/20	NAS	Review revised Mundipharma management forecast.	1.60
04/29/20	NAS	Revise Mundipharma business plan model to incorporate new G&A, other income, expenses and R&D per revised forecast.	1.80
04/29/20	NAS	Discussion with G. Koch (AlixPartners) re: revised Mundipharma management forecast and implications for business plan model and interim report.	1.10
04/29/20	NAS	Change fixed/variable cost formulas in Mundipharma business plan model to incorporate revised management forecast.	1.80
04/29/20	NAS	Call with G. Koch (AlixPartners) re: status of Mundipharma diligence and review business plan model after incorporating revised forecast.	0.70
04/29/20	NAS	Ensure all products in Mundipharma business plan model have associated costs and correct where necessary.	2.90
04/29/20	NAS	Revise Mundipharma business plan model to align with management's product reporting segments.	1.60
04/29/20	GJK	Call with I. McClatchy (Norton Rose) re: diligence process.	0.70
04/29/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) re: update on IAC diligence.	0.50
04/29/20	GJK	Call with B. Bromberg (FTI) re: re-forecasted Mundipharma business plan.	0.30
04/29/20	GJK	Discussion with N. Simon (AlixPartners) re: revised Mundipharma management forecast and implications for	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan model and interim report.	
04/29/20	GJK	Calls with N. Simon (AlixPartners) re: status of Mundipharma diligence and review business plan model after incorporating revised forecast.	0.70
04/29/20	GJK	Walkthrough Mundipharma revised business plan.	2.90
04/29/20	GJK	Mundipharma diligence planning activities including follow up exchanges with Huron re: re-forecasted business plan.	2.50
04/29/20	IA	Follow up with human resources on questions re: current employee roster and headcount allocations for PHI cash flow analysis.	0.90
04/29/20	IA	Review April market consumption and market share data for Avrio products.	1.30
04/29/20	IA	Call with J. DelConte, I. Arana (both AlixPartners), J. Lowne (Purdue), J. Turner and R. Schnitzler (both PJT) re: business planning scenarios.	0.80
04/29/20	IA	Update PHI cash flow analysis to include comments from J. Lowne and PJT.	1.40
04/29/20	IA	Update PHI cash flow analysis to separate costs for business development assets.	2.20
04/29/20	IA	Call with E. Liesman (Purdue) re: Adhansia headcount in business plan.	0.30
04/29/20	RDS	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty (AlixPartners) re: financial impact of latest data on Project Catalyst.	1.10
04/29/20	RDS	Call with D. Lundie, D. Fogel, W. DiNicola (Purdue), K. McCafferty (AlixPartners) re: Project Catalyst figures to share with board members.	1.40
04/29/20	RDS	Analysis of various scenarios for Project Catalyst.	0.40
04/29/20	KM	Analysis re: Project Catalyst.	1.00
04/29/20	KM	Meeting with D. Fogel, W. DiNicola (both Purdue) re:	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Project Catalyst.	
04/29/20	KM	Analysis re: API volume and IQVIA analysis.	0.30
04/29/20	KM	Meeting with R. Shamblen (Purdue) re: Project Catalyst.	1.00
04/29/20	KM	Meeting with D. Fogel, W. DiNicola, D. Lundie (all Purdue) re: Catalyst Board slide.	0.50
04/29/20	KM	Meeting with D. Fogel, W. DiNicola (Purdue), R. Sublett (AlixPartners) re: financial impact of latest data on Project Catalyst.	1.10
04/29/20	KM	Analysis re: go forward strategic options.	1.90
04/29/20	KM	Analysis re: API volume and IQVIA analysis (continued).	0.30
04/29/20	KM	Analysis re: go forward strategic options (continued).	0.50
04/29/20	KM	Call with D. Lundie, D. Fogel, W. DiNicola (Purdue), R. Sublett (AlixPartners) re: Project Catalyst figures to share with board members.	1.40
04/30/20	KM	Finance re-engineering survey.	0.60
04/30/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
04/30/20	KM	Project Catalyst strategic planning review.	0.40
04/30/20	KM	Finance re-engineering data request.	0.50
04/30/20	KM	Analysis re: Project Catalyst strategic options.	1.00
04/30/20	KM	Analysis re: Project Catalyst strategic options (cont.).	0.50
04/30/20	KM	Analysis and summary re: Project Catalyst financial requirements.	2.00
04/30/20	RDS	Review of third-Party API insourcing opportunity sizing.	0.70
04/30/20	RDS	Review potential insourcing opportunities.	0.70
04/30/20	GJK	Revisions to Mundipharma business model.	0.30
04/30/20	GJK	Calls with N. Simon (AlixPartners) re: review analysis of Mundipharma 2019 year-end estimate vs. actuals and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		discuss how to revise business plan model.	
04/30/20	GJK	Call with N. Simon (AlixPartners) re: Mundipharma business plan and model walkthrough to review revised S&P model, comparison to management forecast, and new P&L format.	2.30
04/30/20	GJK	Call with Mundipharma, Huron, Advisor re: Iqvia data provided by Mundipharma.	0.50
04/30/20	GJK	Draft Mundipharma interim diligence report - P&L analysis and edits.	3.00
04/30/20	GJK	Draft Mundipharma interim report - business strategy narrative and supporting analysis.	3.00
04/30/20	MH	Walkthrough accounts payable release process with M. Hartley (AlixPartners) and S. Lemack (AlixPartners).	0.70
04/30/20	NAS	Compare current Mundipharma business plan model to latest forecast provided by management.	0.30
04/30/20	NAS	Adjust costs for specific products in Mundipharma business plan model following internal discussions.	0.70
04/30/20	NAS	Call with G. Koch (AlixPartners) re: Mundipharma business plan and model walkthrough to review revised S&P model, comparison to management forecast, and new P&L format.	2.30
04/30/20	NAS	Call with D. Freeman (Mundipharma) and Mundipharma diligence advisors re: IQVIA data provided.	0.50
04/30/20	NAS	Revise P&Ls in Mundipharma business plan model to conform with new structure presented in 4/29 revised forecast.	2.90
04/30/20	NAS	Analysis of variance in financials provided by Mundipharma between 2019 year-end estimate and actual performance.	1.00
04/30/20	NAS	Call with G. Koch (AlixPartners) re: review analysis of	0.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma 2019 year-end estimate vs. actuals and discuss how to revise business plan model.	
04/30/20	NAS	Provide overview of Mundipharma net working capital assumptions for PJT.	1.20
04/30/20	NAS	Analysis of depreciation and amortization line items incorporated in management's revised forecast and ensure alignment with latest draft of Mundipharma business plan model.	1.80
04/30/20	IA	Update PHI cash flow scenario and costs analysis to include comments from J. Lowne (Purdue).	1.70
04/30/20	IA	Call with J. Lowne (Purdue) and I. Arana, J. DelConte (both AlixPartners) re: updated PHI cash flow scenarios and cost estimates.	0.30
04/30/20	IA	Update PHI cash flow and costs analysis to show additional years for sale scenarios.	1.90
04/30/20	JD	Update latest professional fee forecast for recently filed fee apps.	0.60
04/30/20	JD	Review and provide comments on latest business scenario analysis.	0.70
04/30/20	JD	Review pre-read board materials prior to Board meeting.	1.00
04/30/20	JD	Participate in Purdue Board meeting.	3.50
04/30/20	JD	Call with J. Lowne (Purdue) and I. Arana, J. DelConte (both AlixPartners) re: updated PHI cash flow scenarios and cost estimates.	0.30
04/30/20	JD	Call with J. Turner (PJT) and R. Aleali (Purdue) re: post-Board meeting catch up.	0.30
04/30/20	JD	Review quarterly financial presentations to be provided to the committee advisors.	0.80
05/01/20	JD	Call with I. Arana, J. DelConte (both AlixPartners), K. Laurel, J. Lowne (both Purdue) re: PHI scenarios	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		requested by the committees.	
05/01/20	JD	Review summary materials re: COVID donation recipients.	0.40
05/01/20	IA	Review G&A detail file for Purdue 2020 budget to be incorporated into cash flow model.	1.20
05/01/20	IA	Call with I. Arana, J. DelConte (both AlixPartners), K. Laurel, J. Lowne (both Purdue) re: PHI scenarios requested by the committees.	0.60
05/01/20	NAS	Consolidate and prioritize remaining open items for Mundipharma business plan model.	0.40
05/01/20	NAS	Separate Israel joint venture and allocate other line items in Mundipharma business plan model.	2.00
05/01/20	NAS	Call with J. Arsic (PJT), N. Simon, G. Koch (both AlixPartners) re: latest draft of Mundipharma business plan model; follow-up discussion with G. Koch (AlixPartners) afterwards.	0.80
05/01/20	NAS	Update Mundipharma individual country/product P&Ls to incorporate revisions to management's forecast.	1.40
05/01/20	NAS	Call with N. Simon, G. Koch (both AlixPartners) to compare latest Mundipharma business plan model output with management's revised forecast.	0.70
05/01/20	NAS	Analyze Mundipharma net working capital by region as shown in most recent balance sheet and income statement.	2.40
05/01/20	GJK	Call with J. Arsic (PJT), N. Simon, G. Koch (both AlixPartners) re: latest draft of Mundipharma business plan model; follow-up discussion with N. Simon (AlixPartners) afterwards.	0.80
05/01/20	GJK	Call with N. Simon, G. Koch (both AlixPartners) to compare latest Mundipharma business plan model output with management's revised forecast.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/01/20	GJK	Mundipharma NWC review and follow up.	0.50
05/01/20	GJK	Draft background slides for Mundipharma interim report.	3.00
05/01/20	GJK	Analysis of Mundipharma revised business plan.	2.00
05/01/20	GJK	Analysis of analgesics product category for draft Mundipharma diligence interim report slides.	3.50
05/01/20	KM	Analysis re: Project Catalyst insourcing savings.	1.00
05/01/20	KM	Call with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: financial benefits of potential partnership.	1.00
05/01/20	KM	Prepare Rhodes finance re-engineering stages of excellence.	0.90
05/01/20	KM	Analysis re: Rhodes finance stages of excellence.	0.60
05/01/20	KM	Call with R. Shamblan, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst insourcing savings analysis.	0.90
05/01/20	KM	Analysis and slide creation re: Project Catalyst insourcing savings analysis.	0.70
05/01/20	RDS	Call with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: financial benefits of potential partnership.	1.00
05/01/20	RDS	Call with R. Shamblan, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst insourcing savings analysis.	0.90
05/01/20	RDS	Review case progress and follow up on CPP and Project Catalyst.	0.40
05/02/20	GJK	Analysis of Canada region for draft Mundipharma diligence interim report slides.	3.00
05/02/20	GJK	Create comparative geographic regions slides for draft Mundipharma diligence interim report slides.	3.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/02/20	GJK	Analyze variance between OB 2020 and April Revised Mundipharma business plans.	2.00
05/02/20	GJK	Call with J. Turner (PJT) re: potential Mundipharma transaction structure.	0.30
05/03/20	GJK	Create slides on key products by geographic region for Mundipharma interim diligence report.	4.00
05/03/20	GJK	Assess S&P and MA spend for certain products for Mundipharma interim diligence report.	1.00
05/03/20	GJK	Update base case deck for Mundipharma interim diligence report.	3.00
05/03/20	NAS	Revise individual country P&L in Mundipharma business plan model.	2.30
05/03/20	JD	Review potential segment financial materials for 5/4 call with creditors.	0.70
05/03/20	JD	Review diligence questions from M. Atkinson (Province) and proposed responses from management re: business plan presentation.	0.80
05/04/20	JD	Correspondence with J. Turner (PJT) and J. Lowne (Purdue) re: follow up questions from Jefferies after the business plan call.	0.70
05/04/20	JD	Review March financial overview presentation in advance of creating the monthly flash report for creditors.	1.00
05/04/20	JD	Correspondence with R. Aleali (Purdue) and J. Turner (PJT) re: Project Catalyst.	0.30
05/04/20	JD	Review follow up questions from Province re: business plan overview conversation.	0.40
05/04/20	JD	Review RALP segment financials in order to be uploaded to the data room.	0.60
05/04/20	JD	Review updated Rhodes and Purdue NSP and NPA data to be uploaded for creditor advisors.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/04/20	NAS	Edit and update to Mundipharma diligence report draft.	1.00
05/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to plan Mundipharma diligence priorities for week.	0.50
05/04/20	NAS	Review latest version of Mundipharma business plan model for completeness.	1.60
05/04/20	NAS	Revise P&L format in Mundipharma business plan model to match new format used in management forecast.	0.40
05/04/20	NAS	Translate country adjustments in Mundipharma business plan model to consolidated P&L.	2.30
05/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma business plan model.	1.20
05/04/20	NAS	Revise Mundipharma China/LAM section of diligence report.	2.00
05/04/20	NAS	Review draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.60
05/04/20	NAS	Compare Mundipharma China EBIT in model relative to management forecast.	1.40
05/04/20	NAS	Revise process overview and Mundipharma Europe section of diligence report.	2.90
05/04/20	GJK	Call with G. Koch, N. Simon, (both AlixPartners) to plan Mundipharma diligence priorities for week.	0.50
05/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma business plan model.	1.20
05/04/20	GJK	Review draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.60
05/04/20	GJK	Draft updates to general overview and diligence process slides for Mundipharma interim diligence report.	3.00
05/04/20	GJK	Draft key findings overview for analgesic category for Mundipharma interim diligence report.	3.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/04/20	GJK	Update analysis around analgesics based on revised model (Matla format).	3.00
05/04/20	GJK	Finalize draft section for analgesics for Mundipharma interim diligence report.	2.40
05/04/20	IA	Review March results board update presentation, to be used for March monthly flash report.	1.40
05/04/20	RDS	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R. Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/04/20	RDS	Prepare finance transformation interview / survey data.	0.30
05/04/20	KM	Analysis and report creation re. Finance Stages of Excellence survey.	1.90
05/04/20	KM	Prepare deck re: finance re-engineering kickoff presentation.	2.30
05/04/20	KM	Edit deck re: finance re-engineering kickoff presentation.	0.80
05/05/20	KM	Prepare finance re-engineering kick-off document.	1.60
05/05/20	KM	Analysis and presentation materials creation re: finance stages of maturity assessment.	1.40
05/05/20	KM	Prepare for finance re-engineering workshop.	0.50
05/05/20	KM	Call with D. Lundi, D. Fogel, R. Shamblen, V. Mancinelli and others (all Purdue) and J. DelConte, K. McCafferty and R. Sublett (all AlixPartners) re: finance transformation.	1.50
05/05/20	KM	Analysis and hypothesis development re: finance re-engineering.	1.80
05/05/20	RDS	Review finance transformation meeting presentation and agenda in preparation of RALP meeting.	0.80
05/05/20	RDS	Build spider charts for finance organization assessment	1.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		data.	
05/05/20	RDS	Call with D. Lundi, D. Fogel, R. Shamblen, V. Mancinelli and others (all Purdue) and J. DelConte, K. McCafferty and R. Sublett (all AlixPartners) re: finance transformation.	1.50
05/05/20	RDS	Assemble materials and setup meetings for finance transformation next steps.	0.90
05/05/20	GJK	Update China analysis based on revised Malta model for Mundipharma interim diligence report.	3.50
05/05/20	GJK	Drafting Mundipharma diligence report - China product sales pages.	3.50
05/05/20	GJK	Update analysis of Europe and Canada analgesic products for Mundipharma interim diligence report.	3.00
05/05/20	GJK	Update analysis of Europe and Canada analgesic products for Mundipharma interim diligence report (cont).	2.00
05/05/20	GJK	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	1.00
05/05/20	GJK	Partial participation in call with G. Koch, N. Simon (both AlixPartners), J. Arsic, I. Mian (both PJT) re: latest drafts of Mundipharma model and report.	0.50
05/05/20	NAS	Respond to question from PJT re: expiration dates of Mundipharma licensing agreements.	1.00
05/05/20	NAS	Provide update on Mundipharma business plan model to PJT.	0.80
05/05/20	NAS	Draft Mundipharma Germany commentary for Europe section of diligence report.	0.60
05/05/20	NAS	Review responses to Mundipharma Europe Q&A provided by Huron.	0.80
05/05/20	NAS	Call with N. Simon, G. Koch (both AlixPartners), J. Arsic, I. Mian (both PJT) re: latest drafts of Mundipharma model	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and report.	
05/05/20	NAS	Revise Consumer Health section of Mundipharma business plan model.	1.00
05/05/20	NAS	Draft Mundipharma Consumer Health slides for diligence report.	1.90
05/05/20	NAS	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	1.00
05/05/20	NAS	Revise overview section of Mundipharma diligence report.	1.10
05/05/20	NAS	Build product-level metrics for Mundipharma Southeast Asia region in business plan model.	2.00
05/05/20	JD	Call with D. Lundi, D. Fogel, R. Shamblen, V. Mancinelli and others (all Purdue) and J. DelConte, K. McCafferty and R. Sublett (all AlixPartners) re: finance transformation.	1.50
05/05/20	JD	Correspondence with K. Laurel and J. Lowne (both Purdue) re: contract sales force.	0.30
05/05/20	JD	Review materials re: proposed licensing transaction.	0.70
05/06/20	JD	Review and provide comments on draft PJT analysis.	1.20
05/06/20	JD	Review draft analyses of standalone Adhansia and Oncology FCF to provide to the UCC.	0.60
05/06/20	NAS	Revise Consumer Health slides in Mundipharma diligence report.	2.70
05/06/20	NAS	Investigate mix of Mundipharma Consumer Health products in new data provided by management.	1.50
05/06/20	NAS	Revise free cash flow section of Mundipharma model following discussion with PJT.	1.80
05/06/20	NAS	Draft Mundipharma Selling & Promotion slides for diligence report.	2.40
05/06/20	NAS	Revise model output reports to include 2018 and 2019	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		year-end estimated financials.	
05/06/20	NAS	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.50
05/06/20	NAS	Draft Mundipharma Medical Affairs slides for diligence report.	1.10
05/06/20	NAS	Draft Mundipharma G&A expense slides for diligence report.	1.90
05/06/20	JD	Participate in call with J. Lowne (Purdue), I. Arana, J. DelConte (both AlixPartners) and R. Schnitzler, J. Turner, J. Wang (all PJT) re: PHI scenario analysis.	0.80
05/06/20	GJK	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.50
05/06/20	GJK	Edits and updates to Mundipharma diligence report draft.	1.00
05/06/20	GJK	Draft biosimilar product category slides for Mundipharma interim diligence report .	3.00
05/06/20	GJK	Draft slides for Respiratory and Diabetes product category for Mundipharma interim diligence report .	3.00
05/06/20	GJK	Draft Oncology slides for Mundipharma interim diligence report .	3.00
05/06/20	GJK	Draft Other Ethical product slides for Mundipharma interim diligence report .	3.00
05/06/20	IA	Participate in call with J. Lowne (Purdue), I. Arana, J. DelConte (both AlixPartners) and R. Schnitzler, J. Turner, J. Wang (all PJT) re: PHI scenario analysis.	0.80
05/06/20	IA	Review 4 and 12 week April consumption data for Avrio products and calculated market share to update Avrio dashboard.	1.70
05/06/20	RDS	Call with K. McCafferty, R. Sublett (both AlixPartners), D. Fogel (Purdue) re: Rhodes Finance transformation daily update.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/06/20	RDS	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: client interview in connection with finance transformation.	0.50
05/06/20	KM	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: client interview in connection with finance transformation.	0.50
05/06/20	KM	Call with K. McCafferty, R. Sublett (both AlixPartners), D. Fogel (Purdue) re: Rhodes Finance transformation daily update.	0.90
05/06/20	KM	Analysis re: re-engineering opps.	0.60
05/06/20	KM	Interview with R. Shamblen (Purdue) re: Finance re-engineering opportunities.	1.10
05/06/20	KM	Analysis re: finance re-engineering.	0.20
05/06/20	KM	Interview with D. McGuire (Purdue) re: Finance re-engineering opportunities.	1.10
05/07/20	KM	Meeting with Rhodes supply chain team re. monthly S&OP process.	1.00
05/07/20	KM	Call with J. Northington (Purdue), R. Sublett (partial attendance), K. McCafferty (both AlixPartners) re: initial customer interview for finance transformation.	0.90
05/07/20	KM	Analysis re: Quality-related financial reporting improvement opportunities.	0.60
05/07/20	KM	Meeting with R. Shamblen (Purdue) re: cost allocations details for Bup-Nal and Hydrocodone.	0.50
05/07/20	KM	Analysis re: Bup-Nal cost accounting.	0.30
05/07/20	RDS	Call with J. Northington (Purdue), R. Sublett (partial attendance), K. McCafferty (both AlixPartners) re: initial customer interview for finance transformation.	0.40
05/07/20	RDS	Review latest pricing model for bid and provide commentary to D. Fogel (Purdue).	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/07/20	RDS	Prepare conclusions and subsequent notes coming out of interviews with R. Shamblen, D. McGuire and J. Northington (all Purdue).	1.40
05/07/20	GJK	Draft other Ethical product slides for Mundipharma interim diligence report (cont).	3.00
05/07/20	GJK	Edit key findings sections for Mundipharma interim diligence report .	3.00
05/07/20	GJK	Finalize draft of interim report general overview and key findings for PJT review and comments/edits for Mundipharma interim diligence report .	2.00
05/07/20	GJK	Mundipharma diligence reporting drafting - layout of adjusted section items for modeling by N. Simon (AlixPartners).	2.00
05/07/20	GJK	Call with N. Simon, G. Koch (both AlixPartners) re: Mundipharma adjusted case.	0.40
05/07/20	GJK	Series of calls with N Simon (AlixPartners) re: updates to draft Mundipharma diligence report.	1.20
05/07/20	GJK	Company and advisor status update and coordination call.	0.80
05/07/20	JD	Call with J. Turner and T. Melvin (both PJT), E. Ruiz and J. Lowne (both Purdue) re: business segment cash flows.	0.60
05/07/20	JD	Call with J. Lowne (Purdue) re: business plan cash flows.	0.10
05/07/20	NAS	Revise slides in consolidated Mundipharma diligence report.	2.20
05/07/20	NAS	Build P&L slides for Mundipharma Oncology and Other Ethical segments.	0.50
05/07/20	NAS	Draft Mundipharma Other Ethical segment slides for diligence report.	1.40
05/07/20	NAS	Draft overview slide of data provided and limitations for Mundipharma diligence report.	1.00
05/07/20	NAS	Review latest draft of Mundipharma diligence report.	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/07/20	NAS	Call with N. Simon, G. Koch (both AlixPartners) re: Mundipharma adjusted case.	0.40
05/07/20	NAS	Set up Mundipharma model to incorporate adjusted case and calculate changes relative to base case.	1.90
05/07/20	NAS	Test first two changes in adjustment case within Mundipharma business plan model.	0.20
05/08/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: type and magnitude of adjustments to be made in adjusted case Mundipharma business plan model.	1.40
05/08/20	NAS	Incorporate initial adjustments in Mundipharma business plan model.	2.50
05/08/20	NAS	Review all tabs in Mundipharma business plan model and current slides in diligence report for accuracy.	2.70
05/08/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: initial draft of Mundipharma adjusted case.	2.90
05/08/20	NAS	Revise adjustments in Mundipharma business plan model adjusted case following discussion with G. Koch (AlixPartners).	1.70
05/08/20	JD	Review financial analysis of potential licensing agreement.	0.70
05/08/20	JD	Review correspondence from R. Aleali (Purdue) and A. DePalma (AlixPartners) re: UCC diligence response.	0.30
05/08/20	JD	Review preliminary professional fee estimates for company month end accruals.	0.50
05/08/20	JD	Correspondence with R. Aleali (Purdue) and S. Lemack (AlixPartners) re: publicly filed financial reports.	0.30
05/08/20	JD	Review updated comments from J. Lowne (Purdue) re: AHC diligence requests.	0.40
05/08/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: type and magnitude of adjustments to be made in adjusted case Mundipharma business plan model.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/08/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: initial draft of Mundipharma adjusted case.	2.90
05/08/20	LJD	Call with R. Aleali (Purdue) re: audit committee meeting.	0.60
05/08/20	LJD	Review and comment on draft IAC report.	3.50
05/08/20	GJK	Create key adjustments impact analysis for Mundipharma interim diligence report .	3.00
05/08/20	GJK	Create key adjustments impact analysis on volume drivers for Mundipharma interim diligence report .	1.00
05/08/20	RDS	Call with V. Mancinelli (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: customer interview.	1.20
05/08/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: finance re-engineering opportunities.	1.50
05/08/20	KM	Coordination of Rhodes partnership implementation effort.	0.80
05/08/20	KM	Analysis and follow up re: finance interviews with BU leaders.	1.40
05/08/20	KM	Call with D. Fogel (Purdue) re: data collection.	0.10
05/08/20	KM	Analysis and hypothesis development re: finance re-engineering.	0.90
05/08/20	KM	Analysis and edit re. flash report and update presentation finance re-engineering project.	1.90
05/08/20	KM	Call with V. Mancinelli (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: customer interview.	1.20
05/08/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: finance re-engineering opportunities.	1.50
05/08/20	KM	Research and planning re: finance re-engineering opportunities.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/08/20	RDS	Review and provide commentary for week 1 flash report of finance transformation strategy analysis.	0.40
05/09/20	GJK	Edit key adjustments impact slides for Mundipharma interim diligence report .	3.00
05/09/20	GJK	Review key adjustments and reduce impact of certain items and analysis of EBIT impact; variance review.	3.50
05/09/20	LJD	Review documents and correspondence from creditors.	0.90
05/09/20	LJD	Review discussion docs for creditor meetings.	0.90
05/09/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: walk through specific adjustments to base case Mundipharma business model.	0.40
05/09/20	NAS	Incorporate revisions to Mundipharma adjusted case following correspondence with G. Koch (AlixPartners).	2.40
05/09/20	NAS	Respond to question from PJT re: Mundipharma capital structure.	0.80
05/09/20	NAS	Review latest Mundipharma adjusted case following revisions to magnitude of adjustments.	0.30
05/09/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: walk through specific adjustments to base case Mundipharma business model.	0.40
05/10/20	NAS	Provide Mundipharma adjusted case model to PJT and corresponding overview.	0.50
05/10/20	GJK	Tie out risk adjustments from analysis.	2.00
05/10/20	GJK	Create risk adjustment overview slides for Mundipharma interim diligence report.	2.00
05/10/20	GJK	Draft risk adjustment slides for Mundipharma interim diligence report on impact of changes in OxyContin prices and impact of SG&A.	2.00
05/10/20	GJK	Analyze FTEs related to S&P in China and draft related slide.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/11/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma adjusted case presentation and discuss latest developments in diligence process.	1.00
05/11/20	GJK	Call with I. McClatchey (Norton Rose) re: Mundipharma board process.	0.70
05/11/20	GJK	Follow up call with J. Turner (PJT) re: Deutsche Bank.	0.20
05/11/20	GJK	Revised risk adjustment slides for Mundipharma interim diligence report.	3.00
05/11/20	GJK	Follow up analysis on risk adjustment impact for Mundipharma interim diligence report.	2.00
05/11/20	GJK	Coordinate on plan for open issues in Mundipharma diligence.	2.00
05/11/20	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	0.20
05/11/20	LJD	Review correspondence re: Mundipharma sales process.	0.40
05/11/20	NAS	Review initial draft of slides related to Mundipharma adjusted case.	2.10
05/11/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma adjusted case presentation and discuss latest developments in diligence process.	1.00
05/11/20	NAS	Correspondence with PJT re: latest draft of Mundipharma diligence report.	0.20
05/11/20	IA	Review and edit April business plan presentation to be shared on non PEO basis with creditors, for review by management and legal.	2.30
05/11/20	IA	Draft summary of changes to April business plan presentation to be shared on non PEO basis with creditors, for review by management and legal.	0.90
05/11/20	IA	Provide comments to latest version of side by side requested by creditors.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/11/20	IA	Update side by side cost assumptions to reflect comments received from Purdue management.	1.20
05/11/20	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	0.20
05/11/20	JD	Call with R. Aleali (Purdue) re: creditor discussions and board meeting agenda.	0.40
05/11/20	JD	Review recent Project Catalyst letter of intent.	0.20
05/11/20	JD	Review initial draft IAC diligence presentation.	1.50
05/11/20	JD	Review flash reports provided to date per company request.	0.50
05/11/20	ADD	Extract and organize data to review and analyze liabilities subject to compromise.	1.50
05/11/20	KM	Analysis re: time allocation tracking for Finance.	0.70
05/11/20	KM	Analysis re: Maraviroc development / regulatory cost allocations.	0.80
05/11/20	KM	Call with D. Fogel (Purdue) re: cost allocation analysis for Wilson e.g. Maraviroc.	0.50
05/11/20	KM	Prepare slide re: re-engineering meeting with D. Lundie (Purdue).	1.00
05/11/20	KM	Meeting with R. Shamblen (Purdue) re: cost allocations details for Bup-Nal and Hydrocodone.	0.50
05/11/20	KM	Analysis re: finance activity by significant contribution.	1.20
05/11/20	KM	Analysis re: unabsorbed overhead for UCC.	0.80
05/11/20	RDS	Review variable pricing finance model for cross-functional work within Rhodes organization - variabalize cost structure for true outside costs.	0.60
05/11/20	RDS	Changes to insourcing model for potential API partnership opportunities.	1.40
05/11/20	RDS	Review M&A document and transaction impact on current	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		work streams, prepare materials for call with Rhodes CFO.	
05/11/20	RDS	Review financial reporting requirements at Rhodes entities and classify along initial order of importance.	0.80
05/12/20	RDS	Prepare for call with D. Fogel (Purdue) re: review CPP information and strategic options for Project Catalyst.	0.20
05/12/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to prepare analytics for Project Catalyst and monthly board reporting updates.	1.30
05/12/20	RDS	Contextualize Project Catalyst offers in a presentation for RELT.	0.90
05/12/20	RDS	Meeting with D. Fogel, D. Lundie (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst and restructuring.	1.80
05/12/20	RDS	Meeting with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: potential strategic partnerships.	1.30
05/12/20	KM	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to prepare analytics for Project Catalyst and monthly board reporting updates.	1.30
05/12/20	KM	Analysis re: Project Catalyst analysis preparation.	0.20
05/12/20	KM	Meeting with D. Fogel, D. Lundie (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst and restructuring.	1.80
05/12/20	KM	Analysis re: Rhodes combined headcount as of March 2020.	0.70
05/12/20	KM	Meeting with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: potential strategic partnerships.	1.30
05/12/20	JD	Call with R. Schnitzler, J. Turner (both PJT), R. Aleali and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		J. Doyle (both Purdue) re: BD opportunity.	
05/12/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence update.	0.30
05/12/20	JD	Call with C. Landau, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT) and L. Donahue, J. DelConte, I. Arana (all AlixPartners) re: updated side by side re: overview presentation and assumptions.	1.10
05/12/20	JD	Review historical 10 year R&D spend in response to open diligence question from the AHC.	0.50
05/12/20	JD	Review and provide comments on the updated side by side analysis.	0.90
05/12/20	JD	Review board slides re: Rhodes BD opportunity.	0.60
05/12/20	JD	Review draft proposed redactions of the business plan creditor presentation to create a non-PEO version from I. Arana (AlixPartners).	0.60
05/12/20	IA	Review updated March monthly flash report to be submitted for approvals.	1.30
05/12/20	NAS	Review latest draft of Mundi report adjusted case slides.	1.10
05/12/20	NAS	Test potential revisions to adjusted case of Mundipharma business plan model.	0.70
05/12/20	NAS	Review Mundipharma LAM diligence Q&A provided by Huron.	0.50
05/12/20	NAS	Call with M. Diaz, B. Bromberg (both FTI) and N. Simon, G. Koch (both AlixPartners) re: Mundipharma diligence process and key areas not responded to.	0.80
05/12/20	NAS	Call with J. Arsic (PJT) re: current status of Mundipharma diligence report and remaining open questions.	0.40
05/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to coordinate on best approach for Mundi diligence process	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and provide update on PJT analysis for report.	
05/12/20	LJD	Review revised UCC deck and comment.	0.80
05/12/20	LJD	Call with PJT.	0.40
05/12/20	LJD	Call with C. Landau, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT) and L. Donahue, J. DelConte, I. Arana (all AlixPartners) re: updated side by side re: overview presentation and assumptions.	1.10
05/12/20	GJK	Coordinate and plan on open items for LAM Region responses.	2.00
05/12/20	GJK	Review of Mundipharma selected responses to LAM region questions.	3.00
05/12/20	GJK	Follow up analysis on SG&A spend for Mundipharma interim diligence report.	2.00
05/12/20	GJK	Review open items for Mundipharma interim diligence report.	2.00
05/12/20	GJK	Call with M. Diaz, B. Bromberg (both FTI) and N. Simon, G. Koch (both AlixPartners) re: Mundipharma diligence process and key areas not responded to.	0.80
05/12/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence update.	0.30
05/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to coordinate on best approach for Mundi diligence process and provide update on PJT analysis for report.	0.70
05/12/20	IA	Call with C. Landau, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT) and L. Donahue, J. DelConte, I. Arana (all AlixPartners) re: updated side by side re: overview presentation and assumptions.	1.10
05/13/20	GJK	Update risk adjustment slides for Mundipharma interim	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence report based on updated Mundipharma responses.	
05/13/20	GJK	Review of Mundipharma selected responses to Europe region questions.	3.00
05/13/20	GJK	Add in product x volume for 2019 for comparative analysis.	3.00
05/13/20	GJK	Call with KPMG, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors re: findings from IAC tax workstream.	1.40
05/13/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report.	0.40
05/13/20	LJD	Review and comment on revised side by side analysis.	0.70
05/13/20	LJD	Call with PJT re: scenarios for UCC and split of AlixPartners work versus PJT work.	0.40
05/13/20	NAS	Review latest draft of diligence requests from Advisor Group to Mundipharma.	0.60
05/13/20	NAS	Review latest draft of Mundipharma diligence report and comment for revisions where necessary.	3.20
05/13/20	NAS	Review KPMG materials in advance of IAC tax discussion.	0.40
05/13/20	NAS	Call with KPMG, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors re: findings from IAC tax workstream.	1.40
05/13/20	IA	Update PHI scenario costs to incorporate Purdue management's comments, updated summaries and submitted for review by PJT and J. Lowne (Purdue).	2.70
05/13/20	IA	Participate in call with I. Arana, J. DelConte (both AlixPartners), R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	0.70
05/13/20	IA	Finalize non PEO draft of April business plan presentation	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		requested by committees and submitted for review by PJT and Purdue management.	
05/13/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report.	0.40
05/13/20	JD	Review draft presentation re: Project Catalyst in advance of call with the team.	0.80
05/13/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst.	0.50
05/13/20	JD	Review updated scenarios for UCC scenario analysis and provide comments.	0.60
05/13/20	JD	Review and provide comments on draft sales reports.	0.40
05/13/20	JD	Review latest weekly NPA data.	0.30
05/13/20	JD	Initial review of emergence structure analysis from Davis Polk.	1.30
05/13/20	JD	Call with J. Lowne (Purdue) re: UCC scenario analysis.	0.20
05/13/20	JD	Participate in call with I. Arana, J. DelConte (both AlixPartners), R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	0.70
05/13/20	JD	Call with D. Lundie, C. Landau, M. Kesselman, J. Lowne and others (Purdue), K. McCafferty, J. DelConte, R. Sublett (AlixPartners) re: Project Catalyst observations, recommendations and conclusions.	1.00
05/13/20	KM	Analysis of sourcing options.	1.00
05/13/20	KM	Analysis and slide preparation re: Project Catalyst 5/13 presentation to Landau/Lowne/Kesselman.	0.90
05/13/20	KM	Meeting with R. Shamblen and D. Fogel (both Purdue) re: potential offer.	0.40
05/13/20	KM	Analysis re: potential insourcing partnership.	0.60
05/13/20	KM	Analysis re: potential insourcing partnership (continued).	1.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/13/20	KM	Call with D. Fogel, D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: updated Project Catalyst comparison presentations.	0.50
05/13/20	KM	Analysis and slide preparation re: Project Catalyst 5/13 presentation to Landau/Lowne/Kesselman.	1.40
05/13/20	KM	Edit presentation re: Project Catalyst 5/13 presentation to Landau/Lowne/Kesselman.	0.40
05/13/20	KM	Call with D. Lundie, C. Landau, M. Kesselman, J. Lowne and others (Purdue), K. McCafferty, J. DelConte, R. Sublett (AlixPartners) re: Project Catalyst observations, recommendations and conclusions.	1.00
05/13/20	KM	Next steps planning for Project Catalyst.	0.20
05/13/20	RDS	Assemble materials re: Project Catalyst with J. Lowne (Purdue) according to input from D. Lundie & D. Fogel (Purdue).	1.00
05/13/20	RDS	Assemble presentation to compare metrics for various Project Catalyst proposals.	1.90
05/13/20	RDS	Call with D. Fogel, D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: updated Project Catalyst comparison presentations.	0.50
05/13/20	RDS	Turn comments from D. Lundie (Purdue), with regard to the Project Catalyst presentation to senior PPLP management.	0.60
05/13/20	RDS	Call with D. Lundie, C. Landau, M. Kesselman, J. Lowne and others (Purdue), K. McCafferty, J. DelConte, R. Sublett (AlixPartners) re: Project Catalyst observations, recommendations and conclusions.	1.00
05/14/20	RDS	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, R. Shamblan, J. Doyle, R. Aleali, D. Fogel (all Purdue), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst and approve next steps for	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		the project.	
05/14/20	RDS	Correspondence and coordination with Windsor advisors in order to prepare materials in support of Project Catalyst.	0.40
05/14/20	KM	Analysis re: Project Catalyst insourcing opportunity valuation.	0.70
05/14/20	KM	Prepare for and attend call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, R. Shamblan, J. Doyle, R. Aleali, D. Fogel (all Purdue), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst and approve next steps for the project.	1.00
05/14/20	KM	Data review and analysis re: finance restructuring.	1.20
05/14/20	KM	Data consolidation re: RALP headcount.	2.90
05/14/20	KM	Analysis and reconciliation re: RALP organizational synergies.	1.20
05/14/20	JD	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, R. Shamblan, J. Doyle, R. Aleali, D. Fogel (all Purdue), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst and approve next steps for the project.	0.70
05/14/20	JD	Mundipharma diligence update call with J Turner (PJT), G. Koch and J. DelConte (both AlixPartners).	0.30
05/14/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst and other go forward planning.	1.20
05/14/20	JD	Review update from G. Koch (AlixPartners) re: IAC diligence process prior to update call.	0.30
05/14/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners), M. Huebner, C. Robertson, T. Graulich (all Davis Polk), J. Turner, T. Coleman, J. O'Connell (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case progress and go forward planning.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/14/20	JD	Participate in PPI Board call with J. DelConte, L. Donahue (both AlixPartners), J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner (PJT), M. Huebner, C. Robertson (both Davis Polk), J. Bragg (Skadden)re: Audit Committee meeting.	1.50
05/14/20	JD	Review due diligence request list from FTI. Review materials provided to date in response to BP questions.	1.30
05/14/20	JD	Review branded P&L by segment analysis in response to open business plan diligence questions.	0.40
05/14/20	JD	Review updated UCC scenario presentation for management comments.	0.80
05/14/20	JD	Review comments and responses to open diligence requests from Province.	0.50
05/14/20	JD	Review latest draft Project Catalyst term sheets.	1.00
05/14/20	NAS	Review second half of Mundipharma diligence report draft and note comments where necessary.	1.90
05/14/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report and discuss revisions where necessary.	1.30
05/14/20	NAS	Review first half of Mundipharma diligence report draft and note comments where applicable.	2.00
05/14/20	NAS	Incorporate revisions to latest draft of Mundipharma diligence report following discussion with G. Koch (AlixPartners).	2.30
05/14/20	IA	Follow up on approvals for non PEO business plan presentation.	0.40
05/14/20	IA	Review updated side by side presentation updated per request received from UCC.	1.30
05/14/20	IA	Update Avrio dashboard to incorporate edits from Avrio management.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/14/20	IA	Gather comments and drafts responses to UCC questions on status of reporting items.	1.10
05/14/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue (both AlixPartners), M. Huebner, C. Robertson, T. Graulich (all Davis Polk), J. Turner, T. Coleman, J. O'Connell (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case progress and go forward planning.	1.10
05/14/20	LJD	Participate in PPI Board call with J. DelConte, L. Donahue (both AlixPartners), J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner (PJT), M. Huebner, C. Robertson (both Davis Polk), J. Bragg (Skadden)re: Audit Committee meeting.	1.50
05/14/20	LJD	Debrief call with J. Dubel - board member.	0.40
05/14/20	LJD	Review and comment on revised side by side presentation.	0.60
05/14/20	GJK	Draft Europe region country slides for Mundipharma interim diligence report.	3.50
05/14/20	GJK	Draft LAM region country slides for Mundipharma interim diligence report.	3.50
05/14/20	GJK	Draft LAM region country slides for Mundipharma interim diligence report (cont).	3.50
05/14/20	GJK	Review/comments/edits to N. Simon edits of Mundipharma interim diligence report.	1.50
05/14/20	GJK	Mundipharma diligence update call with J Turner (PJT), G. Koch and J. DelConte (both AlixPartners).	0.30
05/14/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report and discuss revisions where necessary.	1.30
05/14/20	MH	Discussion with M. Hartley, S. Lemack (both AlixPartners)	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: indemnification cost approval process.	
05/15/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma diligence report.	0.60
05/15/20	GJK	Edit and update to Mundipharma diligence report draft.	2.40
05/15/20	GJK	Walk through for key findings for current Mundipharma interim diligence report.	1.00
05/15/20	LJD	Review side by side UCC presentation.	0.40
05/15/20	LJD	Prepare for and attend call with J. Bragg (Skadden), S. Birnbaum (Dechert), R. Aleali, C. George (both Purdue), J. Turner (PJT) J. DelConte and L. Donahue (both AlixPartners) re: monitor findings.	0.60
05/15/20	IA	Calculate average severance per employee for Purdue, as requested by Purdue finance team for scenario modeling.	0.70
05/15/20	IA	Follow up on approvals and finalize non PEO version of business plan presentation, as requested by the committees.	1.10
05/15/20	NAS	Revise latest draft of Mundipharma diligence report following discussion with G. Koch (AlixPartners).	3.10
05/15/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma diligence report.	0.60
05/15/20	NAS	Plan Mundipharma diligence priorities for following week.	0.50
05/15/20	JD	Call with C. Robertson, E. Vonnegut (both Davis Polk), R. Schnitzler and J. Turner (all PJT) J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst.	0.70
05/15/20	JD	Call with R. Aleali (Purdue) re: monitor report.	0.20
05/15/20	JD	Call with R. Aleali (Purdue) re: UCC scenarios.	0.20
05/15/20	JD	Call with S. Lemack (Purdue) re: diligence items and monthly reporting.	0.20
05/15/20	JD	Call with J. Bragg (Skadden), S. Birnbaum (Dechert), R. Aleali, C. George (both Purdue), J. Turner (PJT) J.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DelConte and L. Donahue (both AlixPartners) re: monitor findings.	
05/15/20	JD	Review and pull MOR from Insys for J. Lowne (Purdue).	0.20
05/15/20	JD	Review analysis of severance by employee for Purdue.	0.50
05/15/20	KM	Analysis re: finance reporting and activity analysis.	1.30
05/15/20	KM	Analysis re: organizational restructuring proposal from Big 4.	0.60
05/15/20	KM	Meeting with R. Haberlin (Purdue) re: finance activity and reporting.	0.50
05/15/20	KM	Meeting with W. DiNicola (Purdue) re: finance activity and reporting.	0.80
05/15/20	KM	Analysis re: finance activity.	0.60
05/15/20	KM	Meeting with J. Carlisle (Purdue) re: finance activity and reporting.	1.00
05/15/20	KM	Analysis re: Quality organization restructuring mapping to roster/salary data.	1.60
05/15/20	KM	Analysis re: Supply Chain organization restructuring mapping to roster/salary data.	0.80
05/15/20	KM	Call with J. Northington (Purdue) re: Quality organization restructuring mapping to roster/salary data.	0.70
05/15/20	KM	Analysis and Slides creation re: recommended Supply Chain organization.	1.30
05/15/20	KM	Call with C. Robertson, E. Vonnegut (both Davis Polk), R. Schnitzler and J. Turner (all PJT) J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst.	0.70
05/15/20	RDS	Call with E. Vonnegut, C. Robertson (DPW), J. DelConte, K. McCafferty (AlixPartners), J. Turner, R. Schnitzler, T. Melvin (PJT) re: Project Catalyst time line and term sheet.	0.70
05/15/20	RDS	Review proposed supply chain organizational	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		restructuring for Rhodes / Avrio.	
05/16/20	RDS	Review Rhodes Pharma generic pharmaceutical valuation analysis and impact on restructuring plans for the cost structure.	0.70
05/18/20	RDS	Assemble headcount reorganization for Rhodes R&D organization, including quality, supply chain, pharm tech and prepare presentation materials.	1.40
05/18/20	RDS	Complete weekly update discussion materials for Rhodes CFO discussion.	0.80
05/18/20	RDS	Complete pivot and other data analysis on finance team survey data for time allocations and report preparation to align strategy to proposed reorganization.	1.80
05/18/20	JD	Review Butrans Mexico royalty details.	0.50
05/18/20	JD	Review latest Project Catalyst update and legal correspondence.	0.60
05/18/20	JD	Call with C. Robertson (Davis Polk) re: open process questions.	0.20
05/18/20	JD	Call with C. Robertson (Davis Polk) and R. Aleali (Purdue) re: Project Catalyst.	0.70
05/18/20	JD	Review and provide comments on updated March flash report before sending around for approvals.	1.20
05/18/20	JD	Review details of unpaid liabilities and LSC footnote in the audited financials.	0.40
05/18/20	GJK	Analysis of key open items including 2019 actual to YEE variance.	3.00
05/18/20	GJK	Review Mundipharma balance sheets and cash forecast from YEE to assess what can be included in interim report.	3.00
05/19/20	GJK	Create draft analysis for product COGs for Mundipharma diligence.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/19/20	GJK	Review back up slides re: Mundipharma VDD for potential inclusion in report.	2.00
05/19/20	GJK	Review Consumer Health VDD for potential inclusions/back up for Mundipharma interim diligence report.	1.00
05/19/20	JD	Call with J. Lowne (Purdue) re: latest side by side deck.	0.20
05/19/20	JD	Call with J. DelConte and A. DePalma (both AlixPartners) re: diligence process and go forward work plan.	0.40
05/19/20	JD	Review and provide comments on presentation created in response to VT AG requests.	0.40
05/19/20	JD	Review latest diligence tracker for IAC diligence questions. Review correspondence re: diligence process.	0.70
05/19/20	JD	Review latest IAC diligence report in conjunction with open diligence requests.	0.80
05/19/20	RDS	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to reconcile headcount estimates to latest items and cost out assumptions.	0.80
05/19/20	RDS	Layout approach for next steps to the reorganization of the R&D organization and correspondence with M. Sisodia, D. Ebere, K. Kolar and R. TheBeau (all Purdue) re: the same.	0.70
05/19/20	RDS	Review R&D org structure and prepare presentation slides to discuss with management.	0.90
05/19/20	RDS	Meeting with D. Lundie, D. Fogel (both Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: organization strawman for Rhodes.	1.60
05/19/20	RDS	Assemble recommendation slides for finance transformation headcount organization.	0.70
05/19/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: weekly finance and R&D	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		turnaround plans.	
05/19/20	RDS	Assemble presentation materials for Rhodes Pharma analysis.	0.60
05/19/20	KM	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: weekly finance and R&D turnaround plans.	2.10
05/19/20	KM	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to reconcile headcount estimates to latest items and cost out assumptions.	0.80
05/19/20	KM	Analysis re: organization restructuring.	0.50
05/19/20	KM	Ideation and activity mapping re: RT R&D organization strawman.	1.20
05/19/20	KM	Analysis re: RT R&D organization strawman.	1.20
05/19/20	KM	Create slide re: RT R&D organization strawman.	0.80
05/19/20	KM	Meeting with D. Lundie, D. Fogel (both Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: organization strawman for Rhodes.	1.60
05/19/20	KM	Analysis re: proposed finance org structure.	0.80
05/19/20	ADD	Call with J. DelConte and A. DePalma (both AlixPartners) re: diligence process and go forward work plan.	0.40
05/20/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
05/20/20	KM	Analysis re: commercial organization restructuring.	1.00
05/20/20	KM	Analysis re: RALP headcount mapping.	1.40
05/20/20	KM	Analysis and report creation re Rhodes organization restructuring for Rhodes Tech R&D.	1.80
05/20/20	KM	Analysis re: Quality organization proposed restructuring reconciliation.	1.20
05/20/20	KM	Meeting with M. Sisoda (Purdue) and K. McCafferty, R.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Sublett (both AlixPartners) re: business development process.	
05/20/20	KM	Analysis re: recommended Rhodes Pharm Product Development org structure.	1.00
05/20/20	KM	Analysis and slide creation re: recommended Rhodes Pharm Product Development org structure.	1.50
05/20/20	KM	Analysis re: Finance re-engineering activity mapping and preliminary opportunity development.	1.10
05/20/20	RDS	Assemble organizational effectiveness materials and prepare for interviews with company representatives re: the same.	2.70
05/20/20	RDS	Review and reconciliation of quality org structure to current headcount file.	1.20
05/20/20	RDS	Prepare question list for M. Sisodia (Purdue) interview.	0.30
05/20/20	RDS	Meeting with M. Sisoda (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: business development process.	1.10
05/20/20	JD	Call with J. Lowne (Purdue) re: opioid only scenario.	0.40
05/20/20	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC update.	0.20
05/20/20	JD	Correspondence with R. Brown (Purdue) re: updated professional fee forecasts and spending to date.	1.30
05/20/20	JD	Review forms and materials collected in relation to Bureau of Economic Analysis forms to be completed and filed.	1.50
05/20/20	JD	Review and provide comments re: weekly agenda.	0.40
05/20/20	JD	Update professional fee tracker and 2020 forecast.	0.80
05/20/20	JD	Review correspondence from I. Arana (AlixPartners), R. Aleali and J. Tran (both Purdue) re: sharing Nielsen data.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/20/20	JD	Review questions from Duff & Phelps and potential responses re: public health initiatives.	1.00
05/20/20	JD	Review and provide comments on updated buyers log draft.	0.20
05/20/20	JD	Review correspondence from E. Ruiz and J. Lowne (both Purdue) re: Duff & Phelps questions.	0.30
05/20/20	NAS	Review latest Mundipharma diligence documents provided and track outstanding requests.	0.70
05/20/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma diligence priorities for remainder of week.	0.30
05/20/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), M. Diaz, B. Bromberg (both FTI) re: outstanding Mundipharma diligence requests and best approach moving forward.	0.40
05/20/20	NAS	Correspondence with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	0.20
05/20/20	GJK	Review Sales and Promotion spend 2017-2018 in VDD for Mundipharma back up.	2.50
05/20/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), M. Diaz, B. Bromberg (both FTI) re: outstanding Mundipharma diligence requests and best approach moving forward.	0.40
05/20/20	GJK	Email C. Robertson (Davis Polk) re: FTI/Kramer Levine next steps for diligence requests for Mundipharma.	0.20
05/20/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to prep for FTI Mundipharma call.	0.30
05/20/20	GJK	Draft follow up email re: Mundipharma outstanding info request items sent to Huron and Advisor group.	0.30
05/20/20	GJK	Email J. Turner (PJT) re: FTI/Kramer Levine next steps for diligence requests for Mundipharma.	0.20
05/20/20	GJK	Email J. DelConte (AlixPartners) re: FTI/Kramer Levine next steps for diligence requests for Mundipharma.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/20/20	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC update.	0.20
05/20/20	IA	Run accounts payable reports for payment review and release process.	0.60
05/20/20	IA	Draft responses to comments received from third party analytics firm on requested consent to share Avrio product information.	1.60
05/21/20	IA	Review third party comments to request for consent to share Avrio product data with the committees and update slides to reflect requested edits.	1.40
05/21/20	IA	Follow up with management on database and report details to be sent to third party as part of commentary on requested consent to share data with committees.	0.80
05/21/20	IA	Update 2021 and 2022 LTRP payment estimates to show 2017 performance breakout and payment details by level (VP and above versus below VP).	2.90
05/21/20	IA	Draft summary and notes to be sent to Davis Polk and Willis Towers Watson, summarizing requested data on 2021 and 2022 LTRP estimated payments.	1.40
05/21/20	IA	Call with I. Arana, J. DelConte (both AlixPartners), R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	0.50
05/21/20	GJK	Review of Mundipharma 2019 board decks for Mundipharma interim diligence report potential back up.	3.00
05/21/20	JD	Prepare for weekly update call.	0.30
05/21/20	JD	Call with J. Lowne (Purdue) re: financials.	0.20
05/21/20	JD	Call with J. Turner and R. Schnitzler (both PJT), J. Lowne and E. Ruiz (both Purdue) re: opioid only scenario.	0.80
05/21/20	JD	Call with I. Arana, J. DelConte (both AlixPartners), R.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	
05/21/20	JD	Review draft Project Catalyst term sheets.	2.50
05/21/20	JD	Review updated draft responses re: Nielsen data sharing.	0.40
05/21/20	JD	Review correspondence from R. Silbert and R. Aleali (both Purdue) re: open AG requests.	0.50
05/21/20	RDS	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: May dashboard update.	1.30
05/21/20	RDS	Review BD notes and prepare conclusions for pipeline process improvements for generic product development.	0.80
05/21/20	RDS	Analysis of data for recommendations re: future organizational structure.	3.10
05/21/20	RDS	Meeting with R. Thebeau (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: commercial operations org opportunities and SWOT.	1.00
05/21/20	RDS	Meeting with D. Ebere (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: product development pipeline and update processes.	1.00
05/21/20	KM	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: May dashboard update.	1.30
05/21/20	KM	Analysis re: RALP salary and wages by level.	1.70
05/21/20	KM	Meeting with R. Thebeau (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: commercial operations org opportunities and SWOT.	1.00
05/21/20	KM	Meeting with D. Ebere (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: product development pipeline and update processes.	1.00
05/21/20	KM	Analysis re: RALP supervisory / management layers and compensation.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/21/20	KM	Analysis re: Rhodes Tech org reduction opportunities.	1.70
05/22/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
05/22/20	KM	Analysis and slide creation re: recommendations for the RELT meeting 5/27.	1.90
05/22/20	KM	Analysis and slide creation re: Rhodes Tech re-org and re-engineering.	0.60
05/22/20	KM	Meeting with K. Kolar (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma R&D org opportunities and SWOT.	1.00
05/22/20	KM	Advisors call with R. Schnitzler (PJT), R. Sublett and J. DelConte (AlixPartners) re: Project Catalyst.	0.40
05/22/20	KM	Plan for Project Catalyst implementation.	0.40
05/22/20	KM	Analysis and slide creation re: Rhodes supply chain re-org and re-engineering.	1.50
05/22/20	KM	Analysis and report creation re Rhodes organization restructuring for Rhodes Tech R&D.	1.50
05/22/20	RDS	Assemble interview notes into management presentation on recommendations for organizational and process restructuring of Rhodes business.	2.40
05/22/20	RDS	Meeting with K. Kolar (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma R&D org opportunities and SWOT.	1.00
05/22/20	RDS	Call with R. Schnitzler (PJT), J. DelConte, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.40
05/22/20	RDS	Assemble slides to outline rationale for supply chain organization.	0.70
05/22/20	RDS	Organize conclusions from R&D process improvement interviews into presentation of recommendations.	2.10
05/22/20	JD	Call with R. Schnitzler (PJT), J. DelConte, K. McCafferty,	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		R. Sublett (all AlixPartners) re: Project Catalyst.	
05/22/20	JD	Call with R. Aleali (Purdue) re: deals.	0.40
05/22/20	JD	Review and provide comments on detailed opioid only business forecast assumptions.	1.00
05/22/20	JD	Review and provide comments on draft slides for Board presentation re: BD deal.	1.10
05/22/20	JD	Call with J. Lowne (Purdue) re: go forward planning.	0.20
05/22/20	JD	Call with J. Turner (PJT) re: deal process.	0.20
05/22/20	JD	Review correspondence from C. DiStefano (Purdue), E. Vonnegut (Davis Polk) and I. Arana (AlixPartners) re: bonus programs.	0.50
05/22/20	JD	Review correspondence and responses from R. Aleali and R. Silbert (both Purdue) re: AG requests.	0.40
05/22/20	NAS	Research question posed by FTI re: Mundipharma tax workstream.	0.10
05/22/20	NAS	Respond to question from J. Arsic (PJT) re: balance sheet valuation of Mundipharma joint ventures.	0.50
05/22/20	GJK	Plan for updates to Mundipharma model and interim report based on Huron's indication of updated key information to be provided.	1.50
05/23/20	JD	Correspondence with Davis Polk re: Project Catalyst.	0.30
05/23/20	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, D. Lundie (both Purdue) and J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst process management.	0.70
05/23/20	RDS	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, D. Lundie (both Purdue) and J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst process management.	0.70
05/23/20	KM	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, D.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Lundie (both Purdue) and J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst process management.	
05/24/20	RDS	Correspondence with D. Fogel, D. Lundie (both Purdue) re: ongoing workstreams.	0.60
05/25/20	RDS	Layout sales process timeline, approval steps to close and DD dataroom index	1.60
05/26/20	RDS	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. Turner, R. Schnitzler (both PJT), M. Florence, M. Gibson, J. Bragg (all Skadden), C. Robertson (Davis Polk) re: Project Catalyst	2.00
05/26/20	RDS	Review org structures before call with D. Fogel (Purdue) re: org structures.	2.20
05/26/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: org structure for BIG 4 meeting 5/27.	1.40
05/26/20	RDS	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index for Project Catalyst.	0.60
05/26/20	RDS	Build presentation for org structure discussion with D. Lundie (Purdue) incorporating commentary from D. Fogel (Purdue).	1.50
05/26/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst action items.	0.70
05/26/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: discussion of organization restructuring options.	1.10
05/26/20	RDS	Advisors meeting with J. DelConte, A. DePalma, K.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	
05/26/20	KM	Analysis and slide creation re: Rhodes Quality re-org and re-engineering.	1.80
05/26/20	KM	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index for Project Catalyst.	0.60
05/26/20	KM	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. Turner, R. Schnitzler (both PJT), M. Florence, M. Gibson, J. Bragg (all Skadden), C. Robertson (Davis Polk) re: Project Catalyst	2.00
05/26/20	KM	Analysis and slide creation re: discussion of organization restructuring options.	0.50
05/26/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst action items.	0.70
05/26/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: discussion of organization restructuring options.	1.10
05/26/20	KM	Analysis and reconciliation re: phase 1 and phase 2 restructuring options versus Jan 30 Board budget.	1.40
05/26/20	KM	Advisors meeting with J. DelConte, A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.70
05/26/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: org structure for BIG 4 meeting 5/27.	1.40
05/26/20	KM	Edit deck and preparation re: org structure for BIG 4 meeting 5/27.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/26/20	ADD	Advisors meeting with J. DelConte, A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.70
05/26/20	ADD	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index for Project Catalyst.	0.60
05/26/20	NAS	Review new Mundipharma diligence materials provided by Huron.	1.00
05/26/20	JD	Review final board slides re: potential BD deal.	0.30
05/26/20	JD	Review draft Board slides re: April financial performance.	1.00
05/26/20	JD	Review and provide comments on Project Catalyst timeline and VDR index.	0.80
05/26/20	JD	Correspondence with S. Lemack (AlixPartners) re: critical vendor payments.	0.30
05/26/20	JD	Correspondence with R. Sublett (AlixPartners) and R. Schnitzler (PJT) re: Project Catalyst.	0.40
05/26/20	JD	Review opioid only and near term sale scenario forecast headcount reduction assumptions.	0.60
05/26/20	JD	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. Turner, R. Schnitzler (both PJT), M. Florence, M. Gibson, J. Bragg (all Skadden), C. Robertson (Davis Polk) re: Project Catalyst	2.00
05/26/20	JD	Advisors meeting with J. DelConte, A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.70
05/26/20	JD	Call with R. Aleali (Purdue) re: upcoming board meeting.	0.60
05/26/20	JD	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		for Project Catalyst.	
05/26/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open critical vendor updates and executed trade agreements	0.40
05/26/20	GJK	Analysis for Mundipharma interim diligence re: review of Huron provided information and follow up email exchange with Huron	1.60
05/26/20	GJK	Analysis of potential downside drivers for Mundipharma beyond noted risk adjustments	2.00
05/26/20	GJK	Review Mundipharma diligence responses.	0.30
05/26/20	IA	Drafted LTRP analysis showing 2020, 2021 and 2022 estimated payments with various reduction assumptions as well as splits by grant year.	3.60
05/26/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open critical vendor updates and executed trade agreements	0.40
05/27/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest status request regarding critical vendor trade agreements.	0.40
05/27/20	GJK	Review of N. Simon (AlixPartners) comparison of COGS between Mundipharma YEE and Revised Forecast	0.50
05/27/20	GJK	Asses potential COGS improvement drivers between Mundipharma YEE budget and revised forecast (including review of Tech Ops and previous comparison of top ten by country products)	2.30
05/27/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update.	0.20
05/27/20	LJD	Prepare for and attend board meeting	3.20
05/27/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest status request regarding critical vendor	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		trade agreements.	
05/27/20	JD	Call with C. Robertson (Davis Polk) re: open items and board meeting prep.	0.40
05/27/20	JD	Participate in PPI Board meeting.	2.80
05/27/20	JD	Call with D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. DelConte (partial attendance), K. McCafferty, R. Sublett, (AlixPartners), PJT, Skadden re: Project Catalyst	1.70
05/27/20	JD	Review and provide comments on updated Project Catalyst timeline.	0.20
05/27/20	JD	Review fee examiner retention docs and prepare cost forecast and correspondence with R. Brown (Purdue) re: same.	0.70
05/27/20	JD	Prepare response to UCC diligence questions re: business forecast sensitivity analysis.	0.90
05/27/20	JD	Review historical financial analysis reports posted to the VDR and correspondence with M. Atkinson (Province) re: same.	1.00
05/27/20	JD	Review draft summary compensation analysis prepared by I. Arana (AlixPartners) for Willis Towers Watson.	0.70
05/27/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update.	0.20
05/27/20	JD	Review correspondence with Willis Towers Watson re: compensation analysis.	0.40
05/27/20	NAS	Review new materials provided by Huron/Mundipharma and compare to prior sources.	2.00
05/27/20	ADD	Discussion with R. Sublett (AlixPartners) re: Project Catalyst VDR	0.30
05/27/20	KM	Analysis and process development re. R&D restructuring support processes and KPIs.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/27/20	KM	Restructuring analysis re: Rhodes Pharma	1.00
05/27/20	KM	Analysis re. Rhodes restructuring reconciliation to Jan Board count for presentation.	0.30
05/27/20	KM	Create report and slides re. Rhodes restructuring summary for presentation to management.	0.70
05/27/20	KM	Call with D. Fogel, D. Lundie, (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: org charts and severance plans ahead of the Big Four management meeting	1.60
05/27/20	KM	Edit deck re: org structure for BIG 4 meeting 5/27	0.60
05/27/20	KM	Meeting with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblen, D. McGuire, J. Northington (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes restructuring recommendations	2.30
05/27/20	KM	Meeting follow up email to D. Lundie (Purdue) re: Rhodes restructuring recommendations	0.20
05/27/20	KM	Call with D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (AlixPartners), PJT, Skadden re: Project Catalyst	1.90
05/27/20	RDS	Provide commentary to back up R&D rationalization methodology based on management discussions.	1.20
05/27/20	RDS	Refine executive summary section for meeting with D. Lundie (Purdue).	1.20
05/27/20	RDS	Call with D. Fogel, D. Lundie, (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: org charts and severance plans ahead of the Big Four management meeting	1.60
05/27/20	RDS	Meeting with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblen, D. McGuire, J. Northington (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes restructuring recommendations	2.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/27/20	RDS	Call with D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (AlixPartners), PJT, Skadden re: Project Catalyst	1.90
05/27/20	RDS	Call with C. Robertson (DPW) re: VDR for Project Catalyst	0.20
05/27/20	RDS	Discussion with A. DePalma (AlixPartners) re: Project Catalyst VDR	0.30
05/28/20	RDS	Correspondence with Rhodes team re: Project Catalyst diligence requests and review of VDR data request list re: the same	0.60
05/28/20	RDS	Review business plan targets as provided and prepare analysis to share with big four re: targets.	1.40
05/28/20	RDS	Research and correspondence with D. Fogel (Purdue) re: Project Catalyst scorecard.	0.80
05/28/20	RDS	Review and assemble working group list for Project Catalyst and correspondence with PJT and DPW RE the same	0.50
05/28/20	RDS	Review VDR contents in preparation for meeting with Project Catalyst meeting	1.70
05/28/20	RDS	Call with A. DePalma, K. McCafferty, R. Sublett (all AlixPartners), D. Fogel, R. Shamblen (both Purdue), R. Schnitzler (PJT) re: Project Catalyst VDR Index	0.90
05/28/20	RDS	Call with D. Fogel, V. Mancinelli, R. Shamblen, J. Northington, D. McGuire, J. Doyle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: update on transformation efforts.	2.40
05/28/20	KM	Analysis and reporting re: Rhodes organization restructuring for presentation at Senior Leadership meeting.	2.20
05/28/20	KM	Analysis and strawman for Rhodes BD process re-	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		engineering	
05/28/20	KM	Analysis and strawman for Rhodes finance re-engineering	1.10
05/28/20	KM	Develop process re. project Catalyst VDR and document tracking development.	0.50
05/28/20	KM	Call with A. DePalma, K. McCafferty, R. Sublett (all AlixPartners), D. Fogel, R. Shamblen (both Purdue), R. Schnitzler (PJT) re. Project Catalyst VDR Index	0.90
05/28/20	KM	Call with D. Fogel, V. Mancinelli, R. Shamblen, J. Northington, D. McGuire, J. Doyle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: update on transformation efforts.	2.40
05/28/20	KM	Support restructuring and communication re. Rhodes organization restructuring to leadership team.	0.40
05/28/20	ADD	Call with A. DePalma, K. McCafferty, R. Sublett (all AlixPartners), D. Fogel, R. Shamblen (both Purdue), R. Schnitzler (PJT) re. Project Catalyst VDR Index	0.90
05/28/20	NAS	Respond to trade agreement question from Purdue/Rhodes Vendor Management Team.	0.50
05/28/20	NAS	Analyze potential upside scenarios for Mundipharma business plan.	1.90
05/28/20	JD	Participate in PPI Board meeting.	3.30
05/28/20	JD	Participate in afternoon PPI board meeting.	1.00
05/28/20	JD	Call with Davis Polk (M. Huebner, E. Vonnegut), PJT (J. O'Connell, R. Schnitzler, J. Turner), Purdue (M. Kesselman, R. Aleali), Dechert (S. Birnbaum, D. Gentin Stock) and AlixPartners (J. DelConte, S. Lemack) re: Monday side by side prep call.	0.60
05/28/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst and board meeting follow ups.	1.00
05/28/20	JD	Correspondence with PJT re: sensitivity forecast	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		assumptions.	
05/28/20	JD	Review correspondence and draft responses from management re: D&P business plan diligence questions.	0.60
05/28/20	JD	Review VDR proposals re: Project Catalyst.	0.40
05/28/20	JD	Review correspondence from R. Sublett (AlixPartners) and D. Fogel (Purdue) re: Project Catalyst scorecard.	0.50
05/28/20	LJD	Prepare for and attend board meeting	3.80
05/28/20	GJK	Assessment of potential upside opportunities for Mundipharma including cost structure improvements from TechOps and upside revenue	2.00
05/28/20	GJK	Review of free cash flow items for potential back up support for Capex and NWC.	2.00
05/28/20	SKL	Prepare for and participate in call with Davis Polk (M. Huebner, E. Vonnegut), PJT (J. O'Connell, R. Schnitzler, J. Turner), Purdue (M. Kesselman, R. Aleali), Dechert (S. Birnbaum, D. Gentin Stock) and AlixPartners (J. DelConte, S. Lemack) re: Monday side by side prep call.	0.80
05/28/20	IA	Update LTRP analysis to include additional scenarios requested by Willis Towers Watson.	2.80
05/29/20	IA	Update LTRP analysis to include changes requested by Willis Towers Watson	1.30
05/29/20	GJK	Call with I. McClatchey (Norton Rose) re: diligence process.	0.80
05/29/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: potential EBIT upsides to Mundipharma business plan; diligence updates	0.80
05/29/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.20
05/29/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Australia TGA revised indications and impact on market	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/29/20	GJK	Review of current draft of Mundi interim diligence report and planning for incorporation of valuation; identification of additional back up detail to note.	1.30
05/29/20	GJK	Follow up discussion with G. Koch, N. Simon (both AlixPartners) re: questions and responses from advisors and Huron regarding outstanding diligence items	0.30
05/29/20	JD	Review and provide comments on Rhodes Tech vendor spend analysis.	0.40
05/29/20	JD	Review updated compensation analysis from I. Arana (AlixPartners).	0.30
05/29/20	JD	Review Rhodes Tech contract list and correspondence with A. DePalma (AlixPartners) and J. Doyle (Purdue) re: same.	0.60
05/29/20	JD	Review and provide comments on updated side by side analysis from PJT.	0.60
05/29/20	JD	Review and provide comments on Project Catalyst working group list.	0.20
05/29/20	JD	Review correspondence from C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: board minute productions.	0.30
05/29/20	NAS	Follow up discussion with G. Koch, N. Simon (both AlixPartners) re: questions and responses from advisors and Huron regarding outstanding diligence items	0.30
05/29/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Australia TGA revised indications and impact on market.	0.20
05/29/20	NAS	Correspondence with other diligence advisors re: Mundipharma diligence requests.	0.40
05/29/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: potential EBIT upsides to Mundipharma business plan; diligence updates	0.80
05/29/20	NAS	Research new pharmaceutical regulations in Australia for	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma diligence.	
05/29/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.20
05/29/20	JD	Catch up call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst.	0.30
05/29/20	JD	Review updated analysis from I. Arana (AlixPartners) re: compensation review.	0.70
05/29/20	KM	Call with J. Northington (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: review of Wilson and SC org structure	0.70
05/29/20	KM	Analysis re: org structure reconciliation vs Jan Budget and short term targets	0.90
05/29/20	KM	Analysis and edits re: supply chain organization	0.50
05/29/20	KM	Analysis and document editing re: alternate supply chain options for RALP	1.30
05/29/20	KM	Analysis and document editing re: RT org structure	0.70
05/29/20	KM	Call with D. Fogel, (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes restructuring adjustments from leadership team	1.20
05/29/20	KM	Analysis and document editing re: RP org structure changes	0.50
05/29/20	KM	Develop scenario re: RP org structure changes	0.50
05/29/20	KM	Create and edit slide re: org structure options.	0.30
05/29/20	KM	Call with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic initiatives.	0.60
05/29/20	KM	Create slide re: RP org structure options.	0.10
05/29/20	KM	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		initiatives.	
05/29/20	RDS	Correspondence with Project Catalyst team re: case updates and distribution lists / WGL	0.90
05/29/20	RDS	Review vendor data for Project Catalyst	0.50
05/29/20	RDS	Process updates to org structure from Big 4 RALP management meeting	2.40
05/29/20	RDS	Call with D. Fogel, (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes restructuring adjustments from leadership team	1.20
05/29/20	RDS	Review Project Catalyst board communication materials	0.30
05/29/20	RDS	Catch up call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst.	0.30
05/29/20	RDS	Call with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic initiatives.	0.60
05/29/20	RDS	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic initiatives.	0.50
05/29/20	RDS	Review of VDR requests	1.10
05/29/20	RDS	Call with J. Northington (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: review of Wilson and SC org structure	0.70
05/29/20	RDS	Prepare presentation org structure for Rhodes pharma R&D functions and share with D. Lundie (Purdue).	0.70
05/30/20	RDS	Correspondence with D. Lundie (Purdue) re: headcount reduction recommendations.	1.30
05/30/20	RDS	Assemble aggregated VDR request list	0.60
05/30/20	RDS	Review headcount reduction commentary from Rhodes management meeting materials	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/30/20	RDS	Review revised draft of APA and TSA	1.60
05/30/20	KM	Edit slide and response for D. Lundie (Purdue).	0.70
05/31/20	JD	Review updated draft side by side analyses.	0.80
05/31/20	JD	Review previous Board materials for summary information.	0.50
Total			<u>3,648.10</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	15.60	515.00	8,034.00
Sam K Lemack	13.70	515.00	7,055.50
Nate A Simon	427.80	515.00	220,317.00
Hart Ku	120.20	515.00	61,903.00
David Samikkannu	260.50	690.00	179,745.00
Isabel Arana de Uriarte	431.90	690.00	298,011.00
Jon D Hecht	0.80	690.00	552.00
Ryan D Sublett	561.70	735.00	412,849.50
Gabe J Koch	533.30	840.00	447,972.00
Michael Hartley	109.00	840.00	91,560.00
Mark F Rule	0.80	910.00	728.00
Jesse DelConte	433.70	950.00	412,015.00
Kevin M McCafferty	594.50	950.00	564,775.00
Barry Folse	0.50	1,090.00	545.00
Richard Collura	0.80	1,090.00	872.00
Lisa Donahue	143.30	1,195.00	171,243.50
Total Hours & Fees	3,648.10		2,878,177.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
02/10/20	JD	Review final lease damages calc.	0.40
03/03/20	JD	Correspondence with R. Aleali and J. Doyle (both Purdue) re: lease extensions.	0.30
03/25/20	JD	Correspondence with H. Ku (AlixPartners) and Davis Polk re: contract database.	0.30
03/31/20	JD	Conversation with J. DelConte (AlixPartners), C. Robertson (Davis Polk), and R. Aleali (Purdue) re: executory contract assumption process.	0.50
04/08/20	JD	Review and provide comments on an outline from C. Robertson (Davis Polk) re: executory contract assumption decision tree.	0.50
04/17/20	JD	Correspondence with E. Diggs (Davis Polk) re: contract database review.	0.40
04/22/20	JD	Participate in a call with T. Melvin and J. Turner (both PJT), E. Diggs, A. Lele (both Davis Polk), J. DelConte, A. DePalma (both AlixPartners) re: NewCo contract transfers.	0.60
04/22/20	JD	Call with J. Lowne (Purdue) re: creditor presentation.	0.20
04/22/20	ADD	Participate in a call with T. Melvin and J. Turner (both PJT), E. Diggs, A. Lele (both Davis Polk), J. DelConte, A. DePalma (both AlixPartners) re: NewCo contract transfers.	0.60
05/08/20	JD	Correspondence with R. Aleali (Purdue) re: unpaid cure amounts.	0.30
05/12/20	JD	Review payment status of Avrio lease and open cure amounts.	0.20
Total			4.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	0.60	515.00	309.00
Jesse DelConte	3.70	950.00	3,515.00
Total Hours & Fees	4.30		3,824.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
04/21/20	JD	Review latest claims filed summaries.	0.40
04/28/20	JD	Review summary claims report to be posted to Intralinks.	0.40
Total			<u>0.80</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Jesse DelConte	0.80	950.00	760.00
Total Hours & Fees	0.80		760.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
02/03/20	JWG	Add Jay Lynn (AlixPartners) to the Windsor - Reviewer Admin group	0.10
02/03/20	JKL	Setup and training redactions for team.	1.00
02/04/20	KG	Format and run search terms in Relativity, create search hit report, and update term highlighting and review layout.	0.40
02/19/20	JWG	Re-enabled/reset Sam Canniff's (AlixPartners) existing CH Relativity account and added it to the Windsor - Reviewer group (same access as Andrew DePalma (AlixPartners)). Credentials were sent to the user directly with Jay Lynn (AlixPartners) copied.	0.10
03/04/20	JKL	QCing production (WIN001) and PDF export settings.	0.90
03/04/20	KG	Stage, process and load documents to Relativity, update/overlay data and index for search/retrieval, and batch document as requested.	0.40
03/04/20	KG	Create requested PDFs for production.	1.90
03/05/20	KG	Create first set of PDFs for production.	0.80
03/05/20	KG	Process and load document to Relativity. Update/overlay data and index for search/retrieval. Batch document as requested.	0.40
03/05/20	JKL	QCing production (WIN002) and PDF export settings.	0.90
03/06/20	JKL	QCing PDF export deliverable. Delivering PDF export.	1.00
03/06/20	KG	Create second set of PDFs for production.	1.30
03/17/20	KG	Create fourth set of PDFs for production.	1.40
03/20/20	KG	Create fifth set of PDFs for production.	2.60
03/30/20	KG	Stage and process data for loading to Relativity, export and import data into Relativity, perform quality control review of data loaded to hosting environment, generate TIF images, update/overlay data and index for	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		search/retrieval, and create review batches.	
04/01/20	KG	Update SPOT tracking information with documents received to date.	0.60
04/03/20	KG	Create sixth PDF production of documents.	1.80
04/06/20	PM	Re-enable Relativity user and add to group.	0.20
04/10/20	KG	Update SPOT tracking information with documents received to date.	0.60
04/13/20	KG	Create seventh PDF production of documents. Stage and process data for loading. Export and import data into Relativity. Update/overlay data and index for search/retrieval. Generate TIF images and create batches.	3.20
04/13/20	JKL	Quality assurance of production deliverable to ensure counts are accurate and redactions have been applied.	0.80
04/13/20	HEW	QC and deliver production volume.	0.30
04/13/20	PM	Add internal Relativity user to group.	0.10
04/14/20	JKL	Quality assurance of production deliverable to ensure counts are accurate and redactions have been applied.	0.80
04/14/20	KG	Create eighth PDF production of documents.	2.30
04/15/20	HEW	QC and deliver production volume.	0.30
04/19/20	PM	Install blackout application in Relativity workspace.	0.20
04/21/20	TLJ	Preparation of blackout redaction rules to facilitate automated document redactions. Perform quality control review of blackout results.	0.30
04/21/20	KG	Create ninth PDF production of documents. Create and run Blackout projects in Relativity. Create and run search hits in Relativity. Create search term report for delivery.	2.90
04/21/20	JKL	Quality assurance of production deliverable to ensure counts are accurate and redactions have been applied.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		Delivery of production to A. DePalma (AlixPartners).	
04/22/20	KG	Create and run search terms in Relativity and create a saved search. Generate search hit report.	0.40
05/08/20	KG	Create tenth production for delivery.	1.80
Total			32.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Paraskevas Moisakis	0.50	250.00	125.00
John W Girgis	0.20	295.00	59.00
Hannah E Wells	0.60	645.00	387.00
Kristina Galbraith	24.60	645.00	15,867.00
Tracy L Jones	0.30	645.00	193.50
Jay K Lynn	6.30	950.00	5,985.00
Total Hours & Fees	32.50		22,616.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
02/21/20	LCV	Review retention documents and supplemental declarations for E. Kardos (AlixPartners) re: information barriers.	0.30
03/30/20	LCV	Review current NDA.	0.20
05/08/20	LJD	Call with internal AlixPartners team re: Purdue disclosure requirements.	0.40
05/18/20	KAS	Review and circulate updated parties-in-interest.	0.30
05/18/20	ESK	Email internal re: obtaining updated PII list.	0.20
05/18/20	JD	Review updated parties-in-interest list to provide to AlixPartners legal.	0.40
05/18/20	BFF	Follow up with J. DelConte (AlixPartners) re: updated parties-in-interest list	0.10
05/26/20	KAS	Review and Circulate updated parties-in-interest list.	0.20
Total			2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Fee Recap:

Consultant	Hours	Rate	Amount
Brooke F Filler	0.10	445.00	44.50
Laurie C Verry	0.50	510.00	255.00
Kaitlyn A Sundt	0.50	510.00	255.00
Elizabeth S Kardos	0.20	710.00	142.00
Jesse DelConte	0.40	950.00	380.00
Lisa Donahue	0.40	1,195.00	478.00
Total Hours & Fees	2.10		1,554.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
02/03/20	LMB	Prepare fourth monthly fee statement and schedule workbook for December 2019	1.00
02/03/20	JD	Review professional fee for December 2019.	1.00
02/04/20	LMB	Prepare third monthly fee statement and schedule workbook for December 2019, supporting schedules and exhibits	1.30
02/04/20	LMB	Review professional fees for December 2019	0.40
02/05/20	LMB	Prepare 4th monthly fee statement, supporting schedules and exhibits (December 2019)	1.50
02/05/20	LMB	Prepare fee application status chart	0.80
02/05/20	ESK	Review fourth monthly fee statement (December 2019)	0.50
02/06/20	JD	Review final December fee application.	0.30
02/06/20	KMD	Preparation of professional fees for January 2020	1.50
02/10/20	KMD	Preparation of professional fees for January 2020	2.40
02/10/20	LMB	Finalize fourth monthly fee statement (December 2019), supporting schedules and exhibits	0.50
02/10/20	LMB	Email to D. Consla, M. Pera, C. Robertson (all Davis Polk) attaching AlixPartners' fourth monthly fee statement (December 2019) for filing on the Court docket	0.20
02/11/20	KMD	Preparation of professional fees for January 2020	1.90
02/12/20	KMD	Preparation of professional fees for January 2020	1.10
02/13/20	KMD	Preparation of professional fees for January 2020	3.00
02/13/20	KMD	Continue preparation of professional fees for January 2020	2.80
02/14/20	KMD	Continue preparation of professional fees for January 2020	1.70
02/14/20	KMD	Preparation of professional fees for January 2020	3.00
02/15/20	KMD	Preparation of professional fees for January 2020	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
02/21/20	LMB	Prepare Amended Monthly Fee Statement for January 2020	0.40
02/22/20	TB	Prepare revised December 2019 staffing and compensation report.	1.40
02/22/20	TB	Prepare monthly fee application and exhibits for January 2020.	2.30
02/24/20	TB	Prepare revised December monthly fee application.	2.00
02/24/20	JD	Internal correspondence re: amended fee application.	0.20
02/28/20	LCV	Emails with D. Consla (Davis Polk) and T. Brewer (AlixPartners) re: interim fee applications.	0.20
03/02/20	JD	Review draft January invoice.	2.60
03/03/20	TB	Correspondence with K. Sundt (AlixPartners) re: time covered for interim fee application.	0.30
03/03/20	TB	Preparation of fifth monthly fee statement and exhibits for January 2020.	1.40
03/03/20	TB	Continue preparation of fifth monthly fee statement and exhibits for January 2020.	1.20
03/03/20	KAS	Correspondence with T. Brewer (AlixPartners) re: time covered for interim fee application.	0.30
03/04/20	KMD	Preparation of professional fees for February 2020	1.40
03/04/20	TB	Preparation of initial schedule workbook for first interim fee application.	3.00
03/04/20	TB	Continue preparation of initial schedule workbook for first interim fee application.	1.70
03/05/20	TB	Update fee application status chart.	0.90
03/05/20	TB	Preparation of initial schedule workbook for first interim fee application.	2.80
03/05/20	KMD	Preparation of professional fees for February 2020	0.90
03/05/20	KAS	Review draft 5th monthly fee application and respond to	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		T. Brewer (AlixPartners) re: same.	
03/05/20	JD	Review and edit the draft narratives for the interim fee statement.	0.50
03/05/20	JD	Review and finalize January fee statement prior to sending off to Davis Polk to file.	0.30
03/05/20	DS	Write professional services summary for interim fee statement	1.80
03/06/20	LMB	Review and revise first interim fee application and supporting schedules	1.40
03/06/20	KMD	Preparation of professional fees for February 2020	1.00
03/06/20	TB	Continue preparation of Interim and exhibit A.	1.60
03/06/20	TB	Preparation of Interim and exhibit A.	3.00
03/07/20	TB	Continue preparation of interim fee application and exhibits.	3.00
03/07/20	TB	Preparation of interim fee application and exhibits.	3.60
03/08/20	TB	Review court docket	0.20
03/09/20	LMB	Review and revise first interim fee application, cover page	0.40
03/09/20	JD	Draft portion of the interim fee application.	0.80
03/10/20	KMD	Preparation of professional fees for February 2020	2.30
03/11/20	KMD	Preparation of professional fees for February 2020	3.40
03/11/20	KAS	Review 1st interim fee application.	0.70
03/11/20	TB	Final preparation of First Interim and exhibits.	3.70
03/12/20	KMD	Preparation of professional fees for February 2020	3.00
03/12/20	KMD	Continue preparation of professional fees for February 2020	1.20
03/13/20	JD	Review and provide comments on first interim fee application.	1.00
03/14/20	TB	Update First Interim Application with exhibits.	1.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
03/16/20	TB	Update First Fee Application.	1.40
03/16/20	JD	Final review of interim fee application.	0.30
03/16/20	JD	Review and revise final fee application and correspondence with T. Brewer (AlixPartners) re: final edits.	0.60
03/26/20	KMD	Preparation of professional fees for March 2020	2.60
03/28/20	KMD	Preparation of professional fees for March 2020	2.30
04/02/20	JD	Review and edit February fee statement.	1.80
04/04/20	KMD	Preparation of professional fees for March 2020.	2.20
04/08/20	TB	Preparation of 6th Monthly Fee Statement and Exhibits.	1.70
04/08/20	JD	Provide final comments to finalize February invoice.	0.30
04/10/20	KAS	Review third monthly fee application.	0.60
04/13/20	TB	Email M. Pera, D. Consla, C. Robertson (all Davis Polk) attaching sixth monthly fee application for filing with the Courts.	0.20
04/17/20	TB	Preparation of professional fees for March 2020.	1.00
04/18/20	AML	Preparation of professional fees for March 2020.	3.00
04/18/20	AML	Continue to prepare professional fees for March 2020.	3.00
04/19/20	TB	Preparation of professional fees and expenses for March 2020.	3.00
04/19/20	TB	Preparation of professional fees and expenses for March 2020 (continued).	3.00
04/20/20	TB	Preparation of professional fee for March 2020.	1.50
04/20/20	TB	Continue preparation of professional fees for March 2020.	4.00
04/20/20	KAS	Respond to E. Kardos (AlixPartners) re: availability to attend 4/22/20 hearing.	0.10
04/20/20	KAS	Email B. Filler (AlixPartners) for 4/22/20 CourtSolutions arrangements.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
04/20/20	AML	Preparation of professional fees for March 2020.	1.50
04/20/20	ESK	Emails with J. DelConte (AlixPartners) re: coordinating time recording activities for the fee application process.	0.30
04/22/20	KAS	Internal email to L. Donahue, J. DelConte, E. Kardos, L. Verry, B. Filler (all AlixPartners), to summarize outcome of the hearing on AlixPartners 1st Interim Fee Application.	0.30
04/22/20	TB	Preparation of professional fees for March 2020.	1.40
04/23/20	TB	Update fee and expense status chart.	0.20
04/23/20	KAS	Review omnibus order re: 1st interim fee applications.	0.30
04/23/20	ESK	Email to D. Consla (Davis Polk) confirming AlixPartners' fee and expenses in the draft proposed omnibus order granting the first interim fee application.	0.20
05/01/20	JD	Review and provide comments re: draft fee statement for March 2020.	3.30
05/01/20	TB	Prepare March 2020 monthly fee statement.	0.50
05/01/20	TB	Update fee and expense status chart.	0.20
05/04/20	JD	Final review of March 2020 monthly fee application.	0.50
05/05/20	TB	Prepared 7th Monthly Fee Statement and exhibits for March 2020.	1.70
05/05/20	KAS	Review draft for 7th Monthly Fee Statement from T. Brewer (AlixPartners).	0.60
05/07/20	LJD	Review and comment on fee statement.	0.90
05/14/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	3.30
05/14/20	MSM	Further preparation of professional fees for April 2020 monthly fee statement.	2.70
05/14/20	IA	Review professional fees for April 2020 monthly fee statement.	1.20
05/14/20	MSM	Prepare professional fees for April 2020 monthly fee	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		statement.	
05/15/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.00
05/15/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	2.60
05/16/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.50
05/16/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	2.60
05/16/20	MSM	Further preparation of professional fees for April 2020 monthly fee statement.	3.00
05/17/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.50
05/17/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	3.90
05/17/20	TB	Prepare professional fees for April 2020 monthly fee statement.	1.60
05/19/20	TB	Prepare professional fees for April 2020 monthly fee statement.	0.80
05/19/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	1.90
05/20/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.20
05/20/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	2.00
05/20/20	IA	Review professional fees for April 2020 monthly fee statement.	1.60
05/21/20	TB	Prepare professional fees for April 2020 monthly fee statement.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
05/21/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	2.00
05/22/20	IA	Review professional fees for April 2020 monthly fee statement.	1.00
05/26/20	IA	Review professional fees for April 2020 monthly fee statement.	2.00
05/27/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	1.80
05/27/20	JD	Initial review of fee statement.	0.50
05/29/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	2.70
Total			184.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Andrea M LeBar	7.50	375.00	2,812.50
Melanie McCabe	45.70	415.00	18,965.50
Kiera M Davids	39.90	415.00	16,558.50
Tammy Brewer	56.60	450.00	25,470.00
Lisa Marie Bonito	7.90	450.00	3,555.00
Laurie C Verry	0.20	510.00	102.00
Kaitlyn A Sundt	3.50	510.00	1,785.00
David Samikkannu	1.80	690.00	1,242.00
Isabel Arana de Uriarte	5.80	690.00	4,002.00
Elizabeth S Kardos	1.00	710.00	710.00
Jesse DelConte	14.00	950.00	13,300.00
Lisa Donahue	0.90	1,195.00	1,075.50
Total Hours & Fees	184.80		89,578.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
03/02/20	JD	Dial in to Court hearing.	0.30
03/03/20	RDS	Review court filings (mediation approval, compensation and PHI) for Rhodes business plan ramifications	0.90
03/18/20	JD	Participate in the court hearing telephonically.	3.00
03/18/20	RC	Dial into a portion of the preliminary injunction hearing.	1.50
03/24/20	JD	Participate in Purdue Board meeting.	1.60
04/22/20	JD	Participate in Purdue court hearing.	2.00
04/22/20	NAS	Attend telephonic hearing (partial).	0.30
04/22/20	KAS	Attend hearing re: 1st Interim fee application.	2.00
05/01/20	NAS	Partial attendance (telephonically) Purdue Pharma discovery hearing.	0.50
05/01/20	RC	Call in to portion of the court hearing re: discovery issues raised by the UCC and Nonconsenting States against the Sacklers and IACs.	2.00
05/01/20	JD	Participate telephonically in court hearing re: discovery.	2.70
Total			16.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Kaitlyn A Sundt	2.00	510.00	1,020.00
Nate A Simon	0.80	515.00	412.00
Ryan D Sublett	0.90	735.00	661.50
Jesse DelConte	9.60	950.00	9,120.00
Richard Collura	3.50	1,090.00	3,815.00
Total Hours & Fees	16.80		15,028.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/02/20	ADD	Compile supporting documentation and files to respond to UCC request.	2.30
02/03/20	JDH	Continue development of family entity database.	1.10
02/03/20	REO	Conference call with M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: coordination on draft intercompany and non-cash transfers report preparation.	0.30
02/03/20	REO	Review of updated files from Company re: foreign sales for finished products and reconciliation to SAP	1.00
02/03/20	REO	Research SAP for foreign sales for finished products re: updated SAP support per updated files and reconciliation to SAP from company	1.00
02/03/20	REO	Prepare reconciliation of BW and SAP re: foreign sales for Mundipharma entities (2008-2014).	0.90
02/03/20	REO	Prepare reconciliation of BW and SAP re: foreign sales for Mundipharma entities (2015-2019).	1.20
02/03/20	JDH	Development of family entity database.	3.00
02/03/20	RC	Review support documentation compiled in response to bank statement requests from the UCC.	1.40
02/03/20	RC	Conference call with R. Collura and M. Rule (both AlixPartners) re: coordination on draft intercompany and non-cash transfers report preparation.	0.60
02/03/20	RC	Review and comment on the support documentation gathered in connection with responding to distribution requests from the UCC.	1.50
02/03/20	RC	Review and update information and data requests for TXP and PRA LP.	0.40
02/03/20	SJC	Analysis of support for samples selected by Province.	3.00
02/03/20	FOS	Compose email to D. Fogel and W. DiNicola (both Purdue) re: markups on sales of API to Purdue and IACs.	0.10
02/03/20	FOS	Compose email to E. Liesman (Purdue) re: accounting for	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		shared services provided by Purdue to Rhodes.	
02/03/20	FOS	Conference call with M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: coordination on draft intercompany and non-cash transfers report preparation.	0.30
02/03/20	MFR	Conference call with M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: coordination on draft intercompany and non-cash transfers report preparation.	0.30
02/03/20	MFR	Conference call with R. Collura and M. Rule (both AlixPartners) re: coordination on draft intercompany and non-cash transfers report preparation.	0.60
02/04/20	MFR	Review of report 1B (non-cash intercompany transfers report) in preparation for providing the UCC a draft copy.	2.70
02/04/20	MFR	Conference call with R. Collura, M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: status update on draft intercompany and non-cash transfers report.	0.20
02/04/20	FOS	Conference call with R. Collura, M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: status update on draft intercompany and non-cash transfers report.	0.20
02/04/20	FOS	Update tracker re: pending and follow-up items on draft intercompany and non-cash transfers report.	0.20
02/04/20	FOS	Edits to draft report re: intercompany and non-cash transfers.	3.00
02/04/20	FOS	Continue edits to draft report re: intercompany and non-cash transfers.	1.70
02/04/20	SJC	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to review progress on distribution support compilation.	2.70
02/04/20	SJC	Review of distribution support for internal meetings.	3.20
02/04/20	SJC	Compile distribution support.	3.00
02/04/20	RC	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to review progress on	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		distribution support compilation	
02/04/20	RC	Prepare for and attend conference call with R. Collura, M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: status update on draft intercompany and non-cash transfers report.	0.40
02/04/20	RC	Review protective order and communicate with risk department on the production of Special Committee related information.	0.40
02/04/20	RC	Review initial support documentation related to tax distribution selections.	1.10
02/04/20	RC	Review distributions related documentation.	1.30
02/04/20	RC	Review and analysis of general ledger activity re: distributions.	1.40
02/04/20	RC	Review and analysis intercompany related activity.	0.30
02/04/20	RC	Review list of bank statements by debtor entity.	0.10
02/04/20	RC	Review and analysis of support for tax distributions.	0.70
02/04/20	RC	Call with R. Collura, A. DePalma (both AlixPartners), and C. McMillian (Davis Polk) to discuss process for producing files under protective order.	0.60
02/04/20	JDH	Verification of cash transactions to bank statements.	3.80
02/04/20	REO	Conference call with Purdue IT re: unlocking Citrix account and restoring access to SAP	0.30
02/04/20	REO	Research SAP for transfer support re: annual activity in intercompany accounts for internal audit, security, and environmental health & safety services between 2008-2019.	1.20
02/04/20	REO	Update slides in transfer pricing deck re: updated SAP support for annual activity in intercompany accounts for internal audit, security, and environmental health & safety services between 2008-2019.	0.80
02/04/20	REO	Research SAP for transfer support re: intercompany	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		accounts for foreign sales for finished goods between 2008-2019.	
02/04/20	REO	Update slides in transfer pricing deck re: updated SAP support for annual activity in intercompany accounts for foreign sales for finished goods between 2008-2019.	1.00
02/04/20	REO	Conference call with R. Collura, M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: status update on draft intercompany and non-cash transfers report.	0.20
02/04/20	REO	Prepare follow-up request to company re: Clarification of discrepancy between SAP and BW queries for foreign sales of finished goods.	0.60
02/04/20	ADD	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to review progress on distribution support compilation	2.70
02/04/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners), and C. McMillian (Davis Polk) to discuss process for producing files under protective order.	0.60
02/05/20	ADD	Locate and review Purdue auditor retention and 2018 audit status.	0.30
02/05/20	REO	Review response to follow-up request to company re: reconciliation of discrepancy between SAP and BW queries for foreign sales of finished goods.	0.80
02/05/20	REO	Prepare summary table for foreign sales re: reconciliation of sales to SAP company codes.	1.80
02/05/20	REO	SAP Research foreign sales re: reconciliation of sales to SAP company codes between 2008-2019	2.00
02/05/20	JDH	Transitioning of information.	2.00
02/05/20	RC	Review support documentation compiled in response to the UCC's requests for transaction activity.	1.30
02/05/20	RC	Review distribution related documentation and prepare requests and questions for TXP and PRA LP.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/05/20	RC	Call with M. Clarens (Davis Polk) to discuss questions and requests for TXP and PRA LP.	0.10
02/05/20	RC	Review and update questions and requests for TXP and PRA LP.	0.60
02/05/20	RC	Review distribution related information in connection with responding to requests from the UCC.	1.30
02/05/20	RC	Review accounting detail and other documentation compiled in response to the UCC's requests.	1.20
02/05/20	RC	Review and comment on the intercompany and non-cash transfers of value report.	1.30
02/05/20	SJC	Review of Province samples and support.	3.00
02/05/20	SJC	Compilation of distribution support.	3.20
02/05/20	SJC	Analysis of support for distribution samples.	2.00
02/05/20	FOS	Compose email to R. Collura and M. Rule (both AlixPartners) re: Kolltan cash and non-cash distribution accounting.	0.50
02/05/20	MFR	Review and analysis of Kolltan cash and non-cash distribution accounting.	1.70
02/05/20	MFR	Review of report 1B (non-cash intercompany transfers report) in preparation for providing the UCC a draft copy.	3.10
02/06/20	MFR	Review of report 1B (non-cash intercompany transfers report) in preparation for providing the UCC a draft copy.	2.90
02/06/20	MFR	Calls with F. Silva and M. Rule (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.30
02/06/20	FOS	Call with R. Ellis Ochoa and F. Silva (both AlixPartners) re: accounting for sales of finished products to foreign IACs.	0.20
02/06/20	FOS	Calls with F. Silva and M. Rule (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/06/20	FOS	Edit draft report re: intercompany and non-cash transfers report.	0.80
02/06/20	SJC	Compile compilation of requested samples from Province.	3.00
02/06/20	RC	Review intercompany and non-cash transfer report.	1.70
02/06/20	RC	Continue to review intercompany and non-cash transfer report.	1.50
02/06/20	RC	Provide comments related to the intercompany and non-cash transfer report.	1.20
02/06/20	RC	Review documentation compiled in response to requests from the UCC.	1.10
02/06/20	RC	Review and comment on rent expense analysis	0.40
02/06/20	RC	Provide additional comments related to the intercompany and non-cash transfer report.	1.00
02/06/20	RC	Review support documentation related to the intercompany and non-cash transfer analysis.	1.10
02/06/20	REO	Call with R. Ellis Ochoa and F. Silva (both AlixPartners) re: accounting for sales of finished products to foreign IACs.	0.20
02/07/20	RC	Review updated draft of the intercompany and non-cash transfer report.	1.70
02/07/20	RC	Prepare comments related to the updated draft intercompany and non-cash transfer report.	1.20
02/07/20	RC	Review support documentation related to the draft intercompany and non-cash transfer report.	1.30
02/07/20	RC	Communicate and coordinate with counsel on responding to the UCC's diligence requests.	0.30
02/07/20	FOS	Review documentation and SAP support re: Kolltan non-cash and cash distributions.	1.40
02/07/20	FOS	Compose emails to R. Collura and M. Rule (both AlixPartners) re: Kolltan non-cash and cash transfers	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		support.	
02/07/20	FOS	Compose emails to M. Clarens (Davis Polk) re: draft intercompany and non-cash transfers report and Millsaw cash distribution.	0.30
02/07/20	FOS	Edit draft report re: intercompany and non-cash transfers report.	3.50
02/07/20	MFR	Review and analysis of Kolltan non-cash and cash transfers support.	1.00
02/07/20	MFR	Review of report 1B (non-cash intercompany transfers report) in preparation for providing the UCC a draft copy.	2.40
02/10/20	MFR	Prepare for and attend call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report status and Millsaw cash transfer.	0.80
02/10/20	FOS	Call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report status and Millsaw cash transfer.	0.40
02/10/20	FOS	Compose email to M. Clarens (Davis Polk) re: follow-ups items on draft intercompany and non-cash transfers report.	0.30
02/10/20	FOS	Email to W. DiNicola and D. Fogel (both Purdue) re: accounting for sales of API to Purdue and IACs.	0.10
02/10/20	SJC	Gather supporting documentation for ex-us distributions.	3.30
02/10/20	RC	Call with J. Dougherty (Haug Partners) to discuss information requests for TXP and PRA LP.	0.50
02/10/20	RC	Review and update information requests in preparation for call with J. Dougherty (Haug Partners).	0.30
02/10/20	RC	Call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		status and Millsaw cash transfer.	
02/10/20	RC	Review support documentation related to non-cash distributions.	1.30
02/10/20	RC	Review tax information produced by the debtor entities.	1.50
02/10/20	RC	Review support documentation related to Ex-US distributions.	1.30
02/10/20	RC	Review cash reconciliation files related to distribution analysis.	1.20
02/10/20	RC	Review intercompany and non-cash transfer report.	1.00
02/10/20	ADD	Locate agreement for transfer pricing report team.	0.30
02/11/20	RC	Review reconciliation of cash distribution amounts in various debtor sources of information.	1.10
02/11/20	RC	Review documentation related to the non-cash transfer report.	1.40
02/11/20	RC	Review and analysis of supporting documentation related to intercompany transactions.	1.70
02/11/20	RC	Review documentation related to Purdue Pharma Inc's payments analysis.	1.30
02/11/20	RC	Review analysis related to payments by debtor entities.	0.80
02/11/20	SJC	Compilation of requested samples from Province.	3.20
02/11/20	SJC	Compilation of distribution support.	3.00
02/11/20	SJC	Analysis of support for distribution samples.	2.00
02/11/20	FOS	Conference call with W. DiNicola, D. Fogel (both Purdue), and F. Silva (AlixPartners) re: cost and sale price markups for products sold to IACs and Purdue.	0.40
02/11/20	MH	Research differences between historical rent payment amounts reported in the value transfer report and the lease documents.	1.10
02/12/20	MH	Reconcile historical lease expenses between transfer of value report and the lease amounts.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/12/20	MH	Call with F. Silva and M. Hartley (both AlixPartners) to discuss historical rent amounts paid to related entities.	0.50
02/12/20	MFR	Review latest status update on report 1B.	0.60
02/12/20	FOS	Call with F. Silva and M. Hartley (both AlixPartners) to discuss historical rent amounts paid to related entities.	0.50
02/12/20	SJC	Meeting with S. Canniff and R. Collura (both AlixPartners) to review and walkthrough progress on distribution support compilation.	1.50
02/12/20	SJC	Compilation of Ex-US samples for Province.	3.20
02/12/20	SJC	Review of samples selected by Province.	3.30
02/12/20	RC	Meeting with S. Canniff and R. Collura (both AlixPartners) to review and walkthrough progress on distribution support compilation.	1.50
02/12/20	RC	Review information related to cash distributions in connection with responding to requests from the UCC's advisors.	1.20
02/12/20	RC	Review lease documentation and prepare comments related to the preliminary rent analysis.	2.00
02/12/20	RC	Review cash distribution files and reconcile information to support documentation.	1.10
02/13/20	RC	Weekly debtor advisor call with R. Collura, M. Rule, G. Koch, F. Silva, M. Hartley, N. Simon (AlixPartners), J. Turner (PJT), J. Lowne (Purdue), and M. Huebner (Davis Polk).	0.40
02/13/20	RC	Review tax related information based on requests from the UCC's advisors.	1.20
02/13/20	RC	Review bank statement tracing analysis in connection with responding to requests from the UCC's advisors.	0.80
02/13/20	RC	Review analysis of payments to IACs and taxing authorities in response to requests from Davis Polk.	1.40
02/13/20	RC	Review additional information related to transactions with	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		IACs.	
02/13/20	RC	Review intercompany and non-cash transfers of value report.	1.20
02/13/20	RC	Review information related to property taxes and other rent related charges.	0.80
02/13/20	NAS	Weekly debtor advisor call with R. Collura, M. Rule, G. Koch, F. Silva, M. Hartley, N. Simon (AlixPartners), J. Turner (PJT), J. Lowne, R. Aleali (Purdue), M. Huebner and C. Robertson (Davis Polk).	0.40
02/13/20	FOS	Weekly debtor advisor call with R. Collura, M. Rule, G. Koch, F. Silva, M. Hartley, N. Simon (AlixPartners), J. Turner (PJT), J. Lowne, R. Aleali (Purdue), M. Huebner and C. Robertson (Davis Polk).	0.40
02/13/20	FOS	Review documents re: product price markup on sales to IACs.	0.10
02/13/20	FOS	Compose email to D. Fogel and W. DiNicola (all Purdue) re: markup on products sold to IACs.	0.10
02/13/20	FOS	Compose email to M. Clarens (Davis Polk) re: status of draft intercompany and non-cash transfers report.	0.40
02/13/20	MFR	Review and analysis of the accounting for transfers between Purdue and PPTI for shared services.	2.20
02/13/20	MFR	Review and analysis of the accounting for transfers between Purdue and PPTI for product purchases.	2.70
02/13/20	MFR	Weekly debtor advisor call with R. Collura, M. Rule, G. Koch, F. Silva, M. Hartley, N. Simon (AlixPartners), J. Turner (PJT), J. Lowne, R. Aleali (Purdue), M. Huebner and C. Robertson (Davis Polk).	0.40
02/13/20	GJK	Weekly debtor advisor call with R. Collura, M. Rule, G. Koch, F. Silva, M. Hartley, N. Simon (AlixPartners), J. Turner (PJT), J. Lowne and R. Aleali (Purdue), M. Huebner and C. Robertson (Davis Polk).	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/13/20	MH	Weekly debtor advisor call with R. Collura, M. Rule, G. Koch, F. Silva, M. Hartley, N. Simon (AlixPartners), J. Turner (PJT), J. Lowne, R. Aleali (Purdue), M. Huebner and C. Robertson (Davis Polk).	0.40
02/14/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and PF Labs.	1.70
02/14/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and Terramar.	1.60
02/14/20	FOS	Compose email to M. Clarens (Davis Polk) re: draft intercompany and non-cash transfers report status.	0.20
02/14/20	FOS	Compose email to J. Lowne (Purdue) re: draft intercompany and non-cash transfers report status.	0.30
02/14/20	SJC	Review of documents related to Ex-Us distributions.	3.10
02/14/20	SJC	Review of distribution analysis.	2.90
02/14/20	SJC	Compilation of documents for Province request.	1.40
02/14/20	RC	Call with R. Collura (AlixPartners) and Z. Levine (Davis Polk) to discuss transactions with IACs.	0.40
02/14/20	RC	Review cash distributions analysis in response to questions from Davis Polk related to transactions with IACs.	1.60
02/14/20	RC	Review and analysis of Tax distributions documentation in response to requests from Davis Polk.	1.20
02/14/20	RC	Review bank statement analysis in response to requests from Davis Polk.	1.10
02/14/20	RC	Review and analysis of payments to IACs and related supporting documentation.	1.50
02/14/20	RC	Review support documentation related to tax distributions.	0.80
02/14/20	RC	Review support documentation related to partner distributions.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/17/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and TXP.	3.20
02/17/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and Mundipharma Research Limited.	2.90
02/18/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and Mundipharma EDO.	2.70
02/18/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and Mundipharma International UK.	2.40
02/18/20	MH	Call with R. Collura and M. Hartley (both AlixPartners) to discuss rent and tax distribution follow-up work.	0.70
02/18/20	MH	Review historical tax data to identify possible data re: basis of prior tax distributions.	1.60
02/18/20	FOS	Compose email to J. Lowne, D. Fogel, and W. DiNicola (all Purdue) re: accounting for API sales, costs and markup.	0.30
02/18/20	SJC	Compilation of distribution support.	3.00
02/18/20	SJC	Review of supporting documents for Ex-US distributions.	3.10
02/18/20	SJC	Analysis of support for samples selected by Province.	2.10
02/18/20	FOS	Compose email to A. DePalma (AlixPartners) re: intercompany agreements for specific countries.	0.20
02/18/20	FOS	Compose email to E. Nowakowski (Purdue) re: follow-up items on draft intercompany and non-cash transfers report.	0.60
02/18/20	FOS	Compose email to D. Wooten and J. Carlisle (both Purdue) re: accounting for shared services between Purdue and Rhodes.	0.10
02/18/20	RC	Review information related to transactions with One Stamford Realty.	1.60
02/18/20	RC	Review availability of documentation related to bank	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		account statements and correspond with Davis Polk.	
02/18/20	RC	Review tax distribution information in preparation for call with Davis Polk.	0.90
02/18/20	RC	Call with M. Clarens, N. Williams, E. Kim (all Davis Polk), and R. Collura (AlixPartners) to discuss tax distribution information and related support documentation.	0.70
02/18/20	RC	Call with R. Collura and M. Hartley (both AlixPartners) to discuss rent and tax distribution follow-up work.	0.70
02/18/20	RC	Review and summarize hours performed on special committee work in response to requests from Davis Polk.	0.10
02/18/20	RC	Review supporting documentation compiled for cash tracing analysis.	0.80
02/18/20	RC	Correspondence with D. Samikkannu, I. Arana and A. DePalma (all AlixPartners) re: availability of bank account statements.	0.10
02/18/20	RC	Review tax worksheets included in SAP for distribution selections.	0.70
02/18/20	RC	Review analysis of payments to IACs in response to requests from Davis Polk.	1.40
02/19/20	RC	Review and analysis of information provided by TXP's counsel related to special committee related document requests.	1.50
02/19/20	RC	Review available bank statement support in connection with responding to requests from UCC.	0.80
02/19/20	RC	Review data room for information related to tax distributions.	1.50
02/19/20	SJC	Compilation of Ex-US samples for Province.	1.00
02/19/20	SJC	Analysis of support for samples selected by Province.	3.00
02/19/20	SJC	Compilation of distribution support.	2.90
02/19/20	SJC	Review of distribution support for internal meetings.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/19/20	FOS	Review of documents re: additional rent payments from Purdue to One Stamford Realty.	1.10
02/19/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: additional rent payments from Purdue to One Stamford Realty.	0.10
02/19/20	FOS	Call with D. Wooten (Purdue) and F. Silva (AlixPartners) re: accounting for shared services between Purdue and Rhodes.	0.40
02/19/20	FOS	Compose email to M. Rule (AlixPartners) re: Additional rent payments from Purdue to One Stamford Realty.	0.10
02/19/20	FOS	Compose emails to M. Hartley (AlixPartners) re: Additional rent payments from Purdue to One Stamford Realty.	0.20
02/19/20	MH	Review historical tax data to identify possible data re: basis of prior tax distributions.	2.70
02/19/20	MH	Provide the transfer pricing team with historical information re: additional rent payments.	0.70
02/19/20	MH	Update drafts of presentation on historical lease payments to the benefit of the equity owners.	1.40
02/19/20	MFR	Review and analysis of transfers between Purdue to Mundipharma A.G.	2.30
02/19/20	MFR	Call with F. Silva and M. Rule (both AlixPartners) re: additional rent payments from Purdue to One Stamford Realty.	0.10
02/19/20	MFR	Review and analysis of additional rent payments from Purdue to One Stamford Realty.	2.30
02/19/20	JDH	Review of bank statements to satisfy request from counsel.	1.80
02/19/20	JDH	Creation of project summary document.	1.60
02/20/20	MFR	Conference call with D. Wooten, J. Carlisle (both Purdue), M. Rule, and F. Silva (both AlixPartners) re: charges for	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		shared services from Purdue to Rhodes.	
02/20/20	MFR	Call with F. Silva and M. Rule (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.50
02/20/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and PRA.	2.10
02/20/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and IACs for shared services.	3.10
02/20/20	FOS	Review of documents re: management fees paid to Purdue by various entities.	0.50
02/20/20	FOS	Conference call with D. Wooten, J. Carlisle (both Purdue), M. Rule, and F. Silva (both AlixPartners) re: charges for shared services from Purdue to Rhodes.	0.40
02/20/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.50
02/20/20	FOS	Review SAP data re: charges for shared services between Purdue and Rhodes.	2.20
02/20/20	SJC	Analysis of support for samples selected by Province.	3.00
02/20/20	SJC	Review of distribution support for internal meetings.	1.00
02/20/20	RC	Review Schedule A to the Stipulation agreement with the UCC and follow-up on available information.	0.70
02/20/20	RC	Review and research data requests made by the UCC's advisors.	1.90
02/20/20	RC	Review documentation related to tax distribution calculations.	1.30
02/20/20	RC	Review documentation related to Ex-US distributions.	1.10
02/20/20	RC	Review tax and accounting information related to Purdue and communicate with team re: next steps.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/20/20	RC	Review draft of the intercompany and non-cash transfer report.	1.50
02/21/20	RC	Respond to questions from Davis Polk re: cash distributions.	0.30
02/21/20	RC	Review tax returns information in response to requests from Davis Polk.	1.20
02/21/20	RC	Review status of responding to various requests received from the UCC's advisors.	0.80
02/21/20	RC	Discussion with A. DePalma and R. Collura (both AlixPartners) re: new UCC diligence request list	0.70
02/21/20	RC	Review support related to tax distributions and communicate with team regarding next steps.	1.10
02/21/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order	3.00
02/21/20	SJC	Continue to redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order	1.50
02/21/20	FOS	Conference Call with J. Lowne, D. Fogel, W. DiNicola (all Purdue), M. Rule, and F. Silva (both AlixPartners) re: accounting for product cost and sales price on API sales by Rhodes Tech.	0.60
02/21/20	FOS	Compose email to M. Clarens (Davis Polk) re: status of follow-up items for draft intercompany and non-cash transfers report.	0.30
02/21/20	FOS	Call with F. Silva and M. Rule (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.20
02/21/20	FOS	Compose emails to E. Nowakowski (Purdue) re: follow-ups on draft intercompany and non-cash transfers report.	0.10
02/21/20	MH	Continue analysis of historical tax documents to validate	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		sources of tax distributions.	
02/21/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and foreign IACs/PPI.	2.20
02/21/20	MFR	Conference Call with J. Lowne, D. Fogel, W. DiNicola (all Purdue), M. Rule, and F. Silva (both AlixPartners) re: accounting for product cost and sales price on API sales by Rhodes Tech.	0.60
02/21/20	MFR	Review and analysis of accounting for product cost and sales price on API sales by Rhodes Tech.	2.60
02/21/20	MFR	Call with F. Silva and M. Rule (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.20
02/21/20	ADD	Discussion with A. DePalma and R. Collura (both AlixPartners) re: new UCC diligence request list	0.70
02/24/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and foreign IACs related to sales of OxyContin.	1.90
02/24/20	MFR	Review and analysis of the accounting and support documentation for transfers between Rhodes and IACs related to API.	2.40
02/24/20	SJC	Analysis of support for samples selected by Province.	3.00
02/24/20	SJC	Review of supporting documents for Ex-US distributions.	2.00
02/24/20	FOS	Compose email to E. Nowakowski (Purdue) re: pending follow-ups on draft intercompany and non-cash report.	0.30
02/24/20	RC	Review documentation gathered in response to information requests made by the UCC's advisors.	1.40
02/24/20	RC	Review support documentation related the intercompany and non-cash transfers report.	1.50
02/24/20	RC	Review and respond to information requests made by Davis Polk regarding the cash transfers of value report.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/24/20	RC	Review list of requests from the UCC's advisors, identify what's been compiled and assess work involved with gathering the remaining requests.	1.10
02/25/20	RC	Review stipulation in connection with identifying information requests by work stream.	0.40
02/25/20	RC	Review information requests included in the stipulation agreement and compare to previous requests from the UCC.	0.60
02/25/20	RC	Communication with TXP's counsel re: follow-up related to information requests.	0.10
02/25/20	RC	Review and compile hours by work stream in response to requests from Davis Polk.	0.30
02/25/20	RC	Review documents gathered and develop plan for quantifying documents reviewed in connection with the special committee investigation.	0.60
02/25/20	RC	Call with R. Collura, S. Canniff, A. DePalma (all AlixPartners), C. McMillian, and A. Guo (both Davis Polk) to discuss discovery requests.	0.50
02/25/20	RC	Review documentation gathered in response to requests to the UCC's requests for tax information.	1.10
02/25/20	RC	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to complete Davis Polk information requests and to discuss outstanding diligence items	1.80
02/25/20	FOS	Analysis of SAP intercompany account activity re: Shared services charges between Rhodes Pharma/Tech and Purdue.	4.00
02/25/20	FOS	Perform analysis re: reconciliation of SOFA schedule to draft intercompany and non-cash transfers report.	0.50
02/25/20	SJC	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to complete Davis Polk information requests and to discuss outstanding diligence	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		items	
02/25/20	SJC	Call with R. Collura, S. Canniff, A. DePalma (all AlixPartners), C. McMillian, and A. Guo (both Davis Polk) to discuss discovery requests.	0.50
02/25/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and Rhodes related to CMO services.	3.30
02/25/20	MFR	Review and analysis of the accounting and support documentation for transfers between Purdue and foreign IACs related to sales of OxyContin.	2.30
02/25/20	ADD	Call with R. Collura, S. Canniff, A. DePalma (all AlixPartners), C. McMillian, and A. Guo (both Davis Polk) to discuss discovery requests.	0.50
02/25/20	ADD	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to complete Davis Polk information requests and to discuss outstanding diligence items	1.80
02/26/20	ADD	Compile hours billed to the cash transfer of value report work stream.	1.10
02/26/20	MFR	Review and analysis of the accounting and support documentation for transfers between Rhodes and Purdue related to shared services.	2.90
02/26/20	MFR	Review and analysis of the accounting and support documentation for transfers between Rhodes and Purdue related to Butrans AG.	2.80
02/26/20	MH	Revise the report on historical lease costs associated with use by the equity owners.	3.60
02/26/20	RC	Review and comment on summary of work performed by task in response to requests from Davis Polk.	0.50
02/26/20	RC	Review information provided by TXP related to the original lease with One Stamford Realty.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/26/20	RC	Review documentation compiled in connection with responding to requests received from the UCC's advisors.	1.10
02/26/20	RC	Review and comment on summary of documents reviewed in connection with the special committee investigation.	0.50
02/26/20	RC	Review audited financial statements and related rent and tax information for the debtor entities.	1.60
02/26/20	RC	Review tax documents and other diligence information related to the IACs.	1.80
02/27/20	RC	Compile updated list of outstanding information and data requests for TXP and PRA LP.	0.50
02/27/20	RC	Review documentation gathered in connection with responding to requests related to Ex-US distributions.	1.60
02/27/20	RC	Review documentation gathered in connection with responding to requests related to Tax distributions.	1.40
02/27/20	NAS	Correspondence with M. Rule and F. Silva (both AlixPartners) re: analysis of payments to IACs.	0.40
02/27/20	MH	Revise the report on historical lease costs associated with use by the equity owners.	3.80
02/27/20	MFR	Review and analysis of the accounting and support documentation for transfers between Rhodes and Purdue related to API.	3.10
02/27/20	MFR	Review and analysis of the accounting and support documentation for transfers related to Coventry Technologies LP.	0.80
02/27/20	MFR	Review and analysis of the accounting and support documentation for transfers related to Infinity Pharmaceuticals Inc.	0.90
02/27/20	MFR	Review and analysis of the accounting and support documentation for transfers related to New Suffolk Holdings LLP.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
02/27/20	FOS	Perform reconciliation re: SOFA schedule to draft of intercompany and non-cash transfers report.	2.50
02/27/20	FOS	Compose email to M. Hartley (AlixPartners) re: rent payments from Purdue to One Stamford Realty.	0.20
02/28/20	FOS	Compose emails to D. Smikkannu (AlixPartners) re: pending follow-ups for draft intercompany and non-cash transfers report.	0.10
02/28/20	MFR	Review and analysis of transfers between Purdue and Purdue Canada.	3.40
02/28/20	MFR	Review and analysis of Purdue SOFA schedules.	2.50
02/28/20	RC	Review tax documentation for the debtors.	1.10
02/28/20	RC	Review additional documents gathered in response to the UCC's requests related to distributions.	1.70
02/28/20	RC	Review documentation and prepare email to Davis Polk regarding tax related requests.	0.20
03/02/20	RC	Call with J. Dougherty (Haug Partners) and R. Collura (AlixPartners) to discuss status of information and data requests from TXP.	1.10
03/02/20	RC	Review information and data requests for TXP and prepare for call with TXP's counsel.	0.50
03/02/20	RC	Review available tax information and tax returns for debtor entities.	1.00
03/02/20	RC	Review intercompany schedules and payments to IACs.	0.80
03/02/20	RC	Review information gathered in response to requests made by the UCC.	1.30
03/02/20	RC	Review tax and rent information included in the Debtors' audited financial statements.	0.80
03/02/20	RC	Review related party information included in the debtors audited financial statements.	1.20
03/02/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re:	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		reconciliation between SOFA schedules and draft intercompany and non-cash transfers report.	
03/02/20	MFR	Review and analysis of Purdue SOFA schedules.	2.20
03/02/20	MFR	Review and analysis of transfers between Purdue and Purdue Canada.	1.80
03/02/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation between SOFA schedules and draft intercompany and non-cash transfers report.	0.40
03/02/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	2.50
03/03/20	FOS	Conference call with E. Nowakowski (Purdue), M. Rule, and F. Silva (both AlixPartners) re: follow-up questions on draft intercompany and non-cash transfers report.	0.70
03/03/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	2.50
03/03/20	MFR	Preparation for and conference call with E. Nowakowski (Purdue), M. Rule, and F. Silva (both AlixPartners) re: follow-up questions on draft intercompany and non-cash transfers report.	1.20
03/03/20	MFR	Review outstanding information requests related to Report 1B (the non-cash transfers report).	0.20
03/03/20	MFR	Review, analysis and reconciliation of SOFA schedules and Report 1B (the non-cash transfers report).	2.70
03/03/20	MFR	Review and analysis of the accounting and support documentation related to transfers between Purdue and Purdue Canada / Adlon.	2.40
03/03/20	MH	Attend call with R. Collura and M. Hartley (both AlixPartners) to discuss status of tax research.	0.40
03/03/20	RC	Call with M. Hartley and R. Collura (both AlixPartners) to	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		discuss tax information and related analysis.	
03/03/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss status of information requests.	0.50
03/03/20	RC	Review documentation gathered in response to the UCC's information requests.	1.70
03/03/20	RC	Review documentation related tax returns and tax calculations in response to requests from Davis Polk.	1.40
03/03/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss status of information requests.	0.50
03/04/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report (continued).	2.80
03/04/20	MFR	Discussion with M. Rule and F. Silva (both AlixPartners) re: SOFA schedules.	0.20
03/04/20	MFR	Review and analysis of Purdue transfers since 9/15/18.	2.90
03/04/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	3.10
03/04/20	FOS	Discussion with M. Rule and F. Silva (both AlixPartners) re: SOFA schedules.	0.20
03/05/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups to draft intercompany and non-cash transfers report.	0.20
03/05/20	FOS	Compose email to K. Shibuya (AlixPartners) re: follow-ups to Mundipharma EDO services provided to Purdue.	0.10
03/05/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	1.50
03/05/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups to draft intercompany and non-cash transfers report.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/05/20	MFR	Review of transfers and supporting documentation for transfers between Purdue and Mundipharma EDO GmbH.	2.10
03/05/20	MFR	Review of transfers and supporting documentation for transfers between Purdue and Mundipharma EDO GmbH.	2.30
03/05/20	MFR	Email to Davis Polk re: transfers between Purdue and Mundipharma EDO GmbH.	0.20
03/05/20	MH	Review 2008 and 2009 tax distributions against tax returns.	2.30
03/05/20	RC	Review tax documentation gathered in response to requests from the UCC's advisors.	0.70
03/05/20	RC	Review correspondence from the UCC's advisors related to requests for tax information.	0.20
03/05/20	RC	Review correspondence from the UCC's advisors related to requests for information related to payments to insiders.	0.10
03/05/20	RC	Review distribution related documentation gathered in response to requests from the UCC's advisors.	1.80
03/06/20	RC	Review IAC payment information.	0.80
03/06/20	RC	Call with M. Rule and R. Collura (both AlixPartners) to discuss intercompany and non-cash transfer of value report.	0.40
03/06/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss status of diligence requests.	0.40
03/06/20	FOS	Compose emails to A. DePalma (AlixPartners) re: Accounts Payable reconciliation to cash distributions.	0.10
03/06/20	FOS	Compose emails to K. Shibuya (AlixPartners) re: follow-ups on draft intercompany and non-cash transfers report.	0.10
03/06/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups on draft intercompany and non-cash transfers report.	0.20
03/06/20	MFR	Call with M. Rule and R. Collura (both AlixPartners) to	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		discuss intercompany and non-cash transfer of value report.	
03/06/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups on draft intercompany and non-cash transfers report.	0.20
03/06/20	MFR	Review and analysis of accounts payable report related to Purdue and Rhodes	3.20
03/06/20	MFR	Communication with A. Lutchen, B. Chen, M. Clarens, E. Kim (all Davis Polk), and M. Rule (AlixPartners) re: transfers between Purdue and Mundipharma EDO and discussion with M. Rule and F. Silva (both AlixPartners) re: the same.	0.30
03/06/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss status of diligence requests.	0.40
03/09/20	ADD	Call with A. DePalma, and R. Collura (both AlixPartners) to discuss building tracker for outstanding TXP requests .	0.20
03/09/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss updates to the information requests tracker.	0.30
03/09/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners), and Davis Polk diligence team to discuss outstanding TXP requests and potential next steps.	0.50
03/09/20	ADD	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests	0.50
03/09/20	ADD	Research and compile all TXP tax request to develop tracker at request of Davis Polk.	2.30
03/09/20	ADD	Upload files to data room requested by various parties and permission the documents accordingly.	1.00
03/09/20	ADD	Develop a list of material to provide to everyone when added to the VDR.	0.70
03/09/20	MFR	Call with A. Lutchen, B. Chen (both Davis Polk), M. Rule,	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		and F. Silva (both AlixPartners) re: transfers between Purdue and Mundipharma EDO	
03/09/20	MFR	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests.	0.50
03/09/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report/UCC Requests.	0.10
03/09/20	MFR	Review and analysis of supporting accounting documentation related to payments between Purdue and Purdue Pharma Technologies	1.80
03/09/20	MFR	Review and analysis of supporting accounting documentation related to payments between Purdue and foreign IACs related to OxyContin royalties.	1.60
03/09/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report/UCC Requests.	0.10
03/09/20	FOS	Compose email to K. Shibuya (AlixPartners) re: Mundipharma EDO services support.	0.20
03/09/20	FOS	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests.	0.50
03/09/20	FOS	Call with A. Lutchen, B. Chen (both Davis Polk), M. Rule, and F. Silva (both AlixPartners) re: transfers between Purdue and Mundipharma EDO	0.20
03/09/20	RC	Review various information requests and prepare for call with Davis Polk.	0.40
03/09/20	RC	Call with A. DePalma, R. Collura (both AlixPartners), and Davis Polk diligence team to discuss outstanding TXP requests and potential next steps.	0.50
03/09/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss building tracker for outstanding TXP requests.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/09/20	RC	Review information request tracker and provide comments.	0.40
03/09/20	RC	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests.	0.50
03/09/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss updates to the information requests tracker.	0.30
03/09/20	RC	Review the UCC's requests for royalty and licensing agreements.	0.20
03/09/20	RC	Review non-cash transfer report and supporting schedules.	1.20
03/10/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss updates to the TXP information request tracker.	0.20
03/10/20	RC	Review and update TXP and PRA LP information request tracker.	1.10
03/10/20	RC	Review communications with Haug Partners and update TXP and PRA LP information request tracker.	1.10
03/10/20	RC	Review documents related organizational structure.	0.70
03/10/20	RC	Review documents gathered in response to requests from the UCC.	1.20
03/10/20	RC	Review and analysis of documents related to organizational changes.	0.70
03/10/20	RC	Review available tax documentation related to debtor entities.	1.40
03/10/20	RC	Review and analysis of intercompany transactions.	1.60
03/10/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.20
03/10/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/10/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and One Stamford Reality.	2.80
03/10/20	MFR	Review and analysis of accounts payable extract from SAP.	0.80
03/10/20	MFR	Review of audited financial statements for information re: related intercompany payments	1.20
03/10/20	ADD	Review data room access and update permissions at direction of Davis Polk.	1.20
03/11/20	MFR	Review and analysis of accounts payable extract from SAP.	1.30
03/11/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and One Stamford Reality.	2.60
03/11/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.40
03/11/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.70
03/11/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.30
03/11/20	FOS	Call with M. Rule and F. Silva(both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.40
03/11/20	FOS	Update tracker re: follow-up items on draft intercompany and non-cash transfers report.	0.50
03/11/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report.	2.00
03/11/20	RC	Review documents and respond to email from Province re: ownership structure.	0.30
03/11/20	REO	Reconcile Transfer pricing deck re: cash and non-cash transfers of value examined by the AlixPartners team to MDL report.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/12/20	RC	Review various supporting documentation related to the cash transfers of value report in response to requests from the UCC.	0.70
03/12/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss requests for supporting documentation related to the cash transfers of value report.	0.50
03/12/20	RC	Review documentation gathered in response to distribution related requests from the UCC.	1.30
03/12/20	RC	Review requests from the UCC related to royalty agreements.	0.20
03/12/20	RC	Review non-cash transfer of value report support schedules and documentation.	1.30
03/12/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report.	3.00
03/12/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report (continued).	3.00
03/12/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.20
03/12/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and One Stamford Reality.	3.20
03/12/20	MFR	Review and analysis of accounts payable extract from SAP.	1.60
03/12/20	MFR	Review of audited financial statements for information re: related intercompany payments	1.40
03/12/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss requests for supporting documentation related to the cash transfers of value report.	0.50
03/12/20	ADD	Upload diligence production to the Purdue data room and update document permissions.	0.80
03/13/20	MFR	Review and analysis of accounts payable extract from SAP.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/13/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and One Stamford Reality.	2.40
03/13/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.40
03/13/20	MFR	Review and analysis of licensing agreements related to UCC request.	2.10
03/13/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report (continued).	2.70
03/13/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report.	3.00
03/13/20	RC	Review special committee related work and respond to requests from Davis Polk.	0.20
03/13/20	RC	Review cash transfers of value report and respond to questions from Purdue.	0.30
03/13/20	RC	Call with R. Collura (AlixPartners) and M. Sharp (Purdue) to discuss response to questions related to the cash transfers of value report.	0.10
03/15/20	RC	Review and respond to questions from Davis Polk related to the cash transfers of value report.	0.30
03/15/20	RC	Review information related to reimbursements from PRA LP and communicate with team.	0.50
03/16/20	RC	Call with R. Collura and N. Simon (both AlixPartners) to discuss analysis of payments to insiders.	0.30
03/16/20	RC	Review analysis of payments to insiders.	0.70
03/16/20	RC	Review draft response to additional requests for information from the UCC's advisors and provide comments.	0.60
03/16/20	RC	Review and analysis of pre-petition transaction with IACs.	1.60
03/16/20	RC	Review tax distribution documentation and related analysis.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/16/20	NAS	Call with R. Collura and N. Simon (both AlixPartners) to discuss analysis of payments to insiders.	0.30
03/16/20	FOS	Analyze and reconcile SAP accounts payable data extract re: draft intercompany and non-cash transfers report (continued).	3.00
03/16/20	FOS	Analyze and reconcile SAP accounts payable data extract re: draft intercompany and non-cash transfers report (continued).	1.70
03/16/20	MFR	Review and analysis of licensing agreements related to UCC request and email response to R. Collura (AlixPartners) re: same.	2.40
03/16/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	2.80
03/16/20	MFR	Review and respond to emails from K. Shibuya (AlixPartners) re: payments between Purdue and Mundipharma EDO.	0.40
03/16/20	MFR	Review and analysis of examples of supporting documentation for payments between Purdue and Mundipharma EDO.	1.10
03/16/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: Accounts Payable extract reconciliation to draft intercompany and non-cash transfers report.	0.20
03/16/20	FOS	Compose email to K. Shibuya (AlixPartners) re: access to SAP/Ariba.	0.10
03/16/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: Accounts Payable extract reconciliation to draft intercompany and non-cash transfers report.	0.20
03/16/20	FOS	Analyze and reconcile SAP accounts payable data extract re: draft intercompany and non-cash transfers report.	3.00
03/16/20	KS	Review transactions and related documents related to	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Mundipharma EDO.	
03/17/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and Purdue Pharma Technologies	2.30
03/17/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	2.10
03/17/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.60
03/17/20	MFR	Review and analysis of licensing agreements related to UCC request and provide additional response to R. Collura (AlixPartners).	2.80
03/17/20	NAS	Correspondence with intercompany payment investigation team M. Rule, F. Silva, N. Simon, and R. Collura (all AlixPartners) re: UCC data requests.	0.40
03/17/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss the recent diligence requests from the UCC's advisors and related responses.	0.50
03/17/20	RC	Review and comment on responses to UCC's advisors' requests for agreements between the Debtors and IACs.	0.70
03/17/20	RC	Review support documentation gathered in response to various financial information requests received from the UCC's advisors.	0.80
03/17/20	RC	Review updated draft of schedule of payments to insiders and provide comments.	1.10
03/17/20	RC	Review additional diligence requests made by the UCC's advisors.	0.40
03/17/20	RC	Review and analysis pre-petition transactions with IACs.	1.30
03/17/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss the recent diligence requests from the UCC's advisors and related responses.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/18/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding UCC request status	0.20
03/18/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners), J. McClammy, M. Clarens, C. Oluwole (all Davis Polk), and J. Dougherty (Haug Partners) to discuss status of TXP's responses to information requests.	0.50
03/18/20	RC	Review tracking list of requests to TXP and prepare for call with TXP's outside counsel.	0.60
03/18/20	RC	Call with R. Collura, A. DePalma (both AlixPartners), J. McClammy, M. Clarens, C. Oluwole (all Davis Polk), and J. Dougherty (Haug Partners) to discuss status of TXP's responses to information requests.	0.50
03/18/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss status of outstanding UCC diligence requests.	0.20
03/18/20	RC	Review documentation related to the distribution's analysis based on call with TXP's counsel.	0.80
03/18/20	RC	Review and analysis of tax related information in connection with responding to requests from the UCC's advisors.	1.20
03/18/20	MFR	Review and analysis of licensing agreements related to UCC request and provide additional response to R. Collura (AlixPartners).	1.80
03/18/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.80
03/18/20	MFR	Review and respond to emails with K. Shibuya (AlixPartners) re: payments between Purdue and Mundipharma EDO and analysis of attached documentation and support.	1.90
03/18/20	MFR	Draft email to A. Lutchen (Davis Polk) re: analysis of supporting documentation of payments between Purdue and Mundipharma EDO.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/18/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and Purdue Pharma Technologies	1.70
03/18/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of SAP accounts payable extract to draft intercompany and non-cash transfers report.	0.80
03/18/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report (continued).	2.00
03/18/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of SAP accounts payable extract to draft intercompany and non-cash transfers report.	0.80
03/18/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report.	3.00
03/18/20	KS	Review inter-company transactions and related attached documents.	1.80
03/19/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
03/19/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report.	3.00
03/19/20	SJC	Review of EX-US requests (continued).	1.80
03/19/20	SJC	Review of EX-US requests.	3.10
03/19/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report (continued).	1.20
03/19/20	MFR	Call with R. Collura and M. Rule (both AlixPartners) to discuss intercompany and non-cash transfers of value report and requests from the UCC's advisors.	0.70
03/19/20	MFR	Review, analysis and organization of workpapers related	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to payments between Purdue and Purdue Pharma Technologies	
03/19/20	MFR	Review of audited financial statements for information re: related intercompany payments	0.80
03/19/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	2.10
03/19/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.40
03/19/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
03/19/20	RC	Call with R. Collura and M. Rule (both AlixPartners) to discuss intercompany and non-cash transfers of value report and requests from the UCC's advisors.	0.70
03/19/20	RC	Review documentation related to the intercompany and non-cash transfers of value report.	1.30
03/20/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss staffing requirements for UCC request for supporting documentation.	0.40
03/20/20	RC	Call with M. Rule and R. Collura (both AlixPartners) to discuss intercompany and non-cash transfers of value report and responses to the UCC's discovery requests.	0.50
03/20/20	RC	Call with S. Canniff and R. Collura (both AlixPartners) to discuss distributions analysis and approach for gathering additional documentation in response to the UCC's requests.	0.40
03/20/20	RC	Review and respond to requests from the UCC's advisors.	0.30
03/20/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/20/20	MFR	Review latest status of open items.	0.50
03/20/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.10
03/20/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.30
03/20/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and Purdue Pharma Technologies	2.10
03/20/20	MFR	Call with E. Ruiz (Purdue), M. Rule, and F. Silva (both AlixPartners) re: intercompany licensing agreements.	0.20
03/20/20	MFR	Call with M. Rule and R. Collura (both AlixPartners) to discuss intercompany and non-cash transfers of value report and responses to the UCC's discovery requests.	0.50
03/20/20	FOS	Call with E. Ruiz (Purdue), M. Rule, and F. Silva (both AlixPartners) re: intercompany licensing agreements.	0.20
03/20/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report.	3.80
03/20/20	SJC	Call with S. Canniff and R. Collura (both AlixPartners) to discuss distributions analysis and approach for gathering additional documentation in response to the UCC's requests.	0.40
03/20/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss staffing requirements for UCC request for supporting documentation.	0.40
03/23/20	JDH	Collection of supporting documentation related to distributions.	3.20
03/23/20	JDH	Conference with Purdue IT.	2.40
03/23/20	JDH	Meeting with J.Hecht and S. Canniff (both AlixPartners) to discuss compiling distribution support and SAP walk through	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/23/20	SJC	Meeting with J.Hecht and S. Canniff (both AlixPartners) to discuss compiling distribution support and SAP walk through.	0.50
03/23/20	SJC	Compile distribution support for UCC request.	3.40
03/23/20	SJC	Compile distribution support for UCC request (continued).	3.10
03/23/20	SJC	Call with R. Collura and S. Canniff (all AlixPartners) to discuss additional work to perform in response to the UCC's information requests.	0.50
03/23/20	FOS	Reconcile Accounts Payable SAP data extract re: draft intercompany and non-cash transfers report.	7.20
03/23/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of Accounts Payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/23/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/23/20	MFR	Review of emails from R. Collura and A. DePalma (both AlixPartners) re: UCC information requests and provide responding email.	0.30
03/23/20	MFR	Review of email from E. Ruiz (Purdue) re: licensing agreements. Provided responding email.	0.20
03/23/20	MFR	Review latest UCC information requests and available information.	0.70
03/23/20	MFR	Review and respond to emails from R. Collura (AlixPartners) re: the UCC's request for licensing agreements.	0.20
03/23/20	MFR	Review and production of documents responsive to the UCC request for royalty payment information.	1.30
03/23/20	MFR	Correspondence with R. Collura and A. DePalma (both AlixPartners) re: licensing agreements.	0.30
03/23/20	MFR	Review and analysis of license agreement related to	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Israel.	
03/23/20	MFR	Review and analysis of examples of Report 1A documentation provided to the UCC.	2.60
03/23/20	RC	Call with R. Collura and S. Canniff (all AlixPartners) to discuss additional work to perform in response to the UCC's information requests.	0.50
03/23/20	RC	Call with R. Collura and J. DelConte (both AlixPartners) to discuss license agreements and related responses to the UCC's requests.	0.50
03/23/20	RC	Review documentation related to the UCC's requests for royalty rate information	0.40
03/23/20	RC	Review documentation related to report 1b in response to requests from the UCC's advisors.	1.10
03/23/20	RC	Review available licensing agreements and communicate with the UCC's advisors.	0.30
03/23/20	RC	Review information related to royalty and licensing agreements in response to requests made by the UCC's advisors.	0.60
03/23/20	RC	Review initial sample selections made by the UCC's advisors re: cash distributions.	1.00
03/23/20	RC	Communicate with TXP's counsel re: follow-up for responses to information requests.	0.10
03/23/20	RC	Communicate with Davis Polk re: requests made to TXP's counsel	0.20
03/23/20	RC	Review documentation related to transactions with IACs in connection with responding to information requests.	0.80
03/23/20	RC	Review information response tracker related to requests made to TXP's counsel.	0.20
03/24/20	RC	Review information provided by TXP's counsel and communicate with team re: next steps.	0.70
03/24/20	RC	Review information and provide list of requests for royalty	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		and license agreements to Davis Polk.	
03/24/20	RC	Review compensation information related to requests received from the UCC's advisors.	0.30
03/24/20	RC	Review royalty rate information requests received from the UCC's advisors and communicate with AlixPartners team on next steps.	0.40
03/24/20	RC	Review and communicate with the AlixPartners team re: information requests related to transactions with IACs.	0.30
03/24/20	RC	Review and analysis of payments to IACs.	0.90
03/24/20	RC	Communicate with Davis Polk re: outstanding requests for information from TXP/PRA LP.	0.20
03/24/20	RC	Review information related to property and withholding taxes provided by TXP's outside counsel.	0.30
03/24/20	RC	Review asset and trust information provided by counsel of the Sacklers.	1.10
03/24/20	RC	Review and analysis of transactions with IACs in response to requests from the UCC's advisors.	0.80
03/24/20	JDH	Meeting with J.Hecht and S. Canniff (both AlixPartners) to walk through SAP and supporting documents for distributions.	1.00
03/24/20	JDH	Call with Purdue IT re: SAP access.	0.70
03/24/20	JDH	Documentation support for distributions.	3.40
03/24/20	MFR	Review and respond to emails from R. Collura (AlixPartners) re: documentation provided to the UCC.	0.30
03/24/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable SAP data to draft report.	0.30
03/24/20	MFR	Review and respond to emails from the UCC re: the proposed information request to Bates White	1.10
03/24/20	MFR	Review, analysis and organization of workpapers related	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to payments between Purdue and MIL USA.	
03/24/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.30
03/24/20	FOS	Call with A. DePalma and F. Silva (both AlixPartners) re: reconciliation of Accounts Payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/24/20	FOS	Reconcile Accounts Payable SAP data extract re: draft intercompany and non-cash transfers report.	4.90
03/24/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable SAP data to draft report.	0.30
03/24/20	SJC	Meeting with J.Hecht and S. Canniff (both AlixPartners) to walk through SAP and supporting documents for distributions.	1.00
03/24/20	SJC	Compilation and analysis of 2017 distribution support from SAP in addition to review of supporting bank statements.	3.00
03/24/20	SJC	Compilation and analysis of 2017 distribution support from SAP in addition to review of supporting bank statements (continued).	3.00
03/24/20	SJC	Compilation and analysis of 2017 distribution support from SAP in addition to review of supporting bank statements (continued).	1.00
03/24/20	JDH	Documentation support for distributions (continued).	3.00
03/24/20	ADD	Call with A. DePalma and F. Silva (both AlixPartners) re: reconciliation of Accounts Payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/25/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) to discuss status of outstanding UCC diligence requests.	0.30
03/25/20	ADD	Call with R. Collura, M. Hartley, and A. DePalma (all AlixPartners) to discuss real estate and tax withholding	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		requests from the UCC.	
03/25/20	JDH	Documentation support for distributions.	3.00
03/25/20	JDH	Documentation support for distributions (continued).	1.10
03/25/20	JDH	Documentation support for distributions (continued).	3.00
03/25/20	SJC	Review of bank statements supporting 2017 distributions as well as compiling and evaluating related distribution support from SAP.	3.00
03/25/20	SJC	Review of bank statements supporting 2017 distributions as well as compiling and evaluating related distribution support from SAP (continued).	3.00
03/25/20	SJC	Review of bank statements supporting 2017 distributions as well as compiling and evaluating related distribution support from SAP (continued).	1.50
03/25/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.50
03/25/20	FOS	Extract data from SAP re: accounts receivable for debtor entities.	2.50
03/25/20	FOS	Analyze SAP accounting records re: cash payments for services provided by Mundipharma International Ltd (USA) to Purdue.	2.50
03/25/20	FOS	Compose email to N. Simon (AlixPartners) re: IAC cash payments.	0.10
03/25/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.60
03/25/20	MH	Call with R. Collura, M. Hartley, and A. DePalma (all AlixPartners) to discuss real estate and tax withholding requests from the UCC.	0.60
03/25/20	MH	Initial research into historical property tax payment records.	1.70
03/25/20	MFR	Review and analysis of accounts payable extract from SAP	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		and reconcile to intercompany and non-cash transfers report analyses	
03/25/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and MIL USA.	2.20
03/25/20	MFR	Discussion with M. Rule and R. Collura (both AlixPartners) re: case status and UCC requests.	0.30
03/25/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.50
03/25/20	JDH	Documentation support for distributions (continued).	2.80
03/25/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) to discuss status of outstanding UCC diligence requests.	0.30
03/25/20	RC	Review support for tax distributions and calculations of such.	1.40
03/25/20	RC	Call with R. Collura, M. Hartley, and A. DePalma (all AlixPartners) to discuss real estate and tax withholding requests from the UCC.	0.60
03/25/20	RC	Discussion with M. Rule and R. Collura (both AlixPartners) re: case status and UCC requests.	0.30
03/25/20	RC	Review support documentation related to distributions requests from the UCC.	1.00
03/25/20	RC	Review updated analysis of payments to insiders.	0.80
03/25/20	RC	Review information provided by TXP's counsel.	0.50
03/25/20	RC	Review and analysis of intercompany transaction support.	0.80
03/25/20	RC	Review documentation related to transaction with IACs.	0.60
03/26/20	RC	Call with M. Hartley and R. Collura (both AlixPartners) to prepare for call with Davis Polk re: tax distributions analysis.	0.50
03/26/20	RC	Review and analysis of documents related to tax distributions.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/26/20	RC	Call with R. Collura and M. Hartley (AlixPartners) and E. Kim and A. Whisenant (Davis Polk) to discuss tax distribution analysis and next steps.	0.60
03/26/20	RC	Review information provided by TXP related to compensation.	0.70
03/26/20	RC	Review and analysis of tax information related to the debtor entities.	1.30
03/26/20	RC	Review tax distributions and related support.	1.30
03/26/20	NAS	Correspondence with M. Hartley (AlixPartners) re: follow-up question related to Cash Transfers of Value investigation report.	0.80
03/26/20	JDH	Documentation support for distributions (continued).	3.00
03/26/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and MIL USA.	3.20
03/26/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.70
03/26/20	MH	Call with M. Hartley and R. Collura (both AlixPartners) to prepare for call with Davis Polk re: tax distributions analysis.	0.50
03/26/20	MH	Call with R. Collura and M. Hartley (AlixPartners) and E. Kim and A. Whisenant (Davis Polk) to discuss tax distribution analysis and next steps.	0.60
03/26/20	MH	Initial research into availability of payroll information for administrative support in equity owner offices.	0.90
03/26/20	MH	Prepare for call with counsel on tax distribution calculations.	1.20
03/26/20	MH	Call with M. Hartley (AlixPartners) and counsel to review progress on validating tax distribution calculations against financial results.	0.90
03/26/20	SJC	Compilation and analysis of 2016 distribution support	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		from SAP in addition to review of supporting bank statements (continued).	
03/26/20	SJC	Compilation and analysis of 2016 distribution support from SAP in addition to review of supporting bank statements.	3.00
03/26/20	SJC	Compilation and analysis of 2016 distribution support from SAP in addition to review of supporting bank statements (continued).	0.80
03/26/20	JDH	Documentation support for distributions.	3.30
03/26/20	JDH	Documentation support for distributions (continued).	2.10
03/27/20	JDH	Documentation support for distributions.	3.50
03/27/20	JDH	Documentation support for distributions (continued).	3.60
03/27/20	SJC	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP (continued).	2.90
03/27/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP.	3.00
03/27/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP (continued).	0.70
03/27/20	FOS	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/27/20	FOS	Analyze cash payment records re: services provided by Mundipharma International Ltd. (US) to Purdue.	0.90
03/27/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: UCC information requests.	0.30
03/27/20	MH	Additional research on historical pay records for equity owner administrative costs.	0.70
03/27/20	MH	Initial research on historical payroll tax withholding amounts.	1.30
03/27/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.80
03/27/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and MIL USA.	2.70
03/27/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: UCC information requests.	0.30
03/27/20	RC	Review support documentation related distributions analysis.	1.40
03/27/20	RC	Review family counsel materials re: holding companies and trust structure.	1.30
03/27/20	RC	Review information compiled in response to requests made by the UCC's advisors.	1.50
03/30/20	RC	Review documentation and follow-up with TXP's outside counsel re: status of information requests.	0.70
03/30/20	RC	Review accounting activity related to transactions with IACs.	1.20
03/30/20	RC	Review analysis of payments to insiders.	0.60
03/30/20	RC	Review information related to rent expense and property taxes.	0.50
03/30/20	RC	Review information related to withholding taxes.	0.60
03/30/20	RC	Review information related to requests for compensation and benefits	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/30/20	JDH	Documentation support for distributions (continued).	5.50
03/30/20	JDH	Documentation support for distributions.	3.00
03/30/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.40
03/30/20	MFR	Review of audited financial statements for information re: related intercompany payments	1.80
03/30/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and P.F. Laboratories.	2.80
03/30/20	MH	Create revised report on Ordinary Course Professionals to include additional requested information.	0.60
03/30/20	SJC	Compiling supporting documentation for tax distributions 2010-2018.	2.50
03/30/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP (continued).	3.00
03/30/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP.	3.00
03/30/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	5.00
03/31/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
03/31/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report (continued)	3.00
03/31/20	SJC	Review and compilation of distribution support for samples selected by Province.	3.00
03/31/20	SJC	Review and compilation of distribution support for samples selected by Province (continued).	3.00
03/31/20	SJC	Review and compilation of distribution support for	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		samples selected by Province (continued).	
03/31/20	MH	Create template for presentation of tax distribution history.	1.60
03/31/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and P.F. Laboratories.	2.80
03/31/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding UCC diligence items.	0.60
03/31/20	RC	Communicate with Province re: requests for information.	0.10
03/31/20	RC	Review and analysis of additional information related to Ex-US distributions.	1.20
03/31/20	RC	Review available bank records and communicate with Davis Polk.	0.30
03/31/20	RC	Review cash flow information related to Ex-US distributions.	1.30
03/31/20	RC	Review support related to the intercompany and non-cash transfers of value report.	1.40
03/31/20	RC	Review status of information responses to various diligence requests from the UCC.	0.50
03/31/20	JDH	Documentation support for distributions (continued).	2.30
03/31/20	JDH	Documentation support for distributions (continued).	3.00
03/31/20	JDH	Documentation support for distributions	3.00
03/31/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding UCC diligence items.	0.60
04/01/20	RC	Call with R. Collura (AlixPartners) and J. Crockett (Province) re: requests for documentation related to transfers to IACs and related follow-up.	0.60
04/01/20	RC	Review cash transfers of value report and request support documentation from team in response to requests from the UCC's advisors.	0.80
04/01/20	RC	Compile list of outstanding requests made to TXP's	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Counsel and send email requesting a status update.	
04/01/20	RC	Provide documentation to Purdue and Davis Polk re: UCC's request for information.	0.20
04/01/20	RC	Call with R. Collura (AlixPartners) and C. Oluwole (Davis Polk) re: requests for IAC agreements and status of other diligence requests.	0.20
04/01/20	RC	Review distribution related information in response to follow-up question made by the UCC's advisors.	0.70
04/01/20	RC	Review available bank records in response to requests made by the UCC's advisors and request additional information from the team.	0.30
04/01/20	RC	Review support documentation related to tax distributions.	0.80
04/01/20	RC	Review documentation related to IAC agreements.	0.50
04/01/20	JDH	Prepare documentation support for distributions.	2.30
04/01/20	JDH	Continue preparation of documentation support for distributions.	3.50
04/01/20	JDH	Review of distribution documentation,	2.40
04/01/20	MFR	Review of emails from R. Collura, A. DePalma (both AlixPartners), Roxana Aleali (Purdue) and Chautney Oluwole (Davis Polk) re: IAC information requests re: licensing agreements. Provided responding email.	0.80
04/01/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.90
04/01/20	FOS	Compose email to M. Clarens (Davis Polk) re: status of draft intercompany and non-cash transfers report.	0.20
04/01/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.90
04/02/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		(continued).	
04/02/20	MH	Call with human resources to review options to gather historical payroll tax records.	0.70
04/02/20	MFR	Call with R. Collura, M. Rule, A. DePalma (all AlixPartners), J. McClammy, C. Oluwole (both Davis Polk), R. Aleali (Purdue), J. Dougherty, and B. Murphy (both Haug Partners) re: status of requests related to IAC agreements and tax information.	0.30
04/02/20	MFR	Review of assumption & assignment agreements from 2017 related to OxyContin license agreements.	0.60
04/02/20	JDH	Review of 2016 distribution documentation.	3.50
04/02/20	JDH	Review of 2017 distribution documentation.	2.10
04/02/20	JDH	Distribution of analytics 2011-2015.	1.30
04/02/20	RC	Call with A. DePalma, R. Collura (both AlixPartners) re: status of TXP diligence requests.	0.60
04/02/20	RC	Call with R. Collura, M. Rule, A. DePalma (all AlixPartners), J. McClammy, C. Oluwole (both Davis Polk), R. Aleali (Purdue), J. Dougherty, and B. Murphy (both Haug Partners) re: status of requests related to IAC agreements and tax information.	0.30
04/02/20	RC	Review bank statements compiled in response to the UCC's requests and communicate with Davis Polk about next steps.	0.90
04/02/20	RC	Review distribution support work and provide direction to team on next steps.	0.90
04/02/20	RC	Review and comment on support documentation compiled in response to the UCC's requests.	0.80
04/02/20	RC	Review information related to tax distribution worksheets and calculations.	1.00
04/02/20	RC	Review and analysis of documentation related to transactions with the IACs.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/02/20	RC	Review summary of licensing agreement information in advance of call with Haug Partners.	0.20
04/02/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: status of TXP diligence requests.	0.60
04/02/20	ADD	Call with R. Collura, M. Rule, A. DePalma (all AlixPartners), J. McClammy, C. Oluwale (both Davis Polk), R. Aleali (Purdue), J. Dougherty, and B. Murphy (both Haug Partners) re: status of requests related to IAC agreements and tax information.	0.30
04/03/20	RC	Review diligence requests from UCC's advisors and information gathered in response to tax requests.	0.80
04/03/20	RC	Review SAP information compiled in response to requests made by the UCC's advisors.	1.10
04/03/20	RC	Review summary of IAC agreement information.	0.30
04/03/20	RC	Review and comment on TXP information request tracker.	0.20
04/03/20	RC	Review supporting documentation compiled for the intercompany and non-cash transfer of value report.	1.00
04/03/20	RC	Respond to questions from Davis Polk re: bank information requests.	0.30
04/03/20	RC	Respond to questions from Davis Polk re: requests for organizational charts.	0.20
04/03/20	RC	Review support documentation related to intercompany transactions.	1.80
04/03/20	JDH	Distribution of PPLP 2016 documentation.	3.10
04/03/20	JDH	Distribution of PPLP 2016 documentation.	2.70
04/03/20	MH	Create analysis of historical payroll withholding amounts for interested parties.	3.30
04/03/20	MH	Extract data required for historical analysis of payroll withholding amounts.	1.80
04/03/20	MH	Verify historical cash funding process for payrolls in	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		support of historical analysis of withholding amounts.	
04/03/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report (continued).	1.30
04/03/20	SJC	Compile distribution support for ex-us distributions.	3.00
04/03/20	SJC	Compile distribution support for ex-us distributions (continued).	2.80
04/03/20	SJC	Compile distribution support for ex-us distributions (continued).	1.00
04/03/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report.	3.00
04/06/20	SJC	Compile distribution support for ex-us distributions (continued).	3.20
04/06/20	MH	Cross reference accounts payable property tax history with general ledger expense entries.	3.70
04/06/20	MFR	Review of accounts payable analysis.	1.60
04/06/20	JDH	Continue to review of 2016 Tax Distributions.	2.30
04/06/20	JDH	Review of 2016 Tax Distributions.	2.60
04/06/20	JDH	Distribution of PPLP Documentation.	3.40
04/06/20	RC	Additional review and research into support documentation related to Tax Distributions.	1.10
04/06/20	RC	Review intercompany activity and related support documentation.	1.20
04/06/20	RC	Review financial information related to Purdue Pharma Inc.	0.80
04/06/20	RC	Review documentation provided by the family Counsel related to trust structure.	0.70
04/06/20	RC	Review support documentation related to Ex-US distributions.	0.90
04/06/20	RC	Review distribution information in connection with	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		responding to the UCC's information requests.	
04/06/20	RC	Review correspondence with Haug Partners re: requests for tax information.	0.30
04/07/20	RC	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence requests, UCC diligence requests, and open items	0.30
04/07/20	RC	Review and update the TXP and PRA LP information and data request tracker.	0.80
04/07/20	RC	Review and respond to communications with the debtors re: the status of information requests made to TXP and PRA LP.	0.20
04/07/20	RC	Review summary of compensations information related to requests from the UCC.	0.40
04/07/20	RC	Review summary of tax withholding and property tax information related to requests from the UCC.	0.70
04/07/20	RC	Review tracking of IAC agreement related requests.	0.20
04/07/20	RC	Review status of cash distribution support documentation project.	0.80
04/07/20	JDH	Distribution of 2016 Ex-US documentation.	2.20
04/07/20	JDH	Analysis of 2015 Distribution.	2.90
04/07/20	JDH	Continue distribution of 2016 Ex-US documentation.	2.20
04/07/20	MFR	Review of accounts payable analysis.	1.40
04/07/20	MFR	Call with F. Silva (AlixPartners) re: case status and accounts payable analysis.	0.50
04/07/20	MFR	Review and reconciliation of licensing agreements received from Norton Rose. Drafted email to R. Collura and A. DePalma (both AlixPartners) re: the UCC's request for licensing agreements.	1.20
04/07/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/07/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.00
04/07/20	FOS	Call with M. Rule (AlixPartners) re: case status and accounts payable analysis.	0.50
04/07/20	SJC	Review support for 2014 distributions.	1.70
04/07/20	SJC	Review support for 2017 distributions.	3.20
04/07/20	SJC	Compile support for 2015 distributions.	3.00
04/07/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence requests, UCC diligence requests, and open items	0.30
04/08/20	SJC	Compile support for 2015 distributions.	3.00
04/08/20	SJC	Compile support for 2015 distributions (continued).	3.10
04/08/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.80
04/08/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.20
04/08/20	JDH	Distribution of 2014 Tax documentation.	2.80
04/08/20	JDH	Distribution of 2014 Ex US documentation.	2.20
04/08/20	JDH	Continue distribution of 2014 Tax documentation.	2.80
04/08/20	RC	Review agreements compiled in response to the UCC's diligence requests.	0.30
04/08/20	RC	Review organizational charts and respond to questions from Davis Polk.	0.50
04/08/20	RC	Review information and responses to tax information requests.	0.70
04/08/20	RC	Review support documentation related to transactions with IACs.	1.30
04/08/20	RC	Review and respond to team re: requests from UCC's	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		advisors re: diligence requests.	
04/08/20	RC	Review information related to distributions to Purdue Pharma Inc.	0.60
04/08/20	RC	Review IAC information compiled in response to requests from the UCC's advisors.	1.00
04/08/20	RC	Review accounting information related to tax withholding information.	0.40
04/08/20	RC	Review accounting information related to property taxes.	0.30
04/08/20	NAS	Respond to follow-up question from R. Collura (AlixPartners) re: Cash Transfers of Value Investigation Report.	0.30
04/09/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and J. McClammy and C. Oluwole (both Davis Polk) re: bank statement requests and next steps.	0.30
04/09/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: diligence requests and status of responses.	0.60
04/09/20	RC	Review information and respond to requests for historical organizational charts.	0.70
04/09/20	RC	Review information included in the cash transfers of value report in preparation for call with Davis Polk.	0.30
04/09/20	RC	Review bank statement information in response to diligence requests made by the UCC's advisors.	0.80
04/09/20	RC	Review support documentation for cash distributions in response to diligence requests made by the UCC's advisors.	1.10
04/09/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	4.00
04/09/20	SJC	Compile support for 2015 distributions.	2.90
04/09/20	SJC	Compile support for 2015 distributions (continued).	3.00
04/09/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re:	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		diligence requests and status of responses.	
04/09/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and J. McClammy and C. Oluwole (both Davis Polk) re: bank statement requests and next steps.	0.30
04/10/20	ADD	Call A. DePalma and R. Collura (AlixPartners) re: UCC follow up diligence requests.	0.30
04/10/20	SJC	Compile support for 2015 distributions.	3.30
04/10/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.20
04/10/20	RC	Call A. DePalma and R. Collura (AlixPartners) re: UCC follow up diligence requests.	0.30
04/10/20	RC	Review distribution support documentation in response to requests from the UCC.	0.70
04/10/20	RC	Review information related to compensation requests and respond to Davis Polk.	0.50
04/10/20	RC	Review UCC's 2004 requests and subpoena to the Sackler Family members.	0.70
04/11/20	MFR	Review of information and documents related to UCC's request for API sales amounts. Drafted email response to A. DePalma and R. Collura (both AlixPartners) re: the same.	0.60
04/13/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	3.00
04/13/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/13/20	SJC	Compile support for 2015 distributions.	3.00
04/13/20	SJC	Compile support for 2015 distributions (continued).	3.00
04/13/20	SJC	Compile support for 2015 distributions (continued).	2.00
04/13/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) to information requests made	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		by the UCC' advisors.	
04/13/20	RC	Review information available in response to requests made by the UCC's advisors.	1.40
04/13/20	RC	Communicate with the AlixPartners teams re: responding to information requests made by the UCC's advisors.	0.30
04/13/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: responding to requests made by the UCC's advisors.	0.30
04/13/20	RC	Review information gathered in connection with the cash transfers of value report.	0.40
04/13/20	NAS	Respond to questions from R. Collura (AlixPartners) via Counsel re: data sources for Cash Transfers of Value Investigation report.	0.70
04/13/20	JDH	Continue documentation of 2014 PPLP distributions.	2.80
04/13/20	JDH	Distribution of documentation of 2014 PPLP.	2.80
04/13/20	JDH	Documentation of 2014 partner distributions.	2.40
04/13/20	JDH	Review of 2014 tax distributions.	1.40
04/13/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: responding to requests made by the UCC's advisors.	0.30
04/13/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) to information requests made by the UCC' advisors.	0.40
04/14/20	JDH	Respond to UCC requests.	2.30
04/14/20	JDH	Review of 2014 distribution documentation.	2.30
04/14/20	JDH	Analysis of 2014 Distribution bank statement.	1.40
04/14/20	JDH	Continue review of 2014 distribution documentation.	2.30
04/14/20	NAS	Respond to follow-up questions from R. Collura (AlixPartners) via Counsel re: data for Cash Transfers of Value investigation report.	0.60
04/14/20	RC	Call with R. Collura, M. Hartley and S. Canniff (all AlixPartners) re: review of compensation report obtained.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/14/20	RC	Review available compensation information in response to requests from the UCC.	0.60
04/14/20	RC	Preparation of communications to Davis Polk re: UCC's information requests.	0.20
04/14/20	RC	Review information available in response to requests from the UCC.	1.20
04/14/20	SJC	Review of documents received for pension benefits paid to Sackler Family Members.	0.60
04/14/20	SJC	Review of documents received for expenses paid to Sackler Family Members.	0.40
04/14/20	SJC	Review of documents received for payroll benefits paid to Sackler Family Members.	3.20
04/14/20	SJC	Review of documents received for payroll benefits paid to Sackler Family Members (continued).	3.00
04/14/20	SJC	Call with R. Collura, M. Hartley, S. Canniff (all AlixPartners) re: review of compensation report obtained.	0.80
04/14/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.90
04/14/20	FOS	Compose email to M. Rule (AlixPartners) re: Butrans licensing agreements.	0.20
04/14/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.90
04/14/20	MH	Research data availability for cash transfers prior to 2008.	2.10
04/14/20	MH	Call with R. Collura, M. Hartley, S. Canniff (all AlixPartners) re: review of compensation report obtained.	0.80
04/14/20	MH	Extract revised accounts payable report for historical payments to equity owners.	0.40
04/14/20	MFR	Review of documents for potential information related to Butrans and Mexico. Email response to A. DePalma (AlixPartners) re: the same.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/14/20	MFR	Review of emails from A. DePalma (AlixPartners) re: UCC requests about API. Review of information re: to API prior to 2008. Responded via email to A. DePalma (AlixPartners) re: the same.	1.10
04/14/20	MFR	Review of email from F. Silva (AlixPartners) re: Butrans.	0.20
04/15/20	MFR	Review of historical accounts payable analysis.	2.20
04/15/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	3.00
04/15/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/15/20	SJC	Review of documents received for payroll benefits paid to Sackler Family Members.	1.10
04/15/20	SJC	Compile support for 2015 distributions.	3.00
04/15/20	SJC	Compile support for 2015 distributions.	3.10
04/15/20	SJC	Call with R. Collura, S. Canniff (both AlixPartners) re: responses to UCC's payroll and distribution related requests.	0.80
04/15/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: status of various responses to the UCC's diligence requests.	0.50
04/15/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: TXP request tracker.	0.20
04/15/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's discovery requests and related responses.	0.40
04/15/20	RC	Follow-up call with A. DePalma and R. Collura (both AlixPartners) re: updates to the TXP request tracker.	0.20
04/15/20	RC	Call with R. Collura, S. Canniff (both AlixPartners) re: responses to UCC's payroll and distribution related requests.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/15/20	RC	Review summary of payroll information and provide comments.	0.70
04/15/20	RC	Review TXP information request tracker.	0.30
04/15/20	RC	Review available information in connection with responding to requests from the UCC's advisors.	0.70
04/15/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) re: status of various responses to the UCC's diligence requests.	0.50
04/15/20	ADD	Call with DPW Diligence team re: the status of diligence items.	0.80
04/15/20	ADD	Follow-up call with A. DePalma and R. Collura (both AlixPartners) re: updates to the TXP request tracker.	0.20
04/15/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's discovery requests and related responses.	0.40
04/15/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) re: TXP request tracker.	0.20
04/16/20	ADD	Research Purdue accounting system transaction types.	0.70
04/16/20	RC	Review and update summary of information prepared in response to the UCC's requests.	0.90
04/16/20	RC	Review and comment on updated TXP request tracker.	0.30
04/16/20	RC	Communicate with Davis Polk re: requests for bank statements.	0.10
04/16/20	RC	Review various support documentation gathered in response to requests made by the UCC's advisors.	1.60
04/16/20	RC	Review additional documentation compiled in response to requests related to transactions with IACs.	1.30
04/16/20	RC	Review additional diligence requests and research available information.	0.50
04/16/20	SJC	Review of documents compiled for 2015 distributions.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/16/20	SJC	Review of documents compiled for 2015 distributions (continued).	3.00
04/16/20	SJC	Compile support for 2013 distributions.	1.30
04/16/20	FOS	Call with M. Rule (AlixPartners) re: reconciliation of Accounts Payable data to draft intercompany and non-cash transfers report.	0.80
04/16/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.60
04/16/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.60
04/16/20	MFR	Call with F. Silva (AlixPartners) re: reconciliation of Accounts Payable data to draft intercompany and non-cash transfers report.	0.80
04/16/20	MFR	Review of accounts payable analysis.	2.10
04/17/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.50
04/17/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.70
04/17/20	SJC	Compile support for 2013 distributions.	3.00
04/17/20	SJC	Compile support for 2013 distributions (continued).	1.70
04/17/20	RC	Review diligence requests from the UCC re: distributions and tax information.	0.20
04/17/20	RC	Review diligence requests from the UCC re: bank statements.	0.10
04/17/20	JDH	Continue review of 2014 distribution documentation.	2.40
04/17/20	JDH	Testing of 2012 partner distribution.	1.70
04/17/20	JDH	Review of 2014 distribution documentation.	2.10
04/19/20	RC	Review correspondence with the UCC's advisors and	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		research status of responding to various requests and identify next steps.	
04/20/20	RC	Review summary of distribution selections in connection with gathering information in response to the UCC's requests.	0.80
04/20/20	RC	Review and update information gathered in response to the UCC's requests related to the cash transfers of value report.	1.40
04/20/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: availability of bank statement for the debtor entities.	0.20
04/20/20	RC	Review and respond to questions from Davis Polk re: availability of bank statements for various entities.	0.30
04/20/20	JDH	Continue production of 2012 tax distribution documentation.	2.50
04/20/20	JDH	Production of 2012 tax distribution document.	2.60
04/20/20	JDH	Production of 2012 non-tax distribution documentation.	3.60
04/20/20	SJC	Compile support for Province selections.	0.50
04/20/20	SJC	Compile support for 2013 distributions.	3.00
04/20/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/20/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/20/20	MFR	Review and edit non-cash transfer report.	3.20
04/20/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: availability of bank statement for the debtor entities.	0.20
04/21/20	MFR	Review and edit non-cash transfer report.	2.90
04/21/20	MFR	Call with F. Silva (AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		non-cash transfers report.	
04/21/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) to review and discuss the intercompany and non-cash transfers of value report.	0.80
04/21/20	FOS	Call with M. Rule (AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
04/21/20	FOS	Compose email to K. Shibuya and R. Ellis Ochoa (all AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.20
04/21/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.80
04/21/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.70
04/21/20	SJC	Compile support for 2013 distributions.	3.00
04/21/20	SJC	Compile support for 2013 distributions.	3.00
04/21/20	SJC	Compile support for 2013 distributions.	1.00
04/21/20	JDH	Distribution of 2012 non-tax documentation.	2.90
04/21/20	JDH	Distribution of 2012 tax documentation.	2.20
04/21/20	JDH	Continue distribution of 2012 non-tax documentation.	2.80
04/21/20	RC	Review information and respond to questions from Davis Polk re: the Special Committee work streams.	0.20
04/21/20	RC	Call with R. Collura, M. Rule (both AlixPartners) to review and discuss the intercompany and non-cash transfers of value report.	0.80
04/21/20	RC	Review status update for responding to the UCC's distributions requests.	0.20
04/22/20	RC	Review additional information provided by TXP's Counsel	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		and reconciled to specific requests.	
04/22/20	RC	Review supporting documentation related to transactions with the IACs.	1.00
04/22/20	RC	Review documentation related to tax distributions and reconciled to requests made by the UCC.	1.10
04/22/20	RC	Review agreements with IACs collected in response to requests from the UCC.	0.40
04/22/20	RC	Review documentation related transfers to IACs.	0.80
04/22/20	RC	Review documentation gathered in response to the UCC's request for tax-related information.	0.70
04/22/20	RC	Review documentation gathered in response to the UCC's request for bank information.	0.30
04/22/20	JDH	Documentation of 2012 tax distribution.	2.40
04/22/20	JDH	Review of 2012 distribution documentation.	3.40
04/22/20	JDH	Review of additional bank statements provided by Counsel.	0.90
04/22/20	JDH	Continued documentation of 2012 Tax distribution.	2.40
04/22/20	SJC	Compile support for 2015 distributions (continued).	3.00
04/22/20	SJC	Compile support for 2015 distributions.	3.00
04/22/20	FOS	Compose email to K. Shibuya (AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
04/22/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	3.70
04/22/20	MFR	Review and edit non-cash transfer report.	3.80
04/23/20	MFR	Review and edit non-cash transfer report.	2.80
04/23/20	MFR	Call with R. Collura, M. Rule and F. Silva (all AlixPartners) and M. Clarens, C. Kim, E. Kim and A. Whisenant (all Davis Polk) re: the intercompany and non-cash transfers of value report and the UCC's diligence requests.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/23/20	MFR	Review of outstanding issues tracker. Discussion with F. Silva (AlixPartners) re: the same.	0.60
04/23/20	FOS	Review of outstanding issues tracker. Discussion with M. Rule (AlixPartners) re: the same.	0.60
04/23/20	FOS	Call with R. Collura, M. Rule and F. Silva (all AlixPartners) and M. Clarens, C. Kim, E. Kim and A. Whisenant (all Davis Polk) re: the intercompany and non-cash transfers of value report and the UCC's diligence requests.	0.60
04/23/20	FOS	Update Status Tracker re: draft intercompany and non-cash transfers report.	1.20
04/23/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.10
04/23/20	SJC	Compile support for 2015 distributions.	3.00
04/23/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.10
04/23/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	1.40
04/23/20	JDH	Review of PPLP bank statement production by TXP.	5.70
04/23/20	JDH	Analysis of bank statement production by TXP.	1.60
04/23/20	RC	Call with R. Collura, M. Rule and F. Silva (all AlixPartners) and M. Clarens, C. Kim, E. Kim and A. Whisenant (all Davis Polk) re: the intercompany and non-cash transfers of value report and the UCC's diligence requests.	0.60
04/23/20	RC	Review license agreements provided by Davis Polk.	0.30
04/23/20	RC	Review and respond to questions from Davis Polk re: TXP's discovery requests.	0.40
04/23/20	RC	Review status update on information provided by TXP and provide team with next steps.	0.30
04/23/20	RC	Review distributions analysis in connection with researching requests made by the UCC's advisors.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/23/20	RC	Review status of open items related to the intercompany and non-cash transfers of value report.	0.40
04/23/20	RC	Review TXP request tracker.	0.30
04/23/20	RC	Review additional documents gathered in response to the UCC's requests for IAC related information.	0.80
04/23/20	RC	Review additional documents gathered in response to the UCC's request for tax-related information.	1.00
04/24/20	RC	Call with R. Collura, J. Hecht (both AlixPartners) re: distribution support documentation work stream.	0.40
04/24/20	RC	Review UCC's initial distribution testing selections and related support documentation.	1.80
04/24/20	RC	Review and update latest TXP request tracker and provide to Davis Polk.	0.40
04/24/20	RC	Review analysis and supporting documentation related to transactions with IACs.	0.80
04/24/20	RC	Review updated status of bank statements received from TXP and communicate with the team on next steps.	0.20
04/24/20	RC	Review additional information gathered in response to tax-related requests.	1.10
04/24/20	RC	Research available information in response to the UCC's requests for additional support to cash transfers of value report.	0.70
04/24/20	RC	Update support documentation related to requests for the cash transfers of value report.	0.60
04/24/20	RC	Review status of outstanding items related to the intercompany analysis.	0.50
04/24/20	JDH	Analysis of additional bank statements provided by Counsel.	3.60
04/24/20	JDH	Analysis of 2012 distribution bank statement.	3.20
04/24/20	JDH	Call with R. Collura, J. Hecht (both AlixPartners) re:	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		distribution support documentation work stream.	
04/24/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	1.60
04/24/20	SJC	Review support for 2015 distributions.	3.00
04/24/20	SJC	Review support for 2015 distributions (continued).	2.80
04/24/20	FOS	Compose email to M. Rule re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
04/24/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.50
04/24/20	FOS	Call with M. Rule (AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.20
04/24/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.30
04/24/20	MFR	Call with F. Silva (AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.20
04/24/20	MFR	Review and edit non-cash transfer report.	3.80
04/27/20	MFR	Review and edit non-cash transfer report.	2.60
04/27/20	MFR	Call with F. Silva (AlixPartners) re: SAP Accounts payable data reconciliation to Draft intercompany and non-cash transfers report.	0.20
04/27/20	MFR	Review of accounting data supporting the non-cash transfer report.	3.00
04/27/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report (continued).	2.50
04/27/20	FOS	Compose emails to R. Collura and A. DePalma (both AlixPartners) re: reconciliation of SAP accounts payable data to draft intercompany and non-cash transfers report.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/27/20	FOS	Call with M. Rule (AlixPartners) re: SAP Accounts payable data reconciliation to Draft intercompany and non-cash transfers report.	0.20
04/27/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	2.60
04/27/20	FOS	Update draft report re: intercompany and non-cash transfers.	0.50
04/27/20	SJC	Compile support for 2011 distributions.	3.00
04/27/20	SJC	Compile support for 2015 distributions.	3.00
04/27/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	2.20
04/27/20	RC	Review support documentation for initial set of distribution selections made by the UCC's advisors.	2.20
04/27/20	RC	Review IAC related documentation gathered in response to requests made by the UCC.	1.30
04/27/20	RC	Review year end files prepared by TXP re: distributions analysis.	2.00
04/27/20	RC	Review documentation related to transactions with IACs and respond to questions from the UCC's advisors.	0.30
04/27/20	RC	Continue to review and comment on documentation related to responses to the UCC's requests.	0.60
04/27/20	JDH	Continue to prepare bank statement index.	3.20
04/27/20	JDH	Prepare bank statement Index.	3.30
04/27/20	JDH	Continue to prepare bank statement index.	1.90
04/28/20	JDH	Prepare bank statement index.	0.10
04/28/20	JDH	Preliminary draft finalization of the bank statement index.	2.60
04/28/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: status of diligence requests and next steps.	0.60
04/28/20	ADD	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	
04/28/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: status of diligence requests and next steps.	0.60
04/28/20	RC	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	1.00
04/28/20	RC	Review summary of additional information provided by TXP in response to requests from the UCC.	0.70
04/28/20	RC	Review and comment on supporting documentation related to tax distribution requests.	1.80
04/28/20	RC	Continue to review supporting documentation compiled in connection with the UCC's tax distribution requests.	1.30
04/28/20	RC	Review and analysis of documentation related to intercompany transactions.	0.80
04/28/20	RC	Review licensing agreements and respond to questions from the UCC's advisors.	0.30
04/28/20	RC	Review documentation related to the debtors' organizational structure and changes over time.	0.20
04/28/20	RC	Review documentation re: transactions with IACs in connection with responding to requests from the UCC.	0.60
04/28/20	JDH	Continue to prepare bank statement index.	2.80
04/28/20	JDH	Continue to review of PPLP bank statement production by TXP.	2.80
04/28/20	SJC	Review of distributions in conjunction with report 1b.	1.00
04/28/20	SJC	Compile support for 2011 distributions.	3.00
04/28/20	SJC	Compile support for 2011 distributions (continued).	3.00
04/28/20	SJC	Compile support for 2011 distributions (continued).	1.00
04/28/20	SJC	Conference call with R. Collura, M. Rule, F. Silva, S.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	
04/28/20	FOS	Call with M. Rule (AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
04/28/20	FOS	Review of royalty transfer pricing valuation reports re: ADF Oxycontin, MS Contin between PPLP and IACs.	0.20
04/28/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	3.90
04/28/20	FOS	Edit draft report re: intercompany and non-cash transfers.	2.50
04/28/20	FOS	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	1.00
04/28/20	MFR	Review of accounting data supporting the non-cash transfer report.	2.00
04/28/20	MFR	Call with S. Fernando (AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
04/28/20	MFR	Review and edit non-cash transfer report.	2.80
04/28/20	MFR	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	1.00
04/29/20	MFR	Conference call with J. Lowne (Purdue), E. Nowakowski (Purdue) and F. Silva (AlixPartners) re: follow-up items on draft intercompany and non-cash transfers report.	1.00
04/29/20	MFR	Review and edit non-cash transfer report.	2.20
04/29/20	MFR	Call with F. Silva (AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
04/29/20	MFR	Review of accounting data supporting the non-cash	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		transfer report.	
04/29/20	FOS	Conference call with J. Lowne, E. Nowakowski (all Purdue) and M. Rule (AlixPartners) re: follow-up items on draft intercompany and non-cash transfers report.	1.00
04/29/20	FOS	Edit draft report re: intercompany and non-cash transfers.	0.20
04/29/20	FOS	Compose email to J. Lowne and E. Nowakowski (both Purdue) re: reconciliation of shared services charges between Purdue and Rhodes entities.	0.50
04/29/20	FOS	Compile data re: royalties paid by IACs to Purdue.	2.70
04/29/20	FOS	Call with M. Rule (AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
04/29/20	SJC	Review of distributions in conjunction with report 1b.	3.70
04/29/20	SJC	Compile support for 2011 distributions.	2.60
04/29/20	SJC	Review support compiled for sample selections for Province and follow up questions.	2.20
04/29/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	0.90
04/29/20	JDH	Continue preliminary draft finalization of the bank statement index.	2.30
04/29/20	REO	Review of support for foreign sales re: foreign sales between 2008-2018 including reconciliation of sales to SAP.	1.50
04/29/20	RC	Review and analysis of transactions related to intercompany transfer analysis.	1.40
04/29/20	RC	Review and comment of support documentation related to Ex-US Distributions.	1.60
04/29/20	RC	Continue analysis of support documentation related to Ex-US loans and distributions.	1.40
04/29/20	RC	Review and comment on testing analysis for transfers included in the intercompany and non-cash transfer of	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		value report.	
04/29/20	RC	Review documents gathered in response to requests from the UCC related to royalty information.	1.10
04/29/20	JDH	Preliminary draft finalization of the bank statement index.	2.30
04/29/20	JDH	Analysis of 2012 distribution bank statement.	2.80
04/29/20	JDH	Review 2012 distribution documentation.	1.40
04/30/20	JDH	Continue review of 2012 distribution documentation	2.70
04/30/20	JDH	Calls and WebEx with J. Koczeniak and W. Sielert (both Mundipharma) to fix SAP access issues.	1.10
04/30/20	JDH	Documentation production of 2010 distribution.	3.10
04/30/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence request and status of UCC diligence request.	0.60
04/30/20	RC	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence request and status of UCC diligence request.	0.60
04/30/20	RC	Review update re: the UCC's requests for information from the Sackler family.	0.20
04/30/20	RC	Review documentation related to royalty agreements in connection with responding to the UCC's requests.	0.40
04/30/20	RC	Review support documentation related to intercompany transactions.	0.80
04/30/20	RC	Review and comment on distribution support documentation work stream.	0.30
04/30/20	RC	Review summary of bank statement information.	0.20
04/30/20	RC	Review intercompany transaction documentation and provide comments to team.	0.50
04/30/20	RC	Review support documentation related to the non-cash transfer analysis.	0.80
04/30/20	RC	Review documentation related to bank statement	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		requests.	
04/30/20	RC	Review tax information documentation gathered in response to the UCC's request.	0.50
04/30/20	KS	Compile the royalty payments for 2015.	2.50
04/30/20	SJC	Analysis of 2017 and 2018 royalties for report 1b.	3.00
04/30/20	SJC	Compile support for 2011 distributions.	3.00
04/30/20	SJC	Compile support for 2011 distributions (cont.).	1.10
04/30/20	FOS	Compose email to K. Shibuya, S. Canniff, R. Ellis Ochoa (all AlixPartners) re: compilation of royalty payments from IACs to Purdue.	0.40
04/30/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes.	2.10
04/30/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes (continued).	2.10
04/30/20	MFR	Review of accounting data supporting the non-cash transfer report.	2.70
04/30/20	MFR	Review and edit non-cash transfer report.	2.80
05/01/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: shared services charges between Purdue and Rhodes.	0.20
05/01/20	MFR	Review and analysis of shares service charges between Purdue and Rhodes.	3.20
05/01/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: shared services charges between Purdue and Rhodes.	0.20
05/01/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes.	2.60
05/01/20	SJC	Analysis of 2018 royalties for report 1B.	3.00
05/01/20	SJC	Analysis of 2017 royalties for report 1B.	2.50
05/01/20	SJC	Continue analysis of 2017 royalties for report 1B.	2.00
05/01/20	KS	Compile the royalty payments for 2015.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/01/20	KS	Continue to compile the royalty payments for 2015.	1.20
05/01/20	KS	Compile the royalty payments for 2016.	2.30
05/01/20	KS	Continue to compile the royalty payments for 2016.	1.90
05/01/20	FOS	Continue to review documents and SAP data re: shared services charges between Purdue and Rhodes.	2.50
05/01/20	RC	Continue to review documentation related to the UCC's initial Ex-US distribution selections and provide comments.	2.30
05/01/20	RC	Review and provide comments on supporting documentation gathered in response to the UCC's requests re: Ex-US distributions.	1.10
05/01/20	JDH	Prepare 2010 Distribution documentation.	3.50
05/01/20	JDH	Continue to prepare 2010 Distribution documentation.	3.40
05/04/20	JDH	Further preparation of 2010 Tax distribution documentation	2.20
05/04/20	RC	Review documentation gathered in response to requests from the UCC re: Ex-US distributions.	1.90
05/04/20	RC	Review documentation gathered in response to requests from the UCC re: Tax distributions.	1.60
05/04/20	RC	Continue to review and comment on support documentation re: the UCC's initial selection of Ex-US distributions.	1.30
05/04/20	RC	Review and comment on documentation gathered in response to the UCC's additional Ex-US distribution selections.	1.70
05/04/20	RC	Review additional information gathered in response to the UCC's requests related to tax distributions.	0.70
05/04/20	JDH	Prepare 2010 Tax distribution documentation	3.20
05/04/20	JDH	Continue preparation of 2010 Tax distribution documentation.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/04/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
05/04/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes.	3.50
05/04/20	FOS	Analyze data and documentation re: royalties between Purdue and IACs.	1.00
05/04/20	KS	Compile the royalty payments data for 2016.	1.80
05/04/20	SJC	Continue review of additional bank statements received supporting 2011-2014 distributions.	1.00
05/04/20	SJC	Review and respond to comments and questions re: distribution analysis previously performed.	2.50
05/04/20	SJC	Review of additional bank statements received supporting 2015 distributions.	1.80
05/04/20	SJC	Review of additional bank statements received supporting 2011 distributions.	1.50
05/04/20	SJC	Review of additional bank statements received supporting 2013 distributions.	1.50
05/04/20	MFR	Review and analysis of accounts payables related to the intercompany and non-cash transfers report.	2.90
05/04/20	MFR	Review and analysis of royalty payments related to the intercompany and non-cash transfers report and supporting analyses.	1.80
05/04/20	MFR	Review of and revisions to the intercompany and non-cash transfers report.	2.10
05/04/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
05/05/20	MFR	Conference call with J. Lowne, J. Carlisle, E. Liesman, W. DiNicola, E. Nowakowski, T. Au, D. Wooten (all Purdue) M. Rule, F. Silva (both AlixPartners) re: pending items on draft intercompany and non-cash transfers report.	0.60
05/05/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		intercompany and non-cash transfers report.	
05/05/20	MFR	Review of accounts payable data related to the intercompany and non-cash transfers report and supporting analyses.	2.40
05/05/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	3.10
05/05/20	FOS	Conference call with J. Lowne, J. Carlisle, E. Liesman, W. DiNicola, E. Nowakowski, T. Au, D. Wooten (all Purdue) M. Rule, F. Silva (both AlixPartners) re: pending items on draft intercompany and non-cash transfers report.	0.60
05/05/20	FOS	Compose email to J. Lowne (Purdue) re: shared services charges between PPLP and Rhodes entities.	0.10
05/05/20	FOS	Compose email to W. DiNicola (Purdue) re: Intercompany account settlement files for Rhodes Tech and Rhodes Pharma.	0.10
05/05/20	FOS	Compose email to E. Liesman (Purdue) re: shared services charges between Rhodes and PPLP.	0.10
05/05/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
05/05/20	FOS	Analyze and reconcile data re: shared services charges between Purdue and Rhodes entities.	2.50
05/05/20	SJC	Review of additional bank statements received supporting 2013 distributions.	3.00
05/05/20	SJC	Continue review of additional bank statements received supporting 2013 distributions.	1.00
05/05/20	SJC	Review of additional bank statements received supporting 2011 distributions.	2.50
05/05/20	SJC	Continue review of additional bank statements received supporting 2013 distributions.	1.50
05/05/20	FOS	Continue to analyze and reconcile data re: shared	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		services charges between Purdue and Rhodes entities.	
05/05/20	JDH	Prepare 2010 Tax distribution documentation	2.60
05/05/20	JDH	Prepare 2010 Non-tax distributions documentation.	3.60
05/05/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: the UCC's Schedule A diligence requests and status of responses.	0.70
05/05/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's Schedule A diligence requests and responses thereto.	0.20
05/05/20	RC	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: responding to Davis Polk's questions related the UCC's Schedule A diligence requests.	0.20
05/05/20	RC	Review Schedule A diligence requests and provide comments to status update for Davis Polk.	0.60
05/05/20	RC	Review and comment on supporting documentation gathered in response to the UCC's Ex-Us distributions.	1.60
05/05/20	RC	Continue review of supporting documentation gathered in response to the UCC's Ex-Us distributions.	1.40
05/05/20	RC	Review documentation related UCC's request for documentation related to loans.	1.10
05/05/20	RC	Review documentation gathered as support to the cash transfers of value report and in response to various parties' requests.	0.80
05/05/20	JDH	Continue preparation of 2010 Tax distribution documentation.	2.20
05/05/20	ADD	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: responding to Davis Polk's questions related the UCC's Schedule A diligence requests.	0.20
05/05/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: the UCC's Schedule A diligence requests and status of responses.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/05/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's Schedule A diligence requests and responses thereto.	0.20
05/06/20	JDH	Continue to review 2012 Distribution.	2.20
05/06/20	JDH	Review 2012 Distribution	3.00
05/06/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.60
05/06/20	RC	Conference call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/06/20	RC	Review information related to the intercompany and non-cash transfers of value report.	0.90
05/06/20	RC	Review and provide comments re: additional work to perform in connection with gathering support for Ex-US and tax distributions.	1.40
05/06/20	RC	Review supporting documentation gathered in response to the UCC's requests for additional distribution selections.	1.20
05/06/20	RC	Review additional information related to the intercompany and non-cash transfers of value report.	0.70
05/06/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.00
05/06/20	SJC	Review and respond to comments and questions re: distribution analysis previously performed.	2.00
05/06/20	SJC	Review of additional bank statements received to identify those that supported distribution samples selected by Province.	3.00
05/06/20	SJC	Continue review of additional bank statements received to identify those that supported distribution samples selected by Province.	3.00
05/06/20	FOS	Compose email to J. Lowne (Purdue) re: draft	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		intercompany and non-cash transfers report pending items.	
05/06/20	FOS	Conference call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/06/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.00
05/06/20	FOS	Calls with F. Silva, M. Rule (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/06/20	MFR	Review of accounts payable data related to the intercompany and non-cash transfers report.	2.30
05/06/20	MFR	Review and analysis of royalty payments related to the intercompany and non-cash transfers report and supporting analyses	2.60
05/06/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	1.40
05/06/20	MFR	Conference call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/06/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/06/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.60
05/07/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: status of intercompany and non-cash transfers of value report and next steps.	0.60
05/07/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/07/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.80
05/07/20	MFR	Review and analysis of intercompany accounts related to	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		the intercompany and non-cash transfers report and supporting analyses.	
05/07/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.40
05/07/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.40
05/07/20	FOS	Edit draft report re: intercompany and non-cash transfers.	2.50
05/07/20	FOS	Compose email to W. DiNicola (Purdue) re: Shared services charges between Purdue and Rhodes entities.	0.20
05/07/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.80
05/07/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/07/20	SJC	Compilation of support from SAP for 2013 distributions as well as analysis of journal entries.	3.00
05/07/20	SJC	Continue compilation of support from SAP for 2013 distributions as well as analysis of journal entries.	2.00
05/07/20	SJC	Compilation of support from SAP for 2011 distributions as well as analysis of journal entries.	3.00
05/07/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: status of intercompany and non-cash transfers of value report and next steps.	0.60
05/07/20	RC	Review comments from J. Lowne (Purdue) related to the intercompany and non-cash transfers of value report.	0.50
05/07/20	RC	Review status of diligence requests made to TXP Services.	0.40
05/07/20	RC	Review Schedule A diligence list and update TXP diligence tracker.	0.30
05/07/20	RC	Review additional documentation gathered in response to the UCC's requests related to royalties.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/07/20	RC	Review additional documentation gathered in response to the UCC's requests related to transactions with IACs.	0.60
05/07/20	RC	Review updated support documentation compiled in response to the UCC's requests re: the cash transfers of value report.	1.60
05/07/20	JD	Review draft investigation report 1B and commentary from J. Lowne (Purdue).	3.30
05/07/20	JDH	Prepare 2010 Distribution documentation.	3.00
05/07/20	JDH	Continue to prepare 2010 Distribution documentation.	2.60
05/08/20	JDH	Continue to prepare 2010 non-tax distributions documentation.	2.50
05/08/20	JDH	Prepare 2010 non-tax distributions documentation.	2.80
05/08/20	JDH	Review of 2010 tax distributions.	2.20
05/08/20	JD	Review correspondence and open questions from management re: investigation report 1B.	0.50
05/08/20	RC	Review and comment on responses to additional testing selections by the UCC's advisors.	1.60
05/08/20	RC	Review comments received in connection with the intercompany and non-cash transfers of value report.	0.40
05/08/20	RC	Review status of responses to the UCC's request for support documentation.	0.70
05/08/20	RC	Review royalty information gathered in response to the UCC's requests.	0.50
05/08/20	RC	Review support documentation gathered in response to requests for IAC agreements.	0.70
05/08/20	RC	Call with R. Collura, J. DelConte (both AlixPartners) re: status of the intercompany and non-cash transfers report and special committee related work.	0.30
05/08/20	SJC	Continue compilation of support from SAP for 2011 distributions as well as analysis of journal entries.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/08/20	SJC	Compilation of supporting documents from SAP for 2009 distributions.	2.00
05/08/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.00
05/08/20	FOS	Conference call with M. Clarens (Davis Polk), E. Kim (Davis Polk), A. Whisenant (Davis Polk), M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/08/20	FOS	Conference call with M. Rule, F. Silva (both AlixPartners) re: reconciliation of shared services charges between Purdue and Rhodes entities.	0.60
05/08/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.30
05/08/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.30
05/08/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	0.80
05/08/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.40
05/08/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.20
05/08/20	MFR	Conference call with M. Clarens (Davis Polk), E. Kim (Davis Polk), A. Whisenant (Davis Polk), M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/08/20	MFR	Conference call with M. Rule, F. Silva (both AlixPartners) re: reconciliation of shared services charges between Purdue and Rhodes entities.	0.60
05/09/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/10/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.00
05/11/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.60
05/11/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.60
05/11/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.20
05/11/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.30
05/11/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	1.70
05/11/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.50
05/11/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.60
05/11/20	FOS	Email to R. Ellis Ochoa (AlixPartners) re: Infinity Pharmaceuticals non-cash transfer.	0.10
05/11/20	FOS	Compose email to J. Lowne (Purdue) re: pending items on draft intercompany and non-cash transfers report.	0.30
05/11/20	FOS	Review documents and edit draft report re: intercompany and non-cash transfers report.	2.00
05/11/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.50
05/11/20	SJC	Compilation of supporting documents from SAP for 2009 distributions from SAP and related analysis.	3.00
05/11/20	SJC	Continue compilation of supporting documents from SAP for 2009 distributions from SAP and related analysis.	3.00
05/11/20	SJC	Further compilation of supporting documents from SAP for 2009 distributions from SAP and related analysis.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/11/20	RC	Review comments related to the intercompany and non-cash transfers of value report.	0.50
05/11/20	RC	Review documentation gathered in connection with tax distributions.	1.60
05/11/20	RC	Review documentation gathered in connection with US distributions.	1.40
05/11/20	RC	Review information re: tax information related requests.	1.10
05/11/20	RC	Review information related to transactions with the IACs.	0.80
05/11/20	RC	Review documentation related to non-cash distributions.	1.30
05/11/20	JDH	Prepare 2010 Tax distribution documentation	2.50
05/11/20	JDH	Perform 2010 QC review.	2.80
05/11/20	REO	Review intercompany transactions re: non-cash transfers to PRA.	0.60
05/11/20	JD	Review correspondence between J. Lowne (Purdue) and F. Silva (AlixPartners) re: Report 1B open items. Review open diligence items and back up information.	1.00
05/11/20	JDH	Continue to prepare 2010 Tax distribution documentation.	2.30
05/12/20	JDH	Continue to finalize 2010 Distribution documentation.	1.90
05/12/20	JDH	Begin to finalize 2010 Distribution documentation.	3.00
05/12/20	JDH	Set up 2008 Distribution documentation.	1.80
05/12/20	JDH	Prepare 2008 Tax distribution documentation.	1.00
05/12/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.70
05/12/20	RC	Review and respond to questions from Province.	0.20
05/12/20	RC	Review schedules prepared in connections with the intercompany and non-cash transfers of value report.	1.10
05/12/20	RC	Review and comment on documentation supporting the tax distributions.	1.40
05/12/20	RC	Review and comment on documentation supporting the	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Ex-US loans.	
05/12/20	RC	Review and analysis of tax related information gathered in response to requests from the UCC.	0.70
05/12/20	RC	Review documentation related rent and real estate taxes.	0.60
05/12/20	RC	Review additional diligence requests related to license agreements with IACs.	0.10
05/12/20	RC	Review additional documents provided by TXP's counsel and communicate with Davis Polk.	0.50
05/12/20	SJC	Compile and evaluate 2009 distribution support from SAP.	3.00
05/12/20	SJC	Review of 2009 distribution support and analysis.	3.00
05/12/20	SJC	Continue review of 2009 distribution support and analysis.	2.00
05/12/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.30
05/12/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.20
05/12/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.40
05/12/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	1.80
05/12/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.00
05/12/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.30
05/12/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.70
05/12/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.30
05/12/20	FOS	Analyze and reconcile SAP data re: shared services	3.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		charges between Purdue and Rhodes entities.	
05/13/20	FOS	Call with J. Lowne (Purdue) re: Purdue Canada reimbursement of Craig Landau expenses.	0.10
05/13/20	FOS	Conference call with J. Lowne (Purdue), M. Rule, F. Silva (both AlixPartners) re: status of pending requests on draft intercompany and non-cash transfers report.	0.40
05/13/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.70
05/13/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	1.50
05/13/20	FOS	Compose email to R. Collura, S. Canniff, K. Shibuya, J. Hecht, and M. Rule (all AlixPartners) re: quality control and review of draft intercompany and non-cash transfers report.	0.30
05/13/20	FOS	Compose emails to J. Lowne (Purdue) re: draft intercompany and non-cash transfers report.	0.20
05/13/20	FOS	Compose and edit draft report re: intercompany and non-cash transfers.	2.40
05/13/20	MFR	Conference call with J. Lowne (Purdue), M. Rule, F. Silva (both AlixPartners) re: status of pending requests on draft intercompany and non-cash transfers report.	0.40
05/13/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.70
05/13/20	MFR	Review of email from F. Silva (AlixPartners) re: quality control and review of draft intercompany and non-cash transfers report.	0.20
05/13/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.10
05/13/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/13/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.50
05/13/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.30
05/13/20	FOS	Continue to compose and edit draft report re: intercompany and non-cash transfers.	2.40
05/13/20	SJC	Review and summary of documents received from Haug Partners on 5.12.20 and updating bank statement index for new documents received.	3.00
05/13/20	SJC	Continue review and summary of documents received from Haug Partners on 5.12.20 and updating bank statement index for new documents received.	3.00
05/13/20	SJC	Continue review and summary of documents received from Haug Partners on 5.12.20 and updating bank statement index for new documents received.	0.90
05/13/20	SJC	Review of SAP documents for 2009 distributions.	1.10
05/13/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to diligence requests.	0.80
05/13/20	RC	Review and respond to Davis Polk re: email from TXP's outside counsel.	0.40
05/13/20	RC	Review documents provided by TXP in response to diligence requests and communicate with Davis Polk re: same.	0.70
05/13/20	RC	Review information provided by TXP's outside in response to diligence requests.	0.60
05/13/20	RC	Review documentation related to transactions with IACs.	1.30
05/13/20	RC	Communicate with Davis Polk re: available bank statement information.	0.20
05/13/20	JDH	Prepare 2008 Distribution documentation.	3.10
05/13/20	JDH	Continue to prepare 2008 Distribution documentation.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/13/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to diligence requests.	0.80
05/13/20	ADD	Review material provided by the client in response to diligence requests for completeness and consistency.	0.70
05/14/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: additional updates to the TXP diligence tracker.	0.40
05/14/20	JDH	Calls with J. Hecht, F. Silva (both AlixPartners) re: charges between Purdue and TXP for services.	0.40
05/14/20	JDH	Conference call with E. Liesman (Purdue), J. Hecht, F. Silva (both AlixPartners) re: charges between Purdue and TXP for services.	0.60
05/14/20	JDH	Review Report 1B	3.60
05/14/20	JDH	Call with E. Liesman (PPLP) re: Report 1B.	0.60
05/14/20	JDH	Perform 2008 Distribution testing.	1.20
05/14/20	RC	Review and update TXP diligence tracker based on additional documentation received.	0.30
05/14/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: additional updates to the TXP diligence tracker.	0.40
05/14/20	RC	Review and respond to questions from Davis Polk re: bank statement information.	0.10
05/14/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: status of the intercompany and non-cash transfers of value report.	0.30
05/14/20	RC	Review status of diligence requests from the UCC.	0.70
05/14/20	SJC	Review of report 3B - reviewed data retrieved from SAP, checked report to PBCs, reviewed for accuracy, reconciled amounts contained within report and PBCs.	2.20
05/14/20	SJC	Analysis of OSR rent related payments in SAP.	3.00
05/14/20	SJC	Analysis of intercompany transfer related payments in SAP for sale of goods.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/14/20	SJC	Continue review of report 3B - reviewed data retrieved from SAP, checked report to PBCs, reviewed for accuracy, reconciled amounts contained within report and PBCs.	2.00
05/14/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.00
05/14/20	KS	Review the transactions in SAP between the IAC and PPLP.	3.00
05/14/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.80
05/14/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.30
05/14/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.80
05/14/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/14/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: status of the intercompany and non-cash transfers of value report.	0.30
05/14/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	0.80
05/14/20	FOS	Compose email to J. Lowne and E. Liesman (all Purdue) re: payments and intercompany charges between Purdue and TXP.	0.40
05/14/20	FOS	Email to R. Collura and K. Shibuya (all AlixPartners) re: intercompany charges between Purdue and Mundipharma International Limited (USA) and Mundipharma International Technical Operations Limited.	0.20
05/14/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/14/20	FOS	Calls with J. Hecht, F. Silva (both AlixPartners) re:	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		charges between Purdue and TXP for services.	
05/14/20	FOS	Conference call with E. Liesman (Purdue), J. Hecht, F. Silva (both AlixPartners) re: charges between Purdue and TXP for services.	0.60
05/14/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.00
05/15/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.00
05/15/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/15/20	FOS	Conference call with J. Lowne (Purdue) and M. Rule, F. Silva (both AlixPartners) re: outstanding information requests for draft intercompany and non-cash transfers report.	0.70
05/15/20	FOS	Conference call with M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: update on status of draft intercompany and non-cash transfers report.	0.90
05/15/20	FOS	Draft and edit report re: intercompany and non-cash transfers report.	3.20
05/15/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.10
05/15/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/15/20	MFR	Conference call with J. Lowne (Purdue) and M. Rule, F. Silva (both AlixPartners) re: outstanding information requests for draft intercompany and non-cash transfers report.	0.70
05/15/20	MFR	Conference call with M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: update on status of draft intercompany and non-cash transfers report.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/15/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.40
05/15/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	3.20
05/15/20	KS	Update a report 1B re: transfer pricing.	1.60
05/15/20	FOS	Continue to draft and edit report re: intercompany and non-cash transfers report.	2.00
05/15/20	SJC	Analysis of intercompany payments in SAP related to Purdue Canada/Avrio.	1.00
05/15/20	SJC	Retrieve Rhodes intercompany payment support from SAP.	1.50
05/15/20	SJC	Analysis of intercompany transfer related payments in SAP for sale of goods.	2.00
05/15/20	SJC	Analysis of intercompany payments in SAP related to Purdue Canada.	2.50
05/15/20	SJC	Analysis of OSR rent related payments in SAP.	1.00
05/15/20	RC	Conference call with M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: update on status of draft intercompany and non-cash transfers report.	0.90
05/15/20	RC	Review additional updates made to the intercompany and non-cash transfers of value report.	1.00
05/15/20	RC	Call with R. Collura, A. DePalma (AlixPartners) re: response to emails from TXP's counsel.	0.20
05/15/20	RC	Review responses from TXP counsel and prepare additional follow-up responses.	0.60
05/15/20	RC	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: additional responses to TXP's counsel.	0.40
05/15/20	RC	Review and comment on intercompany and non-cash transfers of value report.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/15/20	RC	Review updated bank statement index.	0.10
05/15/20	RC	Review various correspondence from TXP's counsel.	0.20
05/15/20	RC	Review additional sections of the intercompany and non-cash transfers of value report.	1.10
05/15/20	RC	Review documentation related to cash distributions.	0.40
05/15/20	JDH	Analysis of 2010 Bank statement.	2.70
05/15/20	JDH	Analysis of 2008 Distribution.	2.60
05/15/20	JDH	Review Report 1B	1.10
05/15/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: response to emails from TXP's counsel.	0.20
05/15/20	ADD	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: additional responses to TXP's counsel.	0.40
05/15/20	ADD	Review responses to UCC tax requests provided by Purdue's accounting tax/services provided.	1.70
05/15/20	ADD	Update diligence request tracker for TXP services.	1.20
05/15/20	ADD	Draft responses to TXPs responsive materials explaining the status of outstanding requests.	0.90
05/16/20	RC	Review comments and updated intercompany and non-cash transfer of value report.	1.40
05/16/20	FOS	Perform quality control on draft report re: intercompany and non-cash transfers.	3.00
05/17/20	FOS	Perform quality control on draft report re: intercompany and non-cash transfers.	4.00
05/17/20	FOS	Continue quality control on draft report re: intercompany and non-cash transfers.	4.00
05/17/20	RC	Review updated draft of the intercompany and non-cash transfer report and provide comments to the team.	2.60
05/18/20	RC	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to requests made to TXP.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/18/20	RC	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to UCC and Ad Hoc Committee's diligence requests.	0.20
05/18/20	RC	Review information related to property taxes.	0.80
05/18/20	RC	Review additional updates and comments related to the intercompany and non-cash transfers report.	1.30
05/18/20	RC	Review supporting documentation related to transactions with IACs.	1.40
05/18/20	RC	Coordinate staffing for quality control review of the intercompany and non-cash transfers report.	0.20
05/18/20	RC	Review support documentation provided in response to requests for information related to the cash transfers of value report.	0.40
05/18/20	RC	Review SAP information related to payroll withholding taxes.	0.60
05/18/20	RC	Review SAP information related to property taxes.	0.30
05/18/20	RC	Review documentation related to non-cash distributions.	0.70
05/18/20	RC	Review SAP information related to transactions with IACs.	0.80
05/18/20	RC	Review reconciliation to the schedules included in the MDL presentation.	0.80
05/18/20	REO	Reconcile and consolidate excel support for international royalties' analysis: quarterly royalties for Q1-Q2 2012.	1.40
05/18/20	REO	Continue to reconcile and consolidate excel support for international royalties' analysis: quarterly royalties for Q1-Q2 2013.	1.00
05/18/20	REO	Continue to reconcile and consolidate excel support for international royalties' analysis: quarterly royalties for Q3-Q4 2012.	1.20
05/18/20	REO	Reconcile and consolidate excel support for international royalties' analysis: quarterly royalties for Q3-Q4 2013.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/18/20	REO	Reconcile and consolidate excel support for international royalties' analysis: quarterly royalties for Q1-Q2 2014.	1.50
05/18/20	REO	Continue to reconcile and consolidate excel support for international royalties' analysis: quarterly royalties for Q3-Q4 2014.	1.40
05/18/20	SJC	Review of report 1B exhibits 1a-1p to underlying documents, accuracy, and internal consistency.	3.00
05/18/20	SJC	Continue review of report 1B exhibits 1a-1p to underlying documents, accuracy, and internal consistency.	3.00
05/18/20	SJC	Further review of report 1B exhibits 1a-1p to underlying documents, accuracy, and internal consistency.	2.50
05/18/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: quality control of draft intercompany and non-cash transfers report.	0.20
05/18/20	FOS	Perform quality control re: draft intercompany and non-cash transfers report.	3.80
05/18/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.50
05/18/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: quality control of draft intercompany and non-cash transfers report.	0.20
05/18/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.20
05/18/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.10
05/18/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.30
05/18/20	ADD	Review (quality control) report 1B for constancy and compared charts to source data.	3.30
05/18/20	ADD	Update diligence responses to incorporate comment from	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Purdue.	
05/18/20	ADD	Review and update liabilities subject to compromise analysis.	2.80
05/18/20	ADD	Compile MOR bank balance and distribution MOR schedules.	0.60
05/18/20	ADD	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to requests made to TXP.	0.60
05/18/20	ADD	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to UCC and Ad Hoc Committee's diligence requests.	0.20
05/18/20	JDH	Continue to Review Report 1B.	2.00
05/18/20	JDH	Review Report 1B.	3.20
05/19/20	JDH	Further review of report 1B.	3.10
05/19/20	JDH	Review of distribution documentation for 2012.	1.90
05/19/20	JDH	Complete review of report 1B.	3.00
05/19/20	ADD	Review 1B report for third-party confidentiality.	2.50
05/19/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.70
05/19/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	3.20
05/19/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.60
05/19/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.80
05/19/20	FOS	Perform quality control re: draft intercompany and non-cash transfers report.	3.50
05/19/20	FOS	Compose email to M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk) re: quality control of draft intercompany and non-cash transfers report.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/19/20	SJC	Review of report 1B exhibits 1q, 1r, 4e, 4g, 4h, 4i, 4j, and 4k to underlying documents, accuracy, and internal consistency.	3.00
05/19/20	SJC	Continue review of report 1B exhibits 1q, 1r, 4e, 4g, 4h, 4i, 4j, and 4k to underlying documents, accuracy, and internal consistency.	3.30
05/19/20	RC	Review communications related to responses provided by TXP's counsel.	0.70
05/19/20	RC	Review support documentation related to transactions with IACs.	0.80
05/19/20	RC	Review support documentation related to non-cash distributions.	1.20
05/19/20	RC	Review transactions detail related to loans to IACs.	1.10
05/19/20	RC	Review support documentation provided to the UCC and NCSG in connection with the cash transfers of value report.	0.50
05/19/20	RC	Review documentation provided by TXP in response to requests from the UCC.	0.60
05/20/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: the intercompany and non-cash transfers report.	0.20
05/20/20	RC	Review additional responses from TXP's counsel.	0.60
05/20/20	RC	Review and respond to questions from the UCC's advisors.	0.10
05/20/20	RC	Review additional data provided by TXP related to distribution requests.	0.80
05/20/20	RC	Review and comment on responses to requests made by the UCC's advisors.	0.30
05/20/20	RC	Review payments to the IACs and research available information in response to requests made by the UCC.	0.70
05/20/20	RC	Review and respond to questions from Davis Polk on status of TXP's responses to various requests.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/20/20	RC	Perform review of information available in connection with responding to tax and payment requests by the UCC.	0.60
05/20/20	RC	Review status of UCC's diligence requests and provide comments.	0.40
05/20/20	RC	Review documentation related to the intercompany and non-cash transfer report.	0.80
05/20/20	SJC	Review of SAP documents for 2009 distributions.	3.50
05/20/20	SJC	Continue review of SAP documents for 2009 distributions.	3.50
05/20/20	FOS	Perform quality control re: draft intercompany and non-cash transfers report.	0.50
05/20/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.10
05/20/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.30
05/20/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	1.90
05/20/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.60
05/20/20	ADD	Review 1B report for third-party confidentiality.	2.10
05/20/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: the intercompany and non-cash transfers report.	0.20
05/20/20	ADD	Research parties provided by David Polk for third party relationships to identify potential confidentiality issues.	2.30
05/20/20	ADD	Review and compile diligence materials and responses to tax requests to discuss with Davis Polk.	2.60
05/20/20	ADD	Compile materials in response to diligence request to be sent to Davis Polk eDiscovery	0.80
05/20/20	JDH	Continue review of bank statement documentation.	2.00
05/20/20	JDH	Review of bank statement documentation.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/20/20	JDH	Distribution of 2010 Tax documentation.	4.00
05/21/20	JDH	Distribution of 2008 tax documentation.	3.20
05/21/20	ADD	Compile materials in response to diligence request to be sent to Davis Polk eDiscovery.	0.60
05/21/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to diligence requests.	0.60
05/21/20	ADD	Review transactions in client's account system to understand account methodology and implications.	2.20
05/21/20	ADD	Review and compile diligence materials and responses to tax requests to discuss with Davis Polk.	1.80
05/21/20	ADD	Research entity relationships for potential redaction.	3.00
05/21/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.90
05/21/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.60
05/21/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.10
05/21/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to diligence requests.	0.60
05/21/20	RC	Review information provided by TXP in response to various diligence requests.	1.20
05/21/20	RC	Communicate with Davis Polk re: status of responses to the UCC's diligence requests.	0.20
05/21/20	RC	Review status of tax return and related information provided by TXP.	0.30
05/21/20	RC	Review documentation provided to the UCC in connection with the cash transfers of value report.	0.70
05/21/20	RC	Review documentation provided to the UCC in response to agreements with IACs.	0.40
05/21/20	RC	Review and provide comments related to the tax	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		information request tracker.	
05/22/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to bank information diligence requests.	0.20
05/22/20	RC	Review updated responses to the UCC's request for tax related information.	0.40
05/22/20	RC	Review bank statement information requests from the UCC.	0.20
05/22/20	RC	Review additional updates to the intercompany and non-cash transfers of value report.	0.90
05/22/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.60
05/22/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	1.40
05/22/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and 2017 distribution testing for completeness, accuracy, and potential open items.	3.50
05/22/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to bank information diligence requests.	0.20
05/22/20	JDH	Distribution of 2010 and 2008 ex-US documentation.	2.80
05/22/20	JDH	Continue distribution of 2010 and 2008 ex-US documentation.	2.50
05/26/20	JDH	Continue documentation of 2008 non-tax distributions.	2.40
05/26/20	JDH	Documentation of 2008 non-tax distributions.	2.40
05/26/20	ADD	Call with R. Collura and A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: responses to the UCC's tax related diligence requests.	0.40
05/26/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and 2017 distribution testing for completeness, accuracy, and potential open items.	3.00
05/26/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and 2017 distribution testing for completeness, accuracy, and	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		potential open items (Continue).	
05/26/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and 2017 distribution testing for completeness, accuracy, and potential open items (Continue).	2.00
05/26/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.80
05/26/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	3.30
05/26/20	MFR	Call with R. Collura, M. Rule and F. Silva (AlixPartners) and M. Claren, E. Kim and A. Whisenant (Davis Polk) re: the intercompany and non-cash transfers of value report.	0.30
05/26/20	FOS	Call with R. Collura, M. Rule and F. Silva (AlixPartners) and M. Claren, E. Kim and A. Whisenant (Davis Polk) re: the intercompany and non-cash transfers of value report.	0.30
05/26/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss updates to the UCC's tax request tracker.	0.30
05/26/20	RC	Call with R. Collura and A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: responses to the UCC's tax related diligence requests.	0.40
05/26/20	RC	Review and comment on responses to the UCC's tax requests.	0.60
05/26/20	RC	Review information provided by TXP's counsel and update comments to tracking schedule.	0.90
05/26/20	RC	Call with R. Collura, M. Rule and F. Silva (AlixPartners) and M. Claren, E. Kim and A. Whisenant (Davis Polk) re: the intercompany and non-cash transfers of value report.	0.30
05/27/20	RC	Review and provide comments re: updating TXP information response tracker.	0.40
05/27/20	RC	Review and comment on support documentation gathered in response to the UCC's tax requests.	0.70
05/27/20	RC	Review and comment on support documentation gathered	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		in response to the UCC's request for information related to the IACs.	
05/27/20	RC	Review additional updates to the intercompany and non-cash transfers of value report.	1.10
05/27/20	JDH	Review of 2014 bank statements.	3.80
05/27/20	JDH	Reviewing of 2012 bank statements.	2.30
05/27/20	JDH	Documentation of 2014 not-tax distributions.	2.10
05/27/20	JD	Meeting with J. DelConte, A. DePalma, S. Lemack (all AlixPartners) re: latest workstream updates and discuss next steps.	0.60
05/27/20	FOS	Perform quality review and edit draft report re: intercompany and non-cash transfers report.	2.10
05/27/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	1.80
05/27/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	3.30
05/27/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	3.60
05/27/20	FOS	Continue to perform quality review and edit draft report re: intercompany and non-cash transfers report.	2.00
05/27/20	SKL	Meeting with J. DelConte, A. DePalma, S. Lemack (all AlixPartners) re: latest workstream updates and discuss next steps.	0.60
05/27/20	ADD	Meeting with J. DelConte, A. DePalma, S. Lemack (all AlixPartners) re: latest workstream updates and discuss next steps.	0.60
05/27/20	ADD	In response to diligence request, research outstanding distribution and identify any supporting material in SAP.	2.40
05/28/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: status of responses received from TXP re: information requests.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/28/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss responses to information provided by TXP's counsel.	0.40
05/28/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.80
05/28/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	3.60
05/28/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	1.60
05/28/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	0.80
05/28/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
05/28/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
05/28/20	JDH	Documentation of 2008 non-tax distributions.	3.90
05/28/20	JDH	Continuation of 2010 non tax distribution documentation.	1.10
05/28/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss responses to information provided by TXP's counsel.	0.40
05/28/20	RC	Review TXP diligence tracker and provide comments related to open items.	0.60
05/28/20	RC	Review intercompany and non-cash transfer report and additional comments provided.	1.20
05/28/20	RC	Review status of documentation gathered in response to requests made by the UCC.	1.30
05/28/20	RC	Review tax related documentation provided by TXP's counsel.	0.70
05/28/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: status of responses received from TXP re: information requests.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/29/20	RC	Review and analysis of documentation provided by TXP in response to various requests for information.	0.70
05/29/20	RC	Review documentation gathered in response to requests from the UCC.	0.80
05/29/20	RC	Review SAP documentation gathered in response to tax requests made by the UCC.	1.10
05/29/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.50
05/29/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	3.40
05/29/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	1.10
Total			<u>2,049.10</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	25.90	420.00	10,878.00
Andrew D DePalma	69.60	515.00	35,844.00
Sam K Lemack	0.60	515.00	309.00
Nate A Simon	3.90	515.00	2,008.50
Sam J Canniff	382.90	645.00	246,970.50
Kyoko Shibuya	26.50	645.00	17,092.50
Fernando O Silva	333.50	645.00	215,107.50
Jon D Hecht	333.00	690.00	229,770.00
Gabe J Koch	0.40	840.00	336.00
Michael Hartley	47.60	840.00	39,984.00
Mark F Rule	425.20	910.00	386,932.00
Jesse DelConte	5.70	950.00	5,415.00
Richard Collura	394.30	1,090.00	429,787.00
Total Hours & Fees	2,049.10		1,620,434.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Non-Working Travel Time
Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
02/03/20	HK	Travel from New York, NY to Stamford, CT	1.00
02/03/20	KM	Travel from YYZ to PVD	4.50
02/03/20	ADD	Travel from MSP to JFK	4.50
02/03/20	JDH	Travel from New York, NY to Stamford, CT	1.00
02/03/20	NAS	Travel from Jersey City, NJ to Stamford, CT.	1.50
02/03/20	SJC	Travel from ORD to HPN	4.00
02/03/20	RDS	Travel from JFK to PVD	4.00
02/03/20	SKL	Travel from DAL to HPN	5.00
02/04/20	RC	Travel to/from New York, NY and Stamford, CT.	1.00
02/05/20	DS	Travel from New York, NY to Stamford, CT	1.00
02/05/20	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
02/06/20	SJC	Travel from HPN to ORD	4.00
02/06/20	DS	Travel from Stamford, CT to New York, NY	1.00
02/06/20	KM	Travel from PVD to YYZ	1.50
02/06/20	ADD	Travel from LGA to MSP	4.50
02/06/20	HK	Travel from Stamford, CT to New York, NY	1.00
02/06/20	SKL	Travel from HPN to DAL.	5.00
02/07/20	KM	Travel from PVD to YYZ (part 2)	3.00
02/07/20	RDS	Travel from PVD to JFK	4.10
02/08/20	NAS	Travel from JFK to DXB (continued)	3.00
02/08/20	GJK	Travel from DFW to DXB	12.00
02/09/20	NAS	Travel from LGA to DXB (travel began on previous day).	13.50
02/09/20	GJK	Travel from DFW to DXB (continued)	12.00
02/10/20	KM	Travel from YYZ to PVD	4.50
02/10/20	RDS	Travel from New York, NY to Providence, RI	4.20
02/10/20	SJC	Travel from ORD to LGA	4.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Non-Working Travel Time
Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
02/10/20	GJK	Travel from DFW to DXB (Part 3)	2.00
02/10/20	HK	Travel from New York, NY to Stamford, CT	1.00
02/11/20	HK	Travel from Stamford, CT to New York, NY	1.00
02/11/20	JD	Travel from New York, NY to Stamford, CT	1.00
02/11/20	JD	Travel from Stamford, CT to New York, NY	1.00
02/12/20	HK	Travel from New York, NY to Stamford, CT	1.00
02/12/20	RC	Travel from New York, NY to Stamford, CT	1.00
02/13/20	HK	Travel from Stamford, CT to New York, NY	1.00
02/13/20	SJC	Travel from HPN to ORD.	4.00
02/13/20	RDS	Travel from Providence, RI to New York, NY	3.30
02/13/20	KM	Travel from Providence to Toronto (part 1)	2.00
02/14/20	KM	Travel from PVD to YYZ (part 2)	2.50
02/14/20	NAS	Travel from DXB to LGA	19.60
02/15/20	GJK	Travel from DXB to DFW	20.00
02/17/20	NAS	Travel from Jersey City, NJ to Stamford, CT.	1.50
02/17/20	SJC	Travel from ORD to HPN.	4.00
02/17/20	SJC	Travel from ORD to HPN.	1.00
02/17/20	ADD	Travel from MSP to LGA.	4.50
02/18/20	JD	Travel from NYC to HPN	1.00
02/18/20	RDS	Travel from LGA to RWI	4.50
02/18/20	SKL	Travel from DAL to LGA	5.00
02/18/20	KM	Travel from YYZ to RWI	4.50
02/19/20	RDS	Travel from RDU to LGA	3.80
02/19/20	JD	Travel from Stamford, CT to New York, NY	1.00
02/20/20	HK	Travel from Stamford, CT to New York, NY	1.00
02/20/20	SKL	Travel from LGA to DAL	5.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Non-Working Travel Time
Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
02/20/20	ADD	Travel from Stamford, CT to New York, NY	1.00
02/20/20	KM	Travel from RWI to YYZ part 1	2.50
02/20/20	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
02/21/20	KM	Travel from RWI to YYZ part 2	2.00
02/21/20	SJC	Travel from Stamford, CT to Boston, MA.	3.00
02/23/20	SJC	Travel from Boston, MA to Stamford, CT.	3.00
02/23/20	ADD	Travel from New York, NY to Stamford, CT	1.00
02/24/20	RDS	Travel from LGA to RWI	4.10
02/24/20	GJK	Travel from DFW to HPN	4.00
02/24/20	HK	Travel from New York, NY to Stamford, CT	1.00
02/24/20	SKL	Travel from DAL to HPN	5.00
02/24/20	NAS	Travel from Jersey City, NJ to Stamford, CT.	1.50
02/25/20	RDS	Travel from RWI to LGA	4.50
02/25/20	RC	Travel from New York, NY to Stamford, CT	1.00
02/26/20	SKL	Travel from HPN to IAH	5.00
02/26/20	GJK	Travel from HPN to DFW	4.50
02/26/20	DS	Travel from New York, NY to Stamford, CT	1.00
02/26/20	DS	Travel from Stamford, CT to New York, NY	1.00
02/27/20	HK	Travel from Stamford, CT to New York, NY	1.00
02/27/20	SJC	Travel from HPN to ORD	4.00
02/27/20	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
02/28/20	ADD	Travel from LGA to MCO	4.00
03/01/20	SJC	Travel from ORD to HPN.	4.00
03/02/20	NAS	Travel from Jersey City, NJ to Stamford, CT.	1.50
03/02/20	RDS	Travel from NYC to Stamford.	1.20
03/02/20	HK	Travel from NYC to Stamford	1.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Non-Working Travel Time
Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
03/02/20	ADD	Travel from MCO to JFK	4.00
03/03/20	KM	Travel from Toronto to Stamford	4.50
03/03/20	JD	Travel from NYC to Stamford.	1.00
03/03/20	DS	Travel to Stamford, CT	1.00
03/04/20	DS	Travel from NYC to Stamford, CT	1.00
03/04/20	SKL	Travel from CT to DAL.	5.00
03/04/20	JD	Travel from Stamford to NYC.	1.00
03/04/20	HK	Travel from Stamford to NYC	1.00
03/04/20	NAS	Travel from Stamford to Jersey City, NJ.	1.50
03/04/20	IA	Travel from NYC to Stamford	1.00
03/05/20	ADD	Travel from LGA to MSP.	4.50
03/05/20	KM	Travel from Stamford to Toronto	4.50
03/05/20	SJC	Travel from HPN to ORD.	4.00
03/08/20	ADD	Travel from MSP to LGA.	4.50
03/09/20	MH	Travel from ATL to HPN.	4.00
03/09/20	SKL	Travel from DAL to CT.	5.00
03/09/20	NAS	Travel from Jersey City, NJ to Stamford, CT.	1.50
03/10/20	JD	Travel from NYC to Stamford.	1.00
03/11/20	JD	Travel from Stamford to NYC.	1.00
03/11/20	NAS	Travel from Stamford to Jersey City, NJ NYC	1.50
03/12/20	ADD	Travel from MSP to LGA.	4.50
03/12/20	SKL	Travel from CT to DAL.	5.00
03/12/20	MH	Travel From HPN to ATL.	4.00
Total			334.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Non-Working Travel Time
Client/Matter # 012589.00150

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	37.00	515.00	19,055.00
Sam K Lemack	45.00	515.00	23,175.00
Hart Ku	11.00	515.00	5,665.00
Nate A Simon	51.10	515.00	26,316.50
Sam J Canniff	39.00	645.00	25,155.00
David Samikkannu	6.00	690.00	4,140.00
Jon D Hecht	1.00	690.00	690.00
Isabel Arana de Uriarte	1.00	690.00	690.00
Ryan D Sublett	33.70	735.00	24,769.50
Michael Hartley	8.00	840.00	6,720.00
Gabe J Koch	54.50	840.00	45,780.00
Kevin M McCafferty	36.00	950.00	34,200.00
Jesse DelConte	8.00	950.00	7,600.00
Richard Collura	3.00	1,090.00	3,270.00
Total Hours & Fees	334.30		227,226.00
Less 50% Travel			(113,613.00)
Total Fees			113,613.00